<SEC-DOCUMENT>0000906709-22-000010.txt : 20220506
<SEC-HEADER>0000906709-22-000010.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505202416
ACCESSION NUMBER:		0000906709-22-000010
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220506
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		22898450

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nktr-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:0975c044-35ac-4551-b121-d6df2cc9796d,g:b0fa7438-204d-4fa1-b132-84f7e9a28d02,d:f0dd445e3956457f908bcf9b5e12885d--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:nktr="http://www.nektar.com/20220331" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nktr-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80L2ZyYWc6NWVkMTJlMjFkOGEyNDQ2ZGE0NWZjYjEyNjc0MWMxYzQvdGFibGU6MDgyNjAyNzU1ZTEzNDljNzgxODc1YWFkMzYyNzU3ZGIvdGFibGVyYW5nZTowODI2MDI3NTVlMTM0OWM3ODE4NzVhYWQzNjI3NTdkYl8yLTEtMS0xLTIzOTk3_e4b21bd0-2557-4fd3-a7fd-ebb2b2c0ada9">false</ix:nonNumeric><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80L2ZyYWc6NWVkMTJlMjFkOGEyNDQ2ZGE0NWZjYjEyNjc0MWMxYzQvdGFibGU6MDgyNjAyNzU1ZTEzNDljNzgxODc1YWFkMzYyNzU3ZGIvdGFibGVyYW5nZTowODI2MDI3NTVlMTM0OWM3ODE4NzVhYWQzNjI3NTdkYl80LTEtMS0xLTIzOTk3_a4b9e6eb-b78b-46b6-abd7-dd6c616341a2">2022</ix:nonNumeric><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80L2ZyYWc6NWVkMTJlMjFkOGEyNDQ2ZGE0NWZjYjEyNjc0MWMxYzQvdGFibGU6MDgyNjAyNzU1ZTEzNDljNzgxODc1YWFkMzYyNzU3ZGIvdGFibGVyYW5nZTowODI2MDI3NTVlMTM0OWM3ODE4NzVhYWQzNjI3NTdkYl81LTEtMS0xLTIzOTk3_00e713e7-bf9d-416a-be63-4961d22ef1d5">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80L2ZyYWc6NWVkMTJlMjFkOGEyNDQ2ZGE0NWZjYjEyNjc0MWMxYzQvdGFibGU6MDgyNjAyNzU1ZTEzNDljNzgxODc1YWFkMzYyNzU3ZGIvdGFibGVyYW5nZTowODI2MDI3NTVlMTM0OWM3ODE4NzVhYWQzNjI3NTdkYl84LTEtMS0xLTIzOTk3_71106e34-4000-40b5-86de-52d7ecce1022">0000906709</ix:nonNumeric><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80L2ZyYWc6NWVkMTJlMjFkOGEyNDQ2ZGE0NWZjYjEyNjc0MWMxYzQvdGFibGU6MDgyNjAyNzU1ZTEzNDljNzgxODc1YWFkMzYyNzU3ZGIvdGFibGVyYW5nZTowODI2MDI3NTVlMTM0OWM3ODE4NzVhYWQzNjI3NTdkYl85LTEtMS0xLTIzOTk3_7ea029e8-d49c-4561-ae8f-3fa4e6f891c8">12-31</ix:nonNumeric><ix:nonNumeric contextRef="ie29adb1fc4684ab0ad0244b29d50d813_D20210101-20211231" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTM5_77184183-0367-45c7-a343-6cddbeacc01a">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i38417cdbca554e42afdd16bfb864bb29_D20220101-20220331" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTM5_bbd38367-e438-4378-87e6-f0c97cd95e48">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nktr-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7493be27952e4e32b337ca0fb6beb344_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i50cc006393ad4e1888a5e96af4811b81_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i0360dfe057384ef3ba43ab8dd1071974_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6d291e1ee86449d78994eae53c1540db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0493e53874bc4daeb52c5b06f4b53a6f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5631866fb8ab42c39ed3826b2e8b778f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f35b8ae306472eb8a7b3141def628a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i549689688dfc4b71bf8359d07ae4b440_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcecb9b74c07454d95c3030eacfc1003_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47e463c44a0047f5afbcfc85015e338b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48ddc45b0f0c4083b93472ac00c57ec5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia03ac38b30664485a603bb967899051f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8db36c3bbf94862b20ee7306f48fec8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c98e2f4e6a9464da1ee6d7c11f30ef9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1920e38e3b36491da8e42b40798bf230_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b52fa5cc03e457a953ca86da5e2495c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2de6ed15fee342229522ad57966bdd88_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c494178abb4445bac7b7c1e7b7011f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eca34de7440481fa184c63c4e404045_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15f2e796e9b648b4b037302677e091aa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i737ff7f610ad425cb44817f0b8750038_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b3e44be00774da7b32a55b730041c18_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a5fea39b5bc466ca1d6c54f925e0d11_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e522901bf134d0aa1265a2daa7a8e8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d218052e54546b08d4740f17cfa7fac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4998b2e879846b19c3d3a8b60109e10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2355825e97324b7fa8064d255dfefb27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i871843ba5eb74770b94f361271dbd894_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30daae3c1fab4806bce1a44e0d836de2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8248c0ee6bae46cb8d2cae0e9c5f9907_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7d3488f0d274f62a82178cb60b7e96b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf4a7ec238a2443fb9cd9d9e2db0d68a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iada92997824446879653178ad1bdbef4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfcf6a6304234f45bb0a0682da1f41f5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2791447615864815a607224b5191a937_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2be3ac308a24e8ca217c972b757f923_D20220425-20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-25</xbrli:startDate><xbrli:endDate>2022-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i2e6976d0fdcb42bba1c4b5e008c93f28_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3e957a413d448a7a3513ceccf209004_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie29adb1fc4684ab0ad0244b29d50d813_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38417cdbca554e42afdd16bfb864bb29_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id45946e930114e44bce50be83bd56339_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d12f77ed264cd9a637f0e3cf2ae918_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i685b6f64ad5c4faa9de52180509da5da_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e22be348e714ef8918b6c87eae1bdcb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd4b2f49b55b430ebc75e5792a0b2792_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafca660c02b34e799b6bda3ecba63141_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33a6252cab2b4155abda79adc4038b32_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01be499d3940498b883cfe405f68c613_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d7497814c41422f9a5b7ea68e05c094_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f6f4d1cbe6a4471822b84152102c34f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98b42c2b599741359d987d496e64c309_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85b44d16760d4680ac9a0259407bc098_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i875ef83363e04d6a85c3349eaf3dd3ab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4c024b46d2c49a3b471bb84a8b0399d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i276bda16441d48ad80af19d97efc426a_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67220c05393f459bb392d5a646a36d88_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib32a3a93199343bfb4bfa43354beb247_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icebb6494d94b4db1a4f1c110b85abaf9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie96ec436f9fc449ebdff998acc527edf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72d23832d5824e05a9160a3dc1fdbe35_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81672743daf84e089f134278b21e4900_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i232e4fff92244a1286cab431418b53bb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c501231db134e1eb8a1723fe66a287d_D20120101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i880e4bb37a104926b7f1b627aba88cce_D20120101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia68e0b50ca474c9fb590f027a73cf228_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ce5f5ad632f42c5ac8d5b2eab7fde07_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i860898a72fc245f2b9c0e62294906402_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nktr:MulquinActionAndDamibaActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="action"><xbrli:measure>nktr:action</xbrli:measure></xbrli:unit><xbrli:context id="i7bf89d8a3c5743f8a48bec4907711413_D20190201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nktr:DerivativeActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ab30e6ae04746708e8844aad00bca73_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c65e86d0ca4792813758a0541762ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06904e4d49ac4e03999c919c6e4361cc_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic736db4d693a4b8595ef22ef35f99636_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16f1e513809d4671b267573756667622_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i037d8ae4d167406ebb243ed52a646788_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a262bb734414dd4857c079289efd56c_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic31ce00edf3c4891b98bdd4f17ff4e56_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6264ab40d7dc48aa86cf10e2b939d8ae_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78c51641e8cc496894dae390b3acb852_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93c0c909992548e0982362d608cdb5c7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48032d659bf148a09d2a83b4693bb85b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2cc7ccba3642dfb8f9446b1b854843_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i887bd71a1b294a4fb94e4d8c2a792b9d_I20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38fc13ebd3cd490ca1a6005558c5ad94_D20170823-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-23</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31ef1bddb0d74c048cd77ffc33b52ad9_D20170823-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-23</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifefea51825e94f008a861cb1ddc9bfe5_D20170823-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-23</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a089f68509044168386924efba61d4e_D20170823-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-23</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib19687a8076a473ba979d1fd42e0df4c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e034360701446c8a364586fa2b0d27b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10110540b97b4a4ab4a50614d0cff3c9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9f8f2918f94fd6923a1d4a51027353_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i728e5d8a85be40679bfe48b2fbce4909_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6179ae9a7f44883ab15f4ae9457eb07_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb2c55128bc8497c8854c8a78a73cd58_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic59b05e471ec4124afe9fde97642790e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if023fd27426a491e84900754f5b3156f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111ab39f489a4f079ea9e751923f01c7_I20220424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nktr:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie8720ccc92154ed5bcfc18a705606b0d_I20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3db39c27bf794516854c382d356e95bb_I20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec2e4f024964e8eb19d315571eb57d8_I20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-25</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if0dd445e3956457f908bcf9b5e12885d_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjU3_985c9dd5-c208-4b8b-8ffe-7307d9706b2c">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6NmZkMjIyM2M4MTczNDQ4Yjk0ZmJhNGY2OTI4MjgzNzgvdGFibGVyYW5nZTo2ZmQyMjIzYzgxNzM0NDhiOTRmYmE0ZjY5MjgyODM3OF8wLTAtMS0xLTIzOTk3_1150c5d3-2796-4b3f-8a7a-e570a618c163">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yNjY_bcc6f082-3713-4219-8938-fafc65de5b85">March&#160;31, 2022</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6NGU4NzMxNjlmNzQ3NGI4OTkzNWQ1YmMzNWQ5ZWE2NzgvdGFibGVyYW5nZTo0ZTg3MzE2OWY3NDc0Yjg5OTM1ZDViYzM1ZDllYTY3OF8wLTAtMS0xLTIzOTk3_cf10b1cc-2d13-4d9e-905f-5d9c679b1ae0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjY0_a3bc5b3e-d735-4419-ac54-c4f028150b47">0-24006</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:23pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjU4_1894b12e-ad53-4917-9345-e588fa153aba">NEKTAR THERAPEUTICS</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.034%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6NjZkZjQ0YjM4NWZhNDZjYjhiYWU2ZjAzMWUwNDIwYTcvdGFibGVyYW5nZTo2NmRmNDRiMzg1ZmE0NmNiOGJhZTZmMDMxZTA0MjBhN18wLTAtMS0xLTIzOTk3_3c70d598-33dd-4a58-8b5d-5697032bfca2">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6NjZkZjQ0YjM4NWZhNDZjYjhiYWU2ZjAzMWUwNDIwYTcvdGFibGVyYW5nZTo2NmRmNDRiMzg1ZmE0NmNiOGJhZTZmMDMxZTA0MjBhN18wLTItMS0xLTIzOTk3_9bb0eb88-c764-4651-bd8f-08dedc7ad6be">94-3134940</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjY1_fe2710a4-e676-442c-9e8e-e2c73f9aadf5">455 Mission Bay Boulevard South</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjY2_a317cd37-fc75-42e3-8703-c516b1b2fa49">San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjU5_ee54c96d-63a1-460e-986b-33128e9accd2">California</ix:nonNumeric> <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjYw_b6fabbae-25fe-465c-8e35-5a1bfa689a4a">94158</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjY3_76284e02-c8dc-4299-82d2-f31930add6a1">415</ix:nonNumeric>-<ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjYx_7b0de5b2-7d52-4801-b559-8269dda41a27">482-5300</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6Yzg1YTRkNmU4ZDI5NDY2OGI2YzMxOTA2MTRiMmM5MzEvdGFibGVyYW5nZTpjODVhNGQ2ZThkMjk0NjY4YjZjMzE5MDYxNGIyYzkzMV8yLTAtMS0xLTIzOTk3_12cfb367-c5d3-491d-a091-a7f4673f7946">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6Yzg1YTRkNmU4ZDI5NDY2OGI2YzMxOTA2MTRiMmM5MzEvdGFibGVyYW5nZTpjODVhNGQ2ZThkMjk0NjY4YjZjMzE5MDYxNGIyYzkzMV8yLTEtMS0xLTIzOTk3_a06d0826-3eb9-45c6-9455-97a906ab0c36">NKTR</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6Yzg1YTRkNmU4ZDI5NDY2OGI2YzMxOTA2MTRiMmM5MzEvdGFibGVyYW5nZTpjODVhNGQ2ZThkMjk0NjY4YjZjMzE5MDYxNGIyYzkzMV8yLTItMS0xLTIzOTk3_a25fba7d-ab0b-4486-b498-20568254dbd3">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjU2_5938cb8a-98b9-4e60-a25f-b0c84f52abab">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No &#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjYy_de413470-4e0f-4e3a-93de-1b9b424e75d8">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No &#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:21.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6N2JkMzgyY2NkOGUwNDc0YTk3NDJlY2NmYTViOGZkZGIvdGFibGVyYW5nZTo3YmQzODJjY2Q4ZTA0NzRhOTc0MmVjY2ZhNWI4ZmRkYl8wLTAtMS0xLTIzOTk3_7e32dcc4-063a-4806-abe2-6d25826cd572">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6N2JkMzgyY2NkOGUwNDc0YTk3NDJlY2NmYTViOGZkZGIvdGFibGVyYW5nZTo3YmQzODJjY2Q4ZTA0NzRhOTc0MmVjY2ZhNWI4ZmRkYl8yLTYtMS0xLTIzOTk3_f1f7a7c0-9520-48fd-998a-73dd742e60cc">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6N2JkMzgyY2NkOGUwNDc0YTk3NDJlY2NmYTViOGZkZGIvdGFibGVyYW5nZTo3YmQzODJjY2Q4ZTA0NzRhOTc0MmVjY2ZhNWI4ZmRkYl80LTItMS0xLTIzOTk3_8402029b-244d-4d7d-a362-e066ae988831">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjYz_4ae4d765-dfce-4612-a7a3-6a5f456d899e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s Common Stock, $0.0001 par value, was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7493be27952e4e32b337ca0fb6beb344_I20220429" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjQ4_3c79bb95-2126-4620-8222-d6eef5a8db3d">186,274,156</ix:nonFraction> o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n April&#160;29, 2022.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_13">Summary of Risks</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_13">4</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_16">PART I: FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_19">Condensed Consolidated Financial Statements &#8212; Unaudited:</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_22">Condensed Consolidated Balance Sheets &#8212; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_22">March 31, 2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_22"> and December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_22">21</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_25">Condensed Consolidated Statements of Operations for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_25">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_25">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_25">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_25">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_25"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_25">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_28">Condensed Consolidated Statements of Comprehensive Loss for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_28">months </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_28">ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_28">M</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_28">arch</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_28"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_28">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_28">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_28">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_28">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_28"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_28">21</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_31">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_31">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_31">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_31"> 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_31">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_31">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_31"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_31">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_34">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_34">three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_34"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_34">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_34"> 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_34">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_34">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_34"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_34">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_37">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_70">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_70">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Item 3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_82">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_82">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_85">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_85">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_85">31</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_88">PART II: OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_91">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_91">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_91">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_94">Item 1A.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_94">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_94">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_97">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_97">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_97">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_100">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_100">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_100">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_103">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_103">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_103">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_106">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_106">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_106">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_109">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_109">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_109">53</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_112">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if0dd445e3956457f908bcf9b5e12885d_112">54</a></span></div></td></tr></table></div><div style="text-indent:-9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this Quarterly Report on Form 10-Q, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements related to our strategic reorganization and cost restructuring plans, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates and our future research and development plans, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation, or success of our collaboration arrangements, commercialization activities and product sales levels by our collaboration partners and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part I, Item&#160;1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this Quarterly Report on Form 10-Q, the &#8220;Company,&#8221; &#8220;Nektar,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nektar brand and product names, including but not limited to Nektar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contained in this document are trademarks and registered trademarks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div id="if0dd445e3956457f908bcf9b5e12885d_13"></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risks</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time, and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks to our business are more fully described below in Item IA in this Form 10-Q, which risks include, among others:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Research and Development Efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">clinical drug development is a lengthy and uncertain process and we may not be able to generate and develop successful drug candidates for commercial use;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on the success of NKTR-358 and NKTR-255 and our business will be significantly harmed if either NKTR-358 or NKTR-255 does not continue to advance in clinical studies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the outcomes from competitive oncology and immunology therapy clinical trials, and the discovery and development of new potential oncology and immunology therapies could have a material and adverse impact on the value of our pipeline;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">significant competition for our polymer conjugate chemistry technology platforms and our products and drug candidates could make our technologies, drug products or drug candidates obsolete or uncompetitive;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">preliminary and interim data from our clinical studies are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">clinical trials for any of our drug candidates could be delayed for a variety of reasons. </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Financial Condition and Capital Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are implementing a new strategic reorganization plan focused on prioritizing key research and development efforts, as well as a cost restructuring plan, and our business will be significantly harmed if either of these plans is unsuccessful; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our revenue is exclusively derived from our collaboration agreements. If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we expect to continue to incur substantial net losses from operations and may not achieve or sustain profitability in the future. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Collaboration Partners</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on Eli Lilly and Company, our collaboration partner for NKTR-358, our lead drug candidate, to initiate, properly conduct and prioritize clinical trials for NKTR-358 and to perform important additional development and commercialization activities, and our business will be significantly harmed if our partner&#8217;s actions deprioritize or otherwise harm the prospects of NKTR-358; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the operations of our collaboration partners have been affected by the COVID-19 pandemic in the past, and it is possible that the COVID-19 pandemic will affect the operations of our collaboration partners in the future, which would cause delays in initiating or completing one or more clinical trials involving our drug candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to the COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our business could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic. While the COVID-19 pandemic has not had a material adverse effect on our current operations, the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ongoing challenges associated with the pandemic, including the emergence of new variants of the coronavirus, such as the Delta and Omicron variants, and resurgences in number and rates of infections, and shortages in raw materials and equipment and other supply chain disruptions, could have a material negative impact on our business and our clinical trial timelines.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Supply and Manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, our business, financial condition and results of operations could be harmed; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause delays, loss of revenue and contract liability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we or our partners may not obtain regulatory approval for our drug candidates on a timely basis, or at all;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required, which may not be available to us on commercially reasonable terms; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">from time to time, we are involved in legal proceedings and may incur substantial litigation costs and liabilities that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above-mentioned risks, our business is subject to a number of additional risks faced by businesses generally. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I: FINANCIAL INFORMATION</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_19"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Condensed Consolidated Financial Statements&#8212;Unaudited:</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_22"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:70.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMy0xLTEtMS0yMzk5Nw_32088268-29d1-40aa-acb0-ca23d092ee66">67,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMy0zLTEtMS0yMzk5Nw_9b8d4163-13d6-48d2-ada2-c3619062b30f">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNC0xLTEtMS0yMzk5Nw_2b75b644-1ad2-46fd-9d50-878a0dfd9ed1">599,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNC0zLTEtMS0yMzk5Nw_2a52f99b-c086-43b0-9010-4f16ea0ebed3">708,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNS0xLTEtMS0yMzk5Nw_186b4763-1cd0-4102-ada5-4d9aafea193e">30,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNS0zLTEtMS0yMzk5Nw_c84e0784-6c2f-4d9f-ada3-aa5bb53d1fc6">22,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNi0xLTEtMS0yMzk5Nw_ae1ffdb3-3539-40f4-a1ad-66198f6770de">15,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNi0zLTEtMS0yMzk5Nw_15f5433d-ec50-4fd7-9201-c6dfaba90d51">15,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNy0xLTEtMS0yMzk5Nw_0b51266f-28a5-4fdd-b749-3050bea41c2f">20,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNy0zLTEtMS0yMzk5Nw_bcea28a8-0bcb-4388-bfe3-1d1a26ca6446">23,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfOC0xLTEtMS0yMzk5Nw_90dd9ec5-6587-47bc-b7d2-eac5ccb88adf">733,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfOC0zLTEtMS0yMzk5Nw_e318e6fc-2939-459a-a8a5-ed8fea8b60d0">795,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfOS0xLTEtMS0yMzk5Nw_d5a61588-f19e-481b-9d6e-1dec5242550c">37,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfOS0zLTEtMS0yMzk5Nw_d00d1775-55d0-442f-a1e9-7fe991ea6b1c">64,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTAtMS0xLTEtMjM5OTc_9b988504-339c-44f6-a52e-e09ce9ffda0f">60,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTAtMy0xLTEtMjM5OTc_8596dee2-4524-4b3d-8d39-6d9e6e986fdc">60,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTEtMS0xLTEtMjM5OTc_72c32d97-8809-4b49-9924-20b52c393b6a">114,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTEtMy0xLTEtMjM5OTc_eed7214d-8e58-45ef-b952-f51a233128f5">117,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTItMS0xLTEtMjM5OTc_c6f0a112-4bcd-4876-9bf2-06785440ed29">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTItMy0xLTEtMjM5OTc_0d294e21-8aa7-43d6-b268-e4789221083c">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTMtMS0xLTEtMjM5OTc_fb7de476-925d-4853-a5cf-1ac21bfad580">1,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTMtMy0xLTEtMjM5OTc_5a7b4afb-3e5c-47e2-acc2-d52f8e7f2acf">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTQtMS0xLTEtMjM5OTc_0706dc29-aa71-42b2-b2e0-72d0a0dbf4de">1,024,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTQtMy0xLTEtMjM5OTc_22a17577-ab7a-4f00-b922-83da7af07a5f">1,117,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTctMS0xLTEtMjM5OTc_efc9f40a-f7f4-42b4-ba9e-c88cf7b28f6d">12,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTctMy0xLTEtMjM5OTc_33472916-6bc2-4635-9040-9e6402ff15f6">9,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTgtMS0xLTEtMjM5OTc_d7144aee-ffae-4962-a7b0-335d917966c6">22,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTgtMy0xLTEtMjM5OTc_279ec78a-e1eb-45bb-8bf1-20b1ebad58e5">15,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued clinical trial expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="nktr:AccruedClinicalTrialExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTktMS0xLTEtMjM5OTc_98b58993-d457-41cb-aa6d-08e40ce3d420">33,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="nktr:AccruedClinicalTrialExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTktMy0xLTEtMjM5OTc_9a604ee6-7447-4b01-bc85-cd6802750fd7">26,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjEtMS0xLTEtMjM5OTc_bfec0e12-b94d-491a-b72a-3e6390bdec30">17,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjEtMy0xLTEtMjM5OTc_cfc58bb7-2591-477f-9843-bd3802eb95ee">15,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjItMS0xLTEtMjM5OTc_4cd4cca4-7ed1-4be8-b1e7-d813ad041e70">19,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjItMy0xLTEtMjM5OTc_21ba7757-0060-4a5c-9056-de23ef9951a7">17,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjMtMS0xLTEtMjM5OTc_dbd1949a-d620-46a2-929a-d316022e89bf">105,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjMtMy0xLTEtMjM5OTc_19f8c08b-14a1-4c3d-8782-93a4be897cd8">85,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjQtMS0xLTEtMjM5OTc_b520eafc-f69c-4bb1-961b-f3a433e285ca">122,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjQtMy0xLTEtMjM5OTc_9771b203-f1af-408c-bdd1-e5f83092fc68">125,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjUtMS0xLTEtMjM5OTc_be3358d1-acec-40a2-922b-936293ba0062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjUtMy0xLTEtMjM5OTc_4b6f0e93-c8d4-4412-be71-29089a5f5e7f">27,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities related to the sales of future royalties, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjYtMS0xLTEtMjM5OTc_b39a73a5-2f0f-429f-bcf5-b0cdbf6068ef">185,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjYtMy0xLTEtMjM5OTc_520e8678-f8a4-41af-a582-05613ced4428">195,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjctMS0xLTEtMjM5OTc_0d76536d-3d00-458d-9d27-3f9b3043af18">2,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjctMy0xLTEtMjM5OTc_892717ef-ce0f-42ed-9d81-4e82ee3edfd0">3,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjgtMS0xLTEtMjM5OTc_f9ca60d6-f33c-48e0-bc9a-14a8caeedbc2">416,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjgtMy0xLTEtMjM5OTc_fd76253a-42cd-4682-9b98-ee7638f318c3">437,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjktMS0xLTEtMjM5OTc_a535f681-e917-47a2-8c4d-924b3800a831"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjktMy0xLTEtMjM5OTc_1deb137e-9bb2-47c9-9ffc-955c7a00baf2"></ix:nonFraction>Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl8yMQ_88db32d5-4a2c-4100-b801-32145246b1f1"><ix:nonFraction unitRef="usdPerShare" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl8yMQ_9e0e8a9d-3172-41d4-9b4e-518cb705eb7f">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl8zNQ_28e076e2-414b-426b-a4b9-a6381dd178d1"><ix:nonFraction unitRef="shares" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl8zNQ_d6e4036b-c40d-47bc-b1f1-f438edb4e0f8">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="INF" name="nktr:PreferredStockShareDesignated" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl81Nw_05325791-b787-49c0-9795-9524ebae425e"><ix:nonFraction unitRef="shares" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl81Nw_0adca7a0-3af5-4adb-9581-2c0c0d660f63"><ix:nonFraction unitRef="shares" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl81Nw_5af56125-24a6-4c32-9df9-1f7e0e75d5c5"><ix:nonFraction unitRef="shares" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="INF" name="nktr:PreferredStockShareDesignated" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl81Nw_c293e021-a994-49b2-ac9b-8f56a3ef7ee0">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares designated or outstanding at March 31, 2022 or December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMS0xLTEtMjM5OTc_f4081aec-6ae9-40ec-bd1a-7b160d0340d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMy0xLTEtMjM5OTc_16bce3e6-11d5-4ab8-82dc-e4a517bbb083">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo5MDI3ODk5MDMxMTg0ZTkxYjMxMmY0MjAxOTZhMzZjMl8xOA_81eb5c58-1e3d-4596-bacb-c6bb6353abc4"><ix:nonFraction unitRef="usdPerShare" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo5MDI3ODk5MDMxMTg0ZTkxYjMxMmY0MjAxOTZhMzZjMl8xOA_881ce4e8-d035-4572-b6ae-b79a22b2f23e">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo5MDI3ODk5MDMxMTg0ZTkxYjMxMmY0MjAxOTZhMzZjMl8zMg_9333bd60-e6eb-4c5c-986d-b70dab172b68"><ix:nonFraction unitRef="shares" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo5MDI3ODk5MDMxMTg0ZTkxYjMxMmY0MjAxOTZhMzZjMl8zMg_f114f0a1-48a3-487d-99b0-4ec2c52a12e5">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo5MDI3ODk5MDMxMTg0ZTkxYjMxMmY0MjAxOTZhMzZjMl81NA_2f242d47-96ae-41ce-a80d-b09cc979432e">186,274</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo5MDI3ODk5MDMxMTg0ZTkxYjMxMmY0MjAxOTZhMzZjMl82OA_fdd5846d-768a-4518-99ea-7cb920437282">185,468</ix:nonFraction> shares outstanding at March 31, 2022 or December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMS0xLTEtMjM5OTc_dcfb40d4-ce65-4221-964e-a41a1dc20321">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMy0xLTEtMjM5OTc_5fc01c0a-17ee-407a-8fc2-7da4e82d86a0">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital in excess of par value</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzMtMS0xLTEtMjM5OTc_c2c3cd78-f8c1-4c39-92b4-ba5370c1d73f">3,537,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzMtMy0xLTEtMjM5OTc_ccab3348-d5ed-4081-afb0-cd368ccd0cd6">3,516,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzQtMS0xLTEtMjM5OTc_56b3d1b0-f9c1-4dd1-885d-d803bff2424c">6,532</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzQtMy0xLTEtMjM5OTc_bcc81f16-d9e8-421e-8751-ac98b83d6946">4,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzUtMS0xLTEtMjM5OTc_dcf1441b-a0a7-40b0-870f-34506d0f660b">2,923,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzUtMy0xLTEtMjM5OTc_b8f8c355-ec3c-4bb4-8de0-49ad5ff22299">2,832,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzYtMS0xLTEtMjM5OTc_b5e81b59-7134-4a50-8bca-a3a07a5ac7dc">607,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzYtMy0xLTEtMjM5OTc_d6e6f55c-2a24-4740-95cd-ffcf11400127">679,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzctMS0xLTEtMjM5OTc_4d2e1ae0-63bd-4557-a1c4-2e60613d46f9">1,024,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzctMy0xLTEtMjM5OTc_710ed402-a50a-4ba3-acdd-c37995d8c1ca">1,117,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share information)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d291e1ee86449d78994eae53c1540db_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMy0xLTEtMS0yMzk5Nw_1444555a-28ae-4ac4-9b99-00325ae9b8f1">5,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0493e53874bc4daeb52c5b06f4b53a6f_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMy0zLTEtMS0yMzk5Nw_47a0bd62-1027-42f0-9ee9-91b2b5449b93">4,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to the sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5631866fb8ab42c39ed3826b2e8b778f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfNS0xLTEtMS0yMzk5Nw_b360a600-c338-42fb-a9e9-fcc43b0d01cf">17,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f35b8ae306472eb8a7b3141def628a_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfNS0zLTEtMS0yMzk5Nw_ab7da408-d321-41bf-9793-0babaa4ad10a">18,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i549689688dfc4b71bf8359d07ae4b440_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfNi0xLTEtMS0yMzk5Nw_cd6e60e4-f0fa-44d5-acbf-502bd7d035e4">1,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcecb9b74c07454d95c3030eacfc1003_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfNi0zLTEtMS0yMzk5Nw_11669f51-6d96-413c-a12c-58510c48748a">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfNy0xLTEtMS0yMzk5Nw_1808df48-fda5-4a38-a41c-8a565fd2fe78">24,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfNy0zLTEtMS0yMzk5Nw_03392947-d7b2-43ed-bc9f-4b71d64b6e55">23,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating costs and expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfOS0xLTEtMS0yMzk5Nw_d73027dd-19b2-4492-b3b2-82ca5e4df68f">5,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfOS0zLTEtMS0yMzk5Nw_22a54358-80f4-48a6-91c4-3aae96e501e0">5,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTAtMS0xLTEtMjM5OTc_5d4a04a2-432c-42b5-b3ae-96ba88627add">107,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTAtMy0xLTEtMjM5OTc_2383c39a-4702-45fc-92ba-d5540c766381">95,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTEtMS0xLTEtMjM5OTc_2c1574d5-c352-47a5-8e10-21000523f7ea">27,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTEtMy0xLTEtMjM5OTc_869e618b-d88c-4273-b872-ef18ed48222a">31,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTItMS0xLTEtMjY5MTg_e62c000d-cc53-4f87-bed4-ec723d361295">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTItMy0xLTEtMjY5MTg_418fd160-e41b-4e42-80d4-5b886e8f51a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTMtMS0xLTEtMjM5OTc_fdca7504-eaac-4ca4-9f70-f12670b7aa07">141,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTMtMy0xLTEtMjM5OTc_1f780cbe-e11e-47d2-8108-54a241898e1a">133,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTQtMS0xLTEtMjM5OTc_1e551cf1-5d91-40da-b44d-82acef675143">116,560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTQtMy0xLTEtMjM5OTc_f67a1bcc-d7c2-4e95-90a0-ca9d45f651a1">109,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income (expense):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTUtMS0xLTEtMjQyNTg_5a5a2d73-f3fe-4252-b2f6-c76ac4ba37fc">33,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTUtMy0xLTEtMjQyNTA_926f896a-c8d0-4fc9-9569-1a6e727e22e8">1,599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liabilities related to the sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTYtMS0xLTEtMjM5OTc_a5693c8c-a195-4a58-8388-95ff477b41e7">7,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTYtMy0xLTEtMjM5OTc_048a3f3f-0431-47e2-81de-94a31752daad">13,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTgtMS0xLTEtMjM5OTc_4f1b5b22-ce34-404c-a69c-bbf246a813cd">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTgtMy0xLTEtMjM5OTc_cfe061e3-8bdb-401c-8982-315b9e6ae0a7">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-operating income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjAtMS0xLTEtMjM5OTc_b4126af7-82e9-4686-8ed8-41813e9e8b2e">26,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjAtMy0xLTEtMjM5OTc_9d674631-36a7-418b-b151-e6ab35a6a763">13,483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjEtMS0xLTEtMjM5OTc_7cd93a7a-a0e0-4b9e-b16d-fe7fb64ae1f7">90,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjEtMy0xLTEtMjM5OTc_f842139b-6067-44e2-9ab0-bb2c49d6f287">122,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjItMS0xLTEtMjM5OTc_c281a75a-3371-475b-bc6e-0c1cb3b28a03">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjItMy0xLTEtMjM5OTc_fdb67c3c-0185-4e09-bfec-def698603a8d">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjMtMS0xLTEtMjM5OTc_9b1108d5-5cef-4ef0-9abc-cce090e17976">90,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjMtMy0xLTEtMjM5OTc_7e146ee8-6821-4c53-855b-653be1b88fb5">122,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjUtMS0xLTEtMjM5OTc_0be6c400-df00-49b5-b234-f53e41a2fcae"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjUtMS0xLTEtMjM5OTc_6b8efe01-560b-4310-941e-0cd9adf8aa90">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjUtMy0xLTEtMjM5OTc_01d3d469-4241-4430-abbe-179948ca56df"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjUtMy0xLTEtMjM5OTc_20e7f839-1f4c-468c-9b46-28a52018c260">0.68</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in computing basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjYtMS0xLTEtMjM5OTc_091c5824-ed3e-4fcb-8733-ffe95b2cc812"><ix:nonFraction unitRef="shares" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjYtMS0xLTEtMjM5OTc_50ebd230-b3f5-4419-bb1c-cb587bd4cf29">185,848</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjYtMy0xLTEtMjM5OTc_4d5c0bbc-688f-4101-ad66-bee3c7a6c33d"><ix:nonFraction unitRef="shares" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjYtMy0xLTEtMjM5OTc_894cfe89-5d75-49d5-8df7-7bd15fc228a1">181,370</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfMi0xLTEtMS0yMzk5Nw_25031e7b-f287-45a7-b8e2-1cc5d5925373">90,393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfMi0zLTEtMS0yMzk5Nw_59ab58a3-adf4-47bb-bbea-8cc0d7d3ef60">122,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNC0xLTEtMS0yMzk5Nw_24b5f934-823e-4259-a5e2-04ac131ea2b7">2,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNC0zLTEtMS0yMzk5Nw_c48fcb54-dc53-4df8-86ac-836d083a2394">766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNS0xLTEtMS0yMzk5Nw_eba72aad-6832-43c4-94db-02419d82984f">284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNS0zLTEtMS0yMzk5Nw_6667a155-f9d7-4107-b767-092bdd75c23c">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNi0xLTEtMS0yMzk5Nw_319d61cf-5cc0-40a9-b379-c38baf495a27">2,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNi0zLTEtMS0yMzk5Nw_11b7c7ca-0cbe-4e23-a540-5d0ee7dfdb01">826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNy0xLTEtMS0yMzk5Nw_a35f32e4-d3ef-4ef8-bbd8-42cd2b8742ba">92,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNy0zLTEtMS0yMzk5Nw_f1284c1a-dfd3-4cf6-a5e0-3e544395cea1">123,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47e463c44a0047f5afbcfc85015e338b_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfOS0xLTEtMS0yMzk5Nw_2bffb798-2e29-4439-a829-7bc696992ba3">180,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e463c44a0047f5afbcfc85015e338b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfOS0zLTEtMS0yMzk5Nw_3c2cfa08-6cf8-4010-9928-491b327bb4f1">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48ddc45b0f0c4083b93472ac00c57ec5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfOS01LTEtMS0yMzk5Nw_7abc9f8f-9187-47e5-8f3d-dfaf1ab2a82a">3,388,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia03ac38b30664485a603bb967899051f_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfOS03LTEtMS0yMzk5Nw_2fde482d-a2d1-4757-af55-8daa2e9010e0">2,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8db36c3bbf94862b20ee7306f48fec8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfOS05LTEtMS0yMzk5Nw_bb1b649e-ed14-4750-95d8-b924594b61e6">2,309,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c98e2f4e6a9464da1ee6d7c11f30ef9_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfOS0xMS0xLTEtMjM5OTc_69df574c-7b5a-4271-92af-980b92f9270e">1,077,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1920e38e3b36491da8e42b40798bf230_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTAtMS0xLTEtMjM5OTc_8ca05cc9-e054-410d-84ee-9f270f9f9558">2,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1920e38e3b36491da8e42b40798bf230_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTAtMy0xLTEtMjM5OTc_d69949ca-9882-42af-8fba-5848389ab95d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b52fa5cc03e457a953ca86da5e2495c_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTAtNS0xLTEtMjM5OTc_d4f10197-90d6-4c2e-bd04-94fed8407da2">17,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTAtMTEtMS0xLTIzOTk3_a360d45b-2618-4412-bcba-42230d3d7391">17,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b52fa5cc03e457a953ca86da5e2495c_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTEtNS0xLTEtMjM5OTc_3e446650-2f62-4fa1-a1a6-293af268b277">23,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTEtMTEtMS0xLTIzOTk3_01aa6bcc-1cd4-4ac8-8bf9-5357f28cf92c">23,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2de6ed15fee342229522ad57966bdd88_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTItNy0xLTEtMjM5OTc_03650ad4-2dea-4167-aadb-e839c883e658">826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34c494178abb4445bac7b7c1e7b7011f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTItOS0xLTEtMjM5OTc_8bdfea4a-338d-4d6a-8d05-ef08c52c0065">122,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTItMTEtMS0xLTIzOTk3_4329fad8-2e44-45d3-b107-2569aa7e5245">123,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2eca34de7440481fa184c63c4e404045_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTMtMS0xLTEtMjM5OTc_5b95c59a-0f16-47c4-a0e2-0c5ab956c621">182,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eca34de7440481fa184c63c4e404045_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTMtMy0xLTEtMjM5OTc_d40b6f11-f759-42f0-8cfc-980a91c5ffff">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f2e796e9b648b4b037302677e091aa_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTMtNS0xLTEtMjM5OTc_2a8eab40-2b48-44be-8a56-c5d7c7e9eb29">3,429,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i737ff7f610ad425cb44817f0b8750038_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTMtNy0xLTEtMjM5OTc_003f6f2c-8b6c-49f3-a473-aef1e2bdb2bb">3,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b3e44be00774da7b32a55b730041c18_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTMtOS0xLTEtMjM5OTc_e3456c6f-97c8-47e4-90b3-a133756db486">2,432,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5fea39b5bc466ca1d6c54f925e0d11_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTMtMTEtMS0xLTIzOTk3_b6544e01-a5f7-4a9a-887c-b25bb61bb952">994,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e522901bf134d0aa1265a2daa7a8e8e_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMS0xLTEtMS0zMDM5MA_3bd1f445-c580-4454-8710-689277bf3af4">185,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e522901bf134d0aa1265a2daa7a8e8e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMS0zLTEtMS0zMDM5MA_9c482362-0196-40cc-9bae-6b12c0b2e3e3">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d218052e54546b08d4740f17cfa7fac_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMS01LTEtMS0zMDM5MA_62261542-ddc7-4b0b-807d-803dbac020d2">3,516,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4998b2e879846b19c3d3a8b60109e10_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMS03LTEtMS0zMDM5MA_d3c18d02-c6d7-498c-bc61-1c6b4463b4e0">4,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2355825e97324b7fa8064d255dfefb27_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMS05LTEtMS0zMDM5MA_5ebf55cd-087e-4db6-974e-c0a9e5868343">2,832,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMS0xMS0xLTEtMzAzOTA_5052e28c-253f-43a1-9ba9-4041fba7ccad">679,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i871843ba5eb74770b94f361271dbd894_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMi0xLTEtMS0zMDM5MA_df1339d3-b8cb-4977-b771-a063ced13ac7">806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871843ba5eb74770b94f361271dbd894_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMi0zLTEtMS0zMDM5MA_4a41366a-3b64-4677-adda-30f3e7380e33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30daae3c1fab4806bce1a44e0d836de2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMi01LTEtMS0zMDM5MA_187c38a7-ad58-48f7-8033-1757e4469aa3">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMi0xMS0xLTEtMzAzOTA_863e6ccd-333c-43e5-aae5-8ef3d9478b22">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30daae3c1fab4806bce1a44e0d836de2_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMy01LTEtMS0zMDM5MA_567f530e-dbc0-4000-8538-beb550fbb6db">20,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMy0xMS0xLTEtMzAzOTA_e0f92587-24f2-463e-ba53-6ef80a2b2268">20,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8248c0ee6bae46cb8d2cae0e9c5f9907_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNC03LTEtMS0zMDM5MA_abc912be-d7fd-4ffb-882d-e9808058f993">2,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7d3488f0d274f62a82178cb60b7e96b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNC05LTEtMS0zMDM5MA_bf27d47b-b84d-4a0a-81da-c40f95abec48">90,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNC0xMS0xLTEtMzAzOTA_3b8c5429-ef61-4384-bd6a-d68da2cd0488">92,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf4a7ec238a2443fb9cd9d9e2db0d68a_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNS0xLTEtMS0zMDM5MA_794fd5a7-155c-4717-bac6-6a336d3198c5">186,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf4a7ec238a2443fb9cd9d9e2db0d68a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNS0zLTEtMS0zMDM5MA_eb465d51-127e-4f82-89d4-59c9f910a877">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada92997824446879653178ad1bdbef4_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNS01LTEtMS0zMDM5MA_a1046659-9eb2-4054-9603-051f4acd097b">3,537,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfcf6a6304234f45bb0a0682da1f41f5_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNS03LTEtMS0zMDM5MA_d18f91c0-6e79-4621-ba6b-cefb905e7729">6,532</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2791447615864815a607224b5191a937_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNS05LTEtMS0zMDM5MA_a59411dd-4df0-4964-9f4d-49238e53bc3e">2,923,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNS0xMS0xLTEtMzAzOTA_e3c1c076-b1b5-4842-8c5a-f4c94f3aac07">607,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMy0xLTEtMS0yMzk5Nw_a56d6eff-b3a1-4c9b-bf23-57e7994195c1">90,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMy0zLTEtMS0yMzk5Nw_0a69b4ce-ee48-416c-9462-2c386e152cfb">122,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to the sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNS0xLTEtMS0yMzk5Nw_0b476af9-1d25-4c4e-8de1-3ab0e046a959">17,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNS0zLTEtMS0yMzk5Nw_c26e19ed-932a-49e9-b9bb-fd19a96ac0f8">18,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on liabilities related to the sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNi0xLTEtMS0yMzk5Nw_0274ae8a-5397-4ae8-aea7-1f6209426f8c">7,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNi0zLTEtMS0yMzk5Nw_f602c4d4-c5b0-4b95-b193-d91d34d4275d">13,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNy0xLTEtMS0yMzk5Nw_5e715232-091d-43df-bfcc-26f3c820b5f8">33,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNy0zLTEtMS0yMzk5Nw_2687e98e-60bc-41b1-a2d7-4bfddca5668a">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfOC0xLTEtMS0yMzk5Nw_b0efd8d1-d1e4-4761-b825-a4b1c34d0a6f">4,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfOC0zLTEtMS0yMzk5Nw_565873cf-b4be-4230-943d-d2a95a9c243c">2,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfOS0xLTEtMS0yMzk5Nw_3dc5bb99-2052-4846-a428-c890167b0b47">20,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfOS0zLTEtMS0yMzk5Nw_6da5840a-e355-407b-9da9-00bb2a90969d">23,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTAtMS0xLTEtMjM5OTc_4592e6fa-a350-4fbb-ba52-45e0470d33eb">3,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTAtMy0xLTEtMjM5OTc_2f62323e-4e21-48be-85c7-f0959cccc896">3,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums (discounts), net and other non-cash transactions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTItMS0xLTEtMjM5OTc_a545a658-0eae-463d-8092-9141548ba964">1,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTItMy0xLTEtMjM5OTc_71285fd8-4056-4cb5-bd05-dfd341801bf8">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTQtMS0xLTEtMjM5OTc_523e0bc5-8c4b-422b-8b42-79d58825a565">7,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTQtMy0xLTEtMjM5OTc_d40721ec-486e-4313-804d-cb9e8ab656b2">9,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTUtMS0xLTEtMjM5OTc_86e276e5-6b6d-4b97-8d05-20ad806e30a6">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTUtMy0xLTEtMjM5OTc_506cba20-b687-4c16-8d63-11e1e4f34eae">1,516</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTYtMS0xLTEtMjM5OTc_1d499fc4-25a6-4a4d-8480-575b933caf21">1,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTYtMy0xLTEtMjM5OTc_b0d2b3de-56f0-40ae-aa1f-ed3347be8775">1,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTctMS0xLTEtMjM5OTc_9201db18-d3f3-4249-8994-714b4da6eff8">2,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTctMy0xLTEtMjM5OTc_8fb2875a-9918-43a0-893d-81a34046950a">6,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTgtMS0xLTEtMjM5OTc_8feea3df-4982-4de0-bed0-024e2f569f4a">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTgtMy0xLTEtMjM5OTc_7340434c-1e95-436a-ac1f-aa94c43e9874">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTktMS0xLTEtMjM5OTc_17a872d5-a0f6-4474-a900-f0ce0b437c36">6,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTktMy0xLTEtMjM5OTc_d9ca3da5-d7c2-414d-9d60-1aa1e082076f">8,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjAtMS0xLTEtMjM5OTc_ef693dd8-3891-4620-b217-f633ae89c5e5">7,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjAtMy0xLTEtMjM5OTc_f4256b8b-7897-491c-9959-c03bfd0180c9">7,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjItMS0xLTEtMjM5OTc_bd4d4027-0b35-4313-bde8-dec56366e2d7">88,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjItMy0xLTEtMjM5OTc_4002b0a4-9692-4037-bc0d-4c15d2069965">77,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjQtMS0xLTEtMjM5OTc_4cb10717-432f-47a4-9bdc-01e8d70ae32f">93,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjQtMy0xLTEtMjM5OTc_8bdd1329-32a2-4496-b1a6-6d8edc68d5a1">295,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjUtMS0xLTEtMjM5OTc_e1e42c3a-3f4a-4549-be02-89fdfdde28b3">227,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjUtMy0xLTEtMjM5OTc_1be7219d-69b6-429e-8c4d-67e0286d3e1f">303,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjYtMS0xLTEtMjM5OTc_704e3ec4-5816-447e-963b-9d4b483c565e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjYtMy0xLTEtMjM5OTc_0354f32b-e23a-43cb-a1e9-e708b09c04db">5,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjctMS0xLTEtMjM5OTc_f955c84f-27d3-4bad-84ca-f2ef477af82e">4,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjctMy0xLTEtMjM5OTc_e2d3857c-e63c-4dab-b096-d941d78974e1">2,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjgtMS0xLTEtMjM5OTc_de9cb717-2ae1-4a08-bc8f-f6c821446924">130,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjgtMy0xLTEtMjM5OTc_8ec8081b-0862-45e3-9146-d07b80521aab">10,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzAtMS0xLTEtMjM5OTc_3e657e5c-61c7-4ae6-a2d5-bf9cf3094fb4">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzAtMy0xLTEtMjM5OTc_8bf4f44f-554d-494b-a485-34c991361cf5">17,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzEtMS0xLTEtMjM5OTc_69bf7570-21fc-4be0-ad01-bdcf2255662d">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzEtMy0xLTEtMjM5OTc_a07575c5-4336-407b-958a-a07625a8e7a2">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzMtMS0xLTEtMjM5OTc_92038b35-cd26-4bc7-9b32-a72e4b16b33f">938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzMtMy0xLTEtMjM5OTc_dad41a11-1df2-40fd-93e9-7c09727a1c97">17,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzQtMS0xLTEtMjM5OTc_3e8c8bac-ccc8-454b-8cb3-80a65ef282b6">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzQtMy0xLTEtMjM5OTc_edefafa5-4e73-4b1e-bedf-c1beb07f6b1f">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzUtMS0xLTEtMjM5OTc_72840695-680a-4d9b-ad62-0cfdbbe88111">42,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzUtMy0xLTEtMjM5OTc_e53b5c6a-7025-452c-8483-2ee85a8bb897">48,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzYtMS0xLTEtMjM5OTc_47162961-f985-42e0-b1db-7178f04ac8d7">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c98e2f4e6a9464da1ee6d7c11f30ef9_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzYtMy0xLTEtMjM5OTc_1774a8bc-bf02-4b98-9809-ee3e08b0c3c5">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzctMS0xLTEtMjM5OTc_16eafc2a-0647-46ee-b9b6-5ce94998f16d">67,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5fea39b5bc466ca1d6c54f925e0d11_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzctMy0xLTEtMjM5OTc_6207c3c2-420d-4e93-87ec-e0fc52ba7ebf">150,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset recognized in exchange for lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNDAtMS0xLTEtMjM5OTc_d3db97ae-228c-4920-845a-5680939f3477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNDAtMy0xLTEtMjM5OTc_f019d9a4-b944-4092-9651-a743a865c6e2">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 &#8212; <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxMzg_83d95f24-6257-4a05-908e-a8b77d462a8b" continuedAt="i9d174f063ab3423489fffbc025b5d3be" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i9d174f063ab3423489fffbc025b5d3be" continuedAt="id9ffe333b60c475a84144bd122cb66db"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="nktr:OrganizationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxMzk_be2770b2-23ed-4f81-87a3-9d193e738c23" continuedAt="ib106f7e58386445883ed38efa79c9c8b" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in oncology and immunology.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib106f7e58386445883ed38efa79c9c8b">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</ix:continuation> As of March&#160;31, 2022, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-5" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMTA0OQ_0a044bcf-7a3f-4f31-be28-3ec58740d2cd">704.4</ix:nonFraction> million in cash and investments in marketable securities.</span></div><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfNDM5ODA0NjU2OTg4Mg_9fe8730e-f7bd-4108-9b13-2a9131baf330" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Impairment and Other Costs of Terminated Program</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans for the Company&#8217;s future:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 14, 2022, BMS  and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 7 for additional information on our BMS Collaboration Agreement.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we made the decision to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 4 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. In addition to announcing the decision to discontinue this Phase 2/3 study, we also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, there are no ongoing clinical development activities of bempegaldesleukin.    </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 25, 2022, we announced our strategic reorganization and cost restructuring plans (together, the Reorganization and Restructuring Plans), which were reviewed and approved by our Board of Directors on April 14, 2022. On April 26, 2022, our duly authorized officers approved certain strategic, operational and organizational steps to undertake in connection with the Reorganization and Restructuring Plans. Under the Reorganization and Restructuring Plans, we are prioritizing key research and development efforts and continuing to evaluate our early stage drug candidate pipeline. We are also reducing our workforce by approximately <ix:nonFraction unitRef="number" contextRef="if2be3ac308a24e8ca217c972b757f923_D20220425-20220425" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfNDM5ODA0NjU3NTA1Mg_f3fbcb68-f46b-4077-80b8-619504be4653">70</ix:nonFraction>%. See Note 10 for additional information regarding our reorganization and restructuring plans.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, restructuring, impairment and other costs for terminated programs primarily include cancellation fees for certain manufacturing activities for bempegaldesleukin which were scheduled to support our efforts at securing potential FDA approval and commercial launch of bempegaldesleukin in metastatic melanoma in 2022.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><ix:continuation id="id9ffe333b60c475a84144bd122cb66db" continuedAt="ib976b52e58424b4992317d766db25048"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxNDA_f42ddf28-7ea1-433d-a78e-bcea5d9fd55a" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2021 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 filed with the SEC on March 1, 2022. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxNDg_47e333f3-b9e3-4309-b2de-948e2fc78f29" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxMzQ_8881ddcd-cf7a-4a33-a806-744e838851c0" continuedAt="ie947b7bb7b9a4ac2afddaa1960291d66" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of March&#160;31, 2022 and December&#160;31, 2021, our accounts receivable includes $<ix:nonFraction unitRef="usd" contextRef="i2e6976d0fdcb42bba1c4b5e008c93f28_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfNTkxMA_b717ad2a-9995-4ddb-8c0d-dac6778acaf8">26.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib3e957a413d448a7a3513ceccf209004_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfNzY5NjU4MTQ1MzMzOQ_6ddc4396-da09-4888-9d32-29c0c2ef62e8">21.4</ix:nonFraction>&#160;million, respectively, for unbilled net expense reimbursements from BMS. The remaining accounts receivable relate primarily to product sales. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three months ended March&#160;31, 2022 and 2021. We have <ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfNjU2Nw_997e91da-f755-4a05-90c6-c562c9bc11f9"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfNjU2Nw_c72df6af-31b1-40ea-9ef3-b16410d1cd02">no</ix:nonFraction></ix:nonFraction>t recorded a reserve for credit losses at March&#160;31, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><ix:continuation id="ib976b52e58424b4992317d766db25048" continuedAt="i09ae8eb82a3a4a5f9270d092eaae42dc"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie947b7bb7b9a4ac2afddaa1960291d66">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic or other factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</ix:continuation></span></div><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxNTA_9461406c-3e40-4960-bff7-15bb40c58170" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxMzc_f8f833f4-9d69-44c3-93ce-90520e28ff0d" continuedAt="i7a4a26df64bf4af9bf6574d07268015f" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash royalty revenue</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2020, we have sold our rights to receive sales-based royalties for </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><ix:continuation id="i09ae8eb82a3a4a5f9270d092eaae42dc" continuedAt="i5c6c3bb6ee164805a0fb6dcefd71ed64"><ix:continuation id="i7a4a26df64bf4af9bf6574d07268015f"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 5. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our non-cash royalty revenue of $<ix:nonFraction unitRef="usd" contextRef="i5631866fb8ab42c39ed3826b2e8b778f_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMTA5OTUxMTY5NjA3Ng_14471313-4580-49ba-b26a-fba3a2c19739">17.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if5f35b8ae306472eb8a7b3141def628a_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMTA5OTUxMTY5NjA2Nw_f3b659ed-77a5-4960-a998-b4b13e6bda4b">18.8</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, represents revenue for granting licenses which we had satisfied in prior periods. Our partners generally pay royalties  after the end of the calendar quarter in accordance with contractual terms. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div></ix:continuation><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxNTE_43d294c1-0782-41e3-a271-2e0d44357370" continuedAt="i1e90ede1508745c5ba2ebb3a802f9441" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratable over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><ix:continuation id="i5c6c3bb6ee164805a0fb6dcefd71ed64"><ix:continuation id="i1e90ede1508745c5ba2ebb3a802f9441"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div></ix:continuation></ix:continuation><div id="if0dd445e3956457f908bcf9b5e12885d_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8212; <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNzMz_df4d6d63-c3da-40da-a1f3-330893d77029" continuedAt="i96f2ae187000484ea85ccbe65525c721" escape="true">Cash and Investments in Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i96f2ae187000484ea85ccbe65525c721"><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNzM2_d1e727c3-d1d1-42a3-9c10-379445611ac7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfMi0xLTEtMS0yMzk5Nw_6642de90-88da-4d10-982a-8278223890bd">67,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfMi0zLTEtMS0yMzk5Nw_c8ea2612-56b2-4248-b7b8-44cb7296401f">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfMy0xLTEtMS0yMzk5Nw_2bf4f9cd-fbe7-49eb-9a05-ef2c34134ec4">599,032</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfMy0zLTEtMS0yMzk5Nw_a94e14b4-08fe-4e07-92da-22fd5d55cb6d">708,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfNC0xLTEtMS0yMzk5Nw_8809bc7f-30ee-465e-880e-cbc7ffd3db69">37,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfNC0zLTEtMS0yMzk5Nw_0f843dc4-8c61-4b0e-b4d7-48ec83582c52">64,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfNS0xLTEtMS0yMzk5Nw_3da52dab-e6aa-48a3-b4bf-75531b78d1e4">704,388</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfNS0zLTEtMS0yMzk5Nw_1892c7c2-b927-4a8c-b3a1-3c6b70c27f1c">798,783</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="nktr:DebtInvestmentMaximumMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfMzk5_e0e6780e-3e40-4a40-962e-c76df55897d8">two years</ix:nonNumeric> or less and maintain a weighted average maturity of <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="nktr:DebtInvestmentMaturityTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNDU0_be9fa91f-fbc0-4f22-bb58-4e9d943c5028">one year</ix:nonNumeric> or less. As of March&#160;31, 2022 and December&#160;31, 2021, all of our long-term investments had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTM5_77184183-0367-45c7-a343-6cddbeacc01a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTM5_bbd38367-e438-4378-87e6-f0c97cd95e48">one</span></span> and <ix:nonNumeric contextRef="id45946e930114e44bce50be83bd56339_D20210101-20211231" name="nktr:LongTermInvestmentMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTQ2_17188d71-65ce-4c1b-b39d-0012c454d07e"><ix:nonNumeric contextRef="id1d12f77ed264cd9a637f0e3cf2ae918_D20220101-20220331" name="nktr:LongTermInvestmentMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTQ2_41e8d7bf-68fe-4b3c-8a70-636524cb4fcc">two years</ix:nonNumeric></ix:nonNumeric>.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNzMy_e0479555-109f-4b37-9594-3a8469c9f585" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685b6f64ad5c4faa9de52180509da5da_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMi0yLTEtMS0yMzk5Nw_04338fe4-2fd7-4dbf-a25d-86dceb89a607">196,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685b6f64ad5c4faa9de52180509da5da_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMi00LTEtMS0yMzk5Nw_01e3aa59-bba1-4718-919d-9d8f5597ad1b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i685b6f64ad5c4faa9de52180509da5da_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMi02LTEtMS0yMzk5Nw_34873d48-5fc0-45a9-9a7d-79ea9a8edcbc">1,270</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685b6f64ad5c4faa9de52180509da5da_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMi04LTEtMS0yMzk5Nw_279834de-e75f-418f-b96e-51317cde1b21">195,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e22be348e714ef8918b6c87eae1bdcb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMi0xMC0xLTEtMjM5OTc_431c670d-6892-4fd1-9c1b-ae4e0321263f">278,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4b2f49b55b430ebc75e5792a0b2792_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMy0yLTEtMS0yMzk5Nw_05fc1c81-debc-45ae-b2cf-eda9991ed924">439,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4b2f49b55b430ebc75e5792a0b2792_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMy00LTEtMS0yMzk5Nw_b6fd8d13-ed1b-4b9f-9df5-a69cd002ffc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd4b2f49b55b430ebc75e5792a0b2792_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMy02LTEtMS0yMzk5Nw_c19b9150-e835-401f-bd5e-781e48e1d183">1,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4b2f49b55b430ebc75e5792a0b2792_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMy04LTEtMS0yMzk5Nw_38ba693e-e0d4-4a98-bf41-b2a76018bd63">437,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafca660c02b34e799b6bda3ecba63141_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMy0xMC0xLTEtMjM5OTc_7277c2cc-6037-4e33-9c56-d92734d02a83">478,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a6252cab2b4155abda79adc4038b32_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNC0yLTEtMS0yMzk5Nw_7c4288f2-5af0-4795-aad7-152734a122ea">4,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a6252cab2b4155abda79adc4038b32_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNC00LTEtMS0yMzk5Nw_70080397-1121-46c8-b412-a334b6657412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33a6252cab2b4155abda79adc4038b32_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNC02LTEtMS0yMzk5Nw_3382b0cd-bd0c-4219-87db-2aa082d5a8a4">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a6252cab2b4155abda79adc4038b32_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNC04LTEtMS0yMzk5Nw_b52fadc2-80d8-4ef1-9d4a-11867b24c0a4">4,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01be499d3940498b883cfe405f68c613_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNC0xMC0xLTEtMjM5OTc_29c5502f-3597-40c5-a825-09a72193cb09">5,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7497814c41422f9a5b7ea68e05c094_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNS0yLTEtMS0yMzk5Nw_6f4c01d2-f5bd-406a-acfb-788183151382">640,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7497814c41422f9a5b7ea68e05c094_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNS00LTEtMS0yMzk5Nw_a9d0d4cc-8b93-4d44-9567-42ba28d4bdb2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d7497814c41422f9a5b7ea68e05c094_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNS02LTEtMS0yMzk5Nw_4778f179-4835-4445-8de6-f0a93a1587fb">2,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7497814c41422f9a5b7ea68e05c094_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNS04LTEtMS0yMzk5Nw_57a8dd93-9e8c-4f41-bc97-4460f1be759c">638,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6f4d1cbe6a4471822b84152102c34f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNS0xMC0xLTEtMjM5OTc_30c7fb55-4458-48ce-9d1a-1e7baa1832c9">762,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b42c2b599741359d987d496e64c309_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNi04LTEtMS0yMzk5Nw_5bfab534-241d-47ff-9ee4-84d1baf43060">43,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85b44d16760d4680ac9a0259407bc098_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNi0xMC0xLTEtMjM5OTc_1e8e5cac-ae34-4eb9-a080-acbc7fac923d">23,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i875ef83363e04d6a85c3349eaf3dd3ab_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNy04LTEtMS0yMzk5Nw_2851a1e8-2ada-4e5d-86b4-e4b4e3c98fea">10,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c024b46d2c49a3b471bb84a8b0399d_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNy0xMC0xLTEtMjM5OTc_ff904ff2-f262-45f1-ad73-bff6db5cd896">10,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfOC04LTEtMS0yMzk5Nw_606c631e-2c8e-4020-b622-f7599938c6c5">11,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfOC0xMC0xLTEtMjM5OTc_e2092286-99a1-49f1-adb2-76bb8d5ccb80">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfOS04LTEtMS0yMzk5Nw_0fee9c00-801c-49d0-a6b7-887b06934307">704,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfOS0xMC0xLTEtMjM5OTc_bcf00ad5-872a-4a19-b6ed-acaa5ebddcd5">798,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022 and 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. At December&#160;31, 2021, our gross unrealized losses totaled $<ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNzY5NjU4MTM5NTcxMg_941f4181-f0b0-4cbb-8e3b-f9b4cf1e7f33">0.7</ix:nonFraction>&#160;million, and our gross unrealized gains were insignificant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8212; <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RleHRyZWdpb246MWI0ZTVhNTdhZjk3NDA5N2JjMzZmZjBlZWU3NWVhN2VfMTA4OA_d1d853c7-1b26-4cc8-9f4c-e1db3c424042" continuedAt="ib3e7bd026dde4a6992ec119bf390bad0" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="ib3e7bd026dde4a6992ec119bf390bad0"><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RleHRyZWdpb246MWI0ZTVhNTdhZjk3NDA5N2JjMzZmZjBlZWU3NWVhN2VfMTA5MA_0a4e02c0-895f-4989-8763-e95fc77b6fa4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfMS0xLTEtMS0yMzk5Nw_39d05993-156a-4c7e-abfa-a8e00dd479a1">2,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfMS0zLTEtMS0yMzk5Nw_25b07162-45f3-4ae5-93a9-fa094339bf71">3,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfMi0xLTEtMS0yMzk5Nw_be232371-daf4-4008-be38-2db2254cd1ad">9,420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfMi0zLTEtMS0yMzk5Nw_b4b66833-d162-4e20-8acb-25f3bc9b9b58">9,342</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfMy0xLTEtMS0yMzk5Nw_01c8a07c-80d0-4afb-a078-08ad3d423aec">3,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfMy0zLTEtMS0yMzk5Nw_966ee4f3-c9ed-41ae-a1eb-e6aa3db73628">3,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfNC0xLTEtMS0yMzk5Nw_3974ef9e-44c9-46e1-8fc1-7c3bbb3423ef">15,379</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfNC0zLTEtMS0yMzk5Nw_e7ddac04-ee89-493d-9377-978f556d3df6">15,801</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RleHRyZWdpb246MWI0ZTVhNTdhZjk3NDA5N2JjMzZmZjBlZWU3NWVhN2VfMTA5MQ_7c78c783-f1c0-41b5-87b4-d1abe7440237" escape="true">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</ix:nonNumeric></span></div></ix:continuation><div id="if0dd445e3956457f908bcf9b5e12885d_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 &#8212; <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="nktr:DevelopmentDerivativeLiabilityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RleHRyZWdpb246YTg2Y2I2OWY1MWY3NDQwMTkwOTJhMDI1YmFjMWVkZDlfNjI5Mg_8887ea83-105f-4739-ad6e-a41d9257ca40" continuedAt="i663e6d2cbe1d4e529e4763f4af6e63f2" escape="true">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</ix:nonNumeric></span></div><ix:continuation id="i663e6d2cbe1d4e529e4763f4af6e63f2" continuedAt="ieba5d7ff8fa54c5482cb41f6ad031e5a"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a Co-Development Agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ would pay up to $<ix:nonFraction unitRef="usd" contextRef="i276bda16441d48ad80af19d97efc426a_D20210212-20210212" decimals="INF" name="nktr:CollaborativeArrangementCommittedFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RleHRyZWdpb246YTg2Y2I2OWY1MWY3NDQwMTkwOTJhMDI1YmFjMWVkZDlfMzAy_7b702c40-cd8a-41dc-9eda-2315b412cd6f">150.0</ix:nonFraction>&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ has primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we are the sponsor of the SCCHN Clinical Trial. The SFJ Agreement provided for us to pay up to $<ix:nonFraction unitRef="usd" contextRef="i276bda16441d48ad80af19d97efc426a_D20210212-20210212" decimals="-5" name="nktr:CollaborativeArrangementSuccessBasedPaymentsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RleHRyZWdpb246YTg2Y2I2OWY1MWY3NDQwMTkwOTJhMDI1YmFjMWVkZDlfMjc0ODc3OTA4NzAxMQ_f3237377-4fe5-4046-9b32-7cacb2fcb8cb">637.5</ix:nonFraction>&#160;million in Success Payments in the event of FDA approval of bempegaldesleukin for the metastatic melanoma, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, on March 14, 2022, we announced that the metastatic melanoma trial did not meet its primary endpoints and that we and BMS decided to discontinue the registrational trials in metastatic melanoma trial and adjuvant melanoma. On April 14, 2022, BMS and we announced that, due to the negative results of our trials for bempegaldesleukin in each of renal cell carcinoma and cisplatin-ineligible, locally advanced or metastatic urothelial cancer, BMS and we decided to end the development for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and that these studies and all other ongoing studies in the bempegaldesleukin program will be discontinued. On April 14, 2022, due to these results, SFJ and we agreed to discontinue the SCCHN Clinical Trial. Accordingly, SFJ will not be entitled to any Success Payments, and SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. SFJ has no right to seek reimbursement from us for any costs incurred for the SCCHN Clinical Trial.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We presented the SFJ Agreement as a Development derivative liability in our Condensed Consolidated Balance Sheets, which we remeasured to fair value at each reporting date. As SFJ conducted the SCCHN Clinical Trial, we recorded non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remitted funding to us to support our internal costs of conducting the trial, we also recorded a corresponding increase to the development derivative liability. We presented the gain (loss) from the remeasurement as change in fair value of development derivative liability in our Condensed Consolidated Statements of Operations. As of March 31, 2022, due to the negative results of the metastatic melanoma trial and initial discussions with SFJ, we concluded that it was remote that SFJ and we would continue the SCCHN Clinical Trial. Accordingly, the fair value of the development derivative liability was reduced to $<ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="INF" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RleHRyZWdpb246YTg2Y2I2OWY1MWY3NDQwMTkwOTJhMDI1YmFjMWVkZDlfNDM5ODA0NjUzNzA4NQ_6123fb88-bf42-4bc3-a070-a5f911089fe4">0</ix:nonFraction> as of March 31, 2022, and we recognized a corresponding gain in the Change in fair value of development derivative liability.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:31.5pt"><ix:continuation id="ieba5d7ff8fa54c5482cb41f6ad031e5a"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RleHRyZWdpb246YTg2Y2I2OWY1MWY3NDQwMTkwOTJhMDI1YmFjMWVkZDlfNjI5NQ_5eaadccd-3d6b-4730-b903-e8e317ddd283" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the development derivative liability for the three months ended March&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67220c05393f459bb392d5a646a36d88_I20210212" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMS00LTEtMS0yNzI5Mw_279b59d5-9796-404d-b464-1975e8c21a2a"><ix:nonFraction unitRef="usd" contextRef="ib32a3a93199343bfb4bfa43354beb247_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMS00LTEtMS0yNzI5Mw_fc848e29-0b34-4bcc-9121-f3ff2f4ce957">27,726</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icebb6494d94b4db1a4f1c110b85abaf9_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMS0yLTEtMS0yMzk5Nw_22a11e0b-3c6b-4571-8fde-7a1c426cb9d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96ec436f9fc449ebdff998acc527edf_D20220101-20220331" decimals="-3" name="nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMi00LTEtMS0yNzI5Mw_8e9abc3e-0bee-4f3c-a2ab-9d0e574e8cf0">4,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d23832d5824e05a9160a3dc1fdbe35_D20210101-20210331" decimals="-3" name="nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMi0yLTEtMS0yMzk5Nw_714863e7-db9b-4e77-a9c2-73c6dcf686c8">2,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96ec436f9fc449ebdff998acc527edf_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMy00LTEtMS0yNzI5Mw_e3d12ee4-9405-4578-8c42-2ddb7164e640">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d23832d5824e05a9160a3dc1fdbe35_D20210101-20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMy0yLTEtMS0yMzk5Nw_8d689ed2-e158-4f92-ad58-c98f3d0455cb">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie96ec436f9fc449ebdff998acc527edf_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfNC00LTEtMS0yNzI5Mw_a81cafec-9d00-48d7-9ed5-f96c41bb3cf9">33,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d23832d5824e05a9160a3dc1fdbe35_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfNC0yLTEtMS0yMzk5Nw_d017dfae-2520-42e0-a4bf-454a0a1e4bdd">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81672743daf84e089f134278b21e4900_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfNS00LTEtMS0yNzI5Nw_eb9b4200-10e2-42d1-a52c-676f7bdc30aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i232e4fff92244a1286cab431418b53bb_I20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfNS0yLTEtMS0yMzk5Nw_2790f71d-abfd-4e8e-b24f-acca29676e2a">4,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="if0dd445e3956457f908bcf9b5e12885d_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 &#8212; <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RleHRyZWdpb246YjAyMTAxZjA3ZTIyNDc4YmJjZmMxODRlYTUwYjVkOWRfNzM2OA_8da597ce-d58d-419f-9da2-23bfb841ddbb" continuedAt="i6304c8f466ff4ae8a884893c5d21cf15" escape="true">Liabilities Related to Sales of Future Royalties</ix:nonNumeric></span></div><ix:continuation id="i6304c8f466ff4ae8a884893c5d21cf15" continuedAt="i104e7b8f2f394a4cb7efb963d1a324a8"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="nktr:ScheduleOfPurchaseAndSaleAgreementTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RleHRyZWdpb246YjAyMTAxZjA3ZTIyNDc4YmJjZmMxODRlYTUwYjVkOWRfNDM5ODA0NjUzODc0MA_6e3b49a3-4592-4a69-be9b-fd8122d6d74f" escape="true"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.999%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Drug</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty under Purchase and Sale Agreement</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Sold</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brand name for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (naloxegol tablets) and  MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brand name for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca AB</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (certolizumab pegol)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCB Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RPI Finance Trust</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2012</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Continuous Erythropoietin Receptor Activator)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F. Hoffmann-La Roche Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RPI Finance Trust</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2012</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our ongoing manufacturing obligations in both arrangements, we account for the proceeds as debt (Royalty Obligations) and therefore continue to recognize these non-cash royalties as revenue. As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RleHRyZWdpb246YjAyMTAxZjA3ZTIyNDc4YmJjZmMxODRlYTUwYjVkOWRfNDM5ODA0NjUzODc0MQ_27ca0e71-6194-4c57-a6ec-0ab755954e28" continuedAt="i1e234525ee5447899a898edb81272259" escape="true">The following table shows the activity within the liability account of each arrangement (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><ix:continuation id="i104e7b8f2f394a4cb7efb963d1a324a8"><div style="margin-top:6pt"><ix:continuation id="i1e234525ee5447899a898edb81272259"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c501231db134e1eb8a1723fe66a287d_D20120101-20220331" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfMy0xLTEtMS0yNzkyMA_6da50e73-78b0-4c77-8ded-fd064534e793">124,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880e4bb37a104926b7f1b627aba88cce_D20120101-20220331" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfMy0zLTEtMS0yNzkyMA_a70711f4-aa65-43fa-b1fe-bdca737d88ae">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfMy01LTEtMS0yNzkyMA_d9c27806-e93e-4da9-b5e0-aa8d98f9bc41">274,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c501231db134e1eb8a1723fe66a287d_D20120101-20220331" decimals="-3" sign="-" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNC0xLTEtMS0yNzkyMA_ee41dda5-e1f1-4dcb-8a2c-4e4804351915">289,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i880e4bb37a104926b7f1b627aba88cce_D20120101-20220331" decimals="-3" sign="-" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNC0zLTEtMS0yNzkyMA_3c319012-a1c2-41a5-8d24-631826a8993a">61,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331" decimals="-3" sign="-" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNC01LTEtMS0yNzkyMA_f5ae4f4d-080a-4a0f-851f-005b0f9a4c03">351,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c501231db134e1eb8a1723fe66a287d_D20120101-20220331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNS0xLTEtMS0yNzkyMA_dc85896a-34ed-4925-9d4d-027c62ca73c4">226,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880e4bb37a104926b7f1b627aba88cce_D20120101-20220331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNS0zLTEtMS0yNzkyMA_5ffe3043-725e-4cf6-9124-381decd91ed2">25,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNS01LTEtMS0yNzkyMA_66956afa-6023-4344-af5a-75e524e02a68">251,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c501231db134e1eb8a1723fe66a287d_D20120101-20220331" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNi0xLTEtMS0yNzkyMA_714f68ce-a671-41df-a093-8cc000588ab2">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880e4bb37a104926b7f1b627aba88cce_D20120101-20220331" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNi0zLTEtMS0yNzkyMA_4ca88fb6-366d-4767-b233-abb88b13928c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNi01LTEtMS0yNzkyMA_b2501cee-7c55-480a-8297-3d4a197b50eb">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c501231db134e1eb8a1723fe66a287d_D20120101-20220331" decimals="-3" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNy0xLTEtMS0yNzkyMA_a41edcf0-a246-446d-b796-1a3519e14ee0">23,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880e4bb37a104926b7f1b627aba88cce_D20120101-20220331" decimals="-3" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNy0zLTEtMS0yNzkyMA_605490a7-791f-439d-89c2-5ef51be0f27d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331" decimals="-3" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNy01LTEtMS0yNzkyMA_d4db6b35-c166-4403-b0e3-a7a787fd288c">23,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68e0b50ca474c9fb590f027a73cf228_I20220331" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfOC0xLTEtMS0yNzkyMA_f1ba7628-4900-48d6-a6d9-de93b5d0cef3">74,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce5f5ad632f42c5ac8d5b2eab7fde07_I20220331" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfOC0zLTEtMS0yNzkyMA_e8684691-7d3e-43f0-afc2-b523389e1080">113,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfOC01LTEtMS0yNzkyMA_79c0b30f-c4d8-4cea-b188-461ac215bbf6">188,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68e0b50ca474c9fb590f027a73cf228_I20220331" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfOS0xLTEtMS0yNzkyMA_075b01c0-2ec5-4449-9d38-d7ba5c5d94e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ce5f5ad632f42c5ac8d5b2eab7fde07_I20220331" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfOS0zLTEtMS0yNzkyMA_c66cb91e-c178-409b-ae4c-8125a7a4a4c4">2,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfOS01LTEtMS0yNzkyMA_6988c603-23ae-4555-84b5-d67a1435a0aa">2,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68e0b50ca474c9fb590f027a73cf228_I20220331" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfMTAtMS0xLTEtMjc5MjA_f94fca89-2d6a-426b-9ad0-ab89d06b6a58">74,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce5f5ad632f42c5ac8d5b2eab7fde07_I20220331" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfMTAtMy0xLTEtMjc5MjA_8a42967b-c0e8-4b88-9913-570d176284ed">111,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfMTAtNS0xLTEtMjc5MjA_00fbd360-6223-450c-90db-97abec28255a">185,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Loss recognized from Settlement Agreement to resolve UCB&#8217;s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.</span></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different from our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the applicable Royalty Obligation. As of March 31, 2022, our imputed interest rates for the arrangements with RPI and HCR were <ix:nonFraction unitRef="number" contextRef="ia68e0b50ca474c9fb590f027a73cf228_I20220331" decimals="2" name="nktr:RoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RleHRyZWdpb246YjAyMTAxZjA3ZTIyNDc4YmJjZmMxODRlYTUwYjVkOWRfNDM5ODA0NjUzODM1Mg_fd7fb352-d261-4ca2-823d-b68c9724caa5">16</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3ce5f5ad632f42c5ac8d5b2eab7fde07_I20220331" decimals="2" name="nktr:RoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RleHRyZWdpb246YjAyMTAxZjA3ZTIyNDc4YmJjZmMxODRlYTUwYjVkOWRfNDM5ODA0NjUzODM1Nw_e9f84075-31e6-4278-a674-3c283084a79b">15</ix:nonFraction>%, respectively.</span></div></ix:continuation><div id="if0dd445e3956457f908bcf9b5e12885d_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8212; <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81NS9mcmFnOmQ0NGVjY2JjM2RjODQzZDU4ZGU3MzlhNjczMWNhZDk1L3RleHRyZWdpb246ZDQ0ZWNjYmMzZGM4NDNkNThkZTczOWE2NzMxY2FkOTVfNjQ4MA_d7a23f9f-0cf0-4f99-ac56-860271ce3a5a" continuedAt="i975c980fa73e4ee98f7718f56ed33ff2" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i975c980fa73e4ee98f7718f56ed33ff2" continuedAt="ibbdb088ace05463f93dccf30cc44b595"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv-06607, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made, between January 2017 and June 2018, about the clinical trials of bempegaldesleukin. The Mulquin complaint was amended in May 2019. The defendants moved to dismiss and the court granted the motion without prejudice in July 2020. The Mulquin plaintiffs again amended their complaint and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice. The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit was completed in September 2021. Oral argument occurred on December 10, 2021, and the matter remains pending with the court. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second putative securities class action was filed against the Company and certain of our executives in the U.S. District Court for the Northern District of California in August 2019 (Case No. 4-19-cv-05173, which we refer to as the Damiba action).  The Damiba plaintiffs challenged public statements Nektar made, between February 2019 and May 2019, about its bempegaldesleukin clinical trials and collaboration with Bristol-Myers Squibb. After the Damiba plaintiffs filed an amended complaint and the defendants moved to dismiss, the court dismissed the action without prejudice in January 2021. The Damiba plaintiffs subsequently voluntarily dismissed the action, with prejudice, in March 2021.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the <ix:nonFraction unitRef="action" contextRef="i860898a72fc245f2b9c0e62294906402_I20190531" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81NS9mcmFnOmQ0NGVjY2JjM2RjODQzZDU4ZGU3MzlhNjczMWNhZDk1L3RleHRyZWdpb246ZDQ0ZWNjYmMzZGM4NDNkNThkZTczOWE2NzMxY2FkOTVfMTA5OTUxMTY0MTM2Ng_3788077c-fba6-4808-b563-9053577a62d8">two</ix:nonFraction> securities actions (the Mulquin action and the Damiba action), <ix:nonFraction unitRef="action" contextRef="i7bf89d8a3c5743f8a48bec4907711413_D20190201-20210228" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81NS9mcmFnOmQ0NGVjY2JjM2RjODQzZDU4ZGU3MzlhNjczMWNhZDk1L3RleHRyZWdpb246ZDQ0ZWNjYmMzZGM4NDNkNThkZTczOWE2NzMxY2FkOTVfMTA5OTUxMTY0MTQzMw_07339662-192b-4e6f-9334-7988b0489ba1">three</ix:nonFraction> additional sets of derivative actions have been filed against certain of the Company&#8217;s current and former officers and directors, purportedly on the Company&#8217;s behalf. These derivative actions are based on the allegations in the securities actions and on the premise that the Company&#8217;s officers and directors breached their fiduciary duties by exposing the Company to one or both of the securities actions. The first derivative action was filed in the U.S. District Court for the District of Delaware in February 2019 (Case No. 1:19-cv-00322-MN-JLH). After amending their complaint several times, the plaintiffs in that action voluntarily dismissed their claims without prejudice in April 2021.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second set of derivative actions was filed in February 2020 in the U.S. District Court for the Northern District of California (Case No. 4:20-cv-01088-JSW). The derivative actions in California were consolidated and the Company moved to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><ix:continuation id="ibbdb088ace05463f93dccf30cc44b595" continuedAt="i79b84541fed24e258e79d92fc7bef193"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dismiss on the basis that the plaintiffs had neither made a demand on the Company&#8217;s board of directors nor shown that a demand would be futile. On September 1, 2021, the court dismissed the action with prejudice.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third derivative complaint was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF). The parties agreed to stay further proceedings in this action until thirty days after the U.S. Court of Appeals for the Ninth Circuit&#8217;s final resolution of the appeal in the Mulquin action.  </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature and status of these securities class action lawsuits and derivative complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded <ix:nonFraction unitRef="usd" contextRef="i0ab30e6ae04746708e8844aad00bca73_I20220331" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81NS9mcmFnOmQ0NGVjY2JjM2RjODQzZDU4ZGU3MzlhNjczMWNhZDk1L3RleHRyZWdpb246ZDQ0ZWNjYmMzZGM4NDNkNThkZTczOWE2NzMxY2FkOTVfMTA5OTUxMTY0MzMzMQ_08901008-9bda-4cc2-8ae7-3a5887090d0b"><ix:nonFraction unitRef="usd" contextRef="if5c65e86d0ca4792813758a0541762ed_I20211231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81NS9mcmFnOmQ0NGVjY2JjM2RjODQzZDU4ZGU3MzlhNjczMWNhZDk1L3RleHRyZWdpb246ZDQ0ZWNjYmMzZGM4NDNkNThkZTczOWE2NzMxY2FkOTVfMTA5OTUxMTY0MzMzMQ_d92b9140-34c8-4aa9-8a6a-6e342cd38001">no</ix:nonFraction></ix:nonFraction> liability for these matters in our Consolidated Balance Sheets at either March&#160;31, 2022 or December&#160;31, 2021. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i79b84541fed24e258e79d92fc7bef193">To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations.</ix:continuation> </span></div><div id="if0dd445e3956457f908bcf9b5e12885d_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 &#8212; <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfMTIwODk_0294c0a1-48b0-4ef9-98db-6f43b11ed6a3" continuedAt="ia0218000727f483d90d2a46f5ed54c5c" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="ia0218000727f483d90d2a46f5ed54c5c" continuedAt="ib5eb3a96cd1b41c29ac70743b4072c06"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our collaboration agreements in the three months ended March&#160;31, 2022, other than as described below for our Strategic Collaboration Agreement with BMS.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (BMS)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS have jointly developed bempegaldesleukin in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="number" contextRef="i06904e4d49ac4e03999c919c6e4361cc_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODUzMg_07709dcf-6c86-4fbf-a954-0c8634ad5e08">67.5</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="ic736db4d693a4b8595ef22ef35f99636_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODUzOQ_c4f01e67-55f1-4307-ba99-cca80187e2a5">32.5</ix:nonFraction>% to Nektar. The parties share costs for the manufacturing and commercialization of bempegaldesleukin, <ix:nonFraction unitRef="number" contextRef="i16f1e513809d4671b267573756667622_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODU0Ng_8be3f89f-b5e6-44a0-b4d9-7fc4cc39ef94">35</ix:nonFraction>% of the costs to BMS and <ix:nonFraction unitRef="number" contextRef="i037d8ae4d167406ebb243ed52a646788_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODU1MQ_46334716-7653-4868-b2da-234cac6b2331">65</ix:nonFraction>% to Nektar. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i5a262bb734414dd4857c079289efd56c_D20180401-20180430" decimals="INF" name="nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODU1Ng_b3919eae-4a96-4f06-bb4d-30f8c070fa64">1.0</ix:nonFraction>&#160;billion and purchased <ix:nonFraction unitRef="shares" contextRef="ic31ce00edf3c4891b98bdd4f17ff4e56_I20180430" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODU3MA_a3aba0a5-7bb1-4d72-a670-f0622124e2a9">8,284,600</ix:nonFraction> shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i6264ab40d7dc48aa86cf10e2b939d8ae_D20180401-20180430" decimals="-5" name="nktr:SaleOfStockConsiderationReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODU4MQ_1e24a11e-36bc-4d34-b7c0-42441af8b711">850.0</ix:nonFraction>&#160;million. In 2020, we received non-refundable milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i78c51641e8cc496894dae390b3acb852_I20201231" decimals="INF" name="nktr:PotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODU5Nw_ee4a3272-5aba-42e7-ae61-776881b6b793">50.0</ix:nonFraction>&#160;million in aggregate for the first patient, first visit in the registrational trials in muscle-invasive bladder cancer and adjuvant melanoma.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><ix:continuation id="ib5eb3a96cd1b41c29ac70743b4072c06"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, on March 14, 2022, we announced our registrational trial in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the trials in metastatic melanoma and adjuvant melanoma. On April 14, 2022, we announced that our registrational trials in each of renal cell carcinoma and cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided that these studies and all other ongoing studies in the program will be discontinued. The decision to terminate the program does not affect the cost-sharing provisions under the BMS Collaboration Agreement. However, without further development of bempegaldesleukin, we will no longer be eligible for the development, regulatory and sales milestones under the arrangement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#8217; expenses as research and development expense. During the three months ended March&#160;31, 2022 and March&#160;31, 2021, we recorded $<ix:nonFraction unitRef="usd" contextRef="i93c0c909992548e0982362d608cdb5c7_D20220101-20220331" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODY1Ng_d2a7bb9b-2dd1-42c3-bf35-0e6e1f399fa5">24.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i48032d659bf148a09d2a83b4693bb85b_D20210101-20210331" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNzY5NjU4MTQzMDU1NA_ebc2ea25-f4ad-4ce6-8cc1-f225d0d1d8fe">26.7</ix:nonFraction>&#160;million, respectively, as reductions of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses. As of March&#160;31, 2022, we have recorded an unbilled receivable of $<ix:nonFraction unitRef="usd" contextRef="i2e6976d0fdcb42bba1c4b5e008c93f28_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNzY5NjU4MTQzMDc2NA_b717ad2a-9995-4ddb-8c0d-dac6778acaf8">26.9</ix:nonFraction>&#160;million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">): NKTR-358 </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) to co-develop NKTR-358, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $<ix:nonFraction unitRef="usd" contextRef="i1a2cc7ccba3642dfb8f9446b1b854843_D20170901-20170930" decimals="INF" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNzgyMQ_661200ee-8185-428c-9cfb-87d9da9052b1">150.0</ix:nonFraction>&#160;million and are eligible for up to $<ix:nonFraction unitRef="usd" contextRef="i887bd71a1b294a4fb94e4d8c2a792b9d_I20170823" decimals="INF" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNzg2OQ_c4d8aa84-2a47-404c-aad4-deab4c3eed1f">250.0</ix:nonFraction>&#160;million in additional development and regulatory milestones. We are currently in Phase 1B and Phase 2 development, where we share costs with <ix:nonFraction unitRef="number" contextRef="i38fc13ebd3cd490ca1a6005558c5ad94_D20170823-20170823" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfODE2Mw_e898f286-9fa7-4970-ae8c-0bcef8feb82d">75</ix:nonFraction>% of the costs borne by Lilly and <ix:nonFraction unitRef="number" contextRef="i31ef1bddb0d74c048cd77ffc33b52ad9_D20170823-20170823" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfODIwMA_691ec4ce-bec9-4fb9-a74d-7727838d2112">25</ix:nonFraction>% of the costs borne by us. Lilly is responsible for the costs of Phase 3 development, but we retain the option to contribute up to <ix:nonFraction unitRef="number" contextRef="ifefea51825e94f008a861cb1ddc9bfe5_D20170823-20170823" decimals="INF" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfODM1Ng_c23061bb-ebf6-4087-b20d-9555ef8a28cd">25</ix:nonFraction>% of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the costs of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 development on an indication-by-indication basis in order for us to achieve maximum royalty level under the Lilly Agreement, and further</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, we will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales.  Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by <ix:nonFraction unitRef="number" contextRef="i3a089f68509044168386924efba61d4e_D20170823-20170823" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfODc2OQ_d5dd9277-6731-4735-8aa4-7171636b1fce">50</ix:nonFraction>% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by <ix:nonFraction unitRef="number" contextRef="i3a089f68509044168386924efba61d4e_D20170823-20170823" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfOTAwNA_aea55946-f0d2-4016-b49a-a9a94b307963">75</ix:nonFraction>% if both conditions occur.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lilly Agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The Lilly Agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are entitled to significant development milestones under this arrangement, through March&#160;31, 2022, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 5, we have sold our rights to receive royalties from these other collaboration agreements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a collaboration agreement for a product under development, under which we are entitled to up to a total of $<ix:nonFraction unitRef="usd" contextRef="ib19687a8076a473ba979d1fd42e0df4c_I20220331" decimals="INF" name="nktr:PotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfMTE2MTU_22db0fb6-8a1c-45b2-a43f-2ed263638d97">40.0</ix:nonFraction>&#160;million of regulatory milestones, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential product under this collaboration agreement, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the transaction price for this agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 &#8212; <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RleHRyZWdpb246ZmQ2ZTNmNjhjN2M4NDQ5YWJjMGZlMjk2MDg0NjA1NTZfNjM5_224ce699-3ea3-432e-aff4-e259cba3d9e1" continuedAt="i26554458d65f42ff9d840f204e8a2cf8" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i26554458d65f42ff9d840f204e8a2cf8"><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RleHRyZWdpb246ZmQ2ZTNmNjhjN2M4NDQ5YWJjMGZlMjk2MDg0NjA1NTZfNjM1_68f75c17-9ba4-4985-aca0-8ffad33dc925" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e034360701446c8a364586fa2b0d27b_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfMi0xLTEtMS0yMzk5Nw_8e8e95a7-9b72-4494-b30a-cd24b6ba6d16">669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10110540b97b4a4ab4a50614d0cff3c9_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfMi0zLTEtMS0yMzk5Nw_c3d20a19-c775-45de-91c0-069d08c0089c">727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9f8f2918f94fd6923a1d4a51027353_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfMy0xLTEtMS0yMzk5Nw_af4a3049-a309-40f5-b8f7-8e0d562ef5f1">12,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i728e5d8a85be40679bfe48b2fbce4909_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfMy0zLTEtMS0yMzk5Nw_f1a4e945-c12b-4aae-ac46-1959daf4597a">14,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6179ae9a7f44883ab15f4ae9457eb07_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfNC0xLTEtMS0yMzk5Nw_a0a23892-be8d-43fb-a68a-7eb3df09d220">8,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2c55128bc8497c8854c8a78a73cd58_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfNC0zLTEtMS0yMzk5Nw_a2d5750d-66b3-4422-9ab4-023ba0aa8ce8">9,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfNi0xLTEtMS0yMzk5Nw_ec7e53c0-ce2f-48dc-8167-f2e3dd1dec0e">20,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfNi0zLTEtMS0yMzk5Nw_53a969d9-f428-447d-972d-3fea8ef07bc0">23,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;text-indent:31.5pt"><ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RleHRyZWdpb246ZmQ2ZTNmNjhjN2M4NDQ5YWJjMGZlMjk2MDg0NjA1NTZfNjM3_50d91bdf-52c3-4c68-8dec-ebf89da91326" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued stock-based awards of our common stock as follows (shares in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfMi0xLTEtMS0yMzk5Nw_e03e28ff-bcec-41fb-8193-ee908dee8aa2">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfMi0zLTEtMS0yMzk5Nw_82e73f87-26ce-46c5-a8c5-1a665747f676">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of options granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfMy0xLTEtMS0yMzk5Nw_50f65467-0594-4b0d-bef1-b01e770ae6b6">6.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfMy0zLTEtMS0yMzk5Nw_1d446080-e01f-4302-a830-039e551d0fc6">10.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic59b05e471ec4124afe9fde97642790e_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfNC0xLTEtMS0yMzk5Nw_53b02a59-7f19-4c5b-bf5e-cd4fd6a5c444">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if023fd27426a491e84900754f5b3156f_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfNC0zLTEtMS0yMzk5Nw_c5a3255e-13cb-40ee-94f2-a8d6e6ef40be">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic59b05e471ec4124afe9fde97642790e_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfNS0xLTEtMS0yMzk5Nw_33560991-7a4b-4db9-8c77-906281203c7d">9.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if023fd27426a491e84900754f5b3156f_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfNS0zLTEtMS0yMzk5Nw_68ba050c-1f88-49dd-974e-08e6902fd54f">20.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="if0dd445e3956457f908bcf9b5e12885d_67"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9 &#8212; <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82Ny9mcmFnOjNmODc1ZGE2YTdlNjQxODI5NWMwOGE1Y2Q3YjNiMmVlL3RleHRyZWdpb246M2Y4NzVkYTZhN2U2NDE4Mjk1YzA4YTVjZDdiM2IyZWVfOTM5_c421b984-9a54-470f-a05e-26c3f61ef007" continuedAt="idd6a2c67a61541c3acad0a7587842857" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="idd6a2c67a61541c3acad0a7587842857"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022 and 2021, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82Ny9mcmFnOjNmODc1ZGE2YTdlNjQxODI5NWMwOGE1Y2Q3YjNiMmVlL3RleHRyZWdpb246M2Y4NzVkYTZhN2U2NDE4Mjk1YzA4YTVjZDdiM2IyZWVfOTQy_42d9099f-e1a2-464b-a05c-251db88d0214" continuedAt="i1fe245d84d1b4253bfe1fdfed13428ee" escape="true">During the three months ended March&#160;31, 2022 and 2021, potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i1fe245d84d1b4253bfe1fdfed13428ee"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82Ny9mcmFnOjNmODc1ZGE2YTdlNjQxODI5NWMwOGE1Y2Q3YjNiMmVlL3RhYmxlOjY5NDhhMWY3ODA4YzQyNGNiNGFjNzhlMDRhZDNlZGRkL3RhYmxlcmFuZ2U6Njk0OGExZjc4MDhjNDI0Y2I0YWM3OGUwNGFkM2VkZGRfMi0xLTEtMS0yMzk5Nw_4619b6c2-75f4-4464-bc20-c1468e98a42b">22,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82Ny9mcmFnOjNmODc1ZGE2YTdlNjQxODI5NWMwOGE1Y2Q3YjNiMmVlL3RhYmxlOjY5NDhhMWY3ODA4YzQyNGNiNGFjNzhlMDRhZDNlZGRkL3RhYmxlcmFuZ2U6Njk0OGExZjc4MDhjNDI0Y2I0YWM3OGUwNGFkM2VkZGRfMi0zLTEtMS0yMzk5Nw_909c0535-90f0-4eaa-be9d-06fef9d28eb4">19,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="if0dd445e3956457f908bcf9b5e12885d_1018"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10 &#8212; <ix:nonNumeric contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xMDE4L2ZyYWc6YmYyMGZiYzE4N2RhNDcxYmE0NGU4OGMzZGY2OGI1NmMvdGV4dHJlZ2lvbjpiZjIwZmJjMTg3ZGE0NzFiYTQ0ZTg4YzNkZjY4YjU2Y180OTQ3ODAyMzI3MTU2_85349b16-df5b-4006-915c-f3a80da1b784" continuedAt="i7afae2b67c11499ca7cd2eb51924b34a" escape="true">Subsequent Event</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7afae2b67c11499ca7cd2eb51924b34a">As discussed in Note 1, on April 25, 2022, we announced our Reorganization and Restructuring Plans, pursuant to which we are prioritizing key research and development efforts and reducing our workforce by approximately <ix:nonFraction unitRef="number" contextRef="if2be3ac308a24e8ca217c972b757f923_D20220425-20220425" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xMDE4L2ZyYWc6YmYyMGZiYzE4N2RhNDcxYmE0NGU4OGMzZGY2OGI1NmMvdGV4dHJlZ2lvbjpiZjIwZmJjMTg3ZGE0NzFiYTQ0ZTg4YzNkZjY4YjU2Y18xMjA5NDYyNzkxMDAwNQ_f3fbcb68-f46b-4077-80b8-619504be4653">70</ix:nonFraction>% from approximately <ix:nonFraction unitRef="segment" contextRef="i111ab39f489a4f079ea9e751923f01c7_I20220424" decimals="INF" name="dei:EntityNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xMDE4L2ZyYWc6YmYyMGZiYzE4N2RhNDcxYmE0NGU4OGMzZGY2OGI1NmMvdGV4dHJlZ2lvbjpiZjIwZmJjMTg3ZGE0NzFiYTQ0ZTg4YzNkZjY4YjU2Y18xNDI5MzY1MTE2NDQzMA_004c2a59-ac4a-4465-bd0e-a085019f164f">735</ix:nonFraction> to approximately <ix:nonFraction unitRef="segment" contextRef="ie8720ccc92154ed5bcfc18a705606b0d_I20220425" decimals="INF" name="dei:EntityNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xMDE4L2ZyYWc6YmYyMGZiYzE4N2RhNDcxYmE0NGU4OGMzZGY2OGI1NmMvdGV4dHJlZ2lvbjpiZjIwZmJjMTg3ZGE0NzFiYTQ0ZTg4YzNkZjY4YjU2Y18xNDI5MzY1MTE2NDQ1MQ_1c8d0a17-2245-4d25-8fbf-95fea013dbb7">225</ix:nonFraction> employees. We will recognize all costs of the Reorganization and Restructuring Plans, including severance and benefits for employees laid off and employee compensation and third-party costs for the wind down of the bempegaldesleukin program, net of BMS&#8217; reimbursement of our costs, in the restructuring, impairment and other costs of terminated program line in our Condensed Consolidated Statement of Operations. We expect to recognize approximately $<ix:nonFraction unitRef="usd" contextRef="i3db39c27bf794516854c382d356e95bb_I20220425" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xMDE4L2ZyYWc6YmYyMGZiYzE4N2RhNDcxYmE0NGU4OGMzZGY2OGI1NmMvdGV4dHJlZ2lvbjpiZjIwZmJjMTg3ZGE0NzFiYTQ0ZTg4YzNkZjY4YjU2Y180OTQ3ODAyMzI3MTcz_3ff0710b-fdc9-4780-9c4f-30d62266d76b">30.0</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="idec2e4f024964e8eb19d315571eb57d8_I20220425" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xMDE4L2ZyYWc6YmYyMGZiYzE4N2RhNDcxYmE0NGU4OGMzZGY2OGI1NmMvdGV4dHJlZ2lvbjpiZjIwZmJjMTg3ZGE0NzFiYTQ0ZTg4YzNkZjY4YjU2Y180OTQ3ODAyMzI3MTgw_676592ff-21ea-4bbb-8037-9477d721a89d">35.0</ix:nonFraction>&#160;million for severance and related benefits for employees laid off under the Reorganization and Restructuring Plans, primarily in the three months ending June 30, 2022</ix:continuation>.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to those discussed in this section as well as factors described in Part II, Item&#160;1A &#8220;Risk Factors.&#8221;</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Direction of Our Business</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative new medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes potential therapies for oncology and immunology. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. We continue to make significant investments in new drug discovery and advancing our pipeline of drug candidates as we believe that this is the best strategy to build long-term stockholder value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In oncology, we focus on developing medicines in immuno-oncology (I-O), which is a therapeutic approach based on targeting biological pathways that stimulate and sustain the body&#8217;s immune response in order to fight cancer. In the I-O area, we executed a broad clinical development program to develop bempegaldesleukin (previously referred to as NKTR-214) in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in collaboration with Bristol-Myers Squibb Company (BMS) under our Strategic Collaboration Agreement. We also conducted independent development work evaluating bempegaldesleukin in combination with other checkpoint inhibitors and agents with potential complementary mechanisms of action, including studies evaluating bempegaldesleukin combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab). In April 2022, we and BMS jointly announced that the companies would be ending the global clinical development program for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and discontinue all ongoing studies in our collaboration with BMS. We also decided to discontinue all studies of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as our studies of NKTR 262, which was being evaluated in combination with bempegaldesleukin. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we announced new strategic reorganization and cost restructuring plans (together, the Reorganization and Restructuring Plans) focused on prioritizing key research and development efforts that will be most impactful to the Company&#8217;s future, including our NKTR-255 and NKTR-358 programs and several core research programs. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body&#8217;s innate and adaptive immunity. Activation of the IL-15 pathway enhances the survival and function of natural killer (NK) cells and induces survival of both effector and CD8+ memory T cells. Recombinant human IL-15 is rapidly cleared from the body and must be administered frequently and in high doses limiting its utility due to toxicity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular cytotoxicity molecules as well as to enhance CAR-T therapies. We have initiated a Phase 1 dose escalation and expansion clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer. We are also continuing our oncology clinical collaboration with Merck KGaA and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255 in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma in the Phase II JAVELIN Bladder Medley study. We are also currently designing a Nektar- sponsored comparative study, which we aim to initiate in the second half of 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In immunology, NKTR-358 targets the underlying immune system imbalance in the body that occurs in patients with autoimmune disease. NKTR-358 is designed to optimally target the IL-2 receptor complex in order to stimulate proliferation and growth of regulatory T cells. NKTR-358 is being developed as a once or twice monthly self-administered injection for a number of autoimmune diseases. In 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly) to develop and commercialize NKTR-358, pursuant to which we received an initial payment of $150.0 million and are eligible for up to an additional $250.0 million for development and regulatory milestones. We have completed our responsibilities for Phase 1 clinical development and certain drug product development and supply activities. We also share Phase 2 development costs with Lilly, with Lilly responsible for 75% and Nektar responsible for 25% of these costs. Lilly is responsible for the costs of Phase 3 development, but we retain the option to contribute up to 25% of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the costs of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 development on an indication-by-indication basis in order for us to achieve maximum royalty level under the Lilly Agreement, and further</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, we will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR-358 in approximately 100 healthy patients. We also completed treatment of a Phase 1 multiple-ascending dose trial to evaluate NKTR-358 in patients with systemic lupus erythematosus (SLE). Lilly is conducting two Phase 1b studies in patients with psoriasis and atopic dermatitis, and based on positive interim Phase 1b results in atopic dermatitis announced in December 2021, Lilly is planning to initiate a Phase 2 study in atopic dermatitis. Lilly also initiated a Phase 2 study in SLE in October 2020 and a Phase 2 study in ulcerative colitis in March 2021. In April 2022, we announced that Lilly had informed us that an interim analysis in the Phase 2 study in ulcerative colitis led to the discontinuation of further development in this indication. Lilly also plans to initiate another Phase 2 study in another immune-mediated disease to potentially start in 2023. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically derived all of our revenue and substantial amounts of operating capital from our collaboration agreements. In addition to our collaborations with BMS and Lilly, we have received upfront and milestone payments under a number of other previous collaboration agreements, several of which have resulted in approved drugs, for which we may continue to manufacture the polymer reagents used in the production of the drug products and may be entitled to royalties for net sales of these approved drugs. As of December 31, 2020, however, we have sold the majority of our rights to receive royalties under these arrangements, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2012 Purchase and Sale Agreement: In 2012, we sold all of our rights to receive royalties from CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of Chron&#8217;s disease and other autoimmune indications) and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of anemia associated with chronic kidney disease) under our collaborations with UCB Pharma and F. Hoffmann-La Roche Ltd, respectively, to RPI Finance Trust (RPI), an affiliate of Royalty Pharma for $124.0 million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2020 Purchase and Sale Agreement: In December 2020, we sold our rights, subject to a cap, to receive royalties from MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> / MOEVNTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of opioid-induced constipation), ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> / ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a half-life extension product of Factor VIII) and other hemophilia products, under our arrangements with AstraZeneca AB, Baxalta, Inc. (a wholly owned-subsidiary of Takeda Pharmaceutical Company Ltd.), and Novo Nordisk A/S, respectively, for $150.0 million to entities managed by HealthCare Royalty Management (HCR) under a capped sale arrangement, such that all future royalties return to Nektar if HCR receives $210.0 million in royalties by December 31, 2025 (the 2025 Threshold) or $240.0 million if the 2025 Threshold is not met.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While in the near-term we continue to expect to generate substantially all of our revenue from collaboration arrangements, our longer-term plan is to generate significant commercial revenue from proprietary products. Over the next several years, we plan to continue to make significant investments to advance our early drug candidate pipeline. We have several drug candidates in earlier stage clinical development or are being explored in research that we are preparing to advance into the clinical trials in future years. We are cultivating several research programs, including a collaboration with Biolojic Design to develop a unique bivalent antibody targeting TNFR2, as well as two Nektar-developed research programs focused in the areas of oncology and auto-immune disease. We believe that our substantial investment in research and development has the potential to create significant value if one or more of our drug candidates demonstrates positive clinical results, receives regulatory approval in one or more major markets and achieves commercial success.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to significant risks, including the risks inherent in our development efforts, the results of our clinical trials, our dependence on the marketing efforts by our collaboration partners, uncertainties associated with obtaining and enforcing patents, the lengthy and expensive regulatory approval process and competition from other products. Drug research and development is an inherently uncertain process with a high risk of failure at every stage prior to approval. The timing and outcome of clinical trial results are extremely difficult to predict. Clinical development successes and failures can have a disproportionately positive or negative impact on our scientific and medical prospects, financial condition and prospects, results of operations and market. For a discussion of these and some of the other key risks and uncertainties affecting our business, see Item 1A &#8220;Risk Factors.&#8221; </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of the COVID-19 Pandemic</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to actively monitor the ongoing COVID-19 pandemic and applicable government recommendations in light of new developments. In particular, the emergence of new variants of the coronavirus, such as the Delta and Omicron variants, and local resurgences in number and rates of infections, and the further spread of the virus may result in the return of prior restrictions or the institution of restrictions in the affected areas, which could have an adverse effect on our business, including our clinical trial timelines.  Currently, our operations in research, manufacturing and maintenance that occur within our facilities are continuing in accordance with applicable guidelines and orders. Across all our locations, we have instituted a temporary work from home policy for office personnel who do not need to work on site to maintain productivity and we allow employees to voluntarily return to work on site with appropriate health and safety measures. The safety and well-being of our employees, and the patients and healthcare providers in our clinical trial programs, are of first and foremost importance to us. We believe that the safety measures we are taking and instructing our contractors to take in response to the COVID-19 pandemic meet or exceed the guidance and requirements issued from government and public health officials. We also continue to monitor our supply chains for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any disruptions or constraints caused by the COVID-19 pandemic. To date, we have not experienced any significant impacts on our supply, but ongoing global shortages in labor, raw materials and equipment could limit our ability to manufacture our products or to supply drug candidates for our clinical trials, or delay our research and development efforts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are currently engaged in the clinical testing of our drug candidates and the COVID-19 pandemic introduces challenges to our clinical development programs which are central to our business. The evolving situation around the COVID-19 pandemic, along with the resulting public health guidance measures that have been put into place, have thus far had varying impacts on the clinical testing of our drug candidates depending on the therapeutic indication, geographic distribution of clinical trial sites, the clinical trial stage, and, in certain cases, our partners&#8217; general corporate approach to the COVID-19 pandemic. Nektar&#8217;s Phase 1 clinical study of NKTR-255 in patients with relapsed/refractory hematologic malignancies has enrolled slower than anticipated due to the challenges caused by the COVID-19 pandemic, and the dose-escalation monotherapy portion of the study is currently expected to be completed in 2022.  While we are not currently aware of significant delays by our partners and collaborators caused the COVID-19 pandemic on clinical trials involving our drug candidates, the fluidity of the COVID-19 pandemic precludes any firm estimates as to the ultimate effect this disease will have on these clinical trials. Any current assessments of the effects of the COVID-19 pandemic on our clinical programs are difficult to predict and subject to change and, with regard to individual clinical trial sites within these studies, will likely vary by the geographic region in which they are located. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to mitigate the negative effects of the COVID-19 pandemic on our clinical trials (both in terms of clinical trial timelines and integrity of clinical study data), we have taken steps to help our clinical trial investigators and their teams continue to provide care and uninterrupted access to their patients. Particularly, in the context of our clinical trials directed to investigational cancer treatments, for example, we are actively working with our study sites to implement measures to prevent study protocol violations, to minimize any disruption of treatment visits, to accommodate for patient visit delays caused by limited access to healthcare facilities, to leverage alternative methods for maintaining clinical trial integrity, and to properly record patient event data that may be influenced by the COVID-19 pandemic. In addition, to the extent that the integrity of individual patient data is negatively affected by the COVID-19 pandemic, we will consider measures to maintain the integrity of the clinical study overall (such as over-enrolling patients into the study and removing all patients originating from an affected study site when performing statistical analyses of study endpoints). Although these measures may have the benefit of preserving the overall integrity of a clinical study, implementing these measures could result in a delay in completing the study.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to financing our near-term business needs, as set forth below in &#8220;Key Developments and Trends in Liquidity and Capital Resources,&#8221; we estimate we have working capital to fund our current business plans through at least the next twelve months.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Developments and Trends in Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that we have working capital to fund our current business plans for at least the next twelve months from the date of filing. At March&#160;31, 2022, we had approximately $704.4 million in cash and investments in marketable securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Three Months Ended March&#160;31, 2022 and 2021</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue (in thousands, except percentages)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:49.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,822&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,647&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue, royalties, and license fees, as well as development and sales milestones and other contingent payments. We recognize revenue when we transfer promised goods or services to our collaboration partners. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as development or manufacturing and supply commitments, is generally recognized as we deliver products or provide development services. As a result, there may be significant variations in the timing of receipt of cash payments and our recognition of revenue. We make our best estimate of the timing and amount of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products and services expected to be required to fulfill our performance obligations. Given the uncertainties in research and development collaborations, significant judgment is required to make these estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales include predominantly fixed price manufacturing and supply agreements with our collaboration partners and are the result of firm purchase orders from those partners. The timing of shipments is based solely on the demand and requirements of our collaboration partners and is not ratable throughout the year.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales increased for the three months ended March&#160;31, 2022 as compared to the three months ended March&#160;31, 2021 primarily due to an increase in product demand from our collaboration partners. We expect product sales for the full year of 2022 to increase compared to 2021 due to increased demand from our collaboration partners.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash Royalty Revenue Related to Sales of Future Royalties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our Non-cash royalty revenue, please see our discussion below &#8220;Non-Cash Royalty Revenue and Non-Cash Interest Expense.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and Other Revenue</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue includes the recognition of upfront payments, milestone and other contingent payments received in connection with our license and collaboration agreements and certain research and development activities. The level of license, collaboration and other revenue depends in part upon the estimated recognition period of the upfront payments allocated to continuing performance obligations, the achievement of milestones and other contingent events, the continuation of existing collaborations, the amount of research and development work, and entering into new collaboration agreements, if any. During the three months ended March&#160;31, 2022, we recognized $1.5 million for a license agreement, under which we are entitled to no further consideration. As a result of the recognition of this revenue in the three months ended March&#160;31, 2022, we expect license, collaboration and other revenue for 2022 to increase compared to 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing and future success of our drug development programs and those of our collaboration partners are subject to a number of risks and uncertainties. See Item&#160;1A.&#160;Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold and Product Gross Margin (in thousands, except percentages)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:49.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross profit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(961)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Percentage change represents an improvement in the gross margin.</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to manufacture and supply polymer reagents to support our proprietary drug candidates or our third-party collaborators where we have a strategic development and commercialization relationship or where we derive substantial economic benefit. We have elected to only enter into and maintain those manufacturing relationships associated with long-term collaboration agreements which include multiple sources of revenue, which we view holistically and in aggregate. We have a predominantly fixed cost base associated with our manufacturing activities. As a result, our product gross profit and margin are significantly impacted by the mix and volume of products sold in each period.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product gross margin improved from the three months ended March 31, 2021 to the three months ended March&#160;31, 2022 due to the mix of manufacturing orders from our customers. Product gross margin was negative for the three months ended March&#160;31, 2021. We have a manufacturing arrangement with a partner that includes a fixed price which is less than the fully burdened manufacturing cost for the reagent, and we expect this situation to continue with this partner in future years. In addition to product sales to this partner, we also receive royalty revenue from this collaboration. In the three months ended March&#160;31, 2022 and 2021, the royalty revenue from this collaboration exceeded the related negative gross profit.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect product gross margin to continue to fluctuate in future periods depending on the level and mix of manufacturing orders from our customers. We expect product gross profit to be negative in 2022 as a result of the collaborative arrangement described above.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense (in thousands, except percentages)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:48.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists primarily of clinical study costs, contract manufacturing costs, direct costs of outside research, materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and facilities-related costs. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the expense reimbursement from our partners as a reduction to research and development expense, and we record our share of our partners&#8217; expenses as an increase to research and development expense. Under the BMS Collaboration Agreement, BMS generally bears 67.5% of development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 35% of costs for manufacturing bempegaldesleukin.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased for the three months ended March&#160;31, 2022 as compared to the three ended March&#160;31, 2021. Research and development expense increased for our clinical trials for bempegaldesleukin in adjuvant melanoma under the BMS Collaboration Agreement and head and neck cancer under our co-development agreement with SFJ, partially offset by a decrease in expense for our clinical trial for bempegaldesleukin in first-line metastatic renal cell carcinoma as we had fully enrolled this trial. During the three months ended March&#160;31, 2022 and March&#160;31, 2021, we recorded $24.9&#160;million and $26.7&#160;million, respectively, as reductions of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, BMS and we have decided to discontinue development of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and will wind down the various trials under the BMS Collaboration Agreement, and we have also decided to discontinue all other development of bempegaldesleukin. The cost sharing under the BMS Collaboration Agreement remains unchanged as a result of our decision. We expect to incur significant expenses associated with the wind down of these trials, which we expect to present in the Restructuring, impairment and other costs of terminated program line in our Condensed Consolidated Statement of Operations for the remainder of 2022. Because we will no longer report these expenses in research and development expense, we expect research and development expense to decrease significantly for 2022 as compared to 2021. Additionally, as discussed in Note 1 to our Condensed Consolidated Financial Statements, we have implemented a restructuring plan to reduce our workforce by approximately 70%. Please see our discussion below in Restructuring, impairment and other costs of terminated program for additional information.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense also increased for the three months ended March&#160;31, 2022 as compared to the three ended March&#160;31, 2021 due to manufacturing activities for NKTR-255 and development costs for NKTR-358 as Lilly conducts its Phase 1B and Phase 2 studies, for which we are responsible for 25% of costs and Lilly is responsible for 75% of costs.&#160;We expect research and development expense for the development of NKTR-255 and NKTR-358 to increase for 2022 as compared to 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing and amount of our future clinical trial expenses will vary significantly based upon our evaluation of ongoing clinical results and the structure, timing, and scope of additional clinical development programs and potential clinical collaboration partnerships (if any) for these programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our drug candidates that we plan to evaluate in clinical development during 2022 and beyond, we believe it is vitally important to continue our substantial investment in a pipeline of new drug candidates to continue to build the value of our drug candidate pipeline and our business. Our discovery research organization is identifying new drug candidates across a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas. We also plan from time to time to evaluate opportunities to in-license potential drug candidates from third parties to add to our drug discovery and development pipeline. We plan to continue to advance our most promising early research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In order to advance our drug candidates through clinical development, each drug candidate must be tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical studies for our drug candidates that take several years to complete. The cost and time required to complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients required for a given clinical study design;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the length of time required to enroll clinical study participants;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and location of sites included in the clinical studies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical study designs required by the health authorities (i.e. primary and secondary endpoints as well as the size of the study population needed to demonstrate efficacy and safety outcomes);</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential for changing standards of care for the target patient population;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the competition for patient recruitment from competitive drug candidates being studied in the same clinical setting;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of producing supplies of the drug candidates needed for clinical trials and regulatory submissions;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety and efficacy profile of the drug candidate;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the use of clinical research organizations to assist with the management of the trials;&#160;and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of, and the ability to secure, approvals from government health authorities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our strategy includes the potential of entering into collaborations with third parties to participate in the development and commercialization of some of our drug candidates such as the collaboration that we have already completed for NKTR-358, or clinical collaborations where we would share costs and operational responsibility with a partner. In certain situations, the clinical development program and process for a drug candidate and the estimated completion date will largely be under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our drug candidates will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense (in thousands, except percentages)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:49.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,339&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,679&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,340)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense includes the cost of administrative staffing, commercial, finance and legal activities. General and administrative expense decreased for the three months ended March&#160;31, 2022 compared with the three months ended March&#160;31, 2021. General and administrative expense for the three months ended March&#160;31, 2021 included non-recurring transaction fees for our SFJ co-development agreement and other legal fees. As discussed in Note 1 to our Condensed Consolidated Financial Statements, we have implemented a restructuring plan to reduce our workforce by approximately 70%. Please see discussion below for additional information. As a result, we expect general and administrative expenses in the full year of 2022 to decrease significantly compared to 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Impairment and Other Costs of Terminated Program (in thousands, except percentages)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment and other costs of terminated program</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1 to our Condensed Consolidated Financial Statements, following the announcements that our registrational trials in bempegaldesleukin failed to meet their primary endpoints, on April 25, 2022, we announced strategic reorganization and cost restructuring plans (together, the Reorganization and Restructuring Plans) to discontinue development of bempegaldesleukin and reduce the workforce from approximately 735 employees to approximately 225 employees, a reduction of approximately 70%. We will recognize all costs of the Reorganization and Restructuring Plans, including severance and benefits for terminated employees and employee compensation and third-party costs for the wind down of the bempegaldesleukin program, net of BMS&#8217; reimbursement of our costs, in the restructuring, impairment and other costs of terminated program line in our Condensed Consolidated Statement of Operations. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to recognize approximately $30.0 to $35.0 million for severance and related benefits for employees laid off under the Reorganization and Restructuring Plans, primarily in the three months ending June 30, 2022. If we conclude that there is no future economic benefit for the wind down of the bempegaldesleukin program, we may accrue a significant liability for these future costs, provided that we are able to reliably estimate those future costs, and we will record future adjustments as new </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information becomes available to us to revise our estimates. The determination to accrue any liability for these future costs does not affect the timing of cash payments to our vendors.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Reorganization and Restructuring Plans, we currently intend to sublease a substantial portion of our facilities in the San Francisco Bay Area while still maintaining sufficient office and laboratory space to allow our team to continue to develop our proprietary programs.  Based on current market conditions in light of the COVID-19 pandemic, we currently expect that any income from a sublease may be less than our lease payments. Accordingly, we may recognize an impairment of our operating lease right-of-use assets and related leasehold improvements and other fixed assets before entering into a sublease, provided that we have committed to the portion of our space which we will sublease and we can develop reliable estimates of the potential sublease income.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, restructuring, impairment and other costs for terminated program consisted primarily of cancellation fees for certain manufacturing activities for bempegaldesleukin.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in fair value of development derivative liability</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:48.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4 to our Condensed Consolidated Financial Statements, we remeasure the development derivative liability under our co-development agreement with SFJ to fair value at each reporting date. As discussed in Note 4, as of March 31, 2022, due to the results of the metastatic melanoma trial, we concluded that it was remote that SFJ and we would continue the clinical trial in head and neck cancer. Accordingly, we reduced the liability to $0 as of March 31, 2022 and recognized a corresponding gain in the change in fair value of development derivative liability. As a result of the decision to discontinue the clinical trial in head and neck cancer, we do not expect any to record any future significant adjustments for the change in fair value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expense recorded for the change in fair value for the three months ended March 31, 2021 primarily reflected the accretion of our obligation to potentially pay Success Payments to SFJ using our imputed borrowing rate.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Cash Royalty Revenue and Non-Cash Interest Expense</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to the sales of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Increase) /<br/>Decrease<br/>2022 vs. 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to the sales of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5 to our Condensed Consolidated Financial Statements, we recognize non-cash royalty revenue for the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2012 Purchase and Sale Agreement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue for the 2012 Purchase and Sale Agreement decreased for the three months ended March&#160;31, 2022 as compared to the three months ended March&#160;31, 2021. Non-cash interest expense for the 2012 Purchase and Sales Agreement decreased significantly for the&#160;three months ended March&#160;31, 2022 as compared to the three months ended March&#160;31, 2021 due to the decrease in the interest rate used to recognize non-cash interest expense from 48% in the three months ended March&#160;31, 2021 to 16% for the three months ended March 31, 2022 as a result of the revaluation of the liability, which we recognized in the three months ended December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To resolve UCB&#8217;s challenges to our patents and their resulting obligation to pay us royalties on net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which we had sold to RPI, RPI and UCB negotiated a reduction in the royalty term and decreased royalty rates over the remaining </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">term, which was implemented through the Settlement Agreement between UCB and us. As a result of accounting for the Settlement Agreement as a debt modification during the three months ended December 31, 2021, we remeasured the liability to fair value using a discount rate of 16%. The Settlement Agreement and revaluation do not affect our cash flows, and the net income statement effect over the term of 2012 Purchase and Sale Agreement remains unchanged.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the term of this arrangement, the net proceeds of the transaction of $114.0 million, consisting of the original proceeds of $124.0 million, net of $10.0 million in payments from us to RPI, is amortized as the difference between the non-cash royalty revenue and the sum of the non-cash interest expense and the loss on the revaluation of the liability. To date, we have amortized $39.6 million of the net proceeds. We periodically assess future non-cash royalty revenues, and we may adjust the prospective effective interest rate based on our best estimates of future non-cash royalty revenue such that future non-cash interest expense will amortize the remaining $74.4 million of the net proceeds, since RPI receives all of the benefits of the increases in future royalties. There are a number of factors that could materially affect our estimated interest rate, in particular, the amount and timing of royalty payments from future net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result, future interest rates could differ significantly, and we will adjust any such change in our estimated interest rate prospectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Purchase and Sale Agreement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue increased for the three months ended March&#160;31, 2022 as compared to the three months ended March&#160;31, 2021 and non-cash interest expense decreased for the three months ended March&#160;31, 2022 as compared to the three months ended March&#160;31, 2021. Our estimate of the imputed interest rate reflects that our estimates for sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will result in meeting the 2025 Threshold. Because the 2025 Threshold of $210.0 million and the increase in the threshold to $240.0 million (if the 2025 Threshold is not timely achieved) limit the amount of royalties payable to HCR, the potential for the implicit interest rate to vary is more limited. Instead, we will receive the benefit of net sales if they exceed the threshold, but do not bear risk of loss or payments to HCR if royalties are less than expected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Other Income (Expense), net (in thousands, except percentages)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:48.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense) decreased for the three months ended March&#160;31, 2022 as compared to the three months ended March&#160;31, 2021 due to lower investment balances which have been utilized to fund our operations. We expect that our interest income and other income (expense), net will decrease for 2022 compared to 2021 for the same reason.</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_76"></div><div style="margin-top:9pt;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations primarily through revenue from upfront and milestone payments under our strategic collaboration agreements, royalties and product sales, as well as public and private placements of debt and equity securities. As of March&#160;31, 2022, we had approximately $704.4 million in cash and investments in marketable securities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that we have working capital to fund our current business plans for at least the next twelve months from the date of filing. As discussed above, on April 25, 2022, we announced our Reorganization and Restructuring Plans to discontinue development of bempegaldesleukin and to reduce our workforce by approximately 70%. We expect that we will pay severance and benefits for the terminated employees of approximately $30.0 million to $35.0 million during 2022. In addition, we currently estimate that we will pay approximately $70.0 million to $80.0 million for third-party vendor and employee costs, net of the net BMS reimbursement, for the wind down of the bempegaldesleukin program. The actual costs may differ as vendor and site contracts are modified and ultimately terminated.   </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the clinical development of our drug candidates, including NKTR-358 and NKTR-255, will continue to require significant investment to continue to advance in clinical development with the objective of obtaining regulatory approval or entering into one or more collaboration partnerships. In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursement from BMS, and a $150.0 million upfront payment from Lilly for our collaboration agreement for NKTR-358. In the future, we have the opportunity to receive up to $250.0 million in milestone payments under our collaboration with Lilly.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current business is subject to significant uncertainties and risks as a result of, among other factors, clinical and regulatory outcomes for NKTR-358 and NKTR-255, the sales levels for those products for which we are entitled to royalties, if and when they are approved, the sales levels of our products, if and when they are approved, clinical program outcomes, whether, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when and on what terms we are able to enter into new collaboration transactions, expenses being higher than anticipated, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no credit facility or any other sources of committed capital. The availability and terms of various financing alternatives, if required in the future, substantially depend on many factors including the success or failure of drug development programs in our pipeline. The availability and terms of financing alternatives and any future significant payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining regulatory authority approvals in major markets, and if approved, the commercial success of these drugs, as well as general capital market conditions. We may pursue various financing alternatives to fund the expansion of our business as appropriate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the short term, we do not anticipate that the effects of the COVID-19 pandemic will have a material effect on our results of operations or financial position since we do not generate significant cash flows from recurring revenues and our revenues are generally less affected by shelter-in place or similar orders. However, if delays caused by the COVID-19 pandemic in commencing and enrolling patients in our clinical trials or those run by our partners result in a delay in completing these trials, our or our partner&#8217;s ability to file for regulatory approval and commercialize these products (if approved) and receive associated milestone payments may also be delayed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the potential for adverse developments in the credit markets, we may experience reduced liquidity with respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises to liquidate such securities before maturity, we may experience losses on liquidation. To date we have not experienced any liquidity issues with respect to these securities. We believe that, even allowing for potential liquidity issues with respect to these securities and the effect of the COVID-19 pandemic or other conditions on the financial markets, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the Securities and Exchange Commission, which expires in March 2024. The 2021 Shelf Registration Statement currently permits the offering, issuance and sale by us of up to an aggregate offering price of $300.0 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which may be offered, issued and sold in &#8220;at-the-market&#8221; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities have been sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from operating activities</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities for the three months ended March&#160;31, 2022 and 2021 totaled $88.4&#160;million and $77.1&#160;million, respectively. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that cash flows used in operating activities, excluding upfront, milestone and other contingent payments received, if any, will decrease for 2022 as compared to 2021 as a result of the various cost restructuring activities described above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from investing activities</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2021, the maturities and sales of our investments, net of purchases, totaled $134.5&#160;million and $13.3&#160;million, respectively, which we used to fund our operations.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid $4.2 million and $2.9&#160;million for the purchase or construction of property, plant and equipment in the three months ended March&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from financing activities</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received proceeds from issuance of common stock related to our employee option and stock purchase plans of $0.2 million and $17.1 million in the three months ended March&#160;31, 2022 and 2021, respectively. Additionally, during the three months ended March&#160;31, 2022 and 2021, we received $0.8 million from SFJ pursuant to our co-development agreement.</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation and presentation of financial statements in conformity with U.S.&#160;generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates on an ongoing basis. Actual results may differ from those estimates under different assumptions or conditions. There have been no material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_82"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.                Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks at March&#160;31, 2022 have not changed materially from those discussed in Item 7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2021 on file with the SEC.</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_85"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout the Company. However, there was no change in our internal control over financial reporting that occurred in the three months ended March&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Specifically, despite the fact that most of our employees are working remotely due to the COVID-19 pandemic, we do not believe that our adjustments to how we work have materially impacted our internal controls over financial reporting. We continue to monitor and assess the potential impact of the COVID-19 pandemic, and the related shelter-in-place requirements, on our internal controls and strive to minimize the impact on our internal control design and operating effectiveness.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II: OTHER INFORMATION</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_91"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is hereby made to our disclosures in &#8220;Legal Matters&#8221; under Note 6 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q and the information under the heading &#8220;Legal Matters&#8221; is incorporated by reference herein.</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_94"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. The risks described below may not be the only ones relating to our company. This description includes any material changes to and supersedes the description of the risk factors associated with our business previously disclosed in Item&#160;1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2021. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the success of drug candidates, including NKTR-358 and NKTR-255.&#160;If these drug candidates fail in clinical development our business will be significantly harmed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is highly dependent on the clinical success of our drug candidates, including NKTR-358 and NKTR-255. In general, most investigational drugs, including immunology and I-O drug candidates such as NKTR-358 and NKTR-255, respectively, do not become approved drugs. Accordingly, there is a very meaningful risk that our drug candidates will not succeed in one or more clinical trials sufficient to support one or more regulatory approvals.&#160;Further, if Lilly,  our collaboration partner for NKTR-358, delays the initiation or completion of one or more clinical trials for reasons outside of our control, or is not successful, it would materially harm our market valuation, prospects, financial condition and results of operations.&#160;For example, under our collaboration agreement with Lilly, we are eligible for up to $250.0 million in additional development and regulatory milestones, and a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. One or more clinical failures of our drug candidates would jeopardize and could result in reduced, delayed or eliminated revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, promising results from earlier trials may not predict similarly favorable outcomes in subsequent trials. For example, several of our past, planned and ongoing clinical trials utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational drug candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational drug candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our drug candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may experience delays in clinical trials of drug candidates. Our partner Lilly is conducting a Phase 2 study of NKTR-358 in patients with SLE as well as two Phase 1b studies in patients with psoriasis and atopic dermatitis.&#160;&#160;In addition, we have initiated a Phase 1 clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">squamous cell carcinoma or colorectal cancer. These and other clinical studies may not begin on time, enroll a sufficient number of patients or be completed on schedule, if at all. Clinical trials for any of our drug candidates could be delayed for a variety of reasons, including:</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in obtaining regulatory authorization to commence a clinical study;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in reaching agreement with applicable regulatory authorities on a clinical study design;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">for drug candidates (such as NKTR-358) partnered with other companies, delays caused by our partner; </span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by the COVID-19 pandemic (see also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">imposition of a clinical hold by the FDA or other health authorities, which may occur at any time including after any inspection of clinical trial operations or trial sites;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspension or termination of a clinical study by us, our partners, the FDA or foreign regulatory authorities due to adverse side effects of a drug on subjects in the trial;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in recruiting suitable patients to participate in a trial;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical sites dropping out of a trial due to the detriment of enrollment rates;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in manufacturing and delivery of sufficient supply of clinical trial materials;</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in regulatory authorities policies or guidance applicable to our drug candidates; and</span></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by changing standards of care or new treatment options.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other reasons, results for the studies would be delayed, and consequently the regulatory approval process would be delayed which would also delay our ability to commercialize these drug candidates, which could have a material adverse effect on our business, financial condition and results of operations. Clinical study delays could also shorten any commercial periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our drug candidates and may harm our business and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies, could have a material and adverse impact on the value of our I-O research and development pipeline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development of I-O therapies is a very competitive global segment in the biopharmaceutical industry attracting tens of billions of dollars of investment each year.&#160; Our clinical trial plans for NKTR-255 and other I-O therapy drug candidates face substantial competition from other I-O combination regimens already approved, and many more combination therapies that are either ahead of or in parallel development in patient populations where we are studying our drug candidates. As I-O combination therapies are relatively new approaches in cancer treatment and few have successfully completed late stage development, I-O drug development entails substantial risks and uncertainties that include rapidly changing standards of care, identifying contribution of component therapies, patient enrollment competition, evolving regulatory frameworks to evaluate combination regimens, and varying risk-benefit profiles of competing therapies, any or all of which could have a material and adverse impact on the probability of success of I-O drug candidates.&#160;</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The risk of clinical failure for any drug candidate remains high prior to regulatory approval and there can be no assurance that our product candidates will obtain regulatory approval.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of companies have suffered significant unforeseen failures in clinical studies due to factors such as inconclusive efficacy or safety, even after achieving preclinical proof-of-concept or positive results from earlier clinical studies that were satisfactory both to them and to reviewing regulatory authorities. Clinical study outcomes remain very unpredictable and it is possible that one or more of our clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory requirements. The results from preclinical testing or early clinical trials of a drug candidate may not predict the results that will be obtained in later phase clinical trials of the drug candidate. We, the FDA, an independent Institutional Review Board (IRB), an independent ethics committee (IEC), or other applicable regulatory authorities may suspend clinical trials of a drug candidate at any time for various reasons, including a belief that patients participating in such trials are being exposed to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unacceptable health risks or adverse side effects. Similarly, an IRB or IEC may suspend a clinical trial at a particular trial site. If one or more of our drug candidates fail in clinical studies, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary drugs and drug candidates could make our technologies, drugs or drug candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our advanced polymer conjugate chemistry platforms and our partnered and proprietary products and drug candidates compete with various pharmaceutical and biotechnology companies. Competitors of our polymer conjugate chemistry technologies include Biogen Inc., Horizon Pharma, Dr.&#160;Reddy&#8217;s Laboratories Ltd., SunBio Corporation, Laysan Bio, Inc., Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), and NOF Corporation. Several other chemical, biotechnology and pharmaceutical companies may also be developing polymer conjugation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many competitors for our drug candidates currently in development. For NKTR-358, there are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease. In particular, we expect to compete with therapies that could be cytokine-based therapies (Symbiotix, LLC, Janssen, AstraZeneca, and Tizona Therapeutics), regulatory T cell therapies (Targazyme, Inc., Caladrius BioSciences, Inc., and Tract Therapeutics, Inc.), or IL-2-based-therapies (Amgen Inc., Celgene Corporation, GentiBio, Inc., ILTOO Pharma, Kyverna Therapeutics, Merck &amp; Co, through its acquisition of Pandion Therapeutics, and Roche). For NKTR-255, we believe companies that are currently researching and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include Artiva Biotherapeutics, Fate Therapeutics, ImmunityBio, Inc., Nkarta therapeutics, NKMax America, and Roche/Genentech (through its partnership with Xencor, Inc.). There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies uncompetitive or obsolete.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Collaboration Partners </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our collaboration partner to initiate, properly conduct and prioritize clinical trials for NKTR-358 and to perform important additional development and commercialization activities, and our business will be significantly harmed if their actions deprioritize or otherwise harm the prospects of our drug candidates. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on Lilly (through the Lilly Agreement) to initiate, properly conduct, and prioritize clinical trials and other development-related activities for NKTR-358.  Furthermore, we will rely Lilly to perform specified commercialization activities for NKTR-358, pursuant to the our collaboration agreement. In the Lilly fails to initiate, properly conduct and prioritize their obligations under their applicable agreement with us, our business will be significantly harmed.  Even if the applicable agreement provides us with enforcement or other curative rights to address the harm caused by Lilly&#8217;s action (or failure to act), our efforts in pursuing a remedy would be costly and there is no guarantee that efforts would succeed or be sufficient to fully address the harm.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for reasons outside of our control, the operations of our collaboration partners may be affected by the COVID-19 pandemic than we are, or they may adopt more restrictive procedures for addressing the COVID-19 pandemic, either of which would delay initiating or completing one or more clinical trials involving our drug candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition and Capital Requirement</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our strategic reorganization plan and cost restructuring plan may not be successful.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, we announced strategic reorganization and cost restructuring plans (together, the Reorganization and Restructuring Plans) to prioritize key research and development efforts that will be most impactful to the Company&#8217;s future, including NKTR-358, NKTR-255 and several core research programs.  In connection with the Reorganization and Restructuring Plans, we also announced cost restructuring measures aimed at ensuring we will have significant capital to fund key programs over a multi-year time horizon. There is no guarantee that the Reorganization and Restructuring Plans will achieve their intended benefits or that our post-restructuring focus will be sufficient for us to achieve success. For example, our cost restructuring efforts may not result in the anticipated savings or other economic benefits, or could result in total costs and expenses that are greater than expected, which would require us to seek potentially dilutive financing alternatives, disrupt or restrain the scope of our business activities, and would make it more difficult to attract and retain qualified personnel, each of which could have a material adverse effect on our business, financial condition and prospects.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreements with various pharmaceutical or biotechnology companies, our collaboration partner is generally solely responsible for:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">designing and conducting large scale clinical studies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">preparing and filing documents necessary to obtain government approvals to sell a given drug candidate; and/or</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">marketing and selling the drugs when and if they are approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on collaboration partners poses a number of significant risks to our business, including risks that:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the amount of investment in sales and marketing personnel, general marketing campaigns, direct-to-consumer advertising, product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and supply of drug product, and other marketing and selling activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaboration partners with commercial rights may choose to devote fewer resources to the development or marketing of our partnered drugs than they devote to their own drugs or other drugs that they have in-licensed;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of drug candidates or to litigation or arbitration proceedings;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business strategy;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may be unable to pay us as expected;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may respond to natural disasters or health epidemics, such as the COVID-19 pandemic, by ceasing all or some of their development responsibilities (including the responsibility to clinical develop our drug candidates).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, the success of our current and future collaboration partnerships is highly unpredictable and can have a substantial negative impact on our business. If the approved drugs fail to achieve commercial success or the drugs in development fail to have positive late stage clinical outcomes sufficient to support regulatory approval in major markets, it could significantly </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impair our access to capital necessary to fund our research and development efforts for our drug candidates. If we are unable to obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have substantial future capital requirements and there is a risk that we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash and investments in marketable securities valued at approximately $704.4 million. While we believe that our cash position will be sufficient to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous unpredictable factors, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost, timing and outcomes of clinical studies and regulatory reviews of our drug candidates, particularly NKTR-358;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those collaborations achieve clinical, regulatory or commercial success;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, timing, cost and results of our clinical development programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net cash, such as the sale of additional royalty interests held by us, term loan or other debt arrangements, and the issuance of securities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the regulatory authorities in order to consider for approval our drug candidates and those of our collaboration partners;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our general and administrative expenses, capital expenditures and other uses of cash; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes concerning patents, proprietary rights, or license and collaboration agreements that could negatively impact our receipt of milestone payments or royalties or require us to make significant payments arising from licenses, settlements, adverse judgments or ongoing royalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant multi-year capital commitment is required to advance our drug candidates through the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not enter into any new collaboration partnerships with significant upfront payments and we choose to continue to advance our drug candidates to later stage research and development, we may need to pursue financing alternatives, including dilutive equity-based financings, such as an offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us or is not available on commercially reasonable terms, it could require us to delay or reduce one or more of our research and development programs. If we are unable to sufficiently advance our research and development programs, it could substantially impair the value of such programs and result in a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is very difficult to estimate the commercial potential of drug candidates due to important factors such as safety and efficacy compared to other available treatments, including changing standards of care, third party payer reimbursement standards, patient and physician preferences, the availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic and biosimilar versions of our drug candidates following approval by regulatory authorities based on the expiration of regulatory exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and negatively impact the commercial potential of the drug candidate, the commercial terms of any collaboration partnership potential for such drug candidate, or if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestone payments could be significantly diminished and this would negatively impact our business, financial condition and results of operations. We also depend on our relationships with other companies for sales and marketing performance and the commercialization of drug candidates. Poor performance by these companies, or disputes with these companies, could negatively impact our revenue and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If government and private insurance programs do not provide payment or reimbursement for our partnered drug or proprietary drugs, those drugs will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and markets in other countries, patients generally rely on third-party payers to reimburse all or part of the costs associated with their treatment. In both domestic and foreign markets, sales of our partnered and proprietary products that receive regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of coverage and payment or reimbursement from third-party payers, such as government programs, including Medicare and Medicaid in the U.S., managed care providers, private health insurers and other organizations. However, eligibility for coverage does not necessarily signify that a biologic candidate will be adequately reimbursed in all cases or at a rate that covers costs related to research, development, manufacture, sale, and distribution. Third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore, significant uncertainty exists as to the coverage and pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products. Further, due to the COVID-19 pandemic, millions of individuals have lost or will be losing employer-based insurance coverage, which may adversely affect our ability to commercialize our biologic candidates even if there is adequate coverage and reimbursement from third-party payers. It is unclear what effect, if any, the American Rescue Plan Act will have on the number of covered individuals.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payers tend to follow CMS to a substantial degree. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors payers consider in determining reimbursement are based on whether the product is (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit coverage or pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures, and the Medicare and other healthcare programs are frequently identified as potential targets for spending cuts. New government legislation or regulations related to pricing or other fundamental changes to the healthcare delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage or reimbursement of, our products hold the potential to severely limit market opportunities of such products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent federal legislation and actions by federal, state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face competition in the United States for our development candidates and investigational medicines, if approved, from therapies sourced from foreign countries that have placed price controls on pharmaceutical products. In the United States, the Medicare Modernization Act (MMA), contains provisions that call for the promulgation of regulations that expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. Further, the MMA provides that these changes to U.S. importation laws will not take effect, unless and until the U.S. Secretary of Health and Human Services (HHS) certifies that the changes will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers. On September 23, 2020, the U.S. Secretary of HHS made such certification to Congress, and on October 1, 2020, FDA published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. Since the issuance of the final rule, several industry groups have filed federal lawsuits challenging multiple aspects of the final rule, and authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. On September 25, 2020, CMS stated drugs imported by States under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The market implications of the final rule and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of potential partners that need to complete due diligence and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find suitable partners or negotiate collaboration arrangements with favorable commercial terms with respect to our existing and future biologic candidates or the licensing of our intellectual property, or if any arrangements we negotiate, or have negotiated, are terminated, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, from which we receive upfront fees, research and development reimbursement and funding, milestone and other contingent payments based on clinical progress, regulatory progress or net sales achievements, royalties and product sales. Significant variations in the timing of receipt of cash payments and our recognition of revenue can result from payments based on the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch or the achievement of certain annual sales thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory approvals in one or more major markets, reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration agreements is not necessarily indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, manufacture or ultimately commercialize any biologic candidate under our collaboration agreement, our business, financial condition, and results of operations could be materially and adversely affected.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, we reported a net loss of $90.4 million. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestones and other contingent payments and royalties received, the timing of revenue under our collaboration agreements, the amount of investments we make in our proprietary biologic candidates and the regulatory approval and market success of our biologic candidates. We may not be able to achieve and sustain profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotechnology companies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively estimate and manage clinical development costs, particularly the cost of the clinical studies for NKTR-358 and NKTR-255;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive necessary regulatory and marketing approvals;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain or expand manufacturing at necessary levels;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">achieve market acceptance of our partnered products;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive revenue or royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain sufficient funds to finance our activities.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected, directly or indirectly, by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, including both our own manufacturing operations as well as the manufacturing operations of third parties upon whom we rely. With respect to the ongoing COVID-19 pandemic, national, state and local governments in regions affected by the COVID-19 pandemic have implemented, and may continue to implement or reinstate safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter-in-place orders and shutdowns, business closures and other measures.  These measures may disrupt normal business operations both in and outside areas affected by COVID-19 and may have significant negative impacts on our business. Even as these safety precautions are eased or reduced over time, there may be long lasting effects of these precautions on our business that may only be fully realized in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic. Throughout the pandemic we have modified our office policies to maintain productivity and safety of our employees. Although we believe these and the other safety measures we have taken in response to the COVID-19 pandemic have not substantially impacted our productivity, it is not certain that this will continue to be the case. Operating requirements may continually change due to the COVID-19 pandemic and we may experience unpredictability in our expenses, employee productivity and availability and employee work culture. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our clinical trials have been and may continue to be affected by the COVID-19 pandemic. Investigator recruitment, clinical site initiation, patient screening and patient enrollment may be delayed due to, for example, prioritization of hospital resources toward the COVID-19 pandemic. Some patients who are successfully enrolled in clinical trials involving our biologic candidates may not be able to comply with clinical trial protocols due to, for example, shelter-in-place orders impeding movement, disrupted healthcare services, or health issues for suspected or confirmed COVID-19 status. Similarly, our ability to recruit and retain patients and principal investigators and site staff, all of whom may have heightened risk for COVID-19, could adversely impact our clinical trial operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays and disruptions experienced by our collaborators or other third parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect clinical development or regulatory approvals of our biologic candidates. For example, due to recent supply chain disruptions, we have been monitoring our supply chains for any disruptions or constraints caused by the COVID-19 pandemic. To date, we have not experienced any supply impact. However, if we, our collaborators or any third parties which we rely on are adversely effected by any supply disruptions or shortages in raw materials and equipment caused by the COVID-19 pandemic, our ability to manufacture our products and to supply drug candidates for our clinical trials could be negatively impacted, which could harm our business prospects, results of operations and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are implementing measures to maintain the integrity of our clinical trials, there is no guarantee that we will prevent all study protocol violations, missed study treatment visits, and other influences that jeopardize reliability and validity of our clinical trial data. If a regulatory authority determines our clinical trial data lacks integrity, there is no guarantee that we will have a remedy to correct or otherwise address the deficiency. Even if such a remedy is identified, the cost for implementing the remedy could be prohibitively expensive, time consuming, or both. As a consequence, a clinical study of our biologic candidate in which the integrity of the clinical study is questioned or doubted may require lengthy and costly remediation measures (such as, for example, over-enrolling patients into the study or repeating the study), thereby causing substantial harm to our business.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the COVID-19 pandemic could postpone necessary interactions with regulators regarding our drug candidates in development and could delay review or approval of our regulatory submissions. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapid development and fluidity of the COVID-19 pandemic results in a substantial number of individual variables that could cause a significant negative impact on our operations and our business, thereby precluding useful predictions as to how this pandemic will ultimately affect us. In particular, it is unclear how our business may be affected by the emergence of new variants of the coronavirus, such as the Delta and Omicron variants, and recent resurgences in number and rates of COVID-19 infections. Thus, any current assessment of the effects of the COVID-19 pandemic, including the impact of this disease on our clinical trial timelines, is subject to change. We do not yet know the full extent of potential impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material negative impact on our operations and our business. Furthermore, to the extent the ongoing COVID-19 pandemic adversely affects our operations and business, it may also heighten the other risks described in this &#8220;Risk Factors&#8221; section. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Supply and Manufacturing</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our contract manufacturers are not able to manufacture biologic substance or substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our contract manufacturing organizations (CMOs) are not able to manufacture and supply sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partners&#8217; clinical studies or result in a breach of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partners&#8217; products. As a result, we could incur substantial costs and damages and any product sales or royalty revenue that we would otherwise be entitled to receive could be reduced, delayed or eliminated. In most cases, we rely on CMOs to manufacture and supply drug product for our clinical studies and those of our collaboration partners. The manufacturing of biologics involves significant risks and uncertainties related to the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and elimination of impurities, optimal formulations, process and analytical methods validations, and challenges in controlling for all of these variables. These risks and uncertainties are compounded by the COVID-19 pandemic wherein the facilities and employees responsible for manufacturing biologics for use in clinical trials may be negatively impacted such that there is an insufficient supply of study biologic drugs. We have faced and may in the future face significant difficulties, delays and unexpected expenses as we validate third party CMOs required for drug supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our CMOs to supply API or drug products in sufficient quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures could significantly and materially delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in response to the COVID-19 pandemic. Throughout the COVID-19 outbreak, there has been public concern over the availability and accessibility of critical medical products, and the CARES Act enhances FDA&#8217;s existing authority with respect to drug shortage measures. Under the CARES Act, we must have in place a risk management plan that identifies and evaluates the risks to the supply of approved drugs for certain serious diseases or conditions for each establishment where the drug or API is manufactured. The risk management plan will be subject to FDA review during an inspection. If we experience shortages in the supply of our marketed products, our results could be materially impacted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any CMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials or commercial distribution could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or biologic candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product according to the specifications previously submitted to or approved by the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop biologic candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our biologic candidate that such CMO owns independently. This would increase our reliance on such a CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our products or biologic candidates. In addition, in the case of the CMOs that supply our biologic candidates, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past, we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making modifications to the drug formulation, which may cause significant delays in clinical development. There continues to be substantial and unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We purchase some of the starting material for biologics and biologic candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often face very limited supply of a critical raw material that can only be obtained from a single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunities or contract liabilities to third parties. For example, there are only a limited number of qualified suppliers, and in some cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply, diminution in quality of raw materials supplied to us or failure to procure such raw materials on commercially feasible terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CMOs are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical ingredients, and drug products, and with laws and regulations governing manufacture and distribution of controlled substances, and are subject to inspections by the FDA, or comparable agencies in other jurisdictions administering such requirements. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our CMOs for compliance with applicable regulatory requirements. Any failure to follow and document our or our CMOs&#8217; adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable laws and regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures, administrative detention, or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. Regulatory inspections could result in costly manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our CMOs, pending resolution of regulatory deficiencies or suspensions could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Business Operations</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third parties to conduct the clinical trials for our biologic candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical trials for our biologic candidates. We rely heavily on these parties for the successful execution of our clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are beyond our control. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our biologic candidates to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or the failure of third parties to properly conduct our clinical trials could hinder or delay the development, approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future depends on the proper management of our current and future business operations and their associated expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy requires us to manage our business to provide for the continued development of our proprietary and partnered biologic candidates. Our strategy also calls for us to manage the capital necessary to fund key programs through value-enhancing data and other milestones. If we are unable to manage effectively our current operations, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our personnel-related costs through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other dilutive financing arrangements on unfavorable terms.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we, or our partners through our collaborations, are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our products, which would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we rely on other pharmaceutical or biotechnology companies with established sales, marketing and distribution systems to market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenue we receive will depend upon the efforts of third parties, which may not be successful and over which we have little or no control. In the event that we market our products without a partner, we would be required to build, either internally or through third-party contracts, a sales and marketing organization and infrastructure, which would require a significant investment, and we may not be successful in building this organization and infrastructure in a timely or efficient manner. We would also incur substantial costs in building such capabilities before receiving regulatory approval of our products, which would have an adverse effect on our financial condition if our products are not ultimately approved.  </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must attract and retain experts in the areas of research, development (including clinical testing), manufacturing, regulatory and finance, and may need to attract and retain commercial, marketing and distribution experts and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock awards they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely affect our ability to attract or retain qualified personnel.  Furthermore, as a result of our Reorganization and Restructuring plans, our employees may experience distractions or decreases in employee morale and we may experience increased levels of employee attrition and turnover, which would adversely affect our business. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners do not obtain regulatory approval for our biologic candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may not obtain regulatory approval for biologic candidates on a timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Biologic candidates must undergo rigorous animal and human testing and an extensive review process for safety and efficacy by the FDA and equivalent foreign regulatory authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. The FDA and other U.S. and foreign regulatory authorities have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. Further, regulatory authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners, which could lead such authorities to arrive at different conclusions regarding the safety or efficacy of a biologic candidate. In addition, undesirable side effects caused by our biologic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. For example, AstraZeneca is&#160;conducting a post-marketing, observational epidemiological study comparing MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to other treatments of opioid-induced constipation in patients with chronic, non-cancer pain and the results of this study could at some point in the future negatively impact the labeling, regulatory status, and commercial potential of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which could reduce our future royalties from sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we or our partners receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. Our and our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of drug candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and expect to derive in the foreseeable future, substantially all of our revenue from collaboration agreements with biotechnology and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of our partner&#8217;s performance;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered biologic candidate development programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the collaboration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent life, generic competitors, bundled pricing and other factors; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">indemnity obligations for intellectual property infringement, product liability and certain other claims.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to numerous significant collaboration agreements and other strategic transaction agreements (e.g., financings and asset divestitures) that contain complex representations and warranties, covenants and indemnification obligations. If we are found to have materially breached such agreements, we could be subject to substantial liabilities, which would harm our financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in litigation matters involving the interpretation and application of complex terms and conditions of our agreements. One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract terms, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property licenses related to the development of our biologic candidates on a commercially reasonable basis, if at all.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent rights will be considered relevant to our or our collaboration partners&#8217; technology or biologic candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In certain cases, we have existing licenses or cross-licenses with third parties; however, the sufficiency of the scope and adequacy of these licenses is very uncertain in view of the long development and commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology to avoid a need to secure a license. If we are required to enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all, we may be prevented from developing and commercializing the biologic, which could significantly harm our business, results of operations, and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own more than 310 U.S. and 1,200 foreign patents and have a number of pending patent applications that cover various aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to opposition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, re-examinations or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant and/or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire prior to the commercialization of the biologic. Moreover, even if a patent encompassing a biologic has not expired prior to the biologic's commercialization, the patent may only provide a short period of protection following the commercialization of products.&#160; In addition, our patents may be subject to post grant proceedings, such as or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examinations, before the U.S. Patent and Trademark Office (or equivalent proceedings in other jurisdictions), which could result in a loss of the patent and/or substantial cost to us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our biologic candidates.&#160;There can be no assurance that the patent applications for which we apply will actually issue as patents, or do so with commercially relevant and/or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued.&#160;The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications.&#160;In addition, there is no guarantee that we will be the first to file a patent application directed to an invention.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute.&#160;In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage (or if we cannot secure product liability insurance), we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, once we begin commercializing our biologic candidates, if approved, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal and state governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any biologic candidates for which we obtain marketing approval. Our future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. On December 2, 2020, the Office of Inspector General, or OIG, published further modifications to the federal Anti-Kickback Statute. Under the final rules, OIG added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements among clinicians, providers, and others. This rule (with exceptions) became effective January 19, 2021. Implementation of this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. We continue to evaluate what effect, if any, the rule will have on our business;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, such as the U.S. federal False Claims Act (FCA), which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payers if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes, referred to as the &#8220;HIPAA All-Payer Fraud Prohibition,&#8221; that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal transparency laws, including the federal Physician Payment Sunshine Act, which require manufacturers of certain drugs and biologics to track and disclose payments and other transfers of value they make to U.S. physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals as well as physician ownership and investment interests in the manufacturer, and that such information is subsequently made publicly available in a searchable format on a CMS website, effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician assistants and nurse practitioners;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information, and also includes the Final Omnibus Rule published in January 2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there  may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">additionally, state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts. These state-equivalent laws may also apply to our business practices, including, but not limited to, research, distribution, and sales or marketing arrangements. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including administrative, civil or criminal penalties, imprisonment, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions to the normal functioning of the FDA and other government agencies could hinder their ability to perform and carry out important roles and activities on which the operation of our business relies, which could negatively impact our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other agencies on which our operations may rely is subject to the political process, which is inherently fluid and unpredictable. Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold due to the COVID-19 pandemic, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. In April 2021, the FDA issued guidance for industry formally announcing plans to employ remote interactive evaluations, suing risk management methods, to meet user fee commitments and goal dates. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be appropriate, FDA has stated that it generally intends to issue a complete response letter.  Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA may defer action on the application until an inspection can be completed. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. Additionally, as of June 23, 2020, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals. On July 16, 2020, the FDA noted that it is continuing to expedite oncology product development with its staff teleworking full-time. However, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the COVID-19 pandemic and travel restrictions the FDA is unable to complete such required inspections during the review period. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future shutdowns of other government agencies, such as the SEC, may also impact our business through review of our public filings and our ability to access the public markets. </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have already been allowed or issued, or otherwise asserting proprietary rights through one or more potential legal remedies. Third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our obligations to them. A third party often bases its assertions on a claim that its patents cover our technology platform or biologic candidates or that we have misappropriated its confidential or proprietary information. Similar assertions of infringement could be based on future patents that may issue to third parties. For example, we are involved in ongoing litigation with Aether Therapeutics Inc., who in March 2020 filed a complaint against AstraZeneca, Nektar and Daiichi-Sanko, Inc. alleging that MOVANTIK&#174; infringes U.S. Patent Nos. 6,713,488, 8,748,448, 8,883,817 and 9,061,024. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our collaboration partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and our partners against any claims. We are also regularly involved in opposition proceedings at the European Patent Office and in inter partes review and re-examination proceedings at the U.S. Patent and Trademark Office where third parties seek to invalidate or limit the scope of our allowed patent applications or issued patents covering (among other things) our biologic candidates and platform technologies.  If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain biologics or biologic candidates in the U.S. and abroad. Costs associated with litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in legal proceedings other than those related to intellectual property.  In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv-06607, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made, between January 2017 and June 2018,  about clinical trials of bempegaldesleukin.  In December 2020, the court dismissed the action with prejudice.  The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit was completed in September 2021. Oral argument was held on December 10, 2021. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, a derivative action was filed against certain of the Company's current and former officers and directors in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF) alleging that the Company's officers and directors breached their fiduciary duties by exposing the Company to securities actions. The parties agreed to stay further proceedings in this action until thirty days after the U.S. Court of Appeal for the Ninth Circuit&#8217;s final resolution of the appeal in the Mulquin action.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost to us in initiating or defending any litigation or other proceeding, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts or result in financial implications either in terms of seeking license arrangements or payment of damages or royalties. There is no guarantee that our insurance coverage for damages resulting from a litigation or the settlement thereof (including the Mulquin action and related shareholder derivative lawsuit) is sufficient, thereby resulting in substantial financial risk to the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of lawsuits and complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses for any of the legal proceedings we are currently involved in. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at March&#160;31, 2022.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found in violation of privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to many laws and regulations intended to protect the privacy and data of individuals participating in our clinical trials and our employees, among others. For example, with regard to individuals participating in our clinical trials, these laws and regulations govern the safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. In addition to federal laws and regulations in the United States, such as the HIPAA requirements relating to the privacy, security and transmission of individually identifiable health information, many state and foreign laws also govern the privacy and security of health information. These laws often differ from each other in significant ways, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the United States, California recently enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has increased our compliance costs and may increase our potential liability. The CCPA has prompted a number of proposals for new federal and state privacy legislation. If passed, these proposals could increase our potential liability, increase our compliance costs and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), and the implementing legislation of EU Member States, which became effective on May 25, 2018, apply to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located in the EU. The GDPR is wide-ranging in scope and imposes strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to, for example, (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, and (iii) ensuring the security and confidentiality of the personal data. The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area (EEA), such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Potential pecuniary fines for noncompliant companies may be up to the greater of &#8364;20 million or 4% of annual global revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we are found liable for the inappropriate collection, storage, use or disclosure of protected information of individuals (such as employees and or clinical patients protected by any privacy or data protection law), we could be subject to reputational harm, monetary fines (such as those imposed by the GDPR and CCPA), civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and the development of our biologic candidates could be delayed. In addition, we continue to be subject to new and evolving data protection laws and regulations from a variety of jurisdictions, and there is a risk that our systems and processes for managing and protecting data may be found to be inadequate, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may involve hazardous materials and are subject to environmental, health, and safety laws and regulations. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a research-based biopharmaceutical company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations (including, but not limited to, the handling and disposal of both our hazardous and non-hazardous waste) is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk related to Investment and Securities</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial                                losses for investors and securities class action and shareholder derivative litigation. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is volatile. During the three months ended March&#160;31, 2022, based on closing prices on the NASDAQ Global Select Market, the closing price of our common stock ranged from $4.16 to $13.72 per share. In response to volatility in the price of our common stock in the past, plaintiffs&#8217; securities litigation firms have sought information from us and/or shareholders as part of their investigation into alleged securities violations and breaches of duties (among other corporate misconduct allegations). Following their investigations, plaintiffs&#8217; securities litigation firms have often initiated legal action, including the filing of class action lawsuits, derivative lawsuits, and other forms of redress. We expect our stock price to remain volatile and we continue to expect the initiation of legal actions by plaintiffs&#8217; securities litigation firms following share price fluctuations. A variety of factors may have a significant effect on the market price of our common stock, including the risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding efficacy and safety, delays in clinical development, regulatory approval or commercial launch &#8211; in particular, data from clinical studies of bempegaldesleukin has had a significant impact on our stock price;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of outcomes from our clinical trials which can be difficult to predict particularly for clinical studies that have event-driven end points such as progression-free survival and overall survival;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by collaboration partners as to their plans or expectations related to biologic candidates and approved biologics in which we have a substantial economic interest;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding terminations or disputes under our collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our results of operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products that may compete with our approved partnered products or products under development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of changes in governmental regulation affecting us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation brought against us or third parties to whom we have indemnification obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of drug formulations developed by us or others;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financing needs and activities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At times, our stock price has been volatile even in the absence of significant news or developments. The stock prices of biotechnology companies and securities markets generally have been subject to dramatic price swings in recent years.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a classified board of directors such that not all members of the board may be elected at one time;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board to authorize the issuance of &#8220;blank check&#8221; preferred stock to increase the number of outstanding shares and thwart a takeover attempt;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on who may call a special meeting of stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We significantly rely on information technology systems, and any failure, inadequacy, interruption, breach, or security lapse of that technology within our internal computer systems, or those of our partners, vendors, CROs, CMOs or other contractors or consultants, may result in a material disruption of our development programs and our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business, we collect, store and transmit large amounts of confidential information, proprietary data, intellectual property and personal data. Despite the implementation of security measures, our internal computer systems and those of our partners, vendors, contract research organizations (CROs), contract manufacturing organizations (CMOs) and other contractors and consultants are vulnerable to loss, damage, denial-of-service, unauthorized access, or misappropriation. Such cybersecurity breaches may be the result of unauthorized activity by our employees and contractors, as well as by third parties who use cyberattack techniques involving malware, hacking and phishing, among others. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of an increase in the number of employees adopting a remote working environment during the COVID-19 pandemic, which may be less secure and more susceptible to hacking attacks. Our information technology systems, and those of our partners, vendors, CROs, CMOs or other contractors or consultants are also vulnerable to natural disasters, terrorism, war and telecommunication and electrical failures. Any such compromise or disruption, no matter the origin, may cause an interruption of our operations. For instance, the loss of preclinical data or data from any clinical trial involving our biologic candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, the loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information could compromise the commercial viability of one or more of our programs, which would negatively affect our business. Also, the costs to us to investigate and mitigate cybersecurity incidents could be significant.  </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous international, federal, state, and other governmental laws, rules, and regulations that may adversely affect our operating results, including, taxation and tax policy changes, tax rate changes, new tax laws, or revised tax law interpretations, which individually or in combination may cause our effective tax rate to increase. In the U.S., the rules dealing with federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, such changes have been made and changes are likely to continue to occur in the future. For example, on March 27, 2020, the CARES Act was signed into law and included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID-19 pandemic, including temporary changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the EU may have a negative effect on global economic conditions, access to patient markets, and regulatory certainty, which could adversely affect our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 31, 2020, the U.K. ceased to be a member state of the EU, a process known as Brexit, and began a transition period, which expired on December 31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the U.K. and the EU agreed on a trade and cooperation agreement, under which the EU and the U.K. will now form two separate markets governed by two distinct regulatory and legal regimes. The trade and cooperation agreement </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">covers the general objectives and framework of the relationship between the U.K. and the EU, including as it relates to trade, transport and visas. Under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the U.K. and the EU. Depending on the application of the terms of the trade and cooperation agreement, we, our collaboration partners and others could face new regulatory costs and challenges.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global economic and political conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance have been, and may continue to be, affected by global economic conditions, including, for example, adverse global economic conditions resulting from the COVID-19 pandemic. See also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; In addition, our operations and performance may be affected by political or civil unrest or military action, terrorist activity, and unstable governments and legal systems. For example, in late February 2022, Russia commenced a military invasion of Ukraine, and the sustained conflict in Ukraine, including the potential effects of sanctions and retaliatory cyber-attacks on the world economy and markets, has contributed to increased market volatility and uncertainty.  In particular, sanctions imposed by the U.S., EU and other countries in response to the conflict between Russia and Ukraine and the potential response to such sanctions may have an adverse impact on our business, including our clinical trials, the financial markets and the global economy.  As the conflict in Ukraine continues, there can be no certainty regarding whether the U.S., EU or other governments will impose additional sanctions, or other economic or military measured relating to Russia.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of global economic and political conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships may also affect patients&#8217; ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. Our ability to conduct clinical trials in regions experiencing political or civil unrest could negatively affect clinical trial enrollment or the timely completion of a clinical trial. We believe the aforementioned economic conditions have led and could continue to lead to reduced demand for our and our collaboration partners&#8217; drug products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with rising international trade tensions or sanctions, our business may be adversely affected following new or increased tariffs that result in increased global clinical trial costs as a result of international transportation of clinical drug supplies, as well as the costs of materials and products imported into the U.S. Tariffs, trade restrictions or sanctions imposed by the U.S. or other countries could increase the prices of our and our collaboration partners&#8217; drug products, affect our and our collaboration partners&#8217; ability to commercialize such drug products, or create adverse tax consequences in the U.S. or other countries. As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by corporate citizenship and&#160;sustainability&#160;matters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increased focus from certain investors, employees, and other stakeholders concerning corporate citizenship and&#160;sustainability&#160;matters, which include environmental concerns and social investments. We could fail to meet, or be perceived to fail to meet, the expectations of these certain investors, employees and other stakeholders concerning corporate citizenship and sustainability matters, thereby resulting in a negative impact to our business. </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If earthquakes or other catastrophic events strike, our business may be harmed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters, including a substantial portion of our research and development operations, are located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our advanced polymer conjugate technologies in Huntsville, Alabama and own and lease offices in Hyderabad, India. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, political instability, or terrorist event in any of these locations, our ability to manufacture and supply materials for biologic candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and financial condition would be harmed. Our collaboration partners and important vendors and suppliers to us or our collaboration partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes, tornadoes and pandemics any of which could harm our business (including, for example, by disrupting supply chains important to the success of our business), results of operations and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur.</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_97"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None, including no purchases of any class of our equity securities by us or any affiliate pursuant to any publicly announced repurchase plan in the three months ended March&#160;31, 2022.</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_100"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_103"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="if0dd445e3956457f908bcf9b5e12885d_106"></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:9pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-indent:54pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Exhibit Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:83%">Description of Documents</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.1(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.2(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.3(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm">Certificate of Ownership and Merger of Nektar Therapeutics.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.4(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">3.5(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000121390020043821/ea132008ex3-1_nektartherap.htm">Amended and Restated Bylaws of Nektar Therapeutics.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">31.1(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2022-03x31xexx311.htm#i3683f73eb6894c41b53e8ac0800b06b2_1">Certification of Nektar Therapeutics&#8217; principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">31.2(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2022-03x31xexx312.htm#ia1bb74e422c340a7a16571d37d383678_1">Certification of Nektar Therapeutics&#8217; principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">32.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="nktr2022-03x31xexx321.htm#i5dfb63a9afa84bd495175cf95fc24851_1">Section 1350 Certifications.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.SCH(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Schema Document.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.CAL(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.LAB(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.PRE(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">101.DEF(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">104(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">_____________________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       1. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               June 30, 1998.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       2. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.3 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended &#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               June 30, 2000.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       3.     Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               January 23, 2003.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       4. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.6 to Nektar Therapeutics&#8217; Annual Report on Form 10-K, for the year ended </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">                December 31, 2009.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       5. &#160;&#160;&#160;&#160;Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">               December 21, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">       6.     Filed herewith.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Exhibit 32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="if0dd445e3956457f908bcf9b5e12885d_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if0dd445e3956457f908bcf9b5e12885d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ GIL M. LABRUCHERIE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gil M. Labrucherie<br/>Senior&#160;Vice&#160;President, Chief Operating Officer, and&#160;Chief&#160;Financial&#160;Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 5, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JILLIAN B. THOMSEN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jillian B. Thomsen<br/>Senior&#160;Vice&#160;President,&#160;Finance&#160;and&#160;Chief&#160;Accounting&#160;Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 5, 2022</span></td></tr></table></div><div style="margin-top:6pt;text-align:right"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>nktr2022-03x31xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3683f73eb6894c41b53e8ac0800b06b2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Howard W. Robin, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2022 of Nektar Therapeutics&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:48.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; HOWARD W. ROBIN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Howard W. Robin<br>Chief Executive Officer, President and Director</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>nktr2022-03x31xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia1bb74e422c340a7a16571d37d383678_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Gil M. Labrucherie, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2022 of Nektar Therapeutics&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:49.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; GIL M. LABRUCHERIE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gil M. Labrucherie<br>Senior Vice President, Chief Operating Officer,  and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>nktr2022-03x31xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5dfb63a9afa84bd495175cf95fc24851_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 CERTIFICATIONS*</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the &#8220;Company&#8221;), and Gil M. Labrucherie, Senior Vice President, Chief Operating Officer, and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the three months ended March&#160;31, 2022, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; HOWARD W. ROBIN</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; GIL M. LABRUCHERIE</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Howard W. Robin</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer, President and Director</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gil M. Labrucherie</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Vice President, Chief Operating Officer,  and Chief Financial Officer</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">___________________________________________</font></div><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nktr-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0975c044-35ac-4551-b121-d6df2cc9796d,g:b0fa7438-204d-4fa1-b132-84f7e9a28d02-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nktr="http://www.nektar.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nektar.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.nektar.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecurities" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities">
        <link:definition>2104102 - Disclosure - Cash and Investments in Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesTables" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail">
        <link:definition>2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
        <link:definition>2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.nektar.com/role/Inventory">
        <link:definition>2109103 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.nektar.com/role/InventoryTables">
        <link:definition>2310302 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.nektar.com/role/InventoryDetails">
        <link:definition>2411405 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability">
        <link:definition>2112104 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables">
        <link:definition>2313303 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails">
        <link:definition>2414406 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails">
        <link:definition>2415407 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoSalesofFutureRoyalties" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties">
        <link:definition>2116105 - Disclosure - Liabilities Related to Sales of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoSalesofFutureRoyaltiesTables" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables">
        <link:definition>2317304 - Disclosure - Liabilities Related to Sales of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails">
        <link:definition>2418408 - Disclosure - Liabilities Related to Sales of Future Royalties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails">
        <link:definition>2419409 - Disclosure - Liabilities Related to Sales of Future Royalties - Activity Within the Liability Account (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.nektar.com/role/CommitmentsandContingencies">
        <link:definition>2120106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2421410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements">
        <link:definition>2122107 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsAdditionalInformationDetails" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>2423411 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.nektar.com/role/StockBasedCompensation">
        <link:definition>2124108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.nektar.com/role/StockBasedCompensationTables">
        <link:definition>2325305 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>2426412 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationActivityDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail">
        <link:definition>2427413 - Disclosure - Stock-Based Compensation - Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.nektar.com/role/NetLossPerShare">
        <link:definition>2128109 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.nektar.com/role/NetLossPerShareTables">
        <link:definition>2329306 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetail" roleURI="http://www.nektar.com/role/NetLossPerShareDetail">
        <link:definition>2430414 - Disclosure - Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.nektar.com/role/SubsequentEvent">
        <link:definition>2131110 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.nektar.com/role/SubsequentEventDetails">
        <link:definition>2432415 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nktr_PotentialDevelopmentMilestones" abstract="false" name="PotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" abstract="false" name="GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PreferredStockShareDesignated" abstract="false" name="PreferredStockShareDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCollaborationAgreementMember" abstract="true" name="BristolMyersSquibbCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SaleOfStockConsiderationReceived" abstract="false" name="SaleOfStockConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2020Member" abstract="true" name="PurchaseAndSaleAgreement2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsAbstract" abstract="true" name="LicenseAndCollaborationAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCompanyMember" abstract="true" name="BristolMyersSquibbCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" abstract="true" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" abstract="false" name="CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementCommittedFunding" abstract="false" name="CollaborativeArrangementCommittedFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_OpdivoMember" abstract="true" name="OpdivoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2012Member" abstract="true" name="PurchaseAndSaleAgreement2012Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SFJPharmaceuticalsMember" abstract="true" name="SFJPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_DevelopmentDerivativeLiabilityTextBlock" abstract="false" name="DevelopmentDerivativeLiabilityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_RoyaltiesLiabilityMeasurementInput" abstract="false" name="RoyaltiesLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nktr_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_DebtInvestmentMaturityTerm" abstract="false" name="DebtInvestmentMaturityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" abstract="false" name="PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_Nektar358Member" abstract="true" name="Nektar358Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_AccruedClinicalTrialExpensesCurrent" abstract="false" name="AccruedClinicalTrialExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_DerivativeActionMember" abstract="true" name="DerivativeActionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_OrganizationPolicyTextBlock" abstract="false" name="OrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PartialRepaymentOfRoyaltySaleProceeds" abstract="false" name="PartialRepaymentOfRoyaltySaleProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" abstract="false" name="NonCashInterestExpenseRelatedToSaleOfRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInProductionCosts" abstract="false" name="PercentageOfSharingInProductionCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_LicenseCollaborationAndOtherRevenueMember" abstract="true" name="LicenseCollaborationAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_RoyaltyMonetizationProceeds" abstract="false" name="RoyaltyMonetizationProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ReimbursementOfExpenses" abstract="false" name="ReimbursementOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" abstract="false" name="PercentageOfSharingInPhaseTwoDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_LegalMattersMember" abstract="true" name="LegalMattersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_MulquinActionAndDamibaActionMember" abstract="true" name="MulquinActionAndDamibaActionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" abstract="false" name="ScheduleOfPurchaseAndSaleAgreementTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" abstract="false" name="LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PotentialDevelopmentAndRegulatoryMilestones" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LongTermInvestmentMaturityPeriod" abstract="false" name="LongTermInvestmentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_OtherPartnerMember" abstract="true" name="OtherPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesTable" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" abstract="false" name="UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInDevelopmentCosts" abstract="false" name="PercentageOfSharingInDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" abstract="false" name="UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_Nektar214Member" abstract="true" name="Nektar214Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_DebtInvestmentMaximumMaturityPeriod" abstract="false" name="DebtInvestmentMaximumMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_EliLillyMember" abstract="true" name="EliLillyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" abstract="false" name="ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_EliLillyAndCompanyMember" abstract="true" name="EliLillyAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>nktr-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0975c044-35ac-4551-b121-d6df2cc9796d,g:b0fa7438-204d-4fa1-b132-84f7e9a28d02-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3851ee5f-753e-4ea1-a93e-1aa4459e6bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8bb4edaf-ddbc-40b9-b62f-6c4d531d583a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3851ee5f-753e-4ea1-a93e-1aa4459e6bab" xlink:to="loc_us-gaap_Liabilities_8bb4edaf-ddbc-40b9-b62f-6c4d531d583a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b21d4716-03c4-4766-9189-d122df63f109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3851ee5f-753e-4ea1-a93e-1aa4459e6bab" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b21d4716-03c4-4766-9189-d122df63f109" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_32ce5633-e698-47ea-8003-a1ae54b3cfec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3851ee5f-753e-4ea1-a93e-1aa4459e6bab" xlink:to="loc_us-gaap_StockholdersEquity_32ce5633-e698-47ea-8003-a1ae54b3cfec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_44ce6f06-cc01-43cd-b7d4-cbb6871f56d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d70b2462-7758-4913-9a83-6472b7bdfcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44ce6f06-cc01-43cd-b7d4-cbb6871f56d2" xlink:to="loc_us-gaap_PreferredStockValue_d70b2462-7758-4913-9a83-6472b7bdfcaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ebcada36-660f-411c-adbc-71f9ce2fabee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44ce6f06-cc01-43cd-b7d4-cbb6871f56d2" xlink:to="loc_us-gaap_CommonStockValue_ebcada36-660f-411c-adbc-71f9ce2fabee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_aad934ee-5fd5-4eaf-a703-b20074032996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44ce6f06-cc01-43cd-b7d4-cbb6871f56d2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_aad934ee-5fd5-4eaf-a703-b20074032996" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_805e8c40-d7ab-4e0e-9ca7-bc7981a7f0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44ce6f06-cc01-43cd-b7d4-cbb6871f56d2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_805e8c40-d7ab-4e0e-9ca7-bc7981a7f0c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_db8a4483-cf55-4df0-946c-bf56460f1794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44ce6f06-cc01-43cd-b7d4-cbb6871f56d2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_db8a4483-cf55-4df0-946c-bf56460f1794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c229f7c3-2021-4796-9733-3e87f23f4be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_32e52b3f-03a4-41b2-82ec-63fd4a67b7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c229f7c3-2021-4796-9733-3e87f23f4be4" xlink:to="loc_us-gaap_AccountsPayableCurrent_32e52b3f-03a4-41b2-82ec-63fd4a67b7b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2bff2e2e-bc97-467b-b0ea-a572e648b08c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c229f7c3-2021-4796-9733-3e87f23f4be4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2bff2e2e-bc97-467b-b0ea-a572e648b08c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_3afdac70-1f7a-41dd-bcf3-c017226155b3" xlink:href="nktr-20220331.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c229f7c3-2021-4796-9733-3e87f23f4be4" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_3afdac70-1f7a-41dd-bcf3-c017226155b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f468ac58-241e-4013-b81a-671de075e1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c229f7c3-2021-4796-9733-3e87f23f4be4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f468ac58-241e-4013-b81a-671de075e1a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d86e22ab-e6ee-4c29-8c94-8c5fe7e8d29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c229f7c3-2021-4796-9733-3e87f23f4be4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d86e22ab-e6ee-4c29-8c94-8c5fe7e8d29b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_02f1563e-7ffc-4a7d-824b-8f8ae764bfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20832c16-3caa-4177-b00c-1a332660e750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02f1563e-7ffc-4a7d-824b-8f8ae764bfb4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20832c16-3caa-4177-b00c-1a332660e750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1164bb8f-05b2-404d-a9f8-953cce837120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02f1563e-7ffc-4a7d-824b-8f8ae764bfb4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1164bb8f-05b2-404d-a9f8-953cce837120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_07b7a916-1f0e-4ff8-86f3-9ae3d44ca50e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02f1563e-7ffc-4a7d-824b-8f8ae764bfb4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_07b7a916-1f0e-4ff8-86f3-9ae3d44ca50e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7eddf9a0-d115-4e79-9f29-920ee7fd5d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02f1563e-7ffc-4a7d-824b-8f8ae764bfb4" xlink:to="loc_us-gaap_InventoryNet_7eddf9a0-d115-4e79-9f29-920ee7fd5d14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_708e4b8e-610c-47e2-ae2b-68b99853a30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_02f1563e-7ffc-4a7d-824b-8f8ae764bfb4" xlink:to="loc_us-gaap_OtherAssetsCurrent_708e4b8e-610c-47e2-ae2b-68b99853a30b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f66ecab4-74bc-466d-899d-f6d3dfe51a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_088a133e-c0e7-42e1-807a-ae5d7436d131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f66ecab4-74bc-466d-899d-f6d3dfe51a87" xlink:to="loc_us-gaap_AssetsCurrent_088a133e-c0e7-42e1-807a-ae5d7436d131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d1c3bc44-fb12-418d-bb0f-39ef45627b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f66ecab4-74bc-466d-899d-f6d3dfe51a87" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d1c3bc44-fb12-418d-bb0f-39ef45627b41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5c999b49-8756-43e0-b017-21b6fbf6a440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f66ecab4-74bc-466d-899d-f6d3dfe51a87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5c999b49-8756-43e0-b017-21b6fbf6a440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6adce159-e005-4dd7-b705-2f248201e1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f66ecab4-74bc-466d-899d-f6d3dfe51a87" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6adce159-e005-4dd7-b705-2f248201e1a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_54443385-72aa-4635-8ef4-18b57ba791fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f66ecab4-74bc-466d-899d-f6d3dfe51a87" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_54443385-72aa-4635-8ef4-18b57ba791fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8705d8c3-ce72-44d8-bf1c-b1d4397de2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f66ecab4-74bc-466d-899d-f6d3dfe51a87" xlink:to="loc_us-gaap_Goodwill_8705d8c3-ce72-44d8-bf1c-b1d4397de2ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7c105ca9-53b1-4150-9e76-798b32f7216d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_895e454c-84b1-412e-9737-190780553720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7c105ca9-53b1-4150-9e76-798b32f7216d" xlink:to="loc_us-gaap_LiabilitiesCurrent_895e454c-84b1-412e-9737-190780553720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a793591e-1e3e-49fc-91af-1e1e6472f006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7c105ca9-53b1-4150-9e76-798b32f7216d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a793591e-1e3e-49fc-91af-1e1e6472f006" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_552d64ce-257f-44e3-a9c7-14ee3c3b75c4" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7c105ca9-53b1-4150-9e76-798b32f7216d" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_552d64ce-257f-44e3-a9c7-14ee3c3b75c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b993a9e0-67c6-4525-969e-8415f378b70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7c105ca9-53b1-4150-9e76-798b32f7216d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b993a9e0-67c6-4525-969e-8415f378b70f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_b3ad5b2e-0371-4121-8baf-eb1bc2676c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7c105ca9-53b1-4150-9e76-798b32f7216d" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_b3ad5b2e-0371-4121-8baf-eb1bc2676c3f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20220331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f2f63f6-9476-41c2-9514-f8a5b7648879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9e1d759c-912a-4d98-86fd-12cde367ea49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f2f63f6-9476-41c2-9514-f8a5b7648879" xlink:to="loc_us-gaap_OperatingIncomeLoss_9e1d759c-912a-4d98-86fd-12cde367ea49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6acbb1f6-deba-4365-9498-2e366076c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f2f63f6-9476-41c2-9514-f8a5b7648879" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6acbb1f6-deba-4365-9498-2e366076c21c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fb29a2be-9bf5-4161-b6f1-d33aa8812868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_17d9d3b8-e06e-4e69-8046-241996bcffe4" xlink:href="nktr-20220331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_fb29a2be-9bf5-4161-b6f1-d33aa8812868" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_17d9d3b8-e06e-4e69-8046-241996bcffe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6ecf1b26-fbad-4a57-9b6d-9ea28751a359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_fb29a2be-9bf5-4161-b6f1-d33aa8812868" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6ecf1b26-fbad-4a57-9b6d-9ea28751a359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_01f7d9db-5ca0-409b-be49-93e8acaf3be1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_fb29a2be-9bf5-4161-b6f1-d33aa8812868" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_01f7d9db-5ca0-409b-be49-93e8acaf3be1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3bd2c230-8829-4baf-be7e-e859dbad90f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5c05b605-0a70-49fd-8950-46a7d6df8143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3bd2c230-8829-4baf-be7e-e859dbad90f6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5c05b605-0a70-49fd-8950-46a7d6df8143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a10ecf54-5e73-451c-b299-375790cd9a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3bd2c230-8829-4baf-be7e-e859dbad90f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a10ecf54-5e73-451c-b299-375790cd9a81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f1667a79-927c-490a-aebd-0c55b1074066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3bd2c230-8829-4baf-be7e-e859dbad90f6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f1667a79-927c-490a-aebd-0c55b1074066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_11cf922f-2373-4b8f-9123-cb1058302fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3bd2c230-8829-4baf-be7e-e859dbad90f6" xlink:to="loc_us-gaap_RestructuringCharges_11cf922f-2373-4b8f-9123-cb1058302fc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eb746a94-a389-4005-b61f-1256c6b80a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a67ca885-46ca-498c-999a-e50e73cc35ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eb746a94-a389-4005-b61f-1256c6b80a17" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a67ca885-46ca-498c-999a-e50e73cc35ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5a5553a6-cdcf-4ef0-8dcb-523ba5d44df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eb746a94-a389-4005-b61f-1256c6b80a17" xlink:to="loc_us-gaap_CostsAndExpenses_5a5553a6-cdcf-4ef0-8dcb-523ba5d44df9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a582017f-5062-434c-bdfa-72a42ebf4e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94ba2e11-d83c-4f6f-9de1-adca973398a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a582017f-5062-434c-bdfa-72a42ebf4e8d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94ba2e11-d83c-4f6f-9de1-adca973398a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a49c7608-20dd-4749-a2cb-aed167d0b593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a582017f-5062-434c-bdfa-72a42ebf4e8d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a49c7608-20dd-4749-a2cb-aed167d0b593" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3f2c61d5-5bc7-4227-b469-58401a41d65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c12a3035-a595-4673-a9c4-f3ab76db1458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3f2c61d5-5bc7-4227-b469-58401a41d65c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c12a3035-a595-4673-a9c4-f3ab76db1458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_61f09c67-39a5-4b17-8051-f2fed12c985a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3f2c61d5-5bc7-4227-b469-58401a41d65c" xlink:to="loc_us-gaap_NetIncomeLoss_61f09c67-39a5-4b17-8051-f2fed12c985a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fb18b511-fab0-4e52-8bb7-4cbb1d8c4508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4727b3ad-1e02-40f5-87f8-bc5b3b13309d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fb18b511-fab0-4e52-8bb7-4cbb1d8c4508" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4727b3ad-1e02-40f5-87f8-bc5b3b13309d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_005ad03b-879e-4243-90d6-9b09acac747d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fb18b511-fab0-4e52-8bb7-4cbb1d8c4508" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_005ad03b-879e-4243-90d6-9b09acac747d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nktr-20220331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5c57adc-c407-473d-9075-c65f5cf73a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_f79395aa-d7cc-4a03-bdef-9e2f2b86b814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5c57adc-c407-473d-9075-c65f5cf73a75" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_f79395aa-d7cc-4a03-bdef-9e2f2b86b814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_fe4fc894-9b95-41ec-9c90-0277f4e0932d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5c57adc-c407-473d-9075-c65f5cf73a75" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_fe4fc894-9b95-41ec-9c90-0277f4e0932d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ef8673cf-ad48-4f68-b858-4e51ecceaab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_us-gaap_ProfitLoss_ef8673cf-ad48-4f68-b858-4e51ecceaab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_89d3aff8-c4c5-4471-b9e6-d45f99dc5d6a" xlink:href="nktr-20220331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_89d3aff8-c4c5-4471-b9e6-d45f99dc5d6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_26427520-8801-424e-96ae-0c30489546ee" xlink:href="nktr-20220331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_26427520-8801-424e-96ae-0c30489546ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8025f8a7-7484-4946-ba31-b85b370adcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8025f8a7-7484-4946-ba31-b85b370adcf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_03a9f0d9-aefe-4a32-8207-79832c444071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_us-gaap_DepreciationAndAmortization_03a9f0d9-aefe-4a32-8207-79832c444071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_fa6088d0-7fa1-4974-8ffc-c4ba96488e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_fa6088d0-7fa1-4974-8ffc-c4ba96488e4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_986518bf-c75a-4b48-87de-708042bb4c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_986518bf-c75a-4b48-87de-708042bb4c3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c89ccb44-8819-49c0-8a38-f88a08613d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c89ccb44-8819-49c0-8a38-f88a08613d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_22d2ecab-5023-4348-847a-34352ef02355" xlink:href="nktr-20220331.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_22d2ecab-5023-4348-847a-34352ef02355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4192c858-58b7-4f9d-b5a3-ae043459e7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4192c858-58b7-4f9d-b5a3-ae043459e7d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0aaac755-d086-44f5-a50b-7aa1a799b733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0aaac755-d086-44f5-a50b-7aa1a799b733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2fd25880-8233-4f2c-9472-cdcbfcff9a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2fd25880-8233-4f2c-9472-cdcbfcff9a30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_e683df4a-f7dd-4410-bdbc-11f3b0fd6ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_e683df4a-f7dd-4410-bdbc-11f3b0fd6ab1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_e29c2e10-2624-4a56-8779-704682e9f0de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_e29c2e10-2624-4a56-8779-704682e9f0de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_8b8167a9-6f90-4ffe-b82e-0023e14c126d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c08f5ff0-60fe-44cf-b3a0-c241df58e633" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_8b8167a9-6f90-4ffe-b82e-0023e14c126d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a1e81526-87c5-4942-98a2-126dfffbbe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f30c59a0-8829-4e94-938b-ffd517e82da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a1e81526-87c5-4942-98a2-126dfffbbe6e" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f30c59a0-8829-4e94-938b-ffd517e82da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_a994c61f-ca39-4559-b4e4-b64ff20f348c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a1e81526-87c5-4942-98a2-126dfffbbe6e" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_a994c61f-ca39-4559-b4e4-b64ff20f348c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5f0aa7ee-815a-4f98-9914-f030b0caaa13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a1e81526-87c5-4942-98a2-126dfffbbe6e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5f0aa7ee-815a-4f98-9914-f030b0caaa13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d17adea7-0ff7-456e-befc-b5b1747dcb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a1e81526-87c5-4942-98a2-126dfffbbe6e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d17adea7-0ff7-456e-befc-b5b1747dcb01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf88b2a9-a2ff-4cbb-b7c0-5c92936d471d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8ab84b4-7c66-4624-ba83-f9bd7cdb30a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf88b2a9-a2ff-4cbb-b7c0-5c92936d471d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8ab84b4-7c66-4624-ba83-f9bd7cdb30a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8b4cd543-2228-4e37-815e-f6c63149407d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf88b2a9-a2ff-4cbb-b7c0-5c92936d471d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8b4cd543-2228-4e37-815e-f6c63149407d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fc9aa9a2-5aa2-4718-a879-e1f116885b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf88b2a9-a2ff-4cbb-b7c0-5c92936d471d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fc9aa9a2-5aa2-4718-a879-e1f116885b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44b04e3d-cdbf-405b-8e2d-ac7af1d7ea2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf88b2a9-a2ff-4cbb-b7c0-5c92936d471d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44b04e3d-cdbf-405b-8e2d-ac7af1d7ea2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_a17526d7-5b6c-4033-8844-d81d05da5ad8" xlink:href="nktr-20220331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46c26ebd-4d45-4be6-b047-4f45248d6f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_a17526d7-5b6c-4033-8844-d81d05da5ad8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46c26ebd-4d45-4be6-b047-4f45248d6f22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b9f0b505-6baf-4d1d-b3f6-cf3075f3746c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_a17526d7-5b6c-4033-8844-d81d05da5ad8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b9f0b505-6baf-4d1d-b3f6-cf3075f3746c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_231cdad8-b794-4256-9f78-991578010840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_a17526d7-5b6c-4033-8844-d81d05da5ad8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_231cdad8-b794-4256-9f78-991578010840" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f344f9f9-c9a2-4345-a0f4-ab62ceea6fc3" xlink:href="nktr-20220331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a9f4571e-3626-46c1-85fb-8be355c737e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f344f9f9-c9a2-4345-a0f4-ab62ceea6fc3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a9f4571e-3626-46c1-85fb-8be355c737e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_c0baec99-23f7-4fae-a8a3-f964da17c09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f344f9f9-c9a2-4345-a0f4-ab62ceea6fc3" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_c0baec99-23f7-4fae-a8a3-f964da17c09f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_839b6e03-e2be-4b4d-aca3-b81b6601af76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f344f9f9-c9a2-4345-a0f4-ab62ceea6fc3" xlink:to="loc_us-gaap_Cash_839b6e03-e2be-4b4d-aca3-b81b6601af76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2f5888c4-82b5-478b-b0d5-c6fecf94e1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_66f53eae-9b12-4c21-905c-48c141f06da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2f5888c4-82b5-478b-b0d5-c6fecf94e1a7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_66f53eae-9b12-4c21-905c-48c141f06da8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cb5121c6-fb9f-4ba3-8135-dd7f576902cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2f5888c4-82b5-478b-b0d5-c6fecf94e1a7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cb5121c6-fb9f-4ba3-8135-dd7f576902cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5b9228f4-cbf9-40f6-9bc5-86221d973446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2f5888c4-82b5-478b-b0d5-c6fecf94e1a7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5b9228f4-cbf9-40f6-9bc5-86221d973446" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_654f93bd-1d0d-4230-85a1-709bcbee827f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_287fda4d-f452-4105-9b64-0d3b4bb97daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_654f93bd-1d0d-4230-85a1-709bcbee827f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_287fda4d-f452-4105-9b64-0d3b4bb97daa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_2b8f2a53-0dad-489a-909f-05f845e99943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_654f93bd-1d0d-4230-85a1-709bcbee827f" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_2b8f2a53-0dad-489a-909f-05f845e99943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_6d5f2a8f-74cd-486a-8e79-daf74fdc8e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_654f93bd-1d0d-4230-85a1-709bcbee827f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_6d5f2a8f-74cd-486a-8e79-daf74fdc8e9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_e11027f4-0be4-40fd-b796-f69fe13ec431" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_1ab60af7-86f9-483e-b864-a46e42b14fb1" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_e11027f4-0be4-40fd-b796-f69fe13ec431" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_1ab60af7-86f9-483e-b864-a46e42b14fb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_2378ef71-84b7-4fab-8fbc-330c066b1516" xlink:href="nktr-20220331.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_e11027f4-0be4-40fd-b796-f69fe13ec431" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_2378ef71-84b7-4fab-8fbc-330c066b1516" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>nktr-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0975c044-35ac-4551-b121-d6df2cc9796d,g:b0fa7438-204d-4fa1-b132-84f7e9a28d02-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20220331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i2c5f9a02e62b4a0b9c2c4caa26331e3a_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_cf7b7da8-e24f-4c46-96fd-25c98258b012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_RevenuesAbstract_cf7b7da8-e24f-4c46-96fd-25c98258b012" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e378b3c-468e-42c3-99a0-78dfd10fabe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_cf7b7da8-e24f-4c46-96fd-25c98258b012" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e378b3c-468e-42c3-99a0-78dfd10fabe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f6386021-9a89-4136-b234-b0623c94ed2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f6386021-9a89-4136-b234-b0623c94ed2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_36718f86-7675-40aa-b089-bed46629b054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_36718f86-7675-40aa-b089-bed46629b054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0b3b61df-d370-4684-a651-1de9cecdc9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0b3b61df-d370-4684-a651-1de9cecdc9bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ce630e99-54ca-457e-88a5-e3855925d163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:to="loc_us-gaap_RestructuringCharges_ce630e99-54ca-457e-88a5-e3855925d163" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_089a7e47-56e2-4d7d-b9d5-0be07032d8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:to="loc_us-gaap_CostsAndExpenses_089a7e47-56e2-4d7d-b9d5-0be07032d8f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7c1cf4c2-9d59-44ea-8090-de5e96b83a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_OperatingIncomeLoss_7c1cf4c2-9d59-44ea-8090-de5e96b83a70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1d1dc160-acd4-477f-a3f1-55250c042ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1d1dc160-acd4-477f-a3f1-55250c042ca7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_6d3b84ea-7545-47bf-8b60-9a100f6973c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1d1dc160-acd4-477f-a3f1-55250c042ca7" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_6d3b84ea-7545-47bf-8b60-9a100f6973c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1d7c6b23-8142-4124-a6aa-92bf58748811" xlink:href="nktr-20220331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1d1dc160-acd4-477f-a3f1-55250c042ca7" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1d7c6b23-8142-4124-a6aa-92bf58748811" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_67e2b048-27c3-417a-94ed-cc718ecb086c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1d1dc160-acd4-477f-a3f1-55250c042ca7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_67e2b048-27c3-417a-94ed-cc718ecb086c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e2b9dc4d-b4c7-4bb3-87ab-b1bd8c40143b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1d1dc160-acd4-477f-a3f1-55250c042ca7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e2b9dc4d-b4c7-4bb3-87ab-b1bd8c40143b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_48ce8ec2-a012-4cb2-816e-4743e9cbb8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_48ce8ec2-a012-4cb2-816e-4743e9cbb8e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1419f40b-2cfd-407c-a25d-3f0081d5a2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1419f40b-2cfd-407c-a25d-3f0081d5a2ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0c84d2bd-5ee0-488b-933f-59aecfb6b8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_NetIncomeLoss_0c84d2bd-5ee0-488b-933f-59aecfb6b8d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_615892e1-f7ec-4be5-9128-3e6c358ef100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_EarningsPerShareBasic_615892e1-f7ec-4be5-9128-3e6c358ef100" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3c1d155e-90bf-453a-94f6-d555b307b473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3c1d155e-90bf-453a-94f6-d555b307b473" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dab51605-3fea-4d85-88a1-4c91971641b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dab51605-3fea-4d85-88a1-4c91971641b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_70402d45-e366-4ba5-bcc8-c3e388d294c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_70402d45-e366-4ba5-bcc8-c3e388d294c1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8b0e0e3d-80b0-4df4-b155-cc8637fd9752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_StatementTable_8b0e0e3d-80b0-4df4-b155-cc8637fd9752" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab38acb3-1f2e-47be-a6d7-30d32a945a99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8b0e0e3d-80b0-4df4-b155-cc8637fd9752" xlink:to="loc_srt_ProductOrServiceAxis_ab38acb3-1f2e-47be-a6d7-30d32a945a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab38acb3-1f2e-47be-a6d7-30d32a945a99_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ab38acb3-1f2e-47be-a6d7-30d32a945a99" xlink:to="loc_srt_ProductsAndServicesDomain_ab38acb3-1f2e-47be-a6d7-30d32a945a99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed3fb882-282a-4682-9254-898f1b496bf1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ab38acb3-1f2e-47be-a6d7-30d32a945a99" xlink:to="loc_srt_ProductsAndServicesDomain_ed3fb882-282a-4682-9254-898f1b496bf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5f47abcb-f859-452d-b316-dc7319746caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ed3fb882-282a-4682-9254-898f1b496bf1" xlink:to="loc_us-gaap_ProductMember_5f47abcb-f859-452d-b316-dc7319746caa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_a3be65b4-d2d2-4d3e-9191-9b0749ab992b" xlink:href="nktr-20220331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ed3fb882-282a-4682-9254-898f1b496bf1" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_a3be65b4-d2d2-4d3e-9191-9b0749ab992b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_a60de371-65e1-4e3e-aaa9-b7b59b74395d" xlink:href="nktr-20220331.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ed3fb882-282a-4682-9254-898f1b496bf1" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_a60de371-65e1-4e3e-aaa9-b7b59b74395d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i33f2034988f2494e9f950a2db6a820d8_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_86a82066-8a7a-4a8b-9d31-08a5f3c6f666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_86a82066-8a7a-4a8b-9d31-08a5f3c6f666" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f923961d-3325-46aa-8794-8f832ffec21b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_SharesOutstanding_f923961d-3325-46aa-8794-8f832ffec21b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04cd34f2-3806-4b71-b4a4-6b698d2f2107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_StockholdersEquity_04cd34f2-3806-4b71-b4a4-6b698d2f2107" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3ae1dfd5-6762-48e9-bf87-a5ca5fdfd207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3ae1dfd5-6762-48e9-bf87-a5ca5fdfd207" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9ccd0e83-f780-4e00-886f-2834c7e117de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9ccd0e83-f780-4e00-886f-2834c7e117de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dc84ddbd-00fb-4de5-9a60-05a92c8bbcfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dc84ddbd-00fb-4de5-9a60-05a92c8bbcfb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e46038d4-48ab-4d7d-95a4-d523da2f4f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e46038d4-48ab-4d7d-95a4-d523da2f4f4f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0372c7b6-799b-42aa-9c65-19f3c066c5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a3a01dd4-fd6e-404c-9005-a1da6441e92e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ed52fadb-8fa4-4d21-8746-16ed100b4b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_86a82066-8a7a-4a8b-9d31-08a5f3c6f666" xlink:to="loc_us-gaap_StatementTable_ed52fadb-8fa4-4d21-8746-16ed100b4b2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_195848da-02b1-4ea2-89b6-648a8bec1fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ed52fadb-8fa4-4d21-8746-16ed100b4b2c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_195848da-02b1-4ea2-89b6-648a8bec1fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_195848da-02b1-4ea2-89b6-648a8bec1fe0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_195848da-02b1-4ea2-89b6-648a8bec1fe0" xlink:to="loc_us-gaap_EquityComponentDomain_195848da-02b1-4ea2-89b6-648a8bec1fe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_38d92770-347e-42ce-b611-c1e22cff8a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_195848da-02b1-4ea2-89b6-648a8bec1fe0" xlink:to="loc_us-gaap_EquityComponentDomain_38d92770-347e-42ce-b611-c1e22cff8a86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_36e83527-457d-4a85-b02f-fb43929b7354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_38d92770-347e-42ce-b611-c1e22cff8a86" xlink:to="loc_us-gaap_CommonStockMember_36e83527-457d-4a85-b02f-fb43929b7354" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f5355eae-b750-492c-980c-826d8b4eb984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_38d92770-347e-42ce-b611-c1e22cff8a86" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f5355eae-b750-492c-980c-826d8b4eb984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1a8ef935-2ded-4a6e-82ce-174d18433907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_38d92770-347e-42ce-b611-c1e22cff8a86" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1a8ef935-2ded-4a6e-82ce-174d18433907" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f87ea71a-9702-4eaa-8c48-2238eb03f61f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_38d92770-347e-42ce-b611-c1e22cff8a86" xlink:to="loc_us-gaap_RetainedEarningsMember_f87ea71a-9702-4eaa-8c48-2238eb03f61f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i0729e665b4e34201b93519e7244ea999_OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:href="nktr-20220331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_e3647dee-0792-4a47-9734-f573451a3d52" xlink:href="nktr-20220331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_e3647dee-0792-4a47-9734-f573451a3d52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_9dd544fd-ed80-437c-9892-45288c995383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_9dd544fd-ed80-437c-9892-45288c995383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_74c1a27e-9884-4086-89ac-f5537cddc44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_74c1a27e-9884-4086-89ac-f5537cddc44c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_04a54446-7caf-4524-b3e8-98f63449a201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_04a54446-7caf-4524-b3e8-98f63449a201" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3198b765-529c-438e-8e0d-90c8bfd569e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3198b765-529c-438e-8e0d-90c8bfd569e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:href="nktr-20220331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8c5ca053-9c1a-4684-8381-d345e4cf6f92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:to="loc_srt_CounterpartyNameAxis_8c5ca053-9c1a-4684-8381-d345e4cf6f92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c5ca053-9c1a-4684-8381-d345e4cf6f92_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8c5ca053-9c1a-4684-8381-d345e4cf6f92" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c5ca053-9c1a-4684-8381-d345e4cf6f92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38811409-008f-4f26-90f6-cd8aed30d390" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8c5ca053-9c1a-4684-8381-d345e4cf6f92" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38811409-008f-4f26-90f6-cd8aed30d390" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_c3be2ce1-218a-4d11-898d-82b2b7f82fd5" xlink:href="nktr-20220331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38811409-008f-4f26-90f6-cd8aed30d390" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_c3be2ce1-218a-4d11-898d-82b2b7f82fd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5eb6d39f-8205-4864-af82-c4f9dcfbdfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5eb6d39f-8205-4864-af82-c4f9dcfbdfb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5eb6d39f-8205-4864-af82-c4f9dcfbdfb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5eb6d39f-8205-4864-af82-c4f9dcfbdfb0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5eb6d39f-8205-4864-af82-c4f9dcfbdfb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d413a5ac-8edc-4560-adb1-440046c80ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5eb6d39f-8205-4864-af82-c4f9dcfbdfb0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d413a5ac-8edc-4560-adb1-440046c80ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b9319efb-28dc-466f-b88b-fbcc99512273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d413a5ac-8edc-4560-adb1-440046c80ee8" xlink:to="loc_us-gaap_SubsequentEventMember_b9319efb-28dc-466f-b88b-fbcc99512273" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_745204ef-8935-43e3-9729-e9f7ff77dbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_745204ef-8935-43e3-9729-e9f7ff77dbbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_745204ef-8935-43e3-9729-e9f7ff77dbbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_745204ef-8935-43e3-9729-e9f7ff77dbbe" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_745204ef-8935-43e3-9729-e9f7ff77dbbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3fc1db92-cd59-4716-8ce6-65e8e16d0eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_745204ef-8935-43e3-9729-e9f7ff77dbbe" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3fc1db92-cd59-4716-8ce6-65e8e16d0eba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_eefeb1c3-55be-4223-99b6-2fd28c2eb5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3fc1db92-cd59-4716-8ce6-65e8e16d0eba" xlink:to="loc_us-gaap_EmployeeSeveranceMember_eefeb1c3-55be-4223-99b6-2fd28c2eb5c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b954dc3-c639-4247-9703-98ec0c030811" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:to="loc_srt_ProductOrServiceAxis_9b954dc3-c639-4247-9703-98ec0c030811" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b954dc3-c639-4247-9703-98ec0c030811_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9b954dc3-c639-4247-9703-98ec0c030811" xlink:to="loc_srt_ProductsAndServicesDomain_9b954dc3-c639-4247-9703-98ec0c030811_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d39e5643-d520-4f69-b170-4c3a851440a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9b954dc3-c639-4247-9703-98ec0c030811" xlink:to="loc_srt_ProductsAndServicesDomain_d39e5643-d520-4f69-b170-4c3a851440a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_97a4a013-3f0b-47c8-8e79-f5350b8162cf" xlink:href="nktr-20220331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d39e5643-d520-4f69-b170-4c3a851440a2" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_97a4a013-3f0b-47c8-8e79-f5350b8162cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended" id="i1cecf05ca25d4827a2d4727d0a19082b_CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:href="nktr-20220331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_dfa0a014-b3d5-482a-bf65-ca00468c0304" xlink:href="nktr-20220331.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:to="loc_nktr_DebtInvestmentMaximumMaturityPeriod_dfa0a014-b3d5-482a-bf65-ca00468c0304" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_9238efc5-80d9-4668-af19-2c8740e649af" xlink:href="nktr-20220331.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:to="loc_nktr_DebtInvestmentMaturityTerm_9238efc5-80d9-4668-af19-2c8740e649af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_7e2d4246-86c5-4101-bd93-40eee41824e8" xlink:href="nktr-20220331.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_7e2d4246-86c5-4101-bd93-40eee41824e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_29f4f9c7-f8ba-436f-aad9-8b696e02be6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_29f4f9c7-f8ba-436f-aad9-8b696e02be6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a1435b42-5a48-4221-ad35-527467815f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a1435b42-5a48-4221-ad35-527467815f99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_5a7a9be1-6891-4c12-bacf-e6cf9a9584d1" xlink:href="nktr-20220331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_5a7a9be1-6891-4c12-bacf-e6cf9a9584d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4cd9ea66-3ed4-495f-bf27-6b2a9ccb902a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_5a7a9be1-6891-4c12-bacf-e6cf9a9584d1" xlink:to="loc_srt_RangeAxis_4cd9ea66-3ed4-495f-bf27-6b2a9ccb902a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4cd9ea66-3ed4-495f-bf27-6b2a9ccb902a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4cd9ea66-3ed4-495f-bf27-6b2a9ccb902a" xlink:to="loc_srt_RangeMember_4cd9ea66-3ed4-495f-bf27-6b2a9ccb902a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_97db9169-ce3b-4c51-a18a-ffbeb4f245aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4cd9ea66-3ed4-495f-bf27-6b2a9ccb902a" xlink:to="loc_srt_RangeMember_97db9169-ce3b-4c51-a18a-ffbeb4f245aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_284fdd65-9132-456f-9a01-29fdd74c95b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_97db9169-ce3b-4c51-a18a-ffbeb4f245aa" xlink:to="loc_srt_MinimumMember_284fdd65-9132-456f-9a01-29fdd74c95b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_85f19b49-5b60-4161-bcda-a18f3889d66a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_97db9169-ce3b-4c51-a18a-ffbeb4f245aa" xlink:to="loc_srt_MaximumMember_85f19b49-5b60-4161-bcda-a18f3889d66a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended" id="i66e08aff111a4d7290d5df1253b239cf_CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_588db3f4-06e5-4a25-a1d8-77784fe4e614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_588db3f4-06e5-4a25-a1d8-77784fe4e614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4d2eebd-514e-4fcf-98fd-9a622a2b410d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4d2eebd-514e-4fcf-98fd-9a622a2b410d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_998ba654-15e4-4be4-8593-a497bb9a9762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_998ba654-15e4-4be4-8593-a497bb9a9762" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_489938e9-00ae-4f50-b048-48cb96d35230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_489938e9-00ae-4f50-b048-48cb96d35230" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_265efa4f-16c7-49bb-a67a-87c7818222f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_265efa4f-16c7-49bb-a67a-87c7818222f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_ecc97b6f-19d0-4fdb-a0f7-83990c112a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_Cash_ecc97b6f-19d0-4fdb-a0f7-83990c112a77" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_eff6928e-35ae-4f0b-8cde-67fa7ce5ea8e" xlink:href="nktr-20220331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_eff6928e-35ae-4f0b-8cde-67fa7ce5ea8e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_939bd11e-7f2d-4a3a-b4b8-d28fee1e3835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_939bd11e-7f2d-4a3a-b4b8-d28fee1e3835" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_958139e4-3a8e-4165-9662-58df8a212826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_939bd11e-7f2d-4a3a-b4b8-d28fee1e3835" xlink:to="loc_us-gaap_InvestmentTypeAxis_958139e4-3a8e-4165-9662-58df8a212826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_958139e4-3a8e-4165-9662-58df8a212826_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_958139e4-3a8e-4165-9662-58df8a212826" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_958139e4-3a8e-4165-9662-58df8a212826_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_958139e4-3a8e-4165-9662-58df8a212826" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_259e9f69-a95a-4e1b-97d0-0ecd58a8273e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_259e9f69-a95a-4e1b-97d0-0ecd58a8273e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8a775c81-deb6-44a1-96fd-4c1feebd1a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:to="loc_us-gaap_CommercialPaperMember_8a775c81-deb6-44a1-96fd-4c1feebd1a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d971937f-4b81-402a-9257-730ee1e30939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d971937f-4b81-402a-9257-730ee1e30939" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b0eb3846-2ca1-4e04-84b7-42ee2a9217fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b0eb3846-2ca1-4e04-84b7-42ee2a9217fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_46e23628-6a02-4440-8530-d7817d85c799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_46e23628-6a02-4440-8530-d7817d85c799" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_60022f86-d84b-4db9-af2b-8afc3f5bde1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_939bd11e-7f2d-4a3a-b4b8-d28fee1e3835" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_60022f86-d84b-4db9-af2b-8afc3f5bde1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60022f86-d84b-4db9-af2b-8afc3f5bde1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_60022f86-d84b-4db9-af2b-8afc3f5bde1e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60022f86-d84b-4db9-af2b-8afc3f5bde1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df7b8250-8cdb-4a04-ad67-fff8b93f17cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_60022f86-d84b-4db9-af2b-8afc3f5bde1e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df7b8250-8cdb-4a04-ad67-fff8b93f17cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a388a597-afb1-46b1-ac6f-49c79f58e85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df7b8250-8cdb-4a04-ad67-fff8b93f17cf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a388a597-afb1-46b1-ac6f-49c79f58e85a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_301f1140-4a49-4c73-9b2e-7832c76410c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df7b8250-8cdb-4a04-ad67-fff8b93f17cf" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_301f1140-4a49-4c73-9b2e-7832c76410c9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="extended" id="ia153e94a80364762adf716213fac3ec1_CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4add300-98f8-474b-89a8-5ac4ed77275c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_822a2fdf-08e1-4652-943a-6325ac639800" xlink:href="nktr-20220331.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4add300-98f8-474b-89a8-5ac4ed77275c" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_822a2fdf-08e1-4652-943a-6325ac639800" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_9a7c3f39-5181-4561-9146-e28975b86d2c" xlink:href="nktr-20220331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4add300-98f8-474b-89a8-5ac4ed77275c" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_9a7c3f39-5181-4561-9146-e28975b86d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5a853313-b643-498c-a510-135167873749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4add300-98f8-474b-89a8-5ac4ed77275c" xlink:to="loc_us-gaap_DerivativeLiabilities_5a853313-b643-498c-a510-135167873749" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ba1a878-cef9-4b82-afae-7b5cc35f5443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4add300-98f8-474b-89a8-5ac4ed77275c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ba1a878-cef9-4b82-afae-7b5cc35f5443" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_75819c1f-fc51-43ab-89f7-91755ee1a6ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ba1a878-cef9-4b82-afae-7b5cc35f5443" xlink:to="loc_srt_CounterpartyNameAxis_75819c1f-fc51-43ab-89f7-91755ee1a6ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_75819c1f-fc51-43ab-89f7-91755ee1a6ab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_75819c1f-fc51-43ab-89f7-91755ee1a6ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_75819c1f-fc51-43ab-89f7-91755ee1a6ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e575693-6a6b-4cd8-98d9-a1d057991639" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_75819c1f-fc51-43ab-89f7-91755ee1a6ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e575693-6a6b-4cd8-98d9-a1d057991639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_d78c2f89-256d-4c95-a4ae-b208189066c5" xlink:href="nktr-20220331.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e575693-6a6b-4cd8-98d9-a1d057991639" xlink:to="loc_nktr_SFJPharmaceuticalsMember_d78c2f89-256d-4c95-a4ae-b208189066c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="extended" id="i11d5fe7f83ad4c4ca0f5c597030c06e3_CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b58f38ac-5192-470e-82bb-57c9ae2d8ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b58f38ac-5192-470e-82bb-57c9ae2d8ced" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_65377b48-5f1a-4663-832f-5fecc6bb9f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_65377b48-5f1a-4663-832f-5fecc6bb9f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9a16276e-3eaf-4aac-a6c6-d0d4793686f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_a49edd9f-c071-4a0e-9f5a-dc4262c60eca" xlink:href="nktr-20220331.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:to="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_a49edd9f-c071-4a0e-9f5a-dc4262c60eca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_ac5e5eb9-606e-4dc2-8852-f31e571eda86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_ac5e5eb9-606e-4dc2-8852-f31e571eda86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_58b515f7-f8b0-4c71-bd78-61eaea659ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_58b515f7-f8b0-4c71-bd78-61eaea659ae9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_706ade30-39bf-4008-935f-d7ac2e8e2c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_30b0058b-7738-4cca-9c01-c045d47c1c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b58f38ac-5192-470e-82bb-57c9ae2d8ced" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_30b0058b-7738-4cca-9c01-c045d47c1c02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_9aabeaff-ebb9-4cd6-80ba-101a16f40e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_30b0058b-7738-4cca-9c01-c045d47c1c02" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_9aabeaff-ebb9-4cd6-80ba-101a16f40e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9aabeaff-ebb9-4cd6-80ba-101a16f40e7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_9aabeaff-ebb9-4cd6-80ba-101a16f40e7e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9aabeaff-ebb9-4cd6-80ba-101a16f40e7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dc707a40-3464-43ec-8dc9-b1d045073a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_9aabeaff-ebb9-4cd6-80ba-101a16f40e7e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dc707a40-3464-43ec-8dc9-b1d045073a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2b77d98e-2f58-4f03-ba02-bb23e56c56a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dc707a40-3464-43ec-8dc9-b1d045073a45" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2b77d98e-2f58-4f03-ba02-bb23e56c56a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_13287cce-4d67-4318-b804-2e4f9fdacd61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_30b0058b-7738-4cca-9c01-c045d47c1c02" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_13287cce-4d67-4318-b804-2e4f9fdacd61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_13287cce-4d67-4318-b804-2e4f9fdacd61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_13287cce-4d67-4318-b804-2e4f9fdacd61" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_13287cce-4d67-4318-b804-2e4f9fdacd61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3652d8a-86cd-4592-a940-45a2e95c89a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_13287cce-4d67-4318-b804-2e4f9fdacd61" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3652d8a-86cd-4592-a940-45a2e95c89a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_77eacc8d-69c4-41f2-bab3-64a935e27684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3652d8a-86cd-4592-a940-45a2e95c89a3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_77eacc8d-69c4-41f2-bab3-64a935e27684" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="extended" id="ibc2765cfe747489c9691036992ef491f_LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_c8c04509-7315-444a-8bd2-d0855d081b19" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput_d089936e-e835-4586-bf05-528d598deaff" xlink:href="nktr-20220331.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_c8c04509-7315-444a-8bd2-d0855d081b19" xlink:to="loc_nktr_RoyaltiesLiabilityMeasurementInput_d089936e-e835-4586-bf05-528d598deaff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_df60c83e-9a05-46f4-8a29-422a58495c70" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_c8c04509-7315-444a-8bd2-d0855d081b19" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_df60c83e-9a05-46f4-8a29-422a58495c70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c74c1731-f769-4783-88a8-6bed808c39cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_df60c83e-9a05-46f4-8a29-422a58495c70" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c74c1731-f769-4783-88a8-6bed808c39cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c74c1731-f769-4783-88a8-6bed808c39cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c74c1731-f769-4783-88a8-6bed808c39cc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c74c1731-f769-4783-88a8-6bed808c39cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ada28e05-9c39-4310-bb53-966c973c0343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c74c1731-f769-4783-88a8-6bed808c39cc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ada28e05-9c39-4310-bb53-966c973c0343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_fd3a369b-725f-4044-b720-505fc4456896" xlink:href="nktr-20220331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ada28e05-9c39-4310-bb53-966c973c0343" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_fd3a369b-725f-4044-b720-505fc4456896" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_5ffaf93f-ba09-47f7-bcca-fd3532c10d77" xlink:href="nktr-20220331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ada28e05-9c39-4310-bb53-966c973c0343" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_5ffaf93f-ba09-47f7-bcca-fd3532c10d77" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" xlink:type="extended" id="i7ec9e71d6f0143a792f5f8d1f86cbf24_LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds_0e938a06-7299-45c8-8565-ae97ed7de6c8" xlink:href="nktr-20220331.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_RoyaltyMonetizationProceeds_0e938a06-7299-45c8-8565-ae97ed7de6c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_1d8074f3-91a2-4b8f-8dee-e6e97d30d02a" xlink:href="nktr-20220331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_1d8074f3-91a2-4b8f-8dee-e6e97d30d02a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_784da1e7-411e-432b-bc4b-22242a98bc13" xlink:href="nktr-20220331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_784da1e7-411e-432b-bc4b-22242a98bc13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_6eac31f5-8427-47c1-8ed7-593a6107a43d" xlink:href="nktr-20220331.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_6eac31f5-8427-47c1-8ed7-593a6107a43d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_d5c7a7d4-10ff-4934-9e66-05297bf07ab0" xlink:href="nktr-20220331.xsd#nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_d5c7a7d4-10ff-4934-9e66-05297bf07ab0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_b990ad5c-2b3c-42e6-9599-6907f0c0c44a" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_b990ad5c-2b3c-42e6-9599-6907f0c0c44a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_ca9c2fd6-6655-494b-8a94-27cee057fa84" xlink:href="nktr-20220331.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_ca9c2fd6-6655-494b-8a94-27cee057fa84" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_f8afc54a-7939-4cf3-99dc-6baa3945fd9d" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_f8afc54a-7939-4cf3-99dc-6baa3945fd9d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_332894b8-1ecb-4e7a-8ada-9e1261a57014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_332894b8-1ecb-4e7a-8ada-9e1261a57014" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ce8db9df-8b82-4fad-b1d9-c0d0864c0b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_332894b8-1ecb-4e7a-8ada-9e1261a57014" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ce8db9df-8b82-4fad-b1d9-c0d0864c0b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce8db9df-8b82-4fad-b1d9-c0d0864c0b6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ce8db9df-8b82-4fad-b1d9-c0d0864c0b6c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce8db9df-8b82-4fad-b1d9-c0d0864c0b6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f9fa81e-2c31-44a2-8e69-6dfc59a3526b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ce8db9df-8b82-4fad-b1d9-c0d0864c0b6c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f9fa81e-2c31-44a2-8e69-6dfc59a3526b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_a34c2b7b-315a-4a55-8714-9fa7074ea448" xlink:href="nktr-20220331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f9fa81e-2c31-44a2-8e69-6dfc59a3526b" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_a34c2b7b-315a-4a55-8714-9fa7074ea448" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_ca8df791-afe6-4f08-ae8c-603a3244c829" xlink:href="nktr-20220331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f9fa81e-2c31-44a2-8e69-6dfc59a3526b" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_ca8df791-afe6-4f08-ae8c-603a3244c829" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i1d0e103553514e949d4100de8c033a75_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5addd5e3-19f6-4bf3-a24f-57ae8a46a4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_c45df185-abd3-4c24-ac14-54b7cd5195f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5addd5e3-19f6-4bf3-a24f-57ae8a46a4a4" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_c45df185-abd3-4c24-ac14-54b7cd5195f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_252778fd-dd84-4cea-8c0b-1c08bd6287ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5addd5e3-19f6-4bf3-a24f-57ae8a46a4a4" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_252778fd-dd84-4cea-8c0b-1c08bd6287ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7cf16ac1-8a26-435b-880b-e65081645b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5addd5e3-19f6-4bf3-a24f-57ae8a46a4a4" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7cf16ac1-8a26-435b-880b-e65081645b87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_9016554d-5a88-4480-bc67-26bcad761308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_5addd5e3-19f6-4bf3-a24f-57ae8a46a4a4" xlink:to="loc_us-gaap_LossContingenciesTable_9016554d-5a88-4480-bc67-26bcad761308" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_722d729f-3e6d-4d67-b782-73e45a1c4677" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9016554d-5a88-4480-bc67-26bcad761308" xlink:to="loc_srt_LitigationCaseAxis_722d729f-3e6d-4d67-b782-73e45a1c4677" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_722d729f-3e6d-4d67-b782-73e45a1c4677_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_722d729f-3e6d-4d67-b782-73e45a1c4677" xlink:to="loc_srt_LitigationCaseTypeDomain_722d729f-3e6d-4d67-b782-73e45a1c4677_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e2ffc0eb-278e-4d00-8734-e1f1b315f7fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_722d729f-3e6d-4d67-b782-73e45a1c4677" xlink:to="loc_srt_LitigationCaseTypeDomain_e2ffc0eb-278e-4d00-8734-e1f1b315f7fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MulquinActionAndDamibaActionMember_b4854a86-607e-4f1a-83c5-7ecfd21ee1e7" xlink:href="nktr-20220331.xsd#nktr_MulquinActionAndDamibaActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2ffc0eb-278e-4d00-8734-e1f1b315f7fa" xlink:to="loc_nktr_MulquinActionAndDamibaActionMember_b4854a86-607e-4f1a-83c5-7ecfd21ee1e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DerivativeActionMember_c4a5c242-87e3-40fd-a65b-3e0183834a02" xlink:href="nktr-20220331.xsd#nktr_DerivativeActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e2ffc0eb-278e-4d00-8734-e1f1b315f7fa" xlink:to="loc_nktr_DerivativeActionMember_c4a5c242-87e3-40fd-a65b-3e0183834a02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_241f9189-0661-4c02-8da4-40da488251fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9016554d-5a88-4480-bc67-26bcad761308" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_241f9189-0661-4c02-8da4-40da488251fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_241f9189-0661-4c02-8da4-40da488251fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_241f9189-0661-4c02-8da4-40da488251fb" xlink:to="loc_us-gaap_LossContingencyNatureDomain_241f9189-0661-4c02-8da4-40da488251fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_612fdd95-96bc-4e5a-80c0-c45caea5719d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_241f9189-0661-4c02-8da4-40da488251fb" xlink:to="loc_us-gaap_LossContingencyNatureDomain_612fdd95-96bc-4e5a-80c0-c45caea5719d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember_3ea2640d-c212-42bf-b840-d80b0636a359" xlink:href="nktr-20220331.xsd#nktr_LegalMattersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_612fdd95-96bc-4e5a-80c0-c45caea5719d" xlink:to="loc_nktr_LegalMattersMember_3ea2640d-c212-42bf-b840-d80b0636a359" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended" id="iba6d7b8116124b90a4d7ccf81ee3a91a_LicenseandCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_aa524773-098f-4ef6-a581-3e6abcfbefd9" xlink:href="nktr-20220331.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_aa524773-098f-4ef6-a581-3e6abcfbefd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_1c68d0e5-9b2d-433a-98c5-a42fe369abdb" xlink:href="nktr-20220331.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_1c68d0e5-9b2d-433a-98c5-a42fe369abdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_58c5aa34-ba49-45b5-8f9e-4e464fb7d024" xlink:href="nktr-20220331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_58c5aa34-ba49-45b5-8f9e-4e464fb7d024" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_5cc7a4c0-cfa6-4cb3-8597-7bbf19683a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_us-gaap_SharesIssued_5cc7a4c0-cfa6-4cb3-8597-7bbf19683a11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_f50a9baf-d85d-47cd-bd3a-40cc589e12d5" xlink:href="nktr-20220331.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_f50a9baf-d85d-47cd-bd3a-40cc589e12d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_473e919e-f763-497a-8088-ce0c02a5eae9" xlink:href="nktr-20220331.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PotentialDevelopmentMilestones_473e919e-f763-497a-8088-ce0c02a5eae9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_76e36243-0e6b-4e04-ae71-1f832a9611c2" xlink:href="nktr-20220331.xsd#nktr_ReimbursementOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_ReimbursementOfExpenses_76e36243-0e6b-4e04-ae71-1f832a9611c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_79acc665-31f3-422a-bf3f-8c86fa53d744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_79acc665-31f3-422a-bf3f-8c86fa53d744" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_8c435e50-8670-4a31-9034-8463fa84d6ac" xlink:href="nktr-20220331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_8c435e50-8670-4a31-9034-8463fa84d6ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_33e04b36-76b8-4be1-8bb0-c025854d61c3" xlink:href="nktr-20220331.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_33e04b36-76b8-4be1-8bb0-c025854d61c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_af639269-65d5-4ebe-8499-90e57d4314db" xlink:href="nktr-20220331.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_af639269-65d5-4ebe-8499-90e57d4314db" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_eba289d2-336a-42d3-b1e1-75428e191ab1" xlink:href="nktr-20220331.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_eba289d2-336a-42d3-b1e1-75428e191ab1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_2acf8775-bbad-445d-9841-4ed2f47b3f0e" xlink:href="nktr-20220331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_2acf8775-bbad-445d-9841-4ed2f47b3f0e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_08220a4b-ac94-40c1-a847-79d408c9e070" xlink:href="nktr-20220331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_08220a4b-ac94-40c1-a847-79d408c9e070" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aede012d-d07b-4a89-8977-b0994ac09926" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_srt_ProductOrServiceAxis_aede012d-d07b-4a89-8977-b0994ac09926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aede012d-d07b-4a89-8977-b0994ac09926_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_aede012d-d07b-4a89-8977-b0994ac09926" xlink:to="loc_srt_ProductsAndServicesDomain_aede012d-d07b-4a89-8977-b0994ac09926_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eec427a4-205d-4286-9bc3-eaeee40ec364" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_aede012d-d07b-4a89-8977-b0994ac09926" xlink:to="loc_srt_ProductsAndServicesDomain_eec427a4-205d-4286-9bc3-eaeee40ec364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_2d925fbf-bd0f-4c8a-bdd3-4228285de284" xlink:href="nktr-20220331.xsd#nktr_Nektar214Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eec427a4-205d-4286-9bc3-eaeee40ec364" xlink:to="loc_nktr_Nektar214Member_2d925fbf-bd0f-4c8a-bdd3-4228285de284" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0814bd1e-febd-4bdc-b114-1a3c23f42f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0814bd1e-febd-4bdc-b114-1a3c23f42f2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0814bd1e-febd-4bdc-b114-1a3c23f42f2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0814bd1e-febd-4bdc-b114-1a3c23f42f2d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0814bd1e-febd-4bdc-b114-1a3c23f42f2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bb399a62-4ee5-4c85-9ab2-067497ec9e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0814bd1e-febd-4bdc-b114-1a3c23f42f2d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bb399a62-4ee5-4c85-9ab2-067497ec9e3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_defb2c53-f81a-4d68-965a-75bda89f4cb0" xlink:href="nktr-20220331.xsd#nktr_OpdivoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bb399a62-4ee5-4c85-9ab2-067497ec9e3c" xlink:to="loc_nktr_OpdivoMember_defb2c53-f81a-4d68-965a-75bda89f4cb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7b2e4337-363f-474d-be0e-d26d9e46f4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7b2e4337-363f-474d-be0e-d26d9e46f4ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7b2e4337-363f-474d-be0e-d26d9e46f4ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7b2e4337-363f-474d-be0e-d26d9e46f4ed" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7b2e4337-363f-474d-be0e-d26d9e46f4ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4cde79c-fff1-4bf2-a542-d48314d6d307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7b2e4337-363f-474d-be0e-d26d9e46f4ed" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4cde79c-fff1-4bf2-a542-d48314d6d307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_6cec3cd8-a0a3-473a-93c4-1214bc032323" xlink:href="nktr-20220331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4cde79c-fff1-4bf2-a542-d48314d6d307" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_6cec3cd8-a0a3-473a-93c4-1214bc032323" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_4cc7675f-04f7-4c37-b4de-786b7a654c36" xlink:href="nktr-20220331.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4cde79c-fff1-4bf2-a542-d48314d6d307" xlink:to="loc_nktr_Nektar358Member_4cc7675f-04f7-4c37-b4de-786b7a654c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9c79012f-7902-4c33-b942-c73bc3dcb047" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_dei_LegalEntityAxis_9c79012f-7902-4c33-b942-c73bc3dcb047" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9c79012f-7902-4c33-b942-c73bc3dcb047_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9c79012f-7902-4c33-b942-c73bc3dcb047" xlink:to="loc_dei_EntityDomain_9c79012f-7902-4c33-b942-c73bc3dcb047_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_46c3a62e-61ac-4666-a742-bce52a0c7379" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9c79012f-7902-4c33-b942-c73bc3dcb047" xlink:to="loc_dei_EntityDomain_46c3a62e-61ac-4666-a742-bce52a0c7379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_2a0802ef-8178-491a-9f95-09cf55a95d6a" xlink:href="nktr-20220331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_46c3a62e-61ac-4666-a742-bce52a0c7379" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_2a0802ef-8178-491a-9f95-09cf55a95d6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_3741a1ea-83f7-4c2e-9e3f-c50c4bb1fdd2" xlink:href="nktr-20220331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_46c3a62e-61ac-4666-a742-bce52a0c7379" xlink:to="loc_nktr_EliLillyAndCompanyMember_3741a1ea-83f7-4c2e-9e3f-c50c4bb1fdd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_28e279ba-60ed-469f-b21c-39f1a5332831" xlink:href="nktr-20220331.xsd#nktr_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_46c3a62e-61ac-4666-a742-bce52a0c7379" xlink:to="loc_nktr_EliLillyMember_28e279ba-60ed-469f-b21c-39f1a5332831" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_1460fe3b-1739-4ec2-99f5-22ffc37fe6dc" xlink:href="nktr-20220331.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_46c3a62e-61ac-4666-a742-bce52a0c7379" xlink:to="loc_nktr_OtherPartnerMember_1460fe3b-1739-4ec2-99f5-22ffc37fe6dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_125994bc-88d9-4f7a-aa98-e2e4dec1de93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_srt_ConsolidatedEntitiesAxis_125994bc-88d9-4f7a-aa98-e2e4dec1de93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_125994bc-88d9-4f7a-aa98-e2e4dec1de93_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_125994bc-88d9-4f7a-aa98-e2e4dec1de93" xlink:to="loc_srt_ConsolidatedEntitiesDomain_125994bc-88d9-4f7a-aa98-e2e4dec1de93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c015e1a4-8092-4ba9-8cc5-44d55623de7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_125994bc-88d9-4f7a-aa98-e2e4dec1de93" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c015e1a4-8092-4ba9-8cc5-44d55623de7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_f2660f27-eb89-41e5-bade-bb17520d4d1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c015e1a4-8092-4ba9-8cc5-44d55623de7d" xlink:to="loc_srt_ParentCompanyMember_f2660f27-eb89-41e5-bade-bb17520d4d1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_438f6dd7-0011-4983-ac57-a6000cf36f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_438f6dd7-0011-4983-ac57-a6000cf36f4f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_438f6dd7-0011-4983-ac57-a6000cf36f4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_438f6dd7-0011-4983-ac57-a6000cf36f4f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_438f6dd7-0011-4983-ac57-a6000cf36f4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_acb6f863-9083-449b-8ffe-de136e1ea4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_438f6dd7-0011-4983-ac57-a6000cf36f4f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_acb6f863-9083-449b-8ffe-de136e1ea4a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_68598e7a-83e6-4b9a-ab98-25302c52d3a6" xlink:href="nktr-20220331.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_acb6f863-9083-449b-8ffe-de136e1ea4a6" xlink:to="loc_nktr_SharePurchaseAgreementMember_68598e7a-83e6-4b9a-ab98-25302c52d3a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_fcb05478-1960-42b2-9dd3-1a04a7a58154" xlink:href="nktr-20220331.xsd#nktr_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_nktr_MilestoneAxis_fcb05478-1960-42b2-9dd3-1a04a7a58154" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_fcb05478-1960-42b2-9dd3-1a04a7a58154_default" xlink:href="nktr-20220331.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nktr_MilestoneAxis_fcb05478-1960-42b2-9dd3-1a04a7a58154" xlink:to="loc_nktr_MilestoneDomain_fcb05478-1960-42b2-9dd3-1a04a7a58154_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_0054b3fb-3084-4333-9c50-5b8370718e03" xlink:href="nktr-20220331.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nktr_MilestoneAxis_fcb05478-1960-42b2-9dd3-1a04a7a58154" xlink:to="loc_nktr_MilestoneDomain_0054b3fb-3084-4333-9c50-5b8370718e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_d74570ff-c9ca-4276-a07b-f79bda875588" xlink:href="nktr-20220331.xsd#nktr_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_MilestoneDomain_0054b3fb-3084-4333-9c50-5b8370718e03" xlink:to="loc_nktr_MilestoneOneMember_d74570ff-c9ca-4276-a07b-f79bda875588" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_303efdbd-a17d-4a4e-abce-7dfd6ee7c5df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_303efdbd-a17d-4a4e-abce-7dfd6ee7c5df" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_303efdbd-a17d-4a4e-abce-7dfd6ee7c5df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_303efdbd-a17d-4a4e-abce-7dfd6ee7c5df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_303efdbd-a17d-4a4e-abce-7dfd6ee7c5df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_049c3d2f-9064-4efa-a6a8-009c37307a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_303efdbd-a17d-4a4e-abce-7dfd6ee7c5df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_049c3d2f-9064-4efa-a6a8-009c37307a62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d58b5505-151d-466c-9ad4-3f389f5aa4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_049c3d2f-9064-4efa-a6a8-009c37307a62" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d58b5505-151d-466c-9ad4-3f389f5aa4cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_020a8af5-4c0d-4e35-ba62-dc94e43f0e4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_srt_CounterpartyNameAxis_020a8af5-4c0d-4e35-ba62-dc94e43f0e4a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_020a8af5-4c0d-4e35-ba62-dc94e43f0e4a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_020a8af5-4c0d-4e35-ba62-dc94e43f0e4a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_020a8af5-4c0d-4e35-ba62-dc94e43f0e4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fbca506-1154-4748-85e9-f78c69a6731e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_020a8af5-4c0d-4e35-ba62-dc94e43f0e4a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fbca506-1154-4748-85e9-f78c69a6731e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_dfb73951-1c87-46b1-938e-822b12b33185" xlink:href="nktr-20220331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fbca506-1154-4748-85e9-f78c69a6731e" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_dfb73951-1c87-46b1-938e-822b12b33185" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3743c409-6959-43aa-bbb5-5e148c5254ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_srt_RangeAxis_3743c409-6959-43aa-bbb5-5e148c5254ab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3743c409-6959-43aa-bbb5-5e148c5254ab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3743c409-6959-43aa-bbb5-5e148c5254ab" xlink:to="loc_srt_RangeMember_3743c409-6959-43aa-bbb5-5e148c5254ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_469f6de0-bc3f-4170-b4d8-436ec3e1a60b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3743c409-6959-43aa-bbb5-5e148c5254ab" xlink:to="loc_srt_RangeMember_469f6de0-bc3f-4170-b4d8-436ec3e1a60b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c5f347c-acde-45d1-acfb-80e4516ac53a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_469f6de0-bc3f-4170-b4d8-436ec3e1a60b" xlink:to="loc_srt_MaximumMember_2c5f347c-acde-45d1-acfb-80e4516ac53a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended" id="i8a5c744d76d84b989b75de588fde3b85_StockBasedCompensationStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3ee998a6-4982-4065-80ec-ef98b9ad4759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d3416c23-9976-4168-849a-02b8274f96de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3ee998a6-4982-4065-80ec-ef98b9ad4759" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d3416c23-9976-4168-849a-02b8274f96de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30d0a955-7850-41c4-8be3-4373c76df3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3ee998a6-4982-4065-80ec-ef98b9ad4759" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30d0a955-7850-41c4-8be3-4373c76df3e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4481f839-9d45-4d62-86bf-48cd7e99c4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30d0a955-7850-41c4-8be3-4373c76df3e0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4481f839-9d45-4d62-86bf-48cd7e99c4cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4481f839-9d45-4d62-86bf-48cd7e99c4cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4481f839-9d45-4d62-86bf-48cd7e99c4cc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4481f839-9d45-4d62-86bf-48cd7e99c4cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3bf764c0-170a-4268-a2e4-c01d3d13dd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4481f839-9d45-4d62-86bf-48cd7e99c4cc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3bf764c0-170a-4268-a2e4-c01d3d13dd00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_c0329c7a-1d10-465c-a711-4c56a2f849cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bf764c0-170a-4268-a2e4-c01d3d13dd00" xlink:to="loc_us-gaap_CostOfSalesMember_c0329c7a-1d10-465c-a711-4c56a2f849cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3b3a24b2-235f-4837-bfd9-380d183b2273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bf764c0-170a-4268-a2e4-c01d3d13dd00" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3b3a24b2-235f-4837-bfd9-380d183b2273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2cef3e8d-c14c-4191-bbb7-deb299bc6b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bf764c0-170a-4268-a2e4-c01d3d13dd00" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2cef3e8d-c14c-4191-bbb7-deb299bc6b21" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#StockBasedCompensationActivityDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended" id="i0268a78049694613affc03065bce94c1_StockBasedCompensationActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cef9a45-99dc-41b3-b464-da80111c8479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_24c36a19-fb09-49a6-a62e-7dd2b6109d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cef9a45-99dc-41b3-b464-da80111c8479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_24c36a19-fb09-49a6-a62e-7dd2b6109d9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14938de7-ec62-4194-90e3-c34daf575e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cef9a45-99dc-41b3-b464-da80111c8479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14938de7-ec62-4194-90e3-c34daf575e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ca812025-cc7a-4d12-8038-cee36143225b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cef9a45-99dc-41b3-b464-da80111c8479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ca812025-cc7a-4d12-8038-cee36143225b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0b5c5b2c-c7e8-42d0-98d7-081e24cb742e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cef9a45-99dc-41b3-b464-da80111c8479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0b5c5b2c-c7e8-42d0-98d7-081e24cb742e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_866529eb-7c62-4480-8865-75da5afc7869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cef9a45-99dc-41b3-b464-da80111c8479" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_866529eb-7c62-4480-8865-75da5afc7869" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4fdb1097-8197-48a5-90ae-69a77e67ae8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_866529eb-7c62-4480-8865-75da5afc7869" xlink:to="loc_us-gaap_AwardTypeAxis_4fdb1097-8197-48a5-90ae-69a77e67ae8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fdb1097-8197-48a5-90ae-69a77e67ae8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4fdb1097-8197-48a5-90ae-69a77e67ae8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fdb1097-8197-48a5-90ae-69a77e67ae8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49de53a9-8f71-48d0-8af7-acc087d55760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4fdb1097-8197-48a5-90ae-69a77e67ae8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49de53a9-8f71-48d0-8af7-acc087d55760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_57f6f6ad-3d74-47fe-b474-541bee5d7307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49de53a9-8f71-48d0-8af7-acc087d55760" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_57f6f6ad-3d74-47fe-b474-541bee5d7307" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="extended" id="i87ba2b6ca3b749a7a2e68f8417587f3c_SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_11585719-2a8f-4848-875e-2f50843aabad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_07f421f1-3e47-4b74-97d0-25b3b5cfa7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_11585719-2a8f-4848-875e-2f50843aabad" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_07f421f1-3e47-4b74-97d0-25b3b5cfa7c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_35bd5e09-32e3-4186-b866-66cfcc1c3d83" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityNumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_11585719-2a8f-4848-875e-2f50843aabad" xlink:to="loc_dei_EntityNumberOfEmployees_35bd5e09-32e3-4186-b866-66cfcc1c3d83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_7231ba50-0c34-4b46-b4df-5768d4df525e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_11585719-2a8f-4848-875e-2f50843aabad" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_7231ba50-0c34-4b46-b4df-5768d4df525e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5ec41918-b246-4b3d-9094-d6976bd8f525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_11585719-2a8f-4848-875e-2f50843aabad" xlink:to="loc_us-gaap_SubsequentEventTable_5ec41918-b246-4b3d-9094-d6976bd8f525" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_45c563c4-bde9-4fc7-b3b5-fc2658869a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5ec41918-b246-4b3d-9094-d6976bd8f525" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_45c563c4-bde9-4fc7-b3b5-fc2658869a0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_45c563c4-bde9-4fc7-b3b5-fc2658869a0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_45c563c4-bde9-4fc7-b3b5-fc2658869a0d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_45c563c4-bde9-4fc7-b3b5-fc2658869a0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19a87efb-c38a-42bd-b4fb-29f567ab342b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_45c563c4-bde9-4fc7-b3b5-fc2658869a0d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19a87efb-c38a-42bd-b4fb-29f567ab342b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1af05754-d715-4b7a-9121-7708dddecbff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_19a87efb-c38a-42bd-b4fb-29f567ab342b" xlink:to="loc_us-gaap_SubsequentEventMember_1af05754-d715-4b7a-9121-7708dddecbff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_14d5744b-fd4d-4d28-ac7f-ad3c0aed3a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5ec41918-b246-4b3d-9094-d6976bd8f525" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_14d5744b-fd4d-4d28-ac7f-ad3c0aed3a95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_14d5744b-fd4d-4d28-ac7f-ad3c0aed3a95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_14d5744b-fd4d-4d28-ac7f-ad3c0aed3a95" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_14d5744b-fd4d-4d28-ac7f-ad3c0aed3a95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_21bfccfe-0610-484e-93aa-ff6750730afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_14d5744b-fd4d-4d28-ac7f-ad3c0aed3a95" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_21bfccfe-0610-484e-93aa-ff6750730afe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_999a2751-b1d2-4090-8f85-9e2f1c40d8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_21bfccfe-0610-484e-93aa-ff6750730afe" xlink:to="loc_us-gaap_EmployeeSeveranceMember_999a2751-b1d2-4090-8f85-9e2f1c40d8cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_464e1d0b-1624-46d2-b3bc-d2ae28e9b351" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5ec41918-b246-4b3d-9094-d6976bd8f525" xlink:to="loc_srt_RangeAxis_464e1d0b-1624-46d2-b3bc-d2ae28e9b351" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_464e1d0b-1624-46d2-b3bc-d2ae28e9b351_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_464e1d0b-1624-46d2-b3bc-d2ae28e9b351" xlink:to="loc_srt_RangeMember_464e1d0b-1624-46d2-b3bc-d2ae28e9b351_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8381a815-142f-4bb6-adde-e52e61a6d387" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_464e1d0b-1624-46d2-b3bc-d2ae28e9b351" xlink:to="loc_srt_RangeMember_8381a815-142f-4bb6-adde-e52e61a6d387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1ccdf9ef-6be2-48d1-bb7f-fb99d757f7bd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8381a815-142f-4bb6-adde-e52e61a6d387" xlink:to="loc_srt_MinimumMember_1ccdf9ef-6be2-48d1-bb7f-fb99d757f7bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_528a28e0-3517-4a2a-9c5e-c2b6636bce49" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8381a815-142f-4bb6-adde-e52e61a6d387" xlink:to="loc_srt_MaximumMember_528a28e0-3517-4a2a-9c5e-c2b6636bce49" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>nktr-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0975c044-35ac-4551-b121-d6df2cc9796d,g:b0fa7438-204d-4fa1-b132-84f7e9a28d02-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_11e31da7-4288-46ce-b59d-269bdcd40eff_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_411a0339-3b35-4da0-84a4-72559ac12160_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_b5f3ced4-0da9-49c4-accc-1512eeb687b5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5cff12f1-6154-4e59-afbf-65439720f6b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_4c54b8ce-fa54-4f20-9d16-e84680a87675_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd7b9ba0-bafb-4f95-8cfc-a5c93e3ccc6d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ab68c2e0-a0a6-4c10-a160-e4b96296c199_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_24650f3a-28c9-41a5-9561-3a3b544617a9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_9ed55bc1-5cda-4831-be79-099d3a081c31_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_363eaed7-8c59-48e8-8d41-02d104d47f27_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_60aefe3a-3be7-4b3b-b36b-1e51585fd10c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b845c00e-4ac2-4bd0-b601-ace4fe1a412d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_155c9fc3-15ea-43c6-8384-f4f1763fec23_terseLabel_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum maturity term for debt securities investment</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_label_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Investment Maximum Maturity Period</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt investment maximum maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:href="nktr-20220331.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:to="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_415aae77-d121-49ac-962f-a8786f5a8710_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1b77d0b8-5d4c-48d0-baa4-f5de42a7b370_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_998fad6c-aac2-4c58-9840-f30b8bd62c43_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d748b60e-16ae-4706-9417-5b374cde3242_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8891d5d8-c1af-44c2-b502-2126fa2b9844_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DerivativeActionMember_eb306e29-548d-4b9a-a850-eadf8537ea0f_terseLabel_en-US" xlink:label="lab_nktr_DerivativeActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Action</link:label>
    <link:label id="lab_nktr_DerivativeActionMember_label_en-US" xlink:label="lab_nktr_DerivativeActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Action [Member]</link:label>
    <link:label id="lab_nktr_DerivativeActionMember_documentation_en-US" xlink:label="lab_nktr_DerivativeActionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DerivativeActionMember" xlink:href="nktr-20220331.xsd#nktr_DerivativeActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DerivativeActionMember" xlink:to="lab_nktr_DerivativeActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_0e6b426b-7cd4-4dbd-90fd-964686c67240_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_19a40faf-d41a-482e-8145-0ef5ccbb0ce8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b4ca3a3f-edc8-4f69-84fc-acd0234cb01c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9d7ca680-6ca0-4bc0-91ff-924edbd57d5d_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_c13f25ea-e54c-4029-bc5c-e2874f5eb04e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_05595cff-7a34-4669-a194-999eb11c52f7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_1e01871e-d4ae-4a8a-9ad9-261a262bfe75_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional development and regulatory milestones (up to)</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20220331.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4eb7458c-2b29-4153-9072-227a1ba852b1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4fbce80f-3216-47b4-b7b4-a1ccce8f94bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c4921e06-821e-4f08-b195-de634828f067_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_6436f1ca-a6ef-426f-99e1-683a0e3b1bc6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_36c31580-9fa6-4dc1-9620-f5ce1e9d671e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_3d54185d-8942-427c-a31b-910b8cd8af28_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityNumberOfEmployees_730d096b-ef16-419f-ad43-07357e0fc943_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Number of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneDomain_d12cf6ce-3c93-4f2d-a500-982c5ec96598_terseLabel_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_label_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_documentation_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain" xlink:href="nktr-20220331.xsd#nktr_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneDomain" xlink:to="lab_nktr_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_23b7c6bf-0e10-48f0-8f49-217e8e230280_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05645382-5db7-48c2-83bb-a0fd6fb343b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_ad87a415-7e57-4023-a15f-83c7d6ab3940_terseLabel_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_label_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember" xlink:href="nktr-20220331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyAndCompanyMember" xlink:to="lab_nktr_EliLillyAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f0de643d-4fee-4081-a2c4-e71e3956168f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4ee55860-4c3e-40a5-a700-e98c8ddc898f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ef98142b-c7ce-460e-839c-018facb31f5c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dae39e2a-a407-4da8-aeee-ed2c75477146_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cf098228-1c81-4047-9ce0-204248a413f0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_fa655af9-b322-49dd-872b-7fd34fbcbf9c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6deba225-36bc-435b-9fa9-3cc07089704f_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_34cd352d-6c18-430e-8b55-87e04286eb6c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_8c4ccc6f-59b8-4c64-a1ec-4bdfce383b52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_55c568ac-bfec-4204-b593-6dd31779155b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_d4242143-b01c-43d9-8cfb-ad78b51d4c23_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e70e2c3b-529c-4db5-8399-a7bdd485fd63_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_9d110dee-6141-4c88-bc09-9f2613b8b2e2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c68b0481-7c95-4755-be4c-9d9e34d181f4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OpdivoMember_282099ac-9989-437a-a7dc-c248c9cdb9e3_terseLabel_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo</link:label>
    <link:label id="lab_nktr_OpdivoMember_label_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo [Member]</link:label>
    <link:label id="lab_nktr_OpdivoMember_documentation_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember" xlink:href="nktr-20220331.xsd#nktr_OpdivoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OpdivoMember" xlink:to="lab_nktr_OpdivoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_535cbae7-a5f4-48c6-90d8-82855e41742c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_ef2da763-9b42-448f-a935-2bb161828400_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_5e138006-a46a-4686-9e3b-3e78b1a2c60e_terseLabel_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</link:label>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_label_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability [Text Block]</link:label>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_documentation_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:href="nktr-20220331.xsd#nktr_DevelopmentDerivativeLiabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:to="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_2d48a953-e127-4e3b-8212-7e91e4ac1b19_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_07dc51c0-293f-4163-91da-a49126bef17f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_478e0a4a-8438-4aa3-8b6b-07007c95c646_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_038dee58-46d3-40d7-8e40-e5ed2939a33b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_b5ac5ba6-3e22-4ff1-825f-99c624f048a4_terseLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ea01b4de-0de1-45f8-8f2b-001432c5654b_totalLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_label_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Restricted Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_documentation_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, restricted cash, cash equivalents, and available for sale investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:href="nktr-20220331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ff137fe8-e6da-47dd-aa90-b1c864017ed8_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7839400d-f4c3-4983-900b-bcbe1e219164_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ee6f73f0-21ef-4133-8f1e-42a4f345302a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_09dbf14c-8645-449b-9e2c-359fc8601b29_terseLabel_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash research and development expense</link:label>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</link:label>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:href="nktr-20220331.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:to="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_53e328fb-5a6c-4963-9d49-d520422eee43_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_61be83ac-4e99-44b8-becd-dd6181203b3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_faf74ebd-dae4-4162-b425-b544586adf7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_5bf680c2-12ba-41db-b396-70891ad4c502_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_label_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue [Member]</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License collaboration and other revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:href="nktr-20220331.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:to="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6d9dc268-686d-4266-b236-61c277be0705_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_faceda5b-c0bf-4973-be95-fc9282deb3fe_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_4c03a798-56d8-46ba-b56d-f18ff67c9036_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_c723068a-8194-4cd3-8037-e914689b07e8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_79c71f65-9bb2-4a5b-b5b0-2f1dca969477_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_535bda19-bda9-4607-b7d8-eb7b5e717d4c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f3d6d34a-e129-4340-bd51-f099bed95737_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value, of RSUs granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_83314eca-24da-4340-b4d0-ccfb57f55cdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_9aaa079c-acfb-4a8e-9899-a6f13aaa1f1c_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:href="nktr-20220331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_bb21caec-8933-4a49-a8f0-1106f8e2e77e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_eb8391cf-9784-4e1f-b5ac-7b5d3d24aaff_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_87634625-41df-44ff-83b3-e4dc7c9e4d30_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_337ac230-97d8-4f6e-a140-d3099fe037fb_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Phase Two Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:href="nktr-20220331.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0bbb9ba4-ec5b-4f06-bbe6-b6fe5bb706e3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_806d9cbb-a41d-4a42-9251-90cf3ea0d517_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29770caa-0fda-4a79-9e3a-25935d5ac73b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d0210f15-8c95-48f7-a852-035dcc5cad66_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_19fbf269-239f-4e00-badf-bd21d5813340_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_65742e6d-825c-45ea-8e43-8ed7fa97a6a1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_b0fc1e2b-7be5-40a3-a8d6-ac25347d1251_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_24460003-d685-4faf-baee-81c2678c518a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a3132656-1aaf-4c88-98a7-e14d499374ad_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2022 or December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d005802e-c625-432f-a35c-9efb2ee97a26_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5611d415-f6bd-465b-88fb-98dd7444aee3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6aef87cf-b4fe-405a-9993-19ac25cd24c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from SFJ</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_d5fcef4c-98e9-4a7d-a5f8-90a98e29f31c_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing production costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Production Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in production costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts" xlink:href="nktr-20220331.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInProductionCosts" xlink:to="lab_nktr_PercentageOfSharingInProductionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8dfed7f4-0aaa-4b18-827b-852715ced1c4_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_5df16632-5bf1-4484-bcca-f6ae698c556f_negatedTerseLabel_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized transaction costs</link:label>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_label_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities On Sale Of Future Royalties Unamortized Transaction Costs</link:label>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_documentation_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities On Sale Of Future Royalties Unamortized Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:href="nktr-20220331.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:to="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_23dbc890-8dec-4a0b-81f1-ef2c533a3c8f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment and Other Costs of Terminated Program</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_15f58f0e-178f-432b-8486-6927c6ea84b0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_83d80920-2303-4f86-836b-1bb37bc10a7f_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced under certain conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received Under Certain Conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received under certain conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:href="nktr-20220331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2328d236-77d0-4356-a0d4-84dcbf167552_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OtherPartnerMember_3b03d33e-ce52-4ec2-8839-1cd8e3eb730a_terseLabel_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Partner</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_label_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Partner [Member]</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_documentation_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember" xlink:href="nktr-20220331.xsd#nktr_OtherPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OtherPartnerMember" xlink:to="lab_nktr_OtherPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_d7e80bd8-c6c2-4b43-948c-5989ff3abdd7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from development derivative liability</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_5af065a9-96b1-4186-9eb5-ba80b3e09ca3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_6f67d788-0b40-4063-bda0-fcdf33944084_negatedLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_ce66e3e6-a75e-46e2-839b-52e8542a4daf_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash royalty revenue related to sale future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:href="nktr-20220331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0afc09b1-b385-4cb5-8656-008331b09c33_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6ba4b822-cbdd-40dc-afaf-a2dcb7a89a74_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_3a453083-e633-4c5b-a9a4-0431eb27abda_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_abae7da9-63b2-45d5-8a7a-f61ab1ad565d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_85ba9d2e-7c56-48c2-bce6-ef05fa4d4420_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6fd899cb-ae03-47fc-9f08-ffa18773c5a6_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_c9a8cb55-d8ce-4a7f-8081-4b82bb0e4592_terseLabel_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_label_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investment Maturity Period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:href="nktr-20220331.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:to="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2a1443ac-7a55-40d9-9b7e-ecdcf8de8596_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dc8038a4-4857-4b6a-afb0-f3d8f00eb863_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset recognized in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_253ae008-7ba0-4349-a045-f849f4a73bb6_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_bd444c22-e852-4842-82a4-e80abd4ae7af_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed funding (up to)</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:href="nktr-20220331.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:to="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_753e1d3e-04b5-41cd-9467-a2f8ae25e4ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_d6b4b625-eabf-4493-aa38-fb0426b1e468_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1a87917d-f976-481d-ad96-427cdaff69ff_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nktr-20220331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00ded2d4-18b6-465f-9eac-61ccb25ec172_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5785c5e6-8b84-4c0b-9cf1-aa551c22c694_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3bc3474a-3f3a-4ad9-91b6-2d3337eccff6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_47577086-dcef-4aeb-8177-9d1de221e757_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:href="nktr-20220331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_32a4eb7f-9a1f-4b8f-8c8d-4256dba01a8d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_db837657-1e18-403b-8664-49190dda6dd1_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:href="nktr-20220331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:to="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3d61fed5-8b0e-4d53-8de3-3fe3955ecaa2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_b09c2a69-39d6-41ba-9dc3-93cb2daa4462_terseLabel_en-US" xlink:label="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on revaluation of liability related to the sale of future royalties</link:label>
    <link:label id="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_label_en-US" xlink:label="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross</link:label>
    <link:label id="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_documentation_en-US" xlink:label="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:href="nktr-20220331.xsd#nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:to="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_f46c3b04-9af1-4b4f-b4cf-72955565b913_negatedLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liabilities related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_00d51c78-9d6c-49dd-af2f-7a3c80bf68bc_terseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liabilities related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a7de1490-4cbf-4cd3-bce7-7c76d3653bb9_verboseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_label_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to sale of royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:href="nktr-20220331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:to="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_df8b5fe9-6e54-41d8-ba88-2ae9096628cb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_ac593d1d-8b7f-4ad2-8a56-368d7ef2d1df_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional payments for development milestones (up to)</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones" xlink:href="nktr-20220331.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentMilestones" xlink:to="lab_nktr_PotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MulquinActionAndDamibaActionMember_40f7e04b-cb6c-4a4f-b92d-04bf77328f27_terseLabel_en-US" xlink:label="lab_nktr_MulquinActionAndDamibaActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mulquin Action And Damiba Action</link:label>
    <link:label id="lab_nktr_MulquinActionAndDamibaActionMember_label_en-US" xlink:label="lab_nktr_MulquinActionAndDamibaActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mulquin Action And Damiba Action [Member]</link:label>
    <link:label id="lab_nktr_MulquinActionAndDamibaActionMember_documentation_en-US" xlink:label="lab_nktr_MulquinActionAndDamibaActionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mulquin Action And Damiba Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MulquinActionAndDamibaActionMember" xlink:href="nktr-20220331.xsd#nktr_MulquinActionAndDamibaActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MulquinActionAndDamibaActionMember" xlink:to="lab_nktr_MulquinActionAndDamibaActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_75f15a7a-5cf1-45ac-bf5b-64d5125d48e3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_71a976d6-349a-47e7-a5e6-fadb1683d073_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected cost to be recognized</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_dcaebf17-bf58-484c-b780-1fbfc59a76f9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previous claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_d3920832-2aae-46cc-bd78-b8472372d214_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_88fb8e33-a32c-48fc-939a-2e48947a52d6_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_d3de8588-ad51-4f61-868d-d01390e5b78e_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar's</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f8c4af6c-0f0d-4b26-a7e0-f99d6fd8184e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_94decffd-7f4d-423e-b459-f31d03a5e164_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_39e57db0-8484-4b78-ac49-238a1d4ee4a0_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a287bf6b-57a2-4493-b5c2-698b0d01bd7c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b0b8594b-59a2-4228-8554-26ebffa9f9b4_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_19c0dd04-0bb9-498f-839a-2d150591612f_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_d8535f35-be93-4c0b-a67d-c302942b4f31_totalLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties non current net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_d1d42d1b-4973-4d34-9441-cfa37f76c3a8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_ebf57e43-ff15-4c27-854d-e37776fa9e05_verboseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received From License Agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:href="nktr-20220331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_965102ba-e822-4fe6-a9d1-93aa888eb0bb_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Company</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Company [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember" xlink:href="nktr-20220331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCompanyMember" xlink:to="lab_nktr_BristolMyersSquibbCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_a7378416-0899-471b-a7a0-a1da1c8f8f0c_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:href="nktr-20220331.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d2294d8-0157-4976-aaad-c673355a94d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_80f7d4b5-acaa-4fe7-b9df-a851d5091975_terseLabel_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember" xlink:href="nktr-20220331.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SharePurchaseAgreementMember" xlink:to="lab_nktr_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2db70e91-75ad-4c45-a76f-e239acbb9599_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1b5bbd3-d921-4a84-8366-ab0dc8a6b323_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_846f1463-17c2-4c3a-ac3a-7b99b71b894f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_8c773889-0080-42fb-8fe3-593f2cd62844_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_acb0f3b3-b44c-42d3-9cf2-d41ab94170d5_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums (discounts), net and other non-cash transactions</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_cc0d9537-2ca9-459e-8fcc-4013dd871890_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_757c3524-eba0-4ae3-9fcb-089b2b31a246_negatedTerseLabel_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to RPI</link:label>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_label_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial Repayment Of Royalty Sale Proceeds</link:label>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_documentation_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial Repayment Of Royalty Sale Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:href="nktr-20220331.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:to="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar214Member_37d90a62-0d4a-4d87-8cd2-7777d2d8974f_terseLabel_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214</link:label>
    <link:label id="lab_nktr_Nektar214Member_label_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214 [Member]</link:label>
    <link:label id="lab_nktr_Nektar214Member_documentation_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member" xlink:href="nktr-20220331.xsd#nktr_Nektar214Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar214Member" xlink:to="lab_nktr_Nektar214Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_147167be-4f89-450a-bbe2-4743daab7ecb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6356313-4535-452b-b42a-438544839c06_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_04afd111-d860-44b3-81e9-52267fef5f3d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_6f615a79-fd9a-4b86-858b-c2b73cbc0370_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Related to Sales of Future Royalties</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Text Block]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_347088ae-7523-4407-84ca-b92ae926870e_terseLabel_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_label_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Policy [Text Block]</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock" xlink:href="nktr-20220331.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationPolicyTextBlock" xlink:to="lab_nktr_OrganizationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_89e64557-40f2-47f6-ab7d-a19787801d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_ae7eb4f0-fad3-4cea-b4d6-27d7a9e51bc4_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:href="nktr-20220331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_1eea42e6-28d2-43c5-8d70-671156b0d97f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e7fe13e2-c832-42d9-8649-c02215c6329b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_396fccdd-e501-47f6-b540-0e8dc160f583_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_41cd2d80-276c-4a30-8abe-116ecf8ff468_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_d9fea21a-5571-4486-8a3b-975839fd9f8e_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_label_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Consideration Received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_documentation_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived" xlink:href="nktr-20220331.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockConsiderationReceived" xlink:to="lab_nktr_SaleOfStockConsiderationReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_bb041dc9-04ac-4696-8fc0-1bb94b95ea38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_96106f31-5288-4916-9d0c-c287e3ade23a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_529803d5-b22a-49fe-bc83-452b903e708c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb346e11-df6a-4a54-878a-596732831560_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_92f8cd73-38dd-4669-8875-e8d1c69c3721_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_c4a946f3-3cbd-479c-a543-f38276248129_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce termination, percentage</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5bca0a09-9166-4e3b-9c72-fc9d1685c8ec_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_3febc3d0-cda7-431c-868d-b8e3db662511_terseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received upfront and milestone payment</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received Under License Agreement</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:href="nktr-20220331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_7da5a81d-938e-4cda-8f24-803547c7a525_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8aa89101-f0d8-426b-b8cd-4672cda64a9e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PreferredStockShareDesignated_f621398d-08c0-4514-a663-b1f599632bba_terseLabel_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated (in shares)</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_label_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Share Designated</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_documentation_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated" xlink:href="nktr-20220331.xsd#nktr_PreferredStockShareDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PreferredStockShareDesignated" xlink:to="lab_nktr_PreferredStockShareDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4cbc7f92-84ea-484c-88b2-15bc3e17b6f0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_a9b85d49-87e0-44ce-acb5-f63617eadb18_terseLabel_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_label_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses Current</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:href="nktr-20220331.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:to="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_e3b01978-c9eb-4bb1-8692-9c200d3d6a03_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_bb2dd6e7-4595-460f-8a2b-88d9029393ec_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment and other costs of terminated program</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c58fd4be-175e-4504-85b3-5bfd99b57a3d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e1f89047-97d9-4f76-be5f-54369e22ddf9_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations of U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_3a9629b9-9914-48a7-a380-10bf71edb1be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Portfolio of Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_470bce40-6000-45e4-b516-0d89efc2c338_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_625e03ac-735d-44f8-b6f8-576caa27a674_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_111a20af-481c-4323-b0f2-e2e6664c375d_terseLabel_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average maturity term for debt securities investment (or less)</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_label_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Investment Maturity Term</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_documentation_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt investment maturity date description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm" xlink:href="nktr-20220331.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtInvestmentMaturityTerm" xlink:to="lab_nktr_DebtInvestmentMaturityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4ee0c876-538f-4b8d-9a0c-db3a9d5078b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4fe9dbf5-033d-420a-9321-fce4f4289106_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_f78935e0-949f-4f9b-b797-e267d40b3741_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_92eaa096-7ad7-4b19-a41a-1b8f2ff0fea0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_11c45496-de65-400d-80c8-ede33d6543e4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d68de596-36a9-4ec0-b251-4108c5633404_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_83e5f524-6d0a-4b51-b3ff-99d2a902b3fa_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ee122428-9415-415c-af19-9203add81d53_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c455d155-969b-493e-983a-918fd0aa025d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4890b71e-d22a-4649-98f3-3f706cf7eb9c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_60092458-3784-48bb-be7e-f38701109472_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneAxis_5e23bcfd-001b-4c66-901e-dbef0c1df190_terseLabel_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_label_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_documentation_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis" xlink:href="nktr-20220331.xsd#nktr_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneAxis" xlink:to="lab_nktr_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3ea64ba5-5b7a-41d1-8abd-c6ee7214c5b5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c1b2e982-3501-4b5d-ae9c-7f1263679b19_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_39fb6608-8103-416c-a0af-417aaf99979c_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7c39a459-2d09-462a-8924-33d804d8d544_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a9d9cf29-60ed-4215-91b6-a852d4d2af8f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_23c68d71-7c5e-4efe-9c1f-b9f2a3495264_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_0b5da52e-3941-4f03-ab7e-71d5a4be97ea_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4f192ac4-081f-4b7b-9ce6-e13fefd5f1c8_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, accumulated gross unrealized gain, before tax</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f19823b2-ceef-4a72-843a-f4cbfa5d044f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_533a2bcc-dd9c-4572-9b55-38607d3f4937_negatedLabel_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, net</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_label_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:href="nktr-20220331.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:to="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_9f414fab-b98d-4bed-beba-aba8bd049992_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties &#8211; ending balance</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c38b3912-0bc5-4f0f-aee2-24fea7637acf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LegalMattersMember_5545c49e-3aa2-4f99-bd03-80a67cc6dcdd_terseLabel_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_nktr_LegalMattersMember_label_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters [Member]</link:label>
    <link:label id="lab_nktr_LegalMattersMember_documentation_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember" xlink:href="nktr-20220331.xsd#nktr_LegalMattersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LegalMattersMember" xlink:to="lab_nktr_LegalMattersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_e8799839-7b27-4447-abb9-320adf7aca75_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_866e0a51-6d79-40a7-a896-05b9fb784c8c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_cc18f4a0-efef-4242-a96e-71d998180758_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_eaa995bc-984f-43df-9c90-2e6f3fe00db6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d2850330-4752-4b2f-aa3f-5f6091f98714_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0dd737e4-e2cb-4d7a-8e16-23c7de8c8a42_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_86ba6718-96d7-4ebc-96a0-9ba6d06651d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_11321032-e133-4abb-a544-5ecd707d9ed8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f8543383-45e3-4733-a5ab-2e79f2b04691_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_592afbe4-df58-43c3-84dd-6c79f1b25363_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_de67b109-e3af-4a41-88d0-3ce2abf3ad8e_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_54f12136-8781-46a7-bfa9-c68886d165bf_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c404a3c8-fb00-4442-9f02-5554599fd54b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_22e7a58b-2404-44ae-bab2-b57ce58be528_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_4451daad-11d8-4cb8-832f-669bb8c4d799_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8591b3d0-0e64-475e-99f0-d7a248f7a7e2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_83257a5d-7bbe-432b-af6a-ae6345fbb0e1_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c77368c5-7a8a-4c17-8239-513f7cbf41e1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_0d130279-bba3-409c-8bf4-497b46e5a41d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation matters, liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_707cfa59-25e9-4b8c-8fb5-1597d497d459_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0a4e3d37-4f05-4cb7-84ac-7ffea2a16115_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000 shares authorized; 186,274 shares and 185,468 shares outstanding at March 31, 2022 or December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_a12fe7a3-63e9-424c-8ec5-a81308318892_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_cc86d634-46aa-4176-a030-0956c7ecd642_terseLabel_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_label_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_documentation_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:href="nktr-20220331.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:to="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_25437396-f535-49ed-af4a-3c89b2238901_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8fa57739-0a81-4785-b042-37fde0e3732d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_3cfd7e1a-4b57-485d-879a-7bd9b2078dba_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b05049a7-ad20-44fc-a008-43c8245cb892_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f880f016-31c2-476d-846c-8572f8f135c5_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a2e8cfd0-9109-4e50-a65f-5b60729e5303_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f4b17959-caf0-46f6-bd20-115934fa4e9e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6bd8cf57-d1b4-4b23-a463-8596c802d3cb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_0a9b5da8-caeb-4424-9c17-82ba158274a2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_adf88525-ff6b-43bc-8b42-87e8cb14f9e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_b0da9a01-ec59-4bbf-8a8e-3309013fe7b8_terseLabel_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_label_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals [Member]</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_documentation_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember" xlink:href="nktr-20220331.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SFJPharmaceuticalsMember" xlink:to="lab_nktr_SFJPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_90aa4992-c4f2-4fc9-a078-2662b7620f97_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_6ffab028-3ecd-441a-8f80-4b3ed87bb987_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_83e41032-fee9-4c81-a88b-2a976994df77_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payments (up to)</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, Amount</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:href="nktr-20220331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_3f1dcf77-8c1a-4f8f-b1e4-8e232f6cfe2b_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_4fee089e-5055-4577-9968-d53f74d52284_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_c1662365-9d68-422b-8566-c5692ab6506a_terseLabel_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty monetization proceeds</link:label>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_label_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetization Proceeds</link:label>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_documentation_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetization Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds" xlink:href="nktr-20220331.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RoyaltyMonetizationProceeds" xlink:to="lab_nktr_RoyaltyMonetizationProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4207a259-6e38-4151-8495-43ad1880b417_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_95229ae7-1237-47da-b23f-06874192f01b_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_98cf5ea3-a71c-44be-a470-4c3271e9f648_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_649faac8-a955-42b1-875e-7cfa29b9bedb_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5b92829a-bc0b-44c2-9d38-0f5416e124dd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_567805d8-296a-47ae-9a03-0ae333da97a2_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_867c811b-99cf-4c5d-9411-d1c9aa710d56_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3b447f82-742e-4f3b-8ea3-36e75e5b5235_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_85b7bd85-2553-47ec-b24c-1eafb1627e49_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_de6996b3-a753-4d09-b15f-262787936068_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:href="nktr-20220331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_14768de5-6650-405f-b885-770f8224eec1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_894b36dd-5c5d-4545-be62-72ba267dd9b6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1e8d2d5e-e00a-4cf6-9d51-c40f9afcb4c5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyMember_751dd1d1-f858-429d-802a-f10c4c41cc6c_terseLabel_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_nktr_EliLillyMember_label_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly [Member]</link:label>
    <link:label id="lab_nktr_EliLillyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember" xlink:href="nktr-20220331.xsd#nktr_EliLillyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyMember" xlink:to="lab_nktr_EliLillyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_4b890a34-c071-4734-89c4-29d8efb0745e_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="nktr-20220331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_13d939e2-d777-4426-9aae-441b989f82b2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_0335db37-ac99-4b01-88ae-5d05fa4d4592_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3e69e640-50aa-427b-91f8-8d800956cb1b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d4258a85-1abf-4d79-9985-1efbcf8f3381_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82b90097-d72c-4ae2-860b-389011d32516_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_4ef96afd-606a-46c3-a3e7-d7a516977e71_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_503b74c6-4223-4095-9700-1c5d62b31399_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_411d0a5f-4406-4f57-a741-027dc9893b1f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7690540-5820-4556-bb9b-27d71b05a9ad_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, excluding assessed tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_4c06c9cf-af9c-494c-afca-4949e652157c_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced if conditions occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received If Conditions Occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received, if conditions occur.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:href="nktr-20220331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_dec2b847-b61d-43f7-bb77-ed857e40815d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneOneMember_4a8c9bf2-78e7-4efc-9387-216f8dd52192_terseLabel_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_label_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_documentation_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember" xlink:href="nktr-20220331.xsd#nktr_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneOneMember" xlink:to="lab_nktr_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3fe3ccd7-b46e-42f2-94f1-0cd96ab668fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_22091033-e17a-40a6-a2d7-5b900e451a1c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_cf8298d8-2414-439b-9350-414d16a24283_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1c8ac1b4-b05b-4bcb-a854-775f5298604d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_ff791524-5bcd-46d6-ba9d-60bce0f58db5_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_e1c9a2f5-29d5-40ef-8d6b-e8154253ccfa_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:href="nktr-20220331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b09e423c-4d7b-4296-b8a1-36ee891ef2a4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8d057c8a-1765-4268-936b-ba7e7da34e35_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d965820-6e3d-4e7f-a776-7eb644b9568c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bfcce9e3-718b-4b9e-b59d-5a844d70078e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_19455a08-b347-4428-87b7-c4a9e5671255_terseLabel_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties liability discount rate</link:label>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_label_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Liability, Measurement Input</link:label>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput" xlink:href="nktr-20220331.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RoyaltiesLiabilityMeasurementInput" xlink:to="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ebf452c9-d14e-40b8-a873-576644e8878f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f27434f2-ec71-4249-9626-b7e9fbfac83b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_65632fd1-fe6b-4274-bb1e-2aebbb51a9a9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8c38066f-30c1-4c72-b286-159c1e95dd63_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_59ccc035-87da-42ee-8dc6-2013cf10f4d2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_10f02871-5730-452c-9528-190742f1942a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ReimbursementOfExpenses_7b4f9efd-538f-4c19-b76a-45912735201d_terseLabel_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_label_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_documentation_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses" xlink:href="nktr-20220331.xsd#nktr_ReimbursementOfExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ReimbursementOfExpenses" xlink:to="lab_nktr_ReimbursementOfExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d96b08d1-f223-463f-a04e-0e6e98a9fb73_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale accumulated gross unrealized loss, before tax</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_97cfdc2b-411c-44a4-b28a-8fc1783382da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_e04c3601-c904-40c9-9e02-022e38a05a3d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_22be9fa9-77bc-42fa-86a3-3dce16eb40bc_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a8e088f5-04f7-4824-acbd-0ec8fc51d21c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_27cd0167-9b6d-41bb-9628-b92af647d9a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8aa63702-b26b-4581-899f-03fbe850ede9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6e45cc58-a3f6-43e4-a890-44f60dbaa875_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f819d87-300d-4f31-beec-4eb6caed8fe2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_1890502a-540c-42b9-8ab5-5c35c4b3fa65_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:href="nktr-20220331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_f4ad067c-97da-4468-88cd-dce9c1de2efb_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_ae6730ed-b16c-427c-97fa-6976be5d96cb_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_cd203c8a-68fa-4cf7-aaa8-380c7e4fb345_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_81964762-41b1-433f-8ee7-17e3d57112c1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7698d307-6bf8-4e08-b0a7-476162ac634f_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c1c43507-a771-469b-bbad-140b1057caef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income and other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6b826767-5a78-48ca-aa0c-2b242ea0f8c8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f4a0f270-bfe1-4d99-be10-d35e0ef31f33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_30e3c6b4-def9-49d8-be6f-bafeab416422_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3f2c4668-29e1-4e7b-942a-335c92bc273d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d9c80c01-7259-4e41-8e4e-230cc3ebc180_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dfb938ce-85a3-4f92-906a-08b34382ee25_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock_0eb3ebd2-8124-4926-a1b2-2bead293249f_terseLabel_en-US" xlink:label="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock_label_en-US" xlink:label="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Purchase and Sale Agreement [Table Text Block]</link:label>
    <link:label id="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock_documentation_en-US" xlink:label="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Purchase and Sale Agreement [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" xlink:href="nktr-20220331.xsd#nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" xlink:to="lab_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_373ac983-de84-49c2-9dac-05782308d85f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_2ae9d6ec-63cc-467f-bbc1-2daa40391f30_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_05d2675a-a0c5-4c22-8230-988a03661ef0_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_e74458cf-8a84-4ec5-be59-8bb5f326f869_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding phase 3 development costs on an indication by indication basis borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_label_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_documentation_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding Phase three development costs on an indication by indication basis borne.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:href="nktr-20220331.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:to="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0fd90f06-1871-4e18-bd6a-dd9d024ebce7_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_05ad5583-7650-406e-bca2-2b8bf90c1258_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_0103626b-f43c-49bf-a492-37ef63e0d2f3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c8c40a12-563e-4380-bc3e-443e2741fe79_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b92bce48-aaa3-4b07-a72d-db99b79408e9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_872d391f-547c-4ae6-b126-41f78078f1ad_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9490549f-3fee-45f7-a3bc-5b6dc1aeb62e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9173af78-aa28-4cec-8a80-2bd329ad30ab_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_88e2c5e7-1112-493e-bf3d-c2970454889a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_5cbd899b-3f95-45f6-89c8-a61b16ce2208_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ffdff1f9-29a2-4eb3-a250-5ef534eefc4b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_878425ed-62d3-47bd-ae02-ba20ff9c977f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b318d81c-b3b6-4595-87c6-de0cd53d4013_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar358Member_5f35ce42-cb47-4f3f-816f-9384fe145c8d_terseLabel_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:label id="lab_nktr_Nektar358Member_label_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358 [Member]</link:label>
    <link:label id="lab_nktr_Nektar358Member_documentation_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member" xlink:href="nktr-20220331.xsd#nktr_Nektar358Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar358Member" xlink:to="lab_nktr_Nektar358Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_fa6d6f8f-218a-4c46-8d14-bf55d4822af4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8065bbbd-c2d1-4cc1-83aa-13000907bb3c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3aebea87-c840-4df2-b96b-325f3ffbf4cb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_75d23fa3-a02a-4d80-903a-bd9c689491f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1dc2ddd2-d0a9-4582-b4e5-3ecb187d64f9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd88e873-a970-4dc7-af3e-452c80d16a64_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>nktr-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0975c044-35ac-4551-b121-d6df2cc9796d,g:b0fa7438-204d-4fa1-b132-84f7e9a28d02-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:type="simple" xlink:href="nktr-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ed81f496-a14b-441d-ade8-e47184485a7f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_DocumentType_ed81f496-a14b-441d-ade8-e47184485a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_70022af9-1137-42c9-b8ae-7f0fd492adc6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_DocumentQuarterlyReport_70022af9-1137-42c9-b8ae-7f0fd492adc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_672e0cc2-ded1-4ce6-a06f-6b5628b419f3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_DocumentPeriodEndDate_672e0cc2-ded1-4ce6-a06f-6b5628b419f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e85a88b7-0808-4f70-9724-f56827c32190" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_DocumentTransitionReport_e85a88b7-0808-4f70-9724-f56827c32190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_eb6fc17e-b5d6-4aec-a39b-d9a18cc97a53" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityFileNumber_eb6fc17e-b5d6-4aec-a39b-d9a18cc97a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_78b0c82b-00e3-49b2-b720-9fddba5a0ecb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityRegistrantName_78b0c82b-00e3-49b2-b720-9fddba5a0ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3c4c1490-4159-4e06-84bc-151cba96e258" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3c4c1490-4159-4e06-84bc-151cba96e258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_af66d062-1ed3-4a4c-ae9c-b69ae6c1964e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityTaxIdentificationNumber_af66d062-1ed3-4a4c-ae9c-b69ae6c1964e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2fb95bd1-ad5d-4908-9fa0-af61d4ade9d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityAddressAddressLine1_2fb95bd1-ad5d-4908-9fa0-af61d4ade9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_042fb472-2de1-4d5b-9052-e15ad79a48c8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityAddressCityOrTown_042fb472-2de1-4d5b-9052-e15ad79a48c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_eeac4490-f73b-42f2-9037-f6cb2c047646" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityAddressStateOrProvince_eeac4490-f73b-42f2-9037-f6cb2c047646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_58f13d59-7d8d-4212-8063-effeac6d0767" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityAddressPostalZipCode_58f13d59-7d8d-4212-8063-effeac6d0767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0066a90c-5e6a-4b2e-a6bd-d0bcc2526fc6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_CityAreaCode_0066a90c-5e6a-4b2e-a6bd-d0bcc2526fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_079b58d6-f06b-410d-8c92-afcd24bfc57d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_LocalPhoneNumber_079b58d6-f06b-410d-8c92-afcd24bfc57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0a87a3e5-cb58-4119-8b0f-161f0d7e7c6b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_Security12bTitle_0a87a3e5-cb58-4119-8b0f-161f0d7e7c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3e3808a2-be1a-4ee8-8624-768178d22e58" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_TradingSymbol_3e3808a2-be1a-4ee8-8624-768178d22e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3bb16235-b60e-4ef4-9d55-5492c1c42672" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_SecurityExchangeName_3bb16235-b60e-4ef4-9d55-5492c1c42672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0e821b62-436b-451d-a848-1299c7c5c171" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityCurrentReportingStatus_0e821b62-436b-451d-a848-1299c7c5c171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_dd70f01d-4f98-48e4-9275-b8b9155bb5f4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityInteractiveDataCurrent_dd70f01d-4f98-48e4-9275-b8b9155bb5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_fe8a5a5a-133d-4608-a4c4-fad39d3e0888" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityFilerCategory_fe8a5a5a-133d-4608-a4c4-fad39d3e0888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ffb8cd9e-18c1-47f4-b739-5fe59f9e7b00" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntitySmallBusiness_ffb8cd9e-18c1-47f4-b739-5fe59f9e7b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_aacdbaea-9c97-4588-9652-04ccf624fe99" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityEmergingGrowthCompany_aacdbaea-9c97-4588-9652-04ccf624fe99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1eb25ffc-39fe-4f2c-a8f7-24115269cf89" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityShellCompany_1eb25ffc-39fe-4f2c-a8f7-24115269cf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bcd9e0de-4f33-4f81-ae40-9c56c450df09" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bcd9e0de-4f33-4f81-ae40-9c56c450df09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_72866ae1-3c73-432d-95a3-02372dfc3f7c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_AmendmentFlag_72866ae1-3c73-432d-95a3-02372dfc3f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a14aaacc-e1de-4aae-9beb-6695ace291f1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_DocumentFiscalYearFocus_a14aaacc-e1de-4aae-9beb-6695ace291f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_10f17f0a-1c69-49d6-baba-3c9acb6abc2c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_DocumentFiscalPeriodFocus_10f17f0a-1c69-49d6-baba-3c9acb6abc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a26d8bbb-9b16-4e14-b9c6-7e951ecd6a27" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_EntityCentralIndexKey_a26d8bbb-9b16-4e14-b9c6-7e951ecd6a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e5a69eb5-1f8a-497a-8199-6f6bdb056eac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2561f482-2695-4204-988c-c6d3886f5b34" xlink:to="loc_dei_CurrentFiscalYearEndDate_e5a69eb5-1f8a-497a-8199-6f6bdb056eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_31af125e-c312-4ab5-96cf-0e58feda6a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b82c4f25-7d9f-4de7-94cb-aafef6dd891c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_31af125e-c312-4ab5-96cf-0e58feda6a2f" xlink:to="loc_us-gaap_AssetsAbstract_b82c4f25-7d9f-4de7-94cb-aafef6dd891c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_93b98ef9-144d-40ff-896c-8a18f202ab9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b82c4f25-7d9f-4de7-94cb-aafef6dd891c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_93b98ef9-144d-40ff-896c-8a18f202ab9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ee03d0f1-3e69-4897-b95e-58df8a976fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93b98ef9-144d-40ff-896c-8a18f202ab9b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ee03d0f1-3e69-4897-b95e-58df8a976fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a2c2a09c-b979-4de2-bffb-0ae3a0b0831e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93b98ef9-144d-40ff-896c-8a18f202ab9b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a2c2a09c-b979-4de2-bffb-0ae3a0b0831e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3b655330-2122-438e-9453-3cd90f8e9d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93b98ef9-144d-40ff-896c-8a18f202ab9b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3b655330-2122-438e-9453-3cd90f8e9d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b8b2edac-d909-465b-bf70-41d7c8a2b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93b98ef9-144d-40ff-896c-8a18f202ab9b" xlink:to="loc_us-gaap_InventoryNet_b8b2edac-d909-465b-bf70-41d7c8a2b7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_af1b07d2-51ec-4377-afc5-aabccab36b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93b98ef9-144d-40ff-896c-8a18f202ab9b" xlink:to="loc_us-gaap_OtherAssetsCurrent_af1b07d2-51ec-4377-afc5-aabccab36b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_24ac4abb-b2a1-441e-8e13-21b88e965a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_93b98ef9-144d-40ff-896c-8a18f202ab9b" xlink:to="loc_us-gaap_AssetsCurrent_24ac4abb-b2a1-441e-8e13-21b88e965a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0765f62e-0c52-4d8c-83cd-9f06947623f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b82c4f25-7d9f-4de7-94cb-aafef6dd891c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0765f62e-0c52-4d8c-83cd-9f06947623f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_985c2674-b658-4ff3-b4db-96a7b51ec65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b82c4f25-7d9f-4de7-94cb-aafef6dd891c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_985c2674-b658-4ff3-b4db-96a7b51ec65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b7396ad-aab0-4653-a648-265d4492baa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b82c4f25-7d9f-4de7-94cb-aafef6dd891c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b7396ad-aab0-4653-a648-265d4492baa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_caaf0f63-ae5b-4b05-9825-0ba59838ab09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b82c4f25-7d9f-4de7-94cb-aafef6dd891c" xlink:to="loc_us-gaap_Goodwill_caaf0f63-ae5b-4b05-9825-0ba59838ab09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_35c135b5-41dd-482f-ab4a-fb9409777367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b82c4f25-7d9f-4de7-94cb-aafef6dd891c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_35c135b5-41dd-482f-ab4a-fb9409777367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8be4695a-ca5b-460e-952f-31d3bfab0691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b82c4f25-7d9f-4de7-94cb-aafef6dd891c" xlink:to="loc_us-gaap_Assets_8be4695a-ca5b-460e-952f-31d3bfab0691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70ecc609-4696-428a-8230-ad100f266694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_31af125e-c312-4ab5-96cf-0e58feda6a2f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70ecc609-4696-428a-8230-ad100f266694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d209600c-1985-45fc-9ace-5954d7066590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70ecc609-4696-428a-8230-ad100f266694" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d209600c-1985-45fc-9ace-5954d7066590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d4174905-235b-4715-82a4-1ccc225b70ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d209600c-1985-45fc-9ace-5954d7066590" xlink:to="loc_us-gaap_AccountsPayableCurrent_d4174905-235b-4715-82a4-1ccc225b70ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ed902c5b-f3ac-4c7f-9772-bbd99ded88ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d209600c-1985-45fc-9ace-5954d7066590" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ed902c5b-f3ac-4c7f-9772-bbd99ded88ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_2b01d543-1e9c-4b7d-8012-34dcc98c34c5" xlink:href="nktr-20220331.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d209600c-1985-45fc-9ace-5954d7066590" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_2b01d543-1e9c-4b7d-8012-34dcc98c34c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d6c5249a-2b69-4521-aacd-00ac9cae6877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d209600c-1985-45fc-9ace-5954d7066590" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d6c5249a-2b69-4521-aacd-00ac9cae6877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e3c5372e-1a76-4710-bfd2-136fbc68b22c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d209600c-1985-45fc-9ace-5954d7066590" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e3c5372e-1a76-4710-bfd2-136fbc68b22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f1fcafa6-6a3d-4f1d-91a3-abaedceec31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d209600c-1985-45fc-9ace-5954d7066590" xlink:to="loc_us-gaap_LiabilitiesCurrent_f1fcafa6-6a3d-4f1d-91a3-abaedceec31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3b7aa3a4-e046-4a80-a479-37a0f2c8c1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70ecc609-4696-428a-8230-ad100f266694" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3b7aa3a4-e046-4a80-a479-37a0f2c8c1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_dc0daaba-96e4-4d79-bffd-f8a7cf1319dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70ecc609-4696-428a-8230-ad100f266694" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_dc0daaba-96e4-4d79-bffd-f8a7cf1319dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_239f7687-df8d-46d7-9e55-37ee124b98e7" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70ecc609-4696-428a-8230-ad100f266694" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_239f7687-df8d-46d7-9e55-37ee124b98e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_acfb1089-7bcd-4303-8f6a-60145eed3fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70ecc609-4696-428a-8230-ad100f266694" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_acfb1089-7bcd-4303-8f6a-60145eed3fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5c7bc37c-716e-47f8-ab26-060375a731a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70ecc609-4696-428a-8230-ad100f266694" xlink:to="loc_us-gaap_Liabilities_5c7bc37c-716e-47f8-ab26-060375a731a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_36ec0dbe-dfce-4427-8dd2-c1651aaf22f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70ecc609-4696-428a-8230-ad100f266694" xlink:to="loc_us-gaap_CommitmentsAndContingencies_36ec0dbe-dfce-4427-8dd2-c1651aaf22f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3fdad833-9adf-4780-aa96-9ac7f0a0a173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70ecc609-4696-428a-8230-ad100f266694" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3fdad833-9adf-4780-aa96-9ac7f0a0a173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_64f2b6c6-eb00-4c03-ba94-7442cc9d0ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3fdad833-9adf-4780-aa96-9ac7f0a0a173" xlink:to="loc_us-gaap_PreferredStockValue_64f2b6c6-eb00-4c03-ba94-7442cc9d0ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_eef3230a-56c8-4ec3-8f55-fce6e3ab3c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3fdad833-9adf-4780-aa96-9ac7f0a0a173" xlink:to="loc_us-gaap_CommonStockValue_eef3230a-56c8-4ec3-8f55-fce6e3ab3c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d4132c83-adb0-4483-8310-162171602181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3fdad833-9adf-4780-aa96-9ac7f0a0a173" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d4132c83-adb0-4483-8310-162171602181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e4130efa-1036-4481-aa63-43d8bf8c67db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3fdad833-9adf-4780-aa96-9ac7f0a0a173" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e4130efa-1036-4481-aa63-43d8bf8c67db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c34fe2aa-3e56-4c98-abe4-30a92994ef0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3fdad833-9adf-4780-aa96-9ac7f0a0a173" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c34fe2aa-3e56-4c98-abe4-30a92994ef0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_71397359-5289-4772-bc1c-8c58cdba7b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3fdad833-9adf-4780-aa96-9ac7f0a0a173" xlink:to="loc_us-gaap_StockholdersEquity_71397359-5289-4772-bc1c-8c58cdba7b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c8fb7ed-6d60-41ae-98d2-4371b5b2ef72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70ecc609-4696-428a-8230-ad100f266694" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c8fb7ed-6d60-41ae-98d2-4371b5b2ef72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="nktr-20220331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e7708ab4-2f24-47b9-8063-675bd4017b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12fded00-e6ac-4b1f-9657-87bb6d301f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7708ab4-2f24-47b9-8063-675bd4017b80" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12fded00-e6ac-4b1f-9657-87bb6d301f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_651e5581-5864-480b-85fd-373100eab21b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7708ab4-2f24-47b9-8063-675bd4017b80" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_651e5581-5864-480b-85fd-373100eab21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated_6b897292-0838-486c-8202-8983b9eaefbd" xlink:href="nktr-20220331.xsd#nktr_PreferredStockShareDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7708ab4-2f24-47b9-8063-675bd4017b80" xlink:to="loc_nktr_PreferredStockShareDesignated_6b897292-0838-486c-8202-8983b9eaefbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f1a35028-a4dc-471d-a865-74761238bd94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7708ab4-2f24-47b9-8063-675bd4017b80" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f1a35028-a4dc-471d-a865-74761238bd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_41a794f3-566e-41b8-864c-25259cec89cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7708ab4-2f24-47b9-8063-675bd4017b80" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_41a794f3-566e-41b8-864c-25259cec89cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0882a502-7cb0-4bd4-931a-87f6cab473c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7708ab4-2f24-47b9-8063-675bd4017b80" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0882a502-7cb0-4bd4-931a-87f6cab473c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_30cda7df-c565-4824-a3ac-38677fb1c6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7708ab4-2f24-47b9-8063-675bd4017b80" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_30cda7df-c565-4824-a3ac-38677fb1c6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20220331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c067cb15-83d0-405b-81fa-6523d4d95614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8b0e0e3d-80b0-4df4-b155-cc8637fd9752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c067cb15-83d0-405b-81fa-6523d4d95614" xlink:to="loc_us-gaap_StatementTable_8b0e0e3d-80b0-4df4-b155-cc8637fd9752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab38acb3-1f2e-47be-a6d7-30d32a945a99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8b0e0e3d-80b0-4df4-b155-cc8637fd9752" xlink:to="loc_srt_ProductOrServiceAxis_ab38acb3-1f2e-47be-a6d7-30d32a945a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed3fb882-282a-4682-9254-898f1b496bf1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ab38acb3-1f2e-47be-a6d7-30d32a945a99" xlink:to="loc_srt_ProductsAndServicesDomain_ed3fb882-282a-4682-9254-898f1b496bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5f47abcb-f859-452d-b316-dc7319746caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ed3fb882-282a-4682-9254-898f1b496bf1" xlink:to="loc_us-gaap_ProductMember_5f47abcb-f859-452d-b316-dc7319746caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_a3be65b4-d2d2-4d3e-9191-9b0749ab992b" xlink:href="nktr-20220331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ed3fb882-282a-4682-9254-898f1b496bf1" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_a3be65b4-d2d2-4d3e-9191-9b0749ab992b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_a60de371-65e1-4e3e-aaa9-b7b59b74395d" xlink:href="nktr-20220331.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ed3fb882-282a-4682-9254-898f1b496bf1" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_a60de371-65e1-4e3e-aaa9-b7b59b74395d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8b0e0e3d-80b0-4df4-b155-cc8637fd9752" xlink:to="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_cf7b7da8-e24f-4c46-96fd-25c98258b012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_RevenuesAbstract_cf7b7da8-e24f-4c46-96fd-25c98258b012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e378b3c-468e-42c3-99a0-78dfd10fabe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_cf7b7da8-e24f-4c46-96fd-25c98258b012" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e378b3c-468e-42c3-99a0-78dfd10fabe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f6386021-9a89-4136-b234-b0623c94ed2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f6386021-9a89-4136-b234-b0623c94ed2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_36718f86-7675-40aa-b089-bed46629b054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_36718f86-7675-40aa-b089-bed46629b054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0b3b61df-d370-4684-a651-1de9cecdc9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0b3b61df-d370-4684-a651-1de9cecdc9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ce630e99-54ca-457e-88a5-e3855925d163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:to="loc_us-gaap_RestructuringCharges_ce630e99-54ca-457e-88a5-e3855925d163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_089a7e47-56e2-4d7d-b9d5-0be07032d8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_88269113-1b16-432f-81a5-d9a120fcd130" xlink:to="loc_us-gaap_CostsAndExpenses_089a7e47-56e2-4d7d-b9d5-0be07032d8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7c1cf4c2-9d59-44ea-8090-de5e96b83a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_OperatingIncomeLoss_7c1cf4c2-9d59-44ea-8090-de5e96b83a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1d1dc160-acd4-477f-a3f1-55250c042ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1d1dc160-acd4-477f-a3f1-55250c042ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_6d3b84ea-7545-47bf-8b60-9a100f6973c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1d1dc160-acd4-477f-a3f1-55250c042ca7" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_6d3b84ea-7545-47bf-8b60-9a100f6973c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1d7c6b23-8142-4124-a6aa-92bf58748811" xlink:href="nktr-20220331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1d1dc160-acd4-477f-a3f1-55250c042ca7" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_1d7c6b23-8142-4124-a6aa-92bf58748811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_67e2b048-27c3-417a-94ed-cc718ecb086c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1d1dc160-acd4-477f-a3f1-55250c042ca7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_67e2b048-27c3-417a-94ed-cc718ecb086c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e2b9dc4d-b4c7-4bb3-87ab-b1bd8c40143b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1d1dc160-acd4-477f-a3f1-55250c042ca7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e2b9dc4d-b4c7-4bb3-87ab-b1bd8c40143b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_48ce8ec2-a012-4cb2-816e-4743e9cbb8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_48ce8ec2-a012-4cb2-816e-4743e9cbb8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1419f40b-2cfd-407c-a25d-3f0081d5a2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1419f40b-2cfd-407c-a25d-3f0081d5a2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0c84d2bd-5ee0-488b-933f-59aecfb6b8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_NetIncomeLoss_0c84d2bd-5ee0-488b-933f-59aecfb6b8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_615892e1-f7ec-4be5-9128-3e6c358ef100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_EarningsPerShareBasic_615892e1-f7ec-4be5-9128-3e6c358ef100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3c1d155e-90bf-453a-94f6-d555b307b473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3c1d155e-90bf-453a-94f6-d555b307b473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dab51605-3fea-4d85-88a1-4c91971641b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dab51605-3fea-4d85-88a1-4c91971641b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_70402d45-e366-4ba5-bcc8-c3e388d294c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572e4ee0-4f23-4d81-9e13-b1c3eccdab7d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_70402d45-e366-4ba5-bcc8-c3e388d294c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f8cf0b0d-6eb3-410c-9ca9-964de74de72c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_969dbdde-b0c0-4f69-81d6-129b1111ff31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f8cf0b0d-6eb3-410c-9ca9-964de74de72c" xlink:to="loc_us-gaap_NetIncomeLoss_969dbdde-b0c0-4f69-81d6-129b1111ff31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4eb03952-7125-4e7b-84ef-b620b54a9e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f8cf0b0d-6eb3-410c-9ca9-964de74de72c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4eb03952-7125-4e7b-84ef-b620b54a9e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5fec1d5c-a309-49f6-ba74-d2bbaa1d46e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4eb03952-7125-4e7b-84ef-b620b54a9e44" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5fec1d5c-a309-49f6-ba74-d2bbaa1d46e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_52dd17de-9308-41e7-9cac-58c6da168640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4eb03952-7125-4e7b-84ef-b620b54a9e44" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_52dd17de-9308-41e7-9cac-58c6da168640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f87093d8-9f28-4ea7-afa5-27fceb2c9a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4eb03952-7125-4e7b-84ef-b620b54a9e44" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f87093d8-9f28-4ea7-afa5-27fceb2c9a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d99dc8fa-43f5-4140-87cd-f89c24528b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f8cf0b0d-6eb3-410c-9ca9-964de74de72c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d99dc8fa-43f5-4140-87cd-f89c24528b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0dc70acf-ed60-47ac-9f65-6b43dfce5fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ed52fadb-8fa4-4d21-8746-16ed100b4b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0dc70acf-ed60-47ac-9f65-6b43dfce5fbe" xlink:to="loc_us-gaap_StatementTable_ed52fadb-8fa4-4d21-8746-16ed100b4b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_195848da-02b1-4ea2-89b6-648a8bec1fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ed52fadb-8fa4-4d21-8746-16ed100b4b2c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_195848da-02b1-4ea2-89b6-648a8bec1fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_38d92770-347e-42ce-b611-c1e22cff8a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_195848da-02b1-4ea2-89b6-648a8bec1fe0" xlink:to="loc_us-gaap_EquityComponentDomain_38d92770-347e-42ce-b611-c1e22cff8a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_36e83527-457d-4a85-b02f-fb43929b7354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_38d92770-347e-42ce-b611-c1e22cff8a86" xlink:to="loc_us-gaap_CommonStockMember_36e83527-457d-4a85-b02f-fb43929b7354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f5355eae-b750-492c-980c-826d8b4eb984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_38d92770-347e-42ce-b611-c1e22cff8a86" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f5355eae-b750-492c-980c-826d8b4eb984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1a8ef935-2ded-4a6e-82ce-174d18433907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_38d92770-347e-42ce-b611-c1e22cff8a86" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1a8ef935-2ded-4a6e-82ce-174d18433907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f87ea71a-9702-4eaa-8c48-2238eb03f61f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_38d92770-347e-42ce-b611-c1e22cff8a86" xlink:to="loc_us-gaap_RetainedEarningsMember_f87ea71a-9702-4eaa-8c48-2238eb03f61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_86a82066-8a7a-4a8b-9d31-08a5f3c6f666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ed52fadb-8fa4-4d21-8746-16ed100b4b2c" xlink:to="loc_us-gaap_StatementLineItems_86a82066-8a7a-4a8b-9d31-08a5f3c6f666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_86a82066-8a7a-4a8b-9d31-08a5f3c6f666" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f923961d-3325-46aa-8794-8f832ffec21b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_SharesOutstanding_f923961d-3325-46aa-8794-8f832ffec21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04cd34f2-3806-4b71-b4a4-6b698d2f2107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_StockholdersEquity_04cd34f2-3806-4b71-b4a4-6b698d2f2107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3ae1dfd5-6762-48e9-bf87-a5ca5fdfd207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3ae1dfd5-6762-48e9-bf87-a5ca5fdfd207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9ccd0e83-f780-4e00-886f-2834c7e117de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9ccd0e83-f780-4e00-886f-2834c7e117de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dc84ddbd-00fb-4de5-9a60-05a92c8bbcfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dc84ddbd-00fb-4de5-9a60-05a92c8bbcfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e46038d4-48ab-4d7d-95a4-d523da2f4f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e46038d4-48ab-4d7d-95a4-d523da2f4f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0372c7b6-799b-42aa-9c65-19f3c066c5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_SharesOutstanding_0372c7b6-799b-42aa-9c65-19f3c066c5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a3a01dd4-fd6e-404c-9005-a1da6441e92e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10c0b38d-73a9-457d-b014-94f2a92fa8a9" xlink:to="loc_us-gaap_StockholdersEquity_a3a01dd4-fd6e-404c-9005-a1da6441e92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nktr-20220331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_55ea2914-24b8-4f8e-a0b2-d9be4f3bd265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c997a010-90e5-400e-8fb5-22dc2c50cf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55ea2914-24b8-4f8e-a0b2-d9be4f3bd265" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c997a010-90e5-400e-8fb5-22dc2c50cf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_976e86b2-d442-4ca2-9c21-56c6bdb3d93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c997a010-90e5-400e-8fb5-22dc2c50cf2e" xlink:to="loc_us-gaap_ProfitLoss_976e86b2-d442-4ca2-9c21-56c6bdb3d93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73b14c04-9020-4c75-89a0-1f0969c21175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c997a010-90e5-400e-8fb5-22dc2c50cf2e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73b14c04-9020-4c75-89a0-1f0969c21175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_fe6ef5d7-6f7b-4ac1-9ac6-17e200cac7cf" xlink:href="nktr-20220331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73b14c04-9020-4c75-89a0-1f0969c21175" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_fe6ef5d7-6f7b-4ac1-9ac6-17e200cac7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_08d342b7-a903-4561-832f-9b0277f4f6d7" xlink:href="nktr-20220331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73b14c04-9020-4c75-89a0-1f0969c21175" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_08d342b7-a903-4561-832f-9b0277f4f6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_1bccadd9-8cc3-4c8d-849a-00fe04f3246f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73b14c04-9020-4c75-89a0-1f0969c21175" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_1bccadd9-8cc3-4c8d-849a-00fe04f3246f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_6632ef6f-013b-4d51-a088-0f62f5275a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73b14c04-9020-4c75-89a0-1f0969c21175" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_6632ef6f-013b-4d51-a088-0f62f5275a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d1b757f3-2e79-4e86-a6b0-0d8250b543a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73b14c04-9020-4c75-89a0-1f0969c21175" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d1b757f3-2e79-4e86-a6b0-0d8250b543a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_9d6a19c2-c242-4a0d-a05d-19bda944a644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73b14c04-9020-4c75-89a0-1f0969c21175" xlink:to="loc_us-gaap_DepreciationAndAmortization_9d6a19c2-c242-4a0d-a05d-19bda944a644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_205906e5-888e-4683-83d4-252a63ad519e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73b14c04-9020-4c75-89a0-1f0969c21175" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_205906e5-888e-4683-83d4-252a63ad519e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae09cdac-6a64-4d6f-b5b5-a17b2a1a5ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73b14c04-9020-4c75-89a0-1f0969c21175" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae09cdac-6a64-4d6f-b5b5-a17b2a1a5ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_162b39e6-b4d3-484b-b363-0f9ebe393e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae09cdac-6a64-4d6f-b5b5-a17b2a1a5ce7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_162b39e6-b4d3-484b-b363-0f9ebe393e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_feaf9a06-716d-40e6-a93c-66a5ad1b9034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae09cdac-6a64-4d6f-b5b5-a17b2a1a5ce7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_feaf9a06-716d-40e6-a93c-66a5ad1b9034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_09536f18-0c5a-408b-b7ab-f6760346e0d8" xlink:href="nktr-20220331.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae09cdac-6a64-4d6f-b5b5-a17b2a1a5ce7" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_09536f18-0c5a-408b-b7ab-f6760346e0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a5fa18a6-43fd-4d09-9cad-f5e0f8d6f2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae09cdac-6a64-4d6f-b5b5-a17b2a1a5ce7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a5fa18a6-43fd-4d09-9cad-f5e0f8d6f2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_79cd1160-32bd-4b1e-ba57-cdec6f8164e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae09cdac-6a64-4d6f-b5b5-a17b2a1a5ce7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_79cd1160-32bd-4b1e-ba57-cdec6f8164e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f19fe9d7-6329-4673-b403-e83c2e230e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae09cdac-6a64-4d6f-b5b5-a17b2a1a5ce7" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f19fe9d7-6329-4673-b403-e83c2e230e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_4123a790-7844-4227-a5e5-7e68fa2bb2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae09cdac-6a64-4d6f-b5b5-a17b2a1a5ce7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_4123a790-7844-4227-a5e5-7e68fa2bb2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54496dc5-5299-4240-bf29-71dbb98d06a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c997a010-90e5-400e-8fb5-22dc2c50cf2e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54496dc5-5299-4240-bf29-71dbb98d06a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_570e7360-d000-498c-b218-58e79f9aeb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55ea2914-24b8-4f8e-a0b2-d9be4f3bd265" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_570e7360-d000-498c-b218-58e79f9aeb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b5be94a-1a9d-405a-8874-522c7b114e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_570e7360-d000-498c-b218-58e79f9aeb88" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b5be94a-1a9d-405a-8874-522c7b114e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_455932fc-f653-4582-b5db-95145a30f09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_570e7360-d000-498c-b218-58e79f9aeb88" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_455932fc-f653-4582-b5db-95145a30f09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_83383855-4487-4c30-82e7-3b26b9299787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_570e7360-d000-498c-b218-58e79f9aeb88" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_83383855-4487-4c30-82e7-3b26b9299787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e4b6079-91ce-4a5d-a7dd-654f3b999467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_570e7360-d000-498c-b218-58e79f9aeb88" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e4b6079-91ce-4a5d-a7dd-654f3b999467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_391cd742-ae67-4fe9-ad23-c26e1a3d3606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_570e7360-d000-498c-b218-58e79f9aeb88" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_391cd742-ae67-4fe9-ad23-c26e1a3d3606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6aa3ad7f-96b6-431e-95bb-9052fa6164e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55ea2914-24b8-4f8e-a0b2-d9be4f3bd265" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6aa3ad7f-96b6-431e-95bb-9052fa6164e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_6dd91b27-63f7-4571-b400-a7638d0beff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6aa3ad7f-96b6-431e-95bb-9052fa6164e3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_6dd91b27-63f7-4571-b400-a7638d0beff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_3d767493-8a87-4906-8b5d-336856746321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6aa3ad7f-96b6-431e-95bb-9052fa6164e3" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_3d767493-8a87-4906-8b5d-336856746321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1ea868c1-6bc2-4a79-bd5f-c948b2cbbb99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6aa3ad7f-96b6-431e-95bb-9052fa6164e3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1ea868c1-6bc2-4a79-bd5f-c948b2cbbb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_430ab466-11eb-4e0e-a7f6-cda7146b4611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55ea2914-24b8-4f8e-a0b2-d9be4f3bd265" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_430ab466-11eb-4e0e-a7f6-cda7146b4611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1fe3e160-452e-4835-9c6a-264095636c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55ea2914-24b8-4f8e-a0b2-d9be4f3bd265" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1fe3e160-452e-4835-9c6a-264095636c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b37156ba-b1cf-4a2b-a185-bf49f04fcc48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55ea2914-24b8-4f8e-a0b2-d9be4f3bd265" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b37156ba-b1cf-4a2b-a185-bf49f04fcc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_53225918-3025-4199-a00d-46689be3b4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55ea2914-24b8-4f8e-a0b2-d9be4f3bd265" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_53225918-3025-4199-a00d-46689be3b4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_781eb332-32fd-4562-bd9a-375685d36f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_55ea2914-24b8-4f8e-a0b2-d9be4f3bd265" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_781eb332-32fd-4562-bd9a-375685d36f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0bc65862-03f1-45d1-87a4-6069b63e7dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_781eb332-32fd-4562-bd9a-375685d36f24" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0bc65862-03f1-45d1-87a4-6069b63e7dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20220331.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a18528ca-bb76-4943-8d51-74ec18251c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c879120d-0469-4aa9-899c-216500750d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a18528ca-bb76-4943-8d51-74ec18251c8a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c879120d-0469-4aa9-899c-216500750d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20220331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb1c5b9f-cbfa-4460-a455-01e91160815f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock_85686a6f-9e47-4f4c-bd58-ce517b7a1c3b" xlink:href="nktr-20220331.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb1c5b9f-cbfa-4460-a455-01e91160815f" xlink:to="loc_nktr_OrganizationPolicyTextBlock_85686a6f-9e47-4f4c-bd58-ce517b7a1c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_aa8d1c5c-4b3b-428e-a058-2c10a029a01b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb1c5b9f-cbfa-4460-a455-01e91160815f" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_aa8d1c5c-4b3b-428e-a058-2c10a029a01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d8bde2ad-ff27-455f-a693-9e21a8f1d3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb1c5b9f-cbfa-4460-a455-01e91160815f" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d8bde2ad-ff27-455f-a693-9e21a8f1d3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_82a0e99a-d3f4-41fa-9f1f-2a799da4505a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb1c5b9f-cbfa-4460-a455-01e91160815f" xlink:to="loc_us-gaap_UseOfEstimates_82a0e99a-d3f4-41fa-9f1f-2a799da4505a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_6976fda3-78a0-43a0-a3f2-714116f24940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb1c5b9f-cbfa-4460-a455-01e91160815f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_6976fda3-78a0-43a0-a3f2-714116f24940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_f7ff1db6-b734-4245-ada5-bd40b95204a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb1c5b9f-cbfa-4460-a455-01e91160815f" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_f7ff1db6-b734-4245-ada5-bd40b95204a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b180dcff-bb11-4177-81ad-f1f73a7ce691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb1c5b9f-cbfa-4460-a455-01e91160815f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b180dcff-bb11-4177-81ad-f1f73a7ce691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e6e2908e-69c7-4c75-a5ba-9d773983c0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb1c5b9f-cbfa-4460-a455-01e91160815f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e6e2908e-69c7-4c75-a5ba-9d773983c0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_9a68ff7e-497b-4e9c-b686-174b193685b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cb1c5b9f-cbfa-4460-a455-01e91160815f" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_9a68ff7e-497b-4e9c-b686-174b193685b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a1e1cfa8-e63d-4d4c-a055-bef3a331cbee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:href="nktr-20220331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a1e1cfa8-e63d-4d4c-a055-bef3a331cbee" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8c5ca053-9c1a-4684-8381-d345e4cf6f92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:to="loc_srt_CounterpartyNameAxis_8c5ca053-9c1a-4684-8381-d345e4cf6f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38811409-008f-4f26-90f6-cd8aed30d390" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8c5ca053-9c1a-4684-8381-d345e4cf6f92" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38811409-008f-4f26-90f6-cd8aed30d390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_c3be2ce1-218a-4d11-898d-82b2b7f82fd5" xlink:href="nktr-20220331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38811409-008f-4f26-90f6-cd8aed30d390" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_c3be2ce1-218a-4d11-898d-82b2b7f82fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5eb6d39f-8205-4864-af82-c4f9dcfbdfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5eb6d39f-8205-4864-af82-c4f9dcfbdfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d413a5ac-8edc-4560-adb1-440046c80ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5eb6d39f-8205-4864-af82-c4f9dcfbdfb0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d413a5ac-8edc-4560-adb1-440046c80ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b9319efb-28dc-466f-b88b-fbcc99512273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d413a5ac-8edc-4560-adb1-440046c80ee8" xlink:to="loc_us-gaap_SubsequentEventMember_b9319efb-28dc-466f-b88b-fbcc99512273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_745204ef-8935-43e3-9729-e9f7ff77dbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_745204ef-8935-43e3-9729-e9f7ff77dbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3fc1db92-cd59-4716-8ce6-65e8e16d0eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_745204ef-8935-43e3-9729-e9f7ff77dbbe" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3fc1db92-cd59-4716-8ce6-65e8e16d0eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_eefeb1c3-55be-4223-99b6-2fd28c2eb5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3fc1db92-cd59-4716-8ce6-65e8e16d0eba" xlink:to="loc_us-gaap_EmployeeSeveranceMember_eefeb1c3-55be-4223-99b6-2fd28c2eb5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b954dc3-c639-4247-9703-98ec0c030811" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:to="loc_srt_ProductOrServiceAxis_9b954dc3-c639-4247-9703-98ec0c030811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d39e5643-d520-4f69-b170-4c3a851440a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9b954dc3-c639-4247-9703-98ec0c030811" xlink:to="loc_srt_ProductsAndServicesDomain_d39e5643-d520-4f69-b170-4c3a851440a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_97a4a013-3f0b-47c8-8e79-f5350b8162cf" xlink:href="nktr-20220331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d39e5643-d520-4f69-b170-4c3a851440a2" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_97a4a013-3f0b-47c8-8e79-f5350b8162cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:href="nktr-20220331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_1ad78ba9-4f61-4162-970a-b809035b1d7a" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_e3647dee-0792-4a47-9734-f573451a3d52" xlink:href="nktr-20220331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_e3647dee-0792-4a47-9734-f573451a3d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_9dd544fd-ed80-437c-9892-45288c995383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_9dd544fd-ed80-437c-9892-45288c995383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_74c1a27e-9884-4086-89ac-f5537cddc44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_74c1a27e-9884-4086-89ac-f5537cddc44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_04a54446-7caf-4524-b3e8-98f63449a201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_04a54446-7caf-4524-b3e8-98f63449a201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3198b765-529c-438e-8e0d-90c8bfd569e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f7a38ef3-a5b8-4bfe-b0ed-e103da143bbe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3198b765-529c-438e-8e0d-90c8bfd569e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20220331.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a6ec933c-f5fc-4720-be63-c4f48dc949a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_0c231c88-04c3-458c-99d1-7df8f42be8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a6ec933c-f5fc-4720-be63-c4f48dc949a6" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_0c231c88-04c3-458c-99d1-7df8f42be8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20220331.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f7e3b4d9-6a89-4c2c-8ed9-a3aef7a5e2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5d15964c-5c02-4a4a-b159-a0272b73b751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7e3b4d9-6a89-4c2c-8ed9-a3aef7a5e2fe" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5d15964c-5c02-4a4a-b159-a0272b73b751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2a8cfad6-b01f-477e-b552-44387ae90aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7e3b4d9-6a89-4c2c-8ed9-a3aef7a5e2fe" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2a8cfad6-b01f-477e-b552-44387ae90aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8436e7f9-a16f-4ee2-a2e6-312ed7a8898f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7730aa68-4589-49f2-a3cf-2af648083379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8436e7f9-a16f-4ee2-a2e6-312ed7a8898f" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7730aa68-4589-49f2-a3cf-2af648083379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_396c912f-c3f8-450e-ad0a-14c2c3a2723b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7730aa68-4589-49f2-a3cf-2af648083379" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_396c912f-c3f8-450e-ad0a-14c2c3a2723b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e662efab-949c-45fa-be8e-b18e819093e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7730aa68-4589-49f2-a3cf-2af648083379" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e662efab-949c-45fa-be8e-b18e819093e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_779fe54f-7b77-4048-a728-4b99972db13e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7730aa68-4589-49f2-a3cf-2af648083379" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_779fe54f-7b77-4048-a728-4b99972db13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_7452c111-b56f-4ea3-994a-bb23dd41406e" xlink:href="nktr-20220331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7730aa68-4589-49f2-a3cf-2af648083379" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_7452c111-b56f-4ea3-994a-bb23dd41406e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_df96d860-d1e7-493b-ba78-989e18aabc45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_5a7a9be1-6891-4c12-bacf-e6cf9a9584d1" xlink:href="nktr-20220331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_df96d860-d1e7-493b-ba78-989e18aabc45" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_5a7a9be1-6891-4c12-bacf-e6cf9a9584d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4cd9ea66-3ed4-495f-bf27-6b2a9ccb902a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_5a7a9be1-6891-4c12-bacf-e6cf9a9584d1" xlink:to="loc_srt_RangeAxis_4cd9ea66-3ed4-495f-bf27-6b2a9ccb902a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_97db9169-ce3b-4c51-a18a-ffbeb4f245aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4cd9ea66-3ed4-495f-bf27-6b2a9ccb902a" xlink:to="loc_srt_RangeMember_97db9169-ce3b-4c51-a18a-ffbeb4f245aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_284fdd65-9132-456f-9a01-29fdd74c95b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_97db9169-ce3b-4c51-a18a-ffbeb4f245aa" xlink:to="loc_srt_MinimumMember_284fdd65-9132-456f-9a01-29fdd74c95b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_85f19b49-5b60-4161-bcda-a18f3889d66a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_97db9169-ce3b-4c51-a18a-ffbeb4f245aa" xlink:to="loc_srt_MaximumMember_85f19b49-5b60-4161-bcda-a18f3889d66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:href="nktr-20220331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_5a7a9be1-6891-4c12-bacf-e6cf9a9584d1" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_dfa0a014-b3d5-482a-bf65-ca00468c0304" xlink:href="nktr-20220331.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:to="loc_nktr_DebtInvestmentMaximumMaturityPeriod_dfa0a014-b3d5-482a-bf65-ca00468c0304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_9238efc5-80d9-4668-af19-2c8740e649af" xlink:href="nktr-20220331.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:to="loc_nktr_DebtInvestmentMaturityTerm_9238efc5-80d9-4668-af19-2c8740e649af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_7e2d4246-86c5-4101-bd93-40eee41824e8" xlink:href="nktr-20220331.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_7e2d4246-86c5-4101-bd93-40eee41824e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_29f4f9c7-f8ba-436f-aad9-8b696e02be6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_29f4f9c7-f8ba-436f-aad9-8b696e02be6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a1435b42-5a48-4221-ad35-527467815f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_9068a14e-b04e-4c73-97c6-af7192ed876c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a1435b42-5a48-4221-ad35-527467815f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cdfeacd4-bb21-4bf0-8991-5cca67709bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_939bd11e-7f2d-4a3a-b4b8-d28fee1e3835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cdfeacd4-bb21-4bf0-8991-5cca67709bf6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_939bd11e-7f2d-4a3a-b4b8-d28fee1e3835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_958139e4-3a8e-4165-9662-58df8a212826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_939bd11e-7f2d-4a3a-b4b8-d28fee1e3835" xlink:to="loc_us-gaap_InvestmentTypeAxis_958139e4-3a8e-4165-9662-58df8a212826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_958139e4-3a8e-4165-9662-58df8a212826" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_259e9f69-a95a-4e1b-97d0-0ecd58a8273e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_259e9f69-a95a-4e1b-97d0-0ecd58a8273e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8a775c81-deb6-44a1-96fd-4c1feebd1a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:to="loc_us-gaap_CommercialPaperMember_8a775c81-deb6-44a1-96fd-4c1feebd1a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d971937f-4b81-402a-9257-730ee1e30939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d971937f-4b81-402a-9257-730ee1e30939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b0eb3846-2ca1-4e04-84b7-42ee2a9217fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b0eb3846-2ca1-4e04-84b7-42ee2a9217fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_46e23628-6a02-4440-8530-d7817d85c799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d19f36b4-f8d7-460d-95b5-2a558b95326f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_46e23628-6a02-4440-8530-d7817d85c799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_60022f86-d84b-4db9-af2b-8afc3f5bde1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_939bd11e-7f2d-4a3a-b4b8-d28fee1e3835" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_60022f86-d84b-4db9-af2b-8afc3f5bde1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df7b8250-8cdb-4a04-ad67-fff8b93f17cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_60022f86-d84b-4db9-af2b-8afc3f5bde1e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df7b8250-8cdb-4a04-ad67-fff8b93f17cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a388a597-afb1-46b1-ac6f-49c79f58e85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df7b8250-8cdb-4a04-ad67-fff8b93f17cf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a388a597-afb1-46b1-ac6f-49c79f58e85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_301f1140-4a49-4c73-9b2e-7832c76410c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df7b8250-8cdb-4a04-ad67-fff8b93f17cf" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_301f1140-4a49-4c73-9b2e-7832c76410c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_939bd11e-7f2d-4a3a-b4b8-d28fee1e3835" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_588db3f4-06e5-4a25-a1d8-77784fe4e614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_588db3f4-06e5-4a25-a1d8-77784fe4e614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4d2eebd-514e-4fcf-98fd-9a622a2b410d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4d2eebd-514e-4fcf-98fd-9a622a2b410d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_998ba654-15e4-4be4-8593-a497bb9a9762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_998ba654-15e4-4be4-8593-a497bb9a9762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_489938e9-00ae-4f50-b048-48cb96d35230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_489938e9-00ae-4f50-b048-48cb96d35230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_265efa4f-16c7-49bb-a67a-87c7818222f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_265efa4f-16c7-49bb-a67a-87c7818222f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_ecc97b6f-19d0-4fdb-a0f7-83990c112a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_us-gaap_Cash_ecc97b6f-19d0-4fdb-a0f7-83990c112a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_eff6928e-35ae-4f0b-8cde-67fa7ce5ea8e" xlink:href="nktr-20220331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a3f2b7c-2369-4263-b987-c0d35bbb821c" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_eff6928e-35ae-4f0b-8cde-67fa7ce5ea8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20220331.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_025c9df5-5680-4867-a2c4-1f4f5811ed5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_b54cfaad-a706-4b97-b98b-da1bd3e06075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_025c9df5-5680-4867-a2c4-1f4f5811ed5c" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_b54cfaad-a706-4b97-b98b-da1bd3e06075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20220331.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2dcb0d82-1c1d-4956-a2fb-d145f55e6949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e51e6eae-d29e-4f95-a57d-105d4bde49ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2dcb0d82-1c1d-4956-a2fb-d145f55e6949" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e51e6eae-d29e-4f95-a57d-105d4bde49ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a79d209e-a38d-4e50-b0a0-8099efec16e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_efff02e7-8ff9-405d-89b3-b52ab6db480a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a79d209e-a38d-4e50-b0a0-8099efec16e4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_efff02e7-8ff9-405d-89b3-b52ab6db480a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c674ccb9-6d5b-4f04-977e-6a069996d047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a79d209e-a38d-4e50-b0a0-8099efec16e4" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c674ccb9-6d5b-4f04-977e-6a069996d047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_900942cc-a6f3-472b-bdc5-7b12096f1598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a79d209e-a38d-4e50-b0a0-8099efec16e4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_900942cc-a6f3-472b-bdc5-7b12096f1598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2aa346f8-30cd-4b38-a705-24c15e3a0d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a79d209e-a38d-4e50-b0a0-8099efec16e4" xlink:to="loc_us-gaap_InventoryNet_2aa346f8-30cd-4b38-a705-24c15e3a0d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="simple" xlink:href="nktr-20220331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a717fa20-2882-4a62-a4b8-d5e967e3d79d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentDerivativeLiabilityTextBlock_c5f3a5be-d758-49e4-97c7-19d2498cdd9d" xlink:href="nktr-20220331.xsd#nktr_DevelopmentDerivativeLiabilityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a717fa20-2882-4a62-a4b8-d5e967e3d79d" xlink:to="loc_nktr_DevelopmentDerivativeLiabilityTextBlock_c5f3a5be-d758-49e4-97c7-19d2498cdd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="simple" xlink:href="nktr-20220331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_cac434a5-01ae-4b79-bb9d-7de6b7a8cbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_21fd7f99-46c2-4c7d-98bb-8379db72699e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_cac434a5-01ae-4b79-bb9d-7de6b7a8cbd2" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_21fd7f99-46c2-4c7d-98bb-8379db72699e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_85e25622-aa9d-42df-9c74-defd7b59a496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ba1a878-cef9-4b82-afae-7b5cc35f5443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_85e25622-aa9d-42df-9c74-defd7b59a496" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ba1a878-cef9-4b82-afae-7b5cc35f5443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_75819c1f-fc51-43ab-89f7-91755ee1a6ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ba1a878-cef9-4b82-afae-7b5cc35f5443" xlink:to="loc_srt_CounterpartyNameAxis_75819c1f-fc51-43ab-89f7-91755ee1a6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e575693-6a6b-4cd8-98d9-a1d057991639" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_75819c1f-fc51-43ab-89f7-91755ee1a6ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e575693-6a6b-4cd8-98d9-a1d057991639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_d78c2f89-256d-4c95-a4ae-b208189066c5" xlink:href="nktr-20220331.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2e575693-6a6b-4cd8-98d9-a1d057991639" xlink:to="loc_nktr_SFJPharmaceuticalsMember_d78c2f89-256d-4c95-a4ae-b208189066c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4add300-98f8-474b-89a8-5ac4ed77275c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ba1a878-cef9-4b82-afae-7b5cc35f5443" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4add300-98f8-474b-89a8-5ac4ed77275c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_822a2fdf-08e1-4652-943a-6325ac639800" xlink:href="nktr-20220331.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4add300-98f8-474b-89a8-5ac4ed77275c" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_822a2fdf-08e1-4652-943a-6325ac639800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_9a7c3f39-5181-4561-9146-e28975b86d2c" xlink:href="nktr-20220331.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4add300-98f8-474b-89a8-5ac4ed77275c" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount_9a7c3f39-5181-4561-9146-e28975b86d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5a853313-b643-498c-a510-135167873749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d4add300-98f8-474b-89a8-5ac4ed77275c" xlink:to="loc_us-gaap_DerivativeLiabilities_5a853313-b643-498c-a510-135167873749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_56c02bcb-3a1a-4519-b86a-07fe60f85061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_30b0058b-7738-4cca-9c01-c045d47c1c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_56c02bcb-3a1a-4519-b86a-07fe60f85061" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_30b0058b-7738-4cca-9c01-c045d47c1c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_9aabeaff-ebb9-4cd6-80ba-101a16f40e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_30b0058b-7738-4cca-9c01-c045d47c1c02" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_9aabeaff-ebb9-4cd6-80ba-101a16f40e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dc707a40-3464-43ec-8dc9-b1d045073a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_9aabeaff-ebb9-4cd6-80ba-101a16f40e7e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dc707a40-3464-43ec-8dc9-b1d045073a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2b77d98e-2f58-4f03-ba02-bb23e56c56a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dc707a40-3464-43ec-8dc9-b1d045073a45" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2b77d98e-2f58-4f03-ba02-bb23e56c56a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_13287cce-4d67-4318-b804-2e4f9fdacd61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_30b0058b-7738-4cca-9c01-c045d47c1c02" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_13287cce-4d67-4318-b804-2e4f9fdacd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3652d8a-86cd-4592-a940-45a2e95c89a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_13287cce-4d67-4318-b804-2e4f9fdacd61" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3652d8a-86cd-4592-a940-45a2e95c89a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_77eacc8d-69c4-41f2-bab3-64a935e27684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3652d8a-86cd-4592-a940-45a2e95c89a3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_77eacc8d-69c4-41f2-bab3-64a935e27684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b58f38ac-5192-470e-82bb-57c9ae2d8ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_30b0058b-7738-4cca-9c01-c045d47c1c02" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b58f38ac-5192-470e-82bb-57c9ae2d8ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b58f38ac-5192-470e-82bb-57c9ae2d8ced" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_65377b48-5f1a-4663-832f-5fecc6bb9f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_65377b48-5f1a-4663-832f-5fecc6bb9f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9a16276e-3eaf-4aac-a6c6-d0d4793686f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9a16276e-3eaf-4aac-a6c6-d0d4793686f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_a49edd9f-c071-4a0e-9f5a-dc4262c60eca" xlink:href="nktr-20220331.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:to="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_a49edd9f-c071-4a0e-9f5a-dc4262c60eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_ac5e5eb9-606e-4dc2-8852-f31e571eda86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_ac5e5eb9-606e-4dc2-8852-f31e571eda86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_58b515f7-f8b0-4c71-bd78-61eaea659ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_58b515f7-f8b0-4c71-bd78-61eaea659ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_706ade30-39bf-4008-935f-d7ac2e8e2c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d131ce9e-909f-40af-acae-927e8c0bc80d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_706ade30-39bf-4008-935f-d7ac2e8e2c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20220331.xsd#LiabilitiesRelatedtoSalesofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_911351e5-5439-4760-aa50-414774fc4c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_8be99207-2901-4fbe-9101-24a8cfda07e0" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_911351e5-5439-4760-aa50-414774fc4c65" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_8be99207-2901-4fbe-9101-24a8cfda07e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables" xlink:type="simple" xlink:href="nktr-20220331.xsd#LiabilitiesRelatedtoSalesofFutureRoyaltiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4edd9a14-78f8-44b1-a271-b03588ac10c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock_ad646a16-38fe-4a40-9ae8-3d4547a78d40" xlink:href="nktr-20220331.xsd#nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4edd9a14-78f8-44b1-a271-b03588ac10c3" xlink:to="loc_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock_ad646a16-38fe-4a40-9ae8-3d4547a78d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_ecd7d0b1-04b4-4054-83df-2feb85aa479f" xlink:href="nktr-20220331.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4edd9a14-78f8-44b1-a271-b03588ac10c3" xlink:to="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_ecd7d0b1-04b4-4054-83df-2feb85aa479f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a0ed2d30-a8ac-45c9-b542-3cb816dea31b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_df60c83e-9a05-46f4-8a29-422a58495c70" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a0ed2d30-a8ac-45c9-b542-3cb816dea31b" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_df60c83e-9a05-46f4-8a29-422a58495c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c74c1731-f769-4783-88a8-6bed808c39cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_df60c83e-9a05-46f4-8a29-422a58495c70" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c74c1731-f769-4783-88a8-6bed808c39cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ada28e05-9c39-4310-bb53-966c973c0343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c74c1731-f769-4783-88a8-6bed808c39cc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ada28e05-9c39-4310-bb53-966c973c0343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_fd3a369b-725f-4044-b720-505fc4456896" xlink:href="nktr-20220331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ada28e05-9c39-4310-bb53-966c973c0343" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_fd3a369b-725f-4044-b720-505fc4456896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_5ffaf93f-ba09-47f7-bcca-fd3532c10d77" xlink:href="nktr-20220331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ada28e05-9c39-4310-bb53-966c973c0343" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_5ffaf93f-ba09-47f7-bcca-fd3532c10d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_c8c04509-7315-444a-8bd2-d0855d081b19" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_df60c83e-9a05-46f4-8a29-422a58495c70" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_c8c04509-7315-444a-8bd2-d0855d081b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput_d089936e-e835-4586-bf05-528d598deaff" xlink:href="nktr-20220331.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_c8c04509-7315-444a-8bd2-d0855d081b19" xlink:to="loc_nktr_RoyaltiesLiabilityMeasurementInput_d089936e-e835-4586-bf05-528d598deaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_095b8d12-9624-4f28-b29b-23c149ef72a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_332894b8-1ecb-4e7a-8ada-9e1261a57014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_095b8d12-9624-4f28-b29b-23c149ef72a5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_332894b8-1ecb-4e7a-8ada-9e1261a57014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ce8db9df-8b82-4fad-b1d9-c0d0864c0b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_332894b8-1ecb-4e7a-8ada-9e1261a57014" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ce8db9df-8b82-4fad-b1d9-c0d0864c0b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f9fa81e-2c31-44a2-8e69-6dfc59a3526b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ce8db9df-8b82-4fad-b1d9-c0d0864c0b6c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f9fa81e-2c31-44a2-8e69-6dfc59a3526b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_a34c2b7b-315a-4a55-8714-9fa7074ea448" xlink:href="nktr-20220331.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f9fa81e-2c31-44a2-8e69-6dfc59a3526b" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_a34c2b7b-315a-4a55-8714-9fa7074ea448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_ca8df791-afe6-4f08-ae8c-603a3244c829" xlink:href="nktr-20220331.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f9fa81e-2c31-44a2-8e69-6dfc59a3526b" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_ca8df791-afe6-4f08-ae8c-603a3244c829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_332894b8-1ecb-4e7a-8ada-9e1261a57014" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds_0e938a06-7299-45c8-8565-ae97ed7de6c8" xlink:href="nktr-20220331.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_RoyaltyMonetizationProceeds_0e938a06-7299-45c8-8565-ae97ed7de6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_1d8074f3-91a2-4b8f-8dee-e6e97d30d02a" xlink:href="nktr-20220331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_1d8074f3-91a2-4b8f-8dee-e6e97d30d02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_784da1e7-411e-432b-bc4b-22242a98bc13" xlink:href="nktr-20220331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_784da1e7-411e-432b-bc4b-22242a98bc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_6eac31f5-8427-47c1-8ed7-593a6107a43d" xlink:href="nktr-20220331.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_6eac31f5-8427-47c1-8ed7-593a6107a43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_d5c7a7d4-10ff-4934-9e66-05297bf07ab0" xlink:href="nktr-20220331.xsd#nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_d5c7a7d4-10ff-4934-9e66-05297bf07ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_b990ad5c-2b3c-42e6-9599-6907f0c0c44a" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_b990ad5c-2b3c-42e6-9599-6907f0c0c44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_ca9c2fd6-6655-494b-8a94-27cee057fa84" xlink:href="nktr-20220331.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_ca9c2fd6-6655-494b-8a94-27cee057fa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_f8afc54a-7939-4cf3-99dc-6baa3945fd9d" xlink:href="nktr-20220331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dd9ac596-d663-4ec7-b791-4311228faa4f" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_f8afc54a-7939-4cf3-99dc-6baa3945fd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f4b345eb-249f-41d8-bffe-914f1c70a9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d63ad616-bbd2-44b3-b1a8-0f0d0e4c00a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f4b345eb-249f-41d8-bffe-914f1c70a9c6" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d63ad616-bbd2-44b3-b1a8-0f0d0e4c00a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eb23bcfd-1567-4651-884c-54ffbb7b36a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_9016554d-5a88-4480-bc67-26bcad761308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eb23bcfd-1567-4651-884c-54ffbb7b36a8" xlink:to="loc_us-gaap_LossContingenciesTable_9016554d-5a88-4480-bc67-26bcad761308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_722d729f-3e6d-4d67-b782-73e45a1c4677" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9016554d-5a88-4480-bc67-26bcad761308" xlink:to="loc_srt_LitigationCaseAxis_722d729f-3e6d-4d67-b782-73e45a1c4677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e2ffc0eb-278e-4d00-8734-e1f1b315f7fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_722d729f-3e6d-4d67-b782-73e45a1c4677" xlink:to="loc_srt_LitigationCaseTypeDomain_e2ffc0eb-278e-4d00-8734-e1f1b315f7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MulquinActionAndDamibaActionMember_b4854a86-607e-4f1a-83c5-7ecfd21ee1e7" xlink:href="nktr-20220331.xsd#nktr_MulquinActionAndDamibaActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2ffc0eb-278e-4d00-8734-e1f1b315f7fa" xlink:to="loc_nktr_MulquinActionAndDamibaActionMember_b4854a86-607e-4f1a-83c5-7ecfd21ee1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DerivativeActionMember_c4a5c242-87e3-40fd-a65b-3e0183834a02" xlink:href="nktr-20220331.xsd#nktr_DerivativeActionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e2ffc0eb-278e-4d00-8734-e1f1b315f7fa" xlink:to="loc_nktr_DerivativeActionMember_c4a5c242-87e3-40fd-a65b-3e0183834a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_241f9189-0661-4c02-8da4-40da488251fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9016554d-5a88-4480-bc67-26bcad761308" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_241f9189-0661-4c02-8da4-40da488251fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_612fdd95-96bc-4e5a-80c0-c45caea5719d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_241f9189-0661-4c02-8da4-40da488251fb" xlink:to="loc_us-gaap_LossContingencyNatureDomain_612fdd95-96bc-4e5a-80c0-c45caea5719d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember_3ea2640d-c212-42bf-b840-d80b0636a359" xlink:href="nktr-20220331.xsd#nktr_LegalMattersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_612fdd95-96bc-4e5a-80c0-c45caea5719d" xlink:to="loc_nktr_LegalMattersMember_3ea2640d-c212-42bf-b840-d80b0636a359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5addd5e3-19f6-4bf3-a24f-57ae8a46a4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9016554d-5a88-4480-bc67-26bcad761308" xlink:to="loc_us-gaap_LossContingenciesLineItems_5addd5e3-19f6-4bf3-a24f-57ae8a46a4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_c45df185-abd3-4c24-ac14-54b7cd5195f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5addd5e3-19f6-4bf3-a24f-57ae8a46a4a4" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_c45df185-abd3-4c24-ac14-54b7cd5195f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_252778fd-dd84-4cea-8c0b-1c08bd6287ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5addd5e3-19f6-4bf3-a24f-57ae8a46a4a4" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_252778fd-dd84-4cea-8c0b-1c08bd6287ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7cf16ac1-8a26-435b-880b-e65081645b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5addd5e3-19f6-4bf3-a24f-57ae8a46a4a4" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7cf16ac1-8a26-435b-880b-e65081645b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20220331.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_524f19f4-af43-4e0b-8909-cf61e822a6f9" xlink:href="nktr-20220331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_0d92e3a4-8d3c-4776-8700-8958b16c325b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_524f19f4-af43-4e0b-8909-cf61e822a6f9" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_0d92e3a4-8d3c-4776-8700-8958b16c325b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_558783e5-808d-4fe5-81a3-e82cf962de4b" xlink:href="nktr-20220331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_558783e5-808d-4fe5-81a3-e82cf962de4b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aede012d-d07b-4a89-8977-b0994ac09926" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_srt_ProductOrServiceAxis_aede012d-d07b-4a89-8977-b0994ac09926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eec427a4-205d-4286-9bc3-eaeee40ec364" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_aede012d-d07b-4a89-8977-b0994ac09926" xlink:to="loc_srt_ProductsAndServicesDomain_eec427a4-205d-4286-9bc3-eaeee40ec364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_2d925fbf-bd0f-4c8a-bdd3-4228285de284" xlink:href="nktr-20220331.xsd#nktr_Nektar214Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eec427a4-205d-4286-9bc3-eaeee40ec364" xlink:to="loc_nktr_Nektar214Member_2d925fbf-bd0f-4c8a-bdd3-4228285de284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0814bd1e-febd-4bdc-b114-1a3c23f42f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0814bd1e-febd-4bdc-b114-1a3c23f42f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bb399a62-4ee5-4c85-9ab2-067497ec9e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0814bd1e-febd-4bdc-b114-1a3c23f42f2d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bb399a62-4ee5-4c85-9ab2-067497ec9e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_defb2c53-f81a-4d68-965a-75bda89f4cb0" xlink:href="nktr-20220331.xsd#nktr_OpdivoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bb399a62-4ee5-4c85-9ab2-067497ec9e3c" xlink:to="loc_nktr_OpdivoMember_defb2c53-f81a-4d68-965a-75bda89f4cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7b2e4337-363f-474d-be0e-d26d9e46f4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7b2e4337-363f-474d-be0e-d26d9e46f4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4cde79c-fff1-4bf2-a542-d48314d6d307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7b2e4337-363f-474d-be0e-d26d9e46f4ed" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4cde79c-fff1-4bf2-a542-d48314d6d307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_6cec3cd8-a0a3-473a-93c4-1214bc032323" xlink:href="nktr-20220331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4cde79c-fff1-4bf2-a542-d48314d6d307" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_6cec3cd8-a0a3-473a-93c4-1214bc032323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_4cc7675f-04f7-4c37-b4de-786b7a654c36" xlink:href="nktr-20220331.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d4cde79c-fff1-4bf2-a542-d48314d6d307" xlink:to="loc_nktr_Nektar358Member_4cc7675f-04f7-4c37-b4de-786b7a654c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9c79012f-7902-4c33-b942-c73bc3dcb047" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_dei_LegalEntityAxis_9c79012f-7902-4c33-b942-c73bc3dcb047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_46c3a62e-61ac-4666-a742-bce52a0c7379" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9c79012f-7902-4c33-b942-c73bc3dcb047" xlink:to="loc_dei_EntityDomain_46c3a62e-61ac-4666-a742-bce52a0c7379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_2a0802ef-8178-491a-9f95-09cf55a95d6a" xlink:href="nktr-20220331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_46c3a62e-61ac-4666-a742-bce52a0c7379" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_2a0802ef-8178-491a-9f95-09cf55a95d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_3741a1ea-83f7-4c2e-9e3f-c50c4bb1fdd2" xlink:href="nktr-20220331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_46c3a62e-61ac-4666-a742-bce52a0c7379" xlink:to="loc_nktr_EliLillyAndCompanyMember_3741a1ea-83f7-4c2e-9e3f-c50c4bb1fdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_28e279ba-60ed-469f-b21c-39f1a5332831" xlink:href="nktr-20220331.xsd#nktr_EliLillyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_46c3a62e-61ac-4666-a742-bce52a0c7379" xlink:to="loc_nktr_EliLillyMember_28e279ba-60ed-469f-b21c-39f1a5332831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_1460fe3b-1739-4ec2-99f5-22ffc37fe6dc" xlink:href="nktr-20220331.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_46c3a62e-61ac-4666-a742-bce52a0c7379" xlink:to="loc_nktr_OtherPartnerMember_1460fe3b-1739-4ec2-99f5-22ffc37fe6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_125994bc-88d9-4f7a-aa98-e2e4dec1de93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_srt_ConsolidatedEntitiesAxis_125994bc-88d9-4f7a-aa98-e2e4dec1de93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c015e1a4-8092-4ba9-8cc5-44d55623de7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_125994bc-88d9-4f7a-aa98-e2e4dec1de93" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c015e1a4-8092-4ba9-8cc5-44d55623de7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_f2660f27-eb89-41e5-bade-bb17520d4d1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c015e1a4-8092-4ba9-8cc5-44d55623de7d" xlink:to="loc_srt_ParentCompanyMember_f2660f27-eb89-41e5-bade-bb17520d4d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_438f6dd7-0011-4983-ac57-a6000cf36f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_438f6dd7-0011-4983-ac57-a6000cf36f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_acb6f863-9083-449b-8ffe-de136e1ea4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_438f6dd7-0011-4983-ac57-a6000cf36f4f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_acb6f863-9083-449b-8ffe-de136e1ea4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_68598e7a-83e6-4b9a-ab98-25302c52d3a6" xlink:href="nktr-20220331.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_acb6f863-9083-449b-8ffe-de136e1ea4a6" xlink:to="loc_nktr_SharePurchaseAgreementMember_68598e7a-83e6-4b9a-ab98-25302c52d3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_fcb05478-1960-42b2-9dd3-1a04a7a58154" xlink:href="nktr-20220331.xsd#nktr_MilestoneAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_nktr_MilestoneAxis_fcb05478-1960-42b2-9dd3-1a04a7a58154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_0054b3fb-3084-4333-9c50-5b8370718e03" xlink:href="nktr-20220331.xsd#nktr_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneAxis_fcb05478-1960-42b2-9dd3-1a04a7a58154" xlink:to="loc_nktr_MilestoneDomain_0054b3fb-3084-4333-9c50-5b8370718e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_d74570ff-c9ca-4276-a07b-f79bda875588" xlink:href="nktr-20220331.xsd#nktr_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneDomain_0054b3fb-3084-4333-9c50-5b8370718e03" xlink:to="loc_nktr_MilestoneOneMember_d74570ff-c9ca-4276-a07b-f79bda875588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_303efdbd-a17d-4a4e-abce-7dfd6ee7c5df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_303efdbd-a17d-4a4e-abce-7dfd6ee7c5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_049c3d2f-9064-4efa-a6a8-009c37307a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_303efdbd-a17d-4a4e-abce-7dfd6ee7c5df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_049c3d2f-9064-4efa-a6a8-009c37307a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d58b5505-151d-466c-9ad4-3f389f5aa4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_049c3d2f-9064-4efa-a6a8-009c37307a62" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d58b5505-151d-466c-9ad4-3f389f5aa4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_020a8af5-4c0d-4e35-ba62-dc94e43f0e4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_srt_CounterpartyNameAxis_020a8af5-4c0d-4e35-ba62-dc94e43f0e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fbca506-1154-4748-85e9-f78c69a6731e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_020a8af5-4c0d-4e35-ba62-dc94e43f0e4a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fbca506-1154-4748-85e9-f78c69a6731e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_dfb73951-1c87-46b1-938e-822b12b33185" xlink:href="nktr-20220331.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fbca506-1154-4748-85e9-f78c69a6731e" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_dfb73951-1c87-46b1-938e-822b12b33185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3743c409-6959-43aa-bbb5-5e148c5254ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_srt_RangeAxis_3743c409-6959-43aa-bbb5-5e148c5254ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_469f6de0-bc3f-4170-b4d8-436ec3e1a60b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3743c409-6959-43aa-bbb5-5e148c5254ab" xlink:to="loc_srt_RangeMember_469f6de0-bc3f-4170-b4d8-436ec3e1a60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c5f347c-acde-45d1-acfb-80e4516ac53a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_469f6de0-bc3f-4170-b4d8-436ec3e1a60b" xlink:to="loc_srt_MaximumMember_2c5f347c-acde-45d1-acfb-80e4516ac53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_94b99613-e822-4e17-95b5-19d78ca74a56" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_aa524773-098f-4ef6-a581-3e6abcfbefd9" xlink:href="nktr-20220331.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_aa524773-098f-4ef6-a581-3e6abcfbefd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_1c68d0e5-9b2d-433a-98c5-a42fe369abdb" xlink:href="nktr-20220331.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_1c68d0e5-9b2d-433a-98c5-a42fe369abdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_58c5aa34-ba49-45b5-8f9e-4e464fb7d024" xlink:href="nktr-20220331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_58c5aa34-ba49-45b5-8f9e-4e464fb7d024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_5cc7a4c0-cfa6-4cb3-8597-7bbf19683a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_us-gaap_SharesIssued_5cc7a4c0-cfa6-4cb3-8597-7bbf19683a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_f50a9baf-d85d-47cd-bd3a-40cc589e12d5" xlink:href="nktr-20220331.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_f50a9baf-d85d-47cd-bd3a-40cc589e12d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_473e919e-f763-497a-8088-ce0c02a5eae9" xlink:href="nktr-20220331.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PotentialDevelopmentMilestones_473e919e-f763-497a-8088-ce0c02a5eae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_76e36243-0e6b-4e04-ae71-1f832a9611c2" xlink:href="nktr-20220331.xsd#nktr_ReimbursementOfExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_ReimbursementOfExpenses_76e36243-0e6b-4e04-ae71-1f832a9611c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_79acc665-31f3-422a-bf3f-8c86fa53d744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_79acc665-31f3-422a-bf3f-8c86fa53d744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_8c435e50-8670-4a31-9034-8463fa84d6ac" xlink:href="nktr-20220331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_8c435e50-8670-4a31-9034-8463fa84d6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_33e04b36-76b8-4be1-8bb0-c025854d61c3" xlink:href="nktr-20220331.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_33e04b36-76b8-4be1-8bb0-c025854d61c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_af639269-65d5-4ebe-8499-90e57d4314db" xlink:href="nktr-20220331.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_af639269-65d5-4ebe-8499-90e57d4314db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_eba289d2-336a-42d3-b1e1-75428e191ab1" xlink:href="nktr-20220331.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_eba289d2-336a-42d3-b1e1-75428e191ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_2acf8775-bbad-445d-9841-4ed2f47b3f0e" xlink:href="nktr-20220331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_2acf8775-bbad-445d-9841-4ed2f47b3f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_08220a4b-ac94-40c1-a847-79d408c9e070" xlink:href="nktr-20220331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22f06830-b557-4077-b88e-81d9797d33a8" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_08220a4b-ac94-40c1-a847-79d408c9e070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20220331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e928cfa-b058-4eee-a1a1-0fb64d2e2970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b96180e3-e3b7-4fe7-b755-cfb8e89d237b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e928cfa-b058-4eee-a1a1-0fb64d2e2970" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b96180e3-e3b7-4fe7-b755-cfb8e89d237b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20220331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_94601d1f-0635-499e-aec4-f68460efd7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2103babf-5562-4509-8421-c8ee9eed5fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_94601d1f-0635-499e-aec4-f68460efd7b0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2103babf-5562-4509-8421-c8ee9eed5fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_7523336d-75a8-4154-801b-63dde2dafb94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_94601d1f-0635-499e-aec4-f68460efd7b0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_7523336d-75a8-4154-801b-63dde2dafb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e80f0ca-0db1-47d0-8d08-aaa8dcee84f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30d0a955-7850-41c4-8be3-4373c76df3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e80f0ca-0db1-47d0-8d08-aaa8dcee84f9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30d0a955-7850-41c4-8be3-4373c76df3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4481f839-9d45-4d62-86bf-48cd7e99c4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30d0a955-7850-41c4-8be3-4373c76df3e0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4481f839-9d45-4d62-86bf-48cd7e99c4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3bf764c0-170a-4268-a2e4-c01d3d13dd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4481f839-9d45-4d62-86bf-48cd7e99c4cc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3bf764c0-170a-4268-a2e4-c01d3d13dd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_c0329c7a-1d10-465c-a711-4c56a2f849cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bf764c0-170a-4268-a2e4-c01d3d13dd00" xlink:to="loc_us-gaap_CostOfSalesMember_c0329c7a-1d10-465c-a711-4c56a2f849cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3b3a24b2-235f-4837-bfd9-380d183b2273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bf764c0-170a-4268-a2e4-c01d3d13dd00" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3b3a24b2-235f-4837-bfd9-380d183b2273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2cef3e8d-c14c-4191-bbb7-deb299bc6b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bf764c0-170a-4268-a2e4-c01d3d13dd00" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2cef3e8d-c14c-4191-bbb7-deb299bc6b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3ee998a6-4982-4065-80ec-ef98b9ad4759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_30d0a955-7850-41c4-8be3-4373c76df3e0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3ee998a6-4982-4065-80ec-ef98b9ad4759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d3416c23-9976-4168-849a-02b8274f96de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3ee998a6-4982-4065-80ec-ef98b9ad4759" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d3416c23-9976-4168-849a-02b8274f96de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#StockBasedCompensationActivityDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e1b7184-147a-4348-819d-b67af4771f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_866529eb-7c62-4480-8865-75da5afc7869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e1b7184-147a-4348-819d-b67af4771f8b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_866529eb-7c62-4480-8865-75da5afc7869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4fdb1097-8197-48a5-90ae-69a77e67ae8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_866529eb-7c62-4480-8865-75da5afc7869" xlink:to="loc_us-gaap_AwardTypeAxis_4fdb1097-8197-48a5-90ae-69a77e67ae8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49de53a9-8f71-48d0-8af7-acc087d55760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4fdb1097-8197-48a5-90ae-69a77e67ae8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49de53a9-8f71-48d0-8af7-acc087d55760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_57f6f6ad-3d74-47fe-b474-541bee5d7307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49de53a9-8f71-48d0-8af7-acc087d55760" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_57f6f6ad-3d74-47fe-b474-541bee5d7307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cef9a45-99dc-41b3-b464-da80111c8479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_866529eb-7c62-4480-8865-75da5afc7869" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cef9a45-99dc-41b3-b464-da80111c8479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_24c36a19-fb09-49a6-a62e-7dd2b6109d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cef9a45-99dc-41b3-b464-da80111c8479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_24c36a19-fb09-49a6-a62e-7dd2b6109d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14938de7-ec62-4194-90e3-c34daf575e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cef9a45-99dc-41b3-b464-da80111c8479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14938de7-ec62-4194-90e3-c34daf575e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ca812025-cc7a-4d12-8038-cee36143225b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cef9a45-99dc-41b3-b464-da80111c8479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ca812025-cc7a-4d12-8038-cee36143225b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0b5c5b2c-c7e8-42d0-98d7-081e24cb742e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cef9a45-99dc-41b3-b464-da80111c8479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0b5c5b2c-c7e8-42d0-98d7-081e24cb742e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShare" xlink:type="simple" xlink:href="nktr-20220331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e175abbe-019a-412e-b929-1d03ddd992df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_a302cb7c-8237-4af0-a38b-df3e50e2157b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e175abbe-019a-412e-b929-1d03ddd992df" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_a302cb7c-8237-4af0-a38b-df3e50e2157b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="nktr-20220331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2ff12e94-4832-4dfa-b51e-7d54deafda9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8e48047f-fd4c-43bf-833d-21fbdf4a878e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ff12e94-4832-4dfa-b51e-7d54deafda9d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8e48047f-fd4c-43bf-833d-21fbdf4a878e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="simple" xlink:href="nktr-20220331.xsd#NetLossPerShareDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cf2b4d76-c929-47b5-b4a5-fce08839cc70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c073dae9-a43f-409f-b8c6-a8488c619a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cf2b4d76-c929-47b5-b4a5-fce08839cc70" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c073dae9-a43f-409f-b8c6-a8488c619a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEvent" xlink:type="simple" xlink:href="nktr-20220331.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_49f2cda3-2af1-45bf-b553-a7e455f247d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3d36b855-56a1-4062-aa2c-169c6e85a3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_49f2cda3-2af1-45bf-b553-a7e455f247d2" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_3d36b855-56a1-4062-aa2c-169c6e85a3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="nktr-20220331.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_add915f5-b297-416b-afe0-b8e365fafbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5ec41918-b246-4b3d-9094-d6976bd8f525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_add915f5-b297-416b-afe0-b8e365fafbaa" xlink:to="loc_us-gaap_SubsequentEventTable_5ec41918-b246-4b3d-9094-d6976bd8f525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_45c563c4-bde9-4fc7-b3b5-fc2658869a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5ec41918-b246-4b3d-9094-d6976bd8f525" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_45c563c4-bde9-4fc7-b3b5-fc2658869a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19a87efb-c38a-42bd-b4fb-29f567ab342b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_45c563c4-bde9-4fc7-b3b5-fc2658869a0d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19a87efb-c38a-42bd-b4fb-29f567ab342b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1af05754-d715-4b7a-9121-7708dddecbff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_19a87efb-c38a-42bd-b4fb-29f567ab342b" xlink:to="loc_us-gaap_SubsequentEventMember_1af05754-d715-4b7a-9121-7708dddecbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_14d5744b-fd4d-4d28-ac7f-ad3c0aed3a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5ec41918-b246-4b3d-9094-d6976bd8f525" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_14d5744b-fd4d-4d28-ac7f-ad3c0aed3a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_21bfccfe-0610-484e-93aa-ff6750730afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_14d5744b-fd4d-4d28-ac7f-ad3c0aed3a95" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_21bfccfe-0610-484e-93aa-ff6750730afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_999a2751-b1d2-4090-8f85-9e2f1c40d8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_21bfccfe-0610-484e-93aa-ff6750730afe" xlink:to="loc_us-gaap_EmployeeSeveranceMember_999a2751-b1d2-4090-8f85-9e2f1c40d8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_464e1d0b-1624-46d2-b3bc-d2ae28e9b351" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5ec41918-b246-4b3d-9094-d6976bd8f525" xlink:to="loc_srt_RangeAxis_464e1d0b-1624-46d2-b3bc-d2ae28e9b351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8381a815-142f-4bb6-adde-e52e61a6d387" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_464e1d0b-1624-46d2-b3bc-d2ae28e9b351" xlink:to="loc_srt_RangeMember_8381a815-142f-4bb6-adde-e52e61a6d387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1ccdf9ef-6be2-48d1-bb7f-fb99d757f7bd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8381a815-142f-4bb6-adde-e52e61a6d387" xlink:to="loc_srt_MinimumMember_1ccdf9ef-6be2-48d1-bb7f-fb99d757f7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_528a28e0-3517-4a2a-9c5e-c2b6636bce49" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8381a815-142f-4bb6-adde-e52e61a6d387" xlink:to="loc_srt_MaximumMember_528a28e0-3517-4a2a-9c5e-c2b6636bce49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_11585719-2a8f-4848-875e-2f50843aabad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5ec41918-b246-4b3d-9094-d6976bd8f525" xlink:to="loc_us-gaap_SubsequentEventLineItems_11585719-2a8f-4848-875e-2f50843aabad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_07f421f1-3e47-4b74-97d0-25b3b5cfa7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_11585719-2a8f-4848-875e-2f50843aabad" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_07f421f1-3e47-4b74-97d0-25b3b5cfa7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_35bd5e09-32e3-4186-b866-66cfcc1c3d83" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityNumberOfEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_11585719-2a8f-4848-875e-2f50843aabad" xlink:to="loc_dei_EntityNumberOfEmployees_35bd5e09-32e3-4186-b866-66cfcc1c3d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_7231ba50-0c34-4b46-b4df-5768d4df525e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_11585719-2a8f-4848-875e-2f50843aabad" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_7231ba50-0c34-4b46-b4df-5768d4df525e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488070638920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3134940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 Mission Bay Boulevard South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">482-5300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,274,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488073211480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 67,993<span></span>
</td>
<td class="nump">$ 25,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">599,032<span></span>
</td>
<td class="nump">708,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">30,220<span></span>
</td>
<td class="nump">22,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">15,379<span></span>
</td>
<td class="nump">15,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">20,831<span></span>
</td>
<td class="nump">23,333<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">733,455<span></span>
</td>
<td class="nump">795,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">37,363<span></span>
</td>
<td class="nump">64,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">60,980<span></span>
</td>
<td class="nump">60,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">114,296<span></span>
</td>
<td class="nump">117,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">76,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,521<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,024,116<span></span>
</td>
<td class="nump">1,117,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,617<span></span>
</td>
<td class="nump">9,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">22,653<span></span>
</td>
<td class="nump">15,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">33,403<span></span>
</td>
<td class="nump">26,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">17,011<span></span>
</td>
<td class="nump">15,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">19,597<span></span>
</td>
<td class="nump">17,441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">105,281<span></span>
</td>
<td class="nump">85,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">122,638<span></span>
</td>
<td class="nump">125,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Development derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">185,604<span></span>
</td>
<td class="nump">195,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">3,592<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">416,227<span></span>
</td>
<td class="nump">437,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2022 or December 31, 2021, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000 shares authorized; 186,274 shares and 185,468 shares outstanding at March 31, 2022 or December 31, 2021, respectively</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,537,790<span></span>
</td>
<td class="nump">3,516,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6,532)<span></span>
</td>
<td class="num">(4,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,923,388)<span></span>
</td>
<td class="num">(2,832,995)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">607,889<span></span>
</td>
<td class="nump">679,508<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,024,116<span></span>
</td>
<td class="nump">$ 1,117,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488070561976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">186,274,000<span></span>
</td>
<td class="nump">185,468,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488076092744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 24,822<span></span>
</td>
<td class="nump">$ 23,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">5,315<span></span>
</td>
<td class="nump">5,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">107,253<span></span>
</td>
<td class="nump">95,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">27,339<span></span>
</td>
<td class="nump">31,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment and other costs of terminated program</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">141,382<span></span>
</td>
<td class="nump">133,039<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(116,560)<span></span>
</td>
<td class="num">(109,392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of development derivative liability</a></td>
<td class="nump">33,427<span></span>
</td>
<td class="num">(1,599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liabilities related to the sales of future royalties</a></td>
<td class="num">(7,529)<span></span>
</td>
<td class="num">(13,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income (expense), net</a></td>
<td class="nump">26,293<span></span>
</td>
<td class="num">(13,483)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(90,267)<span></span>
</td>
<td class="num">(122,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (90,393)<span></span>
</td>
<td class="num">$ (122,967)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding used in computing basic net loss per share (in shares)</a></td>
<td class="nump">185,848<span></span>
</td>
<td class="nump">181,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding used in computing diluted net loss per share (in shares)</a></td>
<td class="nump">185,848<span></span>
</td>
<td class="nump">181,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 5,688<span></span>
</td>
<td class="nump">$ 4,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">17,561<span></span>
</td>
<td class="nump">18,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,573<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488075897048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (90,393)<span></span>
</td>
<td class="num">$ (122,967)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">(2,091)<span></span>
</td>
<td class="num">(766)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss)</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2,375)<span></span>
</td>
<td class="num">(826)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (92,768)<span></span>
</td>
<td class="num">$ (123,793)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488070140632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,077,295<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 3,388,730<span></span>
</td>
<td class="num">$ (2,295)<span></span>
</td>
<td class="num">$ (2,309,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">17,106<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">23,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">(123,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(826)<span></span>
</td>
<td class="num">(122,967)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">994,506<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,429,734<span></span>
</td>
<td class="num">(3,121)<span></span>
</td>
<td class="num">(2,432,125)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">679,508<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">3,516,641<span></span>
</td>
<td class="num">(4,157)<span></span>
</td>
<td class="num">(2,832,995)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">(92,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,375)<span></span>
</td>
<td class="num">(90,393)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 607,889<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 3,537,790<span></span>
</td>
<td class="num">$ (6,532)<span></span>
</td>
<td class="num">$ (2,923,388)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488067365672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">123 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (90,393)<span></span>
</td>
<td class="num">$ (122,967)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="num">(17,561)<span></span>
</td>
<td class="num">(18,798)<span></span>
</td>
<td class="nump">$ 351,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liabilities related to the sales of future royalties</a></td>
<td class="nump">7,529<span></span>
</td>
<td class="nump">13,296<span></span>
</td>
<td class="nump">251,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of development derivative liability</a></td>
<td class="num">(33,427)<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Non-cash research and development expense</a></td>
<td class="nump">4,951<span></span>
</td>
<td class="nump">2,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">20,961<span></span>
</td>
<td class="nump">23,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,730<span></span>
</td>
<td class="nump">3,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Amortization of premiums (discounts), net and other non-cash transactions</a></td>
<td class="nump">1,276<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,728)<span></span>
</td>
<td class="nump">9,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">422<span></span>
</td>
<td class="num">(1,516)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities', window );">Operating leases, net</a></td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">2,864<span></span>
</td>
<td class="nump">6,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,998<span></span>
</td>
<td class="nump">779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">6,918<span></span>
</td>
<td class="nump">8,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="nump">7,249<span></span>
</td>
<td class="num">(7,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(88,424)<span></span>
</td>
<td class="num">(77,085)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(93,493)<span></span>
</td>
<td class="num">(295,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">227,974<span></span>
</td>
<td class="nump">303,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(4,203)<span></span>
</td>
<td class="num">(2,876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">130,278<span></span>
</td>
<td class="nump">10,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued under equity compensation plans</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">17,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities', window );">Cash receipts from development derivative liability</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">17,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">42,775<span></span>
</td>
<td class="num">(48,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">25,218<span></span>
</td>
<td class="nump">198,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">67,993<span></span>
</td>
<td class="nump">150,164<span></span>
</td>
<td class="nump">$ 67,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset recognized in exchange for lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488075711352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in oncology and immunology.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. As of March&#160;31, 2022, we had approximately $704.4 million in cash and investments in marketable securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Impairment and Other Costs of Terminated Program</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans for the Company&#8217;s future:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 14, 2022, BMS  and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 7 for additional information on our BMS Collaboration Agreement.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we made the decision to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 4 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. In addition to announcing the decision to discontinue this Phase 2/3 study, we also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, there are no ongoing clinical development activities of bempegaldesleukin.    </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 25, 2022, we announced our strategic reorganization and cost restructuring plans (together, the Reorganization and Restructuring Plans), which were reviewed and approved by our Board of Directors on April 14, 2022. On April 26, 2022, our duly authorized officers approved certain strategic, operational and organizational steps to undertake in connection with the Reorganization and Restructuring Plans. Under the Reorganization and Restructuring Plans, we are prioritizing key research and development efforts and continuing to evaluate our early stage drug candidate pipeline. We are also reducing our workforce by approximately 70%. See Note 10 for additional information regarding our reorganization and restructuring plans.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, restructuring, impairment and other costs for terminated programs primarily include cancellation fees for certain manufacturing activities for bempegaldesleukin which were scheduled to support our efforts at securing potential FDA approval and commercial launch of bempegaldesleukin in metastatic melanoma in 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2021 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 filed with the SEC on March 1, 2022. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of March&#160;31, 2022 and December&#160;31, 2021, our accounts receivable includes $26.9&#160;million and $21.4&#160;million, respectively, for unbilled net expense reimbursements from BMS. The remaining accounts receivable relate primarily to product sales. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three months ended March&#160;31, 2022 and 2021. We have not recorded a reserve for credit losses at March&#160;31, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic or other factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash royalty revenue</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2020, we have sold our rights to receive sales-based royalties for </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 5. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our non-cash royalty revenue of $17.6&#160;million and $18.8&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, represents revenue for granting licenses which we had satisfied in prior periods. Our partners generally pay royalties  after the end of the calendar quarter in accordance with contractual terms. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratable over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488075874232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash and Investments in Marketable Securities</a></td>
<td class="text">Cash and Investments in Marketable Securities<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,993&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,218&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599,032&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,363&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,828&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,388&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of March&#160;31, 2022 and December&#160;31, 2021, all of our long-term investments had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTM5_77184183-0367-45c7-a343-6cddbeacc01a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTM5_bbd38367-e438-4378-87e6-f0c97cd95e48">one</span></span> and two years.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,643&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,270)</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,377&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,121&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,803&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,758)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,049&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,625&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,388&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022 and 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. At December&#160;31, 2021, our gross unrealized losses totaled $0.7&#160;million, and our gross unrealized gains were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488075758968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,379&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,801&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488076145480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DevelopmentDerivativeLiabilityTextBlock', window );">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</a></td>
<td class="text">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a Co-Development Agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ would pay up to $150.0&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ has primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we are the sponsor of the SCCHN Clinical Trial. The SFJ Agreement provided for us to pay up to $637.5&#160;million in Success Payments in the event of FDA approval of bempegaldesleukin for the metastatic melanoma, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, on March 14, 2022, we announced that the metastatic melanoma trial did not meet its primary endpoints and that we and BMS decided to discontinue the registrational trials in metastatic melanoma trial and adjuvant melanoma. On April 14, 2022, BMS and we announced that, due to the negative results of our trials for bempegaldesleukin in each of renal cell carcinoma and cisplatin-ineligible, locally advanced or metastatic urothelial cancer, BMS and we decided to end the development for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and that these studies and all other ongoing studies in the bempegaldesleukin program will be discontinued. On April 14, 2022, due to these results, SFJ and we agreed to discontinue the SCCHN Clinical Trial. Accordingly, SFJ will not be entitled to any Success Payments, and SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. SFJ has no right to seek reimbursement from us for any costs incurred for the SCCHN Clinical Trial.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We presented the SFJ Agreement as a Development derivative liability in our Condensed Consolidated Balance Sheets, which we remeasured to fair value at each reporting date. As SFJ conducted the SCCHN Clinical Trial, we recorded non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remitted funding to us to support our internal costs of conducting the trial, we also recorded a corresponding increase to the development derivative liability. We presented the gain (loss) from the remeasurement as change in fair value of development derivative liability in our Condensed Consolidated Statements of Operations. As of March 31, 2022, due to the negative results of the metastatic melanoma trial and initial discussions with SFJ, we concluded that it was remote that SFJ and we would continue the SCCHN Clinical Trial. Accordingly, the fair value of the development derivative liability was reduced to $0 as of March 31, 2022, and we recognized a corresponding gain in the Change in fair value of development derivative liability.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the development derivative liability for the three months ended March&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DevelopmentDerivativeLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Derivative Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DevelopmentDerivativeLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488075732168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to Sales of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock', window );">Liabilities Related to Sales of Future Royalties</a></td>
<td class="text">Liabilities Related to Sales of Future Royalties<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.999%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Drug</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty under Purchase and Sale Agreement</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Sold</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brand name for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (naloxegol tablets) and  MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brand name for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca AB</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (certolizumab pegol)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCB Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RPI Finance Trust</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2012</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Continuous Erythropoietin Receptor Activator)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F. Hoffmann-La Roche Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RPI Finance Trust</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2012</span></td></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our ongoing manufacturing obligations in both arrangements, we account for the proceeds as debt (Royalty Obligations) and therefore continue to recognize these non-cash royalties as revenue. As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. The following table shows the activity within the liability account of each arrangement (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289,655)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,373&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,939&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,312&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Loss recognized from Settlement Agreement to resolve UCB&#8217;s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.</span></td></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different from our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the applicable Royalty Obligation. As of March 31, 2022, our imputed interest rates for the arrangements with RPI and HCR were 16% and 15%, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488075705560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv-06607, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made, between January 2017 and June 2018, about the clinical trials of bempegaldesleukin. The Mulquin complaint was amended in May 2019. The defendants moved to dismiss and the court granted the motion without prejudice in July 2020. The Mulquin plaintiffs again amended their complaint and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice. The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit was completed in September 2021. Oral argument occurred on December 10, 2021, and the matter remains pending with the court. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second putative securities class action was filed against the Company and certain of our executives in the U.S. District Court for the Northern District of California in August 2019 (Case No. 4-19-cv-05173, which we refer to as the Damiba action).  The Damiba plaintiffs challenged public statements Nektar made, between February 2019 and May 2019, about its bempegaldesleukin clinical trials and collaboration with Bristol-Myers Squibb. After the Damiba plaintiffs filed an amended complaint and the defendants moved to dismiss, the court dismissed the action without prejudice in January 2021. The Damiba plaintiffs subsequently voluntarily dismissed the action, with prejudice, in March 2021.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the two securities actions (the Mulquin action and the Damiba action), three additional sets of derivative actions have been filed against certain of the Company&#8217;s current and former officers and directors, purportedly on the Company&#8217;s behalf. These derivative actions are based on the allegations in the securities actions and on the premise that the Company&#8217;s officers and directors breached their fiduciary duties by exposing the Company to one or both of the securities actions. The first derivative action was filed in the U.S. District Court for the District of Delaware in February 2019 (Case No. 1:19-cv-00322-MN-JLH). After amending their complaint several times, the plaintiffs in that action voluntarily dismissed their claims without prejudice in April 2021.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second set of derivative actions was filed in February 2020 in the U.S. District Court for the Northern District of California (Case No. 4:20-cv-01088-JSW). The derivative actions in California were consolidated and the Company moved to </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dismiss on the basis that the plaintiffs had neither made a demand on the Company&#8217;s board of directors nor shown that a demand would be futile. On September 1, 2021, the court dismissed the action with prejudice.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third derivative complaint was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF). The parties agreed to stay further proceedings in this action until thirty days after the U.S. Court of Appeals for the Ninth Circuit&#8217;s final resolution of the appeal in the Mulquin action.  </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature and status of these securities class action lawsuits and derivative complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at either March&#160;31, 2022 or December&#160;31, 2021. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div>To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488075734968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License And Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our collaboration agreements in the three months ended March&#160;31, 2022, other than as described below for our Strategic Collaboration Agreement with BMS.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (BMS)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS have jointly developed bempegaldesleukin in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing and commercialization of bempegaldesleukin, 35% of the costs to BMS and 65% to Nektar. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million. In 2020, we received non-refundable milestone payments of $50.0&#160;million in aggregate for the first patient, first visit in the registrational trials in muscle-invasive bladder cancer and adjuvant melanoma.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, on March 14, 2022, we announced our registrational trial in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the trials in metastatic melanoma and adjuvant melanoma. On April 14, 2022, we announced that our registrational trials in each of renal cell carcinoma and cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided that these studies and all other ongoing studies in the program will be discontinued. The decision to terminate the program does not affect the cost-sharing provisions under the BMS Collaboration Agreement. However, without further development of bempegaldesleukin, we will no longer be eligible for the development, regulatory and sales milestones under the arrangement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#8217; expenses as research and development expense. During the three months ended March&#160;31, 2022 and March&#160;31, 2021, we recorded $24.9&#160;million and $26.7&#160;million, respectively, as reductions of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses. As of March&#160;31, 2022, we have recorded an unbilled receivable of $26.9&#160;million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">): NKTR-358 </span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) to co-develop NKTR-358, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $150.0&#160;million and are eligible for up to $250.0&#160;million in additional development and regulatory milestones. We are currently in Phase 1B and Phase 2 development, where we share costs with 75% of the costs borne by Lilly and 25% of the costs borne by us. Lilly is responsible for the costs of Phase 3 development, but we retain the option to contribute up to 25% of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the costs of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 development on an indication-by-indication basis in order for us to achieve maximum royalty level under the Lilly Agreement, and further</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, we will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales.  Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lilly Agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The Lilly Agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are entitled to significant development milestones under this arrangement, through March&#160;31, 2022, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 5, we have sold our rights to receive royalties from these other collaboration agreements.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a collaboration agreement for a product under development, under which we are entitled to up to a total of $40.0&#160;million of regulatory milestones, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential product under this collaboration agreement, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the transaction price for this agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488076159432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,961&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,898&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued stock-based awards of our common stock as follows (shares in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of options granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488076168952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022 and 2021, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the three months ended March&#160;31, 2022 and 2021, potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,338&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,393&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488076168952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent EventAs discussed in Note 1, on April 25, 2022, we announced our Reorganization and Restructuring Plans, pursuant to which we are prioritizing key research and development efforts and reducing our workforce by approximately 70% from approximately 735 to approximately 225 employees. We will recognize all costs of the Reorganization and Restructuring Plans, including severance and benefits for employees laid off and employee compensation and third-party costs for the wind down of the bempegaldesleukin program, net of BMS&#8217; reimbursement of our costs, in the restructuring, impairment and other costs of terminated program line in our Condensed Consolidated Statement of Operations. We expect to recognize approximately $30.0 to $35.0&#160;million for severance and related benefits for employees laid off under the Reorganization and Restructuring Plans, primarily in the three months ending June 30, 2022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488067667160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in oncology and immunology.</span></div>Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Restructuring, Impairment and Other Costs of Terminated Program</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Impairment and Other Costs of Terminated Program</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans for the Company&#8217;s future:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 14, 2022, BMS  and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 7 for additional information on our BMS Collaboration Agreement.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we made the decision to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 4 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. In addition to announcing the decision to discontinue this Phase 2/3 study, we also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, there are no ongoing clinical development activities of bempegaldesleukin.    </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 25, 2022, we announced our strategic reorganization and cost restructuring plans (together, the Reorganization and Restructuring Plans), which were reviewed and approved by our Board of Directors on April 14, 2022. On April 26, 2022, our duly authorized officers approved certain strategic, operational and organizational steps to undertake in connection with the Reorganization and Restructuring Plans. Under the Reorganization and Restructuring Plans, we are prioritizing key research and development efforts and continuing to evaluate our early stage drug candidate pipeline. We are also reducing our workforce by approximately 70%. See Note 10 for additional information regarding our reorganization and restructuring plans.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, restructuring, impairment and other costs for terminated programs primarily include cancellation fees for certain manufacturing activities for bempegaldesleukin which were scheduled to support our efforts at securing potential FDA approval and commercial launch of bempegaldesleukin in metastatic melanoma in 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2021 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 filed with the SEC on March 1, 2022. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Significant Concentrations</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Concentrations</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of March&#160;31, 2022 and December&#160;31, 2021, our accounts receivable includes $26.9&#160;million and $21.4&#160;million, respectively, for unbilled net expense reimbursements from BMS. The remaining accounts receivable relate primarily to product sales. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three months ended March&#160;31, 2022 and 2021. We have not recorded a reserve for credit losses at March&#160;31, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div>For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic or other factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash royalty revenue</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2020, we have sold our rights to receive sales-based royalties for </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 5. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our non-cash royalty revenue of $17.6&#160;million and $18.8&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, represents revenue for granting licenses which we had satisfied in prior periods. Our partners generally pay royalties  after the end of the calendar quarter in accordance with contractual terms. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratable over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488156957112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,993&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,218&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599,032&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,363&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,828&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,388&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Portfolio of Cash and Investments in Marketable Securities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of cash and investments in marketable securities includes (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,643&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,270)</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,377&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,121&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,803&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,758)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,049&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,625&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,388&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488075666056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,379&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,801&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488076153880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities at Fair Value</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the development derivative liability for the three months ended March&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488074909656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to Sales of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock', window );">Schedule of Purchase and Sale Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.999%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Drug</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Manufacturer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty under Purchase and Sale Agreement</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Sold</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brand name for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (naloxegol tablets) and  MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (brand name for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in Europe)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca AB</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Royalty Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (certolizumab pegol)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCB Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RPI Finance Trust</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2012</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Continuous Erythropoietin Receptor Activator)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F. Hoffmann-La Roche Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RPI Finance Trust</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2012</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock', window );">Schedule Of Liability Related To Sale Of Potential Future Royalties</a></td>
<td class="text">The following table shows the activity within the liability account of each arrangement (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289,655)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,373&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,939&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,312&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Loss recognized from Settlement Agreement to resolve UCB&#8217;s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Liability Related To Sale Of Potential Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Purchase and Sale Agreement [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488075872568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,961&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,898&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Share-based Compensation, Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued stock-based awards of our common stock as follows (shares in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of options granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488076159432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">During the three months ended March&#160;31, 2022 and 2021, potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,338&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,393&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488073176600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash and investments in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 704,388,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 798,783,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,492,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,822,000<span></span>
</td>
<td class="nump">$ 23,647,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,561,000<span></span>
</td>
<td class="nump">$ 18,798,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce termination, percentage</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488073085288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 67,993<span></span>
</td>
<td class="nump">$ 25,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">599,032<span></span>
</td>
<td class="nump">708,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">37,363<span></span>
</td>
<td class="nump">64,828<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">$ 704,388<span></span>
</td>
<td class="nump">$ 798,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488073267512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaximumMaturityPeriod', window );">Maximum maturity term for debt securities investment</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaturityTerm', window );">Weighted average maturity term for debt securities investment (or less)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, available-for-sale accumulated gross unrealized loss, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Investments in Marketable Securities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashAndInvestmentsInMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maturity date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maximum maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LongTermInvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LongTermInvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488072399576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 11,922<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">704,388<span></span>
</td>
<td class="nump">798,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">640,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">638,049<span></span>
</td>
<td class="nump">762,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">196,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,270)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">195,377<span></span>
</td>
<td class="nump">278,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Corporate commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">439,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,479)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">437,801<span></span>
</td>
<td class="nump">478,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Obligations of U.S. government agencies | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,871<span></span>
</td>
<td class="nump">5,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">43,523<span></span>
</td>
<td class="nump">23,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value disclosure</a></td>
<td class="nump">$ 10,894<span></span>
</td>
<td class="nump">$ 10,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488070715800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,084<span></span>
</td>
<td class="nump">$ 3,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">9,420<span></span>
</td>
<td class="nump">9,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">3,875<span></span>
</td>
<td class="nump">3,293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 15,379<span></span>
</td>
<td class="nump">$ 15,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488070535768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember', window );">SFJ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementCommittedFunding', window );">Committed funding (up to)</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount', window );">Success payments (up to)</a></td>
<td class="nump">$ 637,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementCommittedFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Committed Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementCommittedFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-Based Payments, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488070765048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details) - Development Derivative Liability - Fair Value, Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</a></td>
<td class="nump">$ 27,726<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,597<span></span>
</td>
<td class="nump">$ 27,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense', window );">Non-cash research and development expense</a></td>
<td class="nump">4,951<span></span>
</td>
<td class="nump">2,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Cash receipts from SFJ</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Change in the fair value of development derivative liability</a></td>
<td class="num">(33,427)<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488075030360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liabilities Related to Sales of Future Royalties - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltiesLiabilityMeasurementInput', window );">Royalties liability discount rate</a></td>
<td class="nump">0.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltiesLiabilityMeasurementInput', window );">Royalties liability discount rate</a></td>
<td class="nump">0.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltiesLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RoyaltiesLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488067504232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to Sales of Future Royalties - Activity Within the Liability Account (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">123 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="nump">$ 17,561<span></span>
</td>
<td class="nump">$ 18,798<span></span>
</td>
<td class="num">(351,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">7,529<span></span>
</td>
<td class="nump">$ 13,296<span></span>
</td>
<td class="nump">251,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties &#8211; ending balance</a></td>
<td class="nump">188,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="num">(2,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">185,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,604<span></span>
</td>
<td class="nump">$ 195,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(289,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties &#8211; ending balance</a></td>
<td class="nump">74,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">74,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties &#8211; ending balance</a></td>
<td class="nump">113,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="num">(2,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">$ 111,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities On Sale Of Future Royalties Unamortized Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Potential Future Royalties Non Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PartialRepaymentOfRoyaltySaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Partial Repayment Of Royalty Sale Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PartialRepaymentOfRoyaltySaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltyMonetizationProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Monetization Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RoyaltyMonetizationProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488070735416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">25 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>action</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>action</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember', window );">Legal Matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=nktr_MulquinActionAndDamibaActionMember', window );">Mulquin Action And Damiba Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Previous claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=nktr_DerivativeActionMember', window );">Derivative Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">New claims</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=nktr_MulquinActionAndDamibaActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=nktr_MulquinActionAndDamibaActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=nktr_DerivativeActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=nktr_DerivativeActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488066318984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2018</div></th>
<th class="th"><div>Aug. 23, 2017</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol Myers Squibb Company | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SaleOfStockConsiderationReceived', window );">Sale of stock consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Eli Lilly And Company | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Eli Lilly And Company | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions', window );">Percentage of regulatory milestones payments will be reduced under certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur', window );">Percentage of regulatory milestones payments will be reduced if conditions occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Eli Lilly And Company | Nektar's | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Eli Lilly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol Myers Squibb Company | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900,000<span></span>
</td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements', window );">Upfront and milestone payments received from license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Nektar's | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Opdivo | Bristol Myers Squibb Collaboration Agreement | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_Nektar214Member', window );">Nektar 214 | Opdivo | Bristol Myers Squibb Collaboration Agreement | Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received, if conditions occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received under certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of funding Phase three development costs on an indication by indication basis borne.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in Phase 2 development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in production costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received from license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar214Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar214Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MilestoneAxis=nktr_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MilestoneAxis=nktr_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488070772712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 20,961<span></span>
</td>
<td class="nump">$ 23,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">669<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">12,041<span></span>
</td>
<td class="nump">14,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 8,251<span></span>
</td>
<td class="nump">$ 9,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488074831928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Activity (Detail) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 6.61<span></span>
</td>
<td class="nump">$ 10.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, of RSUs granted (in dollars per share)</a></td>
<td class="nump">$ 9.39<span></span>
</td>
<td class="nump">$ 20.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488075701960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">22,338<span></span>
</td>
<td class="nump">19,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488073126728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Details) - Subsequent Event - Employee Severance<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 25, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Apr. 24, 2022 </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce termination, percentage</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | segment</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost to be recognized</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost to be recognized</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>nktr-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nktr="http://www.nektar.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nktr-20220331.xsd" xlink:type="simple"/>
    <context id="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7493be27952e4e32b337ca0fb6beb344_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="i50cc006393ad4e1888a5e96af4811b81_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0360dfe057384ef3ba43ab8dd1071974_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d291e1ee86449d78994eae53c1540db_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0493e53874bc4daeb52c5b06f4b53a6f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5631866fb8ab42c39ed3826b2e8b778f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if5f35b8ae306472eb8a7b3141def628a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i549689688dfc4b71bf8359d07ae4b440_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibcecb9b74c07454d95c3030eacfc1003_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i47e463c44a0047f5afbcfc85015e338b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48ddc45b0f0c4083b93472ac00c57ec5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia03ac38b30664485a603bb967899051f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie8db36c3bbf94862b20ee7306f48fec8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c98e2f4e6a9464da1ee6d7c11f30ef9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1920e38e3b36491da8e42b40798bf230_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8b52fa5cc03e457a953ca86da5e2495c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2de6ed15fee342229522ad57966bdd88_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i34c494178abb4445bac7b7c1e7b7011f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2eca34de7440481fa184c63c4e404045_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i15f2e796e9b648b4b037302677e091aa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i737ff7f610ad425cb44817f0b8750038_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5b3e44be00774da7b32a55b730041c18_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4a5fea39b5bc466ca1d6c54f925e0d11_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8e522901bf134d0aa1265a2daa7a8e8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d218052e54546b08d4740f17cfa7fac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4998b2e879846b19c3d3a8b60109e10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2355825e97324b7fa8064d255dfefb27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i871843ba5eb74770b94f361271dbd894_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i30daae3c1fab4806bce1a44e0d836de2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8248c0ee6bae46cb8d2cae0e9c5f9907_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie7d3488f0d274f62a82178cb60b7e96b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idf4a7ec238a2443fb9cd9d9e2db0d68a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iada92997824446879653178ad1bdbef4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icfcf6a6304234f45bb0a0682da1f41f5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2791447615864815a607224b5191a937_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if2be3ac308a24e8ca217c972b757f923_D20220425-20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-25</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="i2e6976d0fdcb42bba1c4b5e008c93f28_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib3e957a413d448a7a3513ceccf209004_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie29adb1fc4684ab0ad0244b29d50d813_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i38417cdbca554e42afdd16bfb864bb29_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id45946e930114e44bce50be83bd56339_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1d12f77ed264cd9a637f0e3cf2ae918_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i685b6f64ad5c4faa9de52180509da5da_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4e22be348e714ef8918b6c87eae1bdcb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd4b2f49b55b430ebc75e5792a0b2792_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iafca660c02b34e799b6bda3ecba63141_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33a6252cab2b4155abda79adc4038b32_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i01be499d3940498b883cfe405f68c613_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d7497814c41422f9a5b7ea68e05c094_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4f6f4d1cbe6a4471822b84152102c34f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98b42c2b599741359d987d496e64c309_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i85b44d16760d4680ac9a0259407bc098_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i875ef83363e04d6a85c3349eaf3dd3ab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if4c024b46d2c49a3b471bb84a8b0399d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i276bda16441d48ad80af19d97efc426a_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="i67220c05393f459bb392d5a646a36d88_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="ib32a3a93199343bfb4bfa43354beb247_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icebb6494d94b4db1a4f1c110b85abaf9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie96ec436f9fc449ebdff998acc527edf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i72d23832d5824e05a9160a3dc1fdbe35_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i81672743daf84e089f134278b21e4900_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i232e4fff92244a1286cab431418b53bb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3c501231db134e1eb8a1723fe66a287d_D20120101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i880e4bb37a104926b7f1b627aba88cce_D20120101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia68e0b50ca474c9fb590f027a73cf228_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3ce5f5ad632f42c5ac8d5b2eab7fde07_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i860898a72fc245f2b9c0e62294906402_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nktr:MulquinActionAndDamibaActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="i7bf89d8a3c5743f8a48bec4907711413_D20190201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nktr:DerivativeActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i0ab30e6ae04746708e8844aad00bca73_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if5c65e86d0ca4792813758a0541762ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06904e4d49ac4e03999c919c6e4361cc_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="ic736db4d693a4b8595ef22ef35f99636_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i16f1e513809d4671b267573756667622_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i037d8ae4d167406ebb243ed52a646788_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i5a262bb734414dd4857c079289efd56c_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ic31ce00edf3c4891b98bdd4f17ff4e56_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i6264ab40d7dc48aa86cf10e2b939d8ae_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i78c51641e8cc496894dae390b3acb852_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93c0c909992548e0982362d608cdb5c7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i48032d659bf148a09d2a83b4693bb85b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1a2cc7ccba3642dfb8f9446b1b854843_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i887bd71a1b294a4fb94e4d8c2a792b9d_I20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-23</instant>
        </period>
    </context>
    <context id="i38fc13ebd3cd490ca1a6005558c5ad94_D20170823-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-23</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i31ef1bddb0d74c048cd77ffc33b52ad9_D20170823-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-23</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="ifefea51825e94f008a861cb1ddc9bfe5_D20170823-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-23</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i3a089f68509044168386924efba61d4e_D20170823-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-23</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="ib19687a8076a473ba979d1fd42e0df4c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1e034360701446c8a364586fa2b0d27b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i10110540b97b4a4ab4a50614d0cff3c9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifd9f8f2918f94fd6923a1d4a51027353_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i728e5d8a85be40679bfe48b2fbce4909_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if6179ae9a7f44883ab15f4ae9457eb07_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieb2c55128bc8497c8854c8a78a73cd58_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic59b05e471ec4124afe9fde97642790e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if023fd27426a491e84900754f5b3156f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i111ab39f489a4f079ea9e751923f01c7_I20220424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-24</instant>
        </period>
    </context>
    <context id="ie8720ccc92154ed5bcfc18a705606b0d_I20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="i3db39c27bf794516854c382d356e95bb_I20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="idec2e4f024964e8eb19d315571eb57d8_I20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="action">
        <measure>nktr:action</measure>
    </unit>
    <unit id="segment">
        <measure>nktr:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80L2ZyYWc6NWVkMTJlMjFkOGEyNDQ2ZGE0NWZjYjEyNjc0MWMxYzQvdGFibGU6MDgyNjAyNzU1ZTEzNDljNzgxODc1YWFkMzYyNzU3ZGIvdGFibGVyYW5nZTowODI2MDI3NTVlMTM0OWM3ODE4NzVhYWQzNjI3NTdkYl8yLTEtMS0xLTIzOTk3_e4b21bd0-2557-4fd3-a7fd-ebb2b2c0ada9">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80L2ZyYWc6NWVkMTJlMjFkOGEyNDQ2ZGE0NWZjYjEyNjc0MWMxYzQvdGFibGU6MDgyNjAyNzU1ZTEzNDljNzgxODc1YWFkMzYyNzU3ZGIvdGFibGVyYW5nZTowODI2MDI3NTVlMTM0OWM3ODE4NzVhYWQzNjI3NTdkYl80LTEtMS0xLTIzOTk3_a4b9e6eb-b78b-46b6-abd7-dd6c616341a2">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80L2ZyYWc6NWVkMTJlMjFkOGEyNDQ2ZGE0NWZjYjEyNjc0MWMxYzQvdGFibGU6MDgyNjAyNzU1ZTEzNDljNzgxODc1YWFkMzYyNzU3ZGIvdGFibGVyYW5nZTowODI2MDI3NTVlMTM0OWM3ODE4NzVhYWQzNjI3NTdkYl81LTEtMS0xLTIzOTk3_00e713e7-bf9d-416a-be63-4961d22ef1d5">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80L2ZyYWc6NWVkMTJlMjFkOGEyNDQ2ZGE0NWZjYjEyNjc0MWMxYzQvdGFibGU6MDgyNjAyNzU1ZTEzNDljNzgxODc1YWFkMzYyNzU3ZGIvdGFibGVyYW5nZTowODI2MDI3NTVlMTM0OWM3ODE4NzVhYWQzNjI3NTdkYl84LTEtMS0xLTIzOTk3_71106e34-4000-40b5-86de-52d7ecce1022">0000906709</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80L2ZyYWc6NWVkMTJlMjFkOGEyNDQ2ZGE0NWZjYjEyNjc0MWMxYzQvdGFibGU6MDgyNjAyNzU1ZTEzNDljNzgxODc1YWFkMzYyNzU3ZGIvdGFibGVyYW5nZTowODI2MDI3NTVlMTM0OWM3ODE4NzVhYWQzNjI3NTdkYl85LTEtMS0xLTIzOTk3_7ea029e8-d49c-4561-ae8f-3fa4e6f891c8">--12-31</dei:CurrentFiscalYearEndDate>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="ie29adb1fc4684ab0ad0244b29d50d813_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTM5_77184183-0367-45c7-a343-6cddbeacc01a">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i38417cdbca554e42afdd16bfb864bb29_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTM5_bbd38367-e438-4378-87e6-f0c97cd95e48">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <dei:DocumentType
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjU3_985c9dd5-c208-4b8b-8ffe-7307d9706b2c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6NmZkMjIyM2M4MTczNDQ4Yjk0ZmJhNGY2OTI4MjgzNzgvdGFibGVyYW5nZTo2ZmQyMjIzYzgxNzM0NDhiOTRmYmE0ZjY5MjgyODM3OF8wLTAtMS0xLTIzOTk3_1150c5d3-2796-4b3f-8a7a-e570a618c163">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yNjY_bcc6f082-3713-4219-8938-fafc65de5b85">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6NGU4NzMxNjlmNzQ3NGI4OTkzNWQ1YmMzNWQ5ZWE2NzgvdGFibGVyYW5nZTo0ZTg3MzE2OWY3NDc0Yjg5OTM1ZDViYzM1ZDllYTY3OF8wLTAtMS0xLTIzOTk3_cf10b1cc-2d13-4d9e-905f-5d9c679b1ae0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjY0_a3bc5b3e-d735-4419-ac54-c4f028150b47">0-24006</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjU4_1894b12e-ad53-4917-9345-e588fa153aba">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6NjZkZjQ0YjM4NWZhNDZjYjhiYWU2ZjAzMWUwNDIwYTcvdGFibGVyYW5nZTo2NmRmNDRiMzg1ZmE0NmNiOGJhZTZmMDMxZTA0MjBhN18wLTAtMS0xLTIzOTk3_3c70d598-33dd-4a58-8b5d-5697032bfca2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6NjZkZjQ0YjM4NWZhNDZjYjhiYWU2ZjAzMWUwNDIwYTcvdGFibGVyYW5nZTo2NmRmNDRiMzg1ZmE0NmNiOGJhZTZmMDMxZTA0MjBhN18wLTItMS0xLTIzOTk3_9bb0eb88-c764-4651-bd8f-08dedc7ad6be">94-3134940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjY1_fe2710a4-e676-442c-9e8e-e2c73f9aadf5">455 Mission Bay Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjY2_a317cd37-fc75-42e3-8703-c516b1b2fa49">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjU5_ee54c96d-63a1-460e-986b-33128e9accd2">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjYw_b6fabbae-25fe-465c-8e35-5a1bfa689a4a">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjY3_76284e02-c8dc-4299-82d2-f31930add6a1">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjYx_7b0de5b2-7d52-4801-b559-8269dda41a27">482-5300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6Yzg1YTRkNmU4ZDI5NDY2OGI2YzMxOTA2MTRiMmM5MzEvdGFibGVyYW5nZTpjODVhNGQ2ZThkMjk0NjY4YjZjMzE5MDYxNGIyYzkzMV8yLTAtMS0xLTIzOTk3_12cfb367-c5d3-491d-a091-a7f4673f7946">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6Yzg1YTRkNmU4ZDI5NDY2OGI2YzMxOTA2MTRiMmM5MzEvdGFibGVyYW5nZTpjODVhNGQ2ZThkMjk0NjY4YjZjMzE5MDYxNGIyYzkzMV8yLTEtMS0xLTIzOTk3_a06d0826-3eb9-45c6-9455-97a906ab0c36">NKTR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6Yzg1YTRkNmU4ZDI5NDY2OGI2YzMxOTA2MTRiMmM5MzEvdGFibGVyYW5nZTpjODVhNGQ2ZThkMjk0NjY4YjZjMzE5MDYxNGIyYzkzMV8yLTItMS0xLTIzOTk3_a25fba7d-ab0b-4486-b498-20568254dbd3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjU2_5938cb8a-98b9-4e60-a25f-b0c84f52abab">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjYy_de413470-4e0f-4e3a-93de-1b9b424e75d8">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6N2JkMzgyY2NkOGUwNDc0YTk3NDJlY2NmYTViOGZkZGIvdGFibGVyYW5nZTo3YmQzODJjY2Q4ZTA0NzRhOTc0MmVjY2ZhNWI4ZmRkYl8wLTAtMS0xLTIzOTk3_7e32dcc4-063a-4806-abe2-6d25826cd572">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6N2JkMzgyY2NkOGUwNDc0YTk3NDJlY2NmYTViOGZkZGIvdGFibGVyYW5nZTo3YmQzODJjY2Q4ZTA0NzRhOTc0MmVjY2ZhNWI4ZmRkYl8yLTYtMS0xLTIzOTk3_f1f7a7c0-9520-48fd-998a-73dd742e60cc">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGFibGU6N2JkMzgyY2NkOGUwNDc0YTk3NDJlY2NmYTViOGZkZGIvdGFibGVyYW5nZTo3YmQzODJjY2Q4ZTA0NzRhOTc0MmVjY2ZhNWI4ZmRkYl80LTItMS0xLTIzOTk3_8402029b-244d-4d7d-a362-e066ae988831">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjYz_4ae4d765-dfce-4612-a7a3-6a5f456d899e">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i7493be27952e4e32b337ca0fb6beb344_I20220429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xL2ZyYWc6NWQ1N2IyMGY3YzRjNDlhZWEzOWYxN2UxOGFkNGMzODYvdGV4dHJlZ2lvbjo1ZDU3YjIwZjdjNGM0OWFlYTM5ZjE3ZTE4YWQ0YzM4Nl8yMjQ4_3c79bb95-2126-4620-8222-d6eef5a8db3d"
      unitRef="shares">186274156</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMy0xLTEtMS0yMzk5Nw_32088268-29d1-40aa-acb0-ca23d092ee66"
      unitRef="usd">67993000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMy0zLTEtMS0yMzk5Nw_9b8d4163-13d6-48d2-ada2-c3619062b30f"
      unitRef="usd">25218000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNC0xLTEtMS0yMzk5Nw_2b75b644-1ad2-46fd-9d50-878a0dfd9ed1"
      unitRef="usd">599032000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNC0zLTEtMS0yMzk5Nw_2a52f99b-c086-43b0-9010-4f16ea0ebed3"
      unitRef="usd">708737000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNS0xLTEtMS0yMzk5Nw_186b4763-1cd0-4102-ada5-4d9aafea193e"
      unitRef="usd">30220000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNS0zLTEtMS0yMzk5Nw_c84e0784-6c2f-4d9f-ada3-aa5bb53d1fc6"
      unitRef="usd">22492000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNi0xLTEtMS0yMzk5Nw_ae1ffdb3-3539-40f4-a1ad-66198f6770de"
      unitRef="usd">15379000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNi0zLTEtMS0yMzk5Nw_15f5433d-ec50-4fd7-9201-c6dfaba90d51"
      unitRef="usd">15801000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNy0xLTEtMS0yMzk5Nw_0b51266f-28a5-4fdd-b749-3050bea41c2f"
      unitRef="usd">20831000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfNy0zLTEtMS0yMzk5Nw_bcea28a8-0bcb-4388-bfe3-1d1a26ca6446"
      unitRef="usd">23333000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfOC0xLTEtMS0yMzk5Nw_90dd9ec5-6587-47bc-b7d2-eac5ccb88adf"
      unitRef="usd">733455000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfOC0zLTEtMS0yMzk5Nw_e318e6fc-2939-459a-a8a5-ed8fea8b60d0"
      unitRef="usd">795581000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfOS0xLTEtMS0yMzk5Nw_d5a61588-f19e-481b-9d6e-1dec5242550c"
      unitRef="usd">37363000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfOS0zLTEtMS0yMzk5Nw_d00d1775-55d0-442f-a1e9-7fe991ea6b1c"
      unitRef="usd">64828000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTAtMS0xLTEtMjM5OTc_9b988504-339c-44f6-a52e-e09ce9ffda0f"
      unitRef="usd">60980000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTAtMy0xLTEtMjM5OTc_8596dee2-4524-4b3d-8d39-6d9e6e986fdc"
      unitRef="usd">60510000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTEtMS0xLTEtMjM5OTc_72c32d97-8809-4b49-9924-20b52c393b6a"
      unitRef="usd">114296000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTEtMy0xLTEtMjM5OTc_eed7214d-8e58-45ef-b952-f51a233128f5"
      unitRef="usd">117025000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTItMS0xLTEtMjM5OTc_c6f0a112-4bcd-4876-9bf2-06785440ed29"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTItMy0xLTEtMjM5OTc_0d294e21-8aa7-43d6-b268-e4789221083c"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTMtMS0xLTEtMjM5OTc_fb7de476-925d-4853-a5cf-1ac21bfad580"
      unitRef="usd">1521000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTMtMy0xLTEtMjM5OTc_5a7b4afb-3e5c-47e2-acc2-d52f8e7f2acf"
      unitRef="usd">2744000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTQtMS0xLTEtMjM5OTc_0706dc29-aa71-42b2-b2e0-72d0a0dbf4de"
      unitRef="usd">1024116000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTQtMy0xLTEtMjM5OTc_22a17577-ab7a-4f00-b922-83da7af07a5f"
      unitRef="usd">1117189000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTctMS0xLTEtMjM5OTc_efc9f40a-f7f4-42b4-ba9e-c88cf7b28f6d"
      unitRef="usd">12617000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTctMy0xLTEtMjM5OTc_33472916-6bc2-4635-9040-9e6402ff15f6"
      unitRef="usd">9747000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTgtMS0xLTEtMjM5OTc_d7144aee-ffae-4962-a7b0-335d917966c6"
      unitRef="usd">22653000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTgtMy0xLTEtMjM5OTc_279ec78a-e1eb-45bb-8bf1-20b1ebad58e5"
      unitRef="usd">15735000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTktMS0xLTEtMjM5OTc_98b58993-d457-41cb-aa6d-08e40ce3d420"
      unitRef="usd">33403000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMTktMy0xLTEtMjM5OTc_9a604ee6-7447-4b01-bc85-cd6802750fd7"
      unitRef="usd">26809000</nktr:AccruedClinicalTrialExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjEtMS0xLTEtMjM5OTc_bfec0e12-b94d-491a-b72a-3e6390bdec30"
      unitRef="usd">17011000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjEtMy0xLTEtMjM5OTc_cfc58bb7-2591-477f-9843-bd3802eb95ee"
      unitRef="usd">15468000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjItMS0xLTEtMjM5OTc_4cd4cca4-7ed1-4be8-b1e7-d813ad041e70"
      unitRef="usd">19597000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjItMy0xLTEtMjM5OTc_21ba7757-0060-4a5c-9056-de23ef9951a7"
      unitRef="usd">17441000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjMtMS0xLTEtMjM5OTc_dbd1949a-d620-46a2-929a-d316022e89bf"
      unitRef="usd">105281000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjMtMy0xLTEtMjM5OTc_19f8c08b-14a1-4c3d-8782-93a4be897cd8"
      unitRef="usd">85200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjQtMS0xLTEtMjM5OTc_b520eafc-f69c-4bb1-961b-f3a433e285ca"
      unitRef="usd">122638000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjQtMy0xLTEtMjM5OTc_9771b203-f1af-408c-bdd1-e5f83092fc68"
      unitRef="usd">125736000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjUtMS0xLTEtMjM5OTc_be3358d1-acec-40a2-922b-936293ba0062"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjUtMy0xLTEtMjM5OTc_4b6f0e93-c8d4-4412-be71-29089a5f5e7f"
      unitRef="usd">27726000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjYtMS0xLTEtMjM5OTc_b39a73a5-2f0f-429f-bcf5-b0cdbf6068ef"
      unitRef="usd">185604000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjYtMy0xLTEtMjM5OTc_520e8678-f8a4-41af-a582-05613ced4428"
      unitRef="usd">195427000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjctMS0xLTEtMjM5OTc_0d76536d-3d00-458d-9d27-3f9b3043af18"
      unitRef="usd">2704000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjctMy0xLTEtMjM5OTc_892717ef-ce0f-42ed-9d81-4e82ee3edfd0"
      unitRef="usd">3592000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjgtMS0xLTEtMjM5OTc_f9ca60d6-f33c-48e0-bc9a-14a8caeedbc2"
      unitRef="usd">416227000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjgtMy0xLTEtMjM5OTc_fd76253a-42cd-4682-9b98-ee7638f318c3"
      unitRef="usd">437681000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjktMS0xLTEtMjM5OTc_a535f681-e917-47a2-8c4d-924b3800a831"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMjktMy0xLTEtMjM5OTc_1deb137e-9bb2-47c9-9ffc-955c7a00baf2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl8yMQ_88db32d5-4a2c-4100-b801-32145246b1f1"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl8yMQ_9e0e8a9d-3172-41d4-9b4e-518cb705eb7f"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl8zNQ_28e076e2-414b-426b-a4b9-a6381dd178d1"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl8zNQ_d6e4036b-c40d-47bc-b1f1-f438edb4e0f8"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <nktr:PreferredStockShareDesignated
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl81Nw_05325791-b787-49c0-9795-9524ebae425e"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl81Nw_0adca7a0-3af5-4adb-9581-2c0c0d660f63"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl81Nw_5af56125-24a6-4c32-9df9-1f7e0e75d5c5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo0OTk0YzQzMWRhMWE0NzcyOGZmOGVhNzQ0NTE3YWFhNl81Nw_c293e021-a994-49b2-ac9b-8f56a3ef7ee0"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockValue
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMS0xLTEtMjM5OTc_f4081aec-6ae9-40ec-bd1a-7b160d0340d8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzEtMy0xLTEtMjM5OTc_16bce3e6-11d5-4ab8-82dc-e4a517bbb083"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo5MDI3ODk5MDMxMTg0ZTkxYjMxMmY0MjAxOTZhMzZjMl8xOA_81eb5c58-1e3d-4596-bacb-c6bb6353abc4"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo5MDI3ODk5MDMxMTg0ZTkxYjMxMmY0MjAxOTZhMzZjMl8xOA_881ce4e8-d035-4572-b6ae-b79a22b2f23e"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo5MDI3ODk5MDMxMTg0ZTkxYjMxMmY0MjAxOTZhMzZjMl8zMg_9333bd60-e6eb-4c5c-986d-b70dab172b68"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo5MDI3ODk5MDMxMTg0ZTkxYjMxMmY0MjAxOTZhMzZjMl8zMg_f114f0a1-48a3-487d-99b0-4ec2c52a12e5"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo5MDI3ODk5MDMxMTg0ZTkxYjMxMmY0MjAxOTZhMzZjMl81NA_2f242d47-96ae-41ce-a80d-b09cc979432e"
      unitRef="shares">186274000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMC0xLTEtMjM5OTcvdGV4dHJlZ2lvbjo5MDI3ODk5MDMxMTg0ZTkxYjMxMmY0MjAxOTZhMzZjMl82OA_fdd5846d-768a-4518-99ea-7cb920437282"
      unitRef="shares">185468000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMS0xLTEtMjM5OTc_dcfb40d4-ce65-4221-964e-a41a1dc20321"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzItMy0xLTEtMjM5OTc_5fc01c0a-17ee-407a-8fc2-7da4e82d86a0"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzMtMS0xLTEtMjM5OTc_c2c3cd78-f8c1-4c39-92b4-ba5370c1d73f"
      unitRef="usd">3537790000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzMtMy0xLTEtMjM5OTc_ccab3348-d5ed-4081-afb0-cd368ccd0cd6"
      unitRef="usd">3516641000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzQtMS0xLTEtMjM5OTc_56b3d1b0-f9c1-4dd1-885d-d803bff2424c"
      unitRef="usd">-6532000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzQtMy0xLTEtMjM5OTc_bcc81f16-d9e8-421e-8751-ac98b83d6946"
      unitRef="usd">-4157000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzUtMS0xLTEtMjM5OTc_dcf1441b-a0a7-40b0-870f-34506d0f660b"
      unitRef="usd">-2923388000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzUtMy0xLTEtMjM5OTc_b8f8c355-ec3c-4bb4-8de0-49ad5ff22299"
      unitRef="usd">-2832995000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzYtMS0xLTEtMjM5OTc_b5e81b59-7134-4a50-8bca-a3a07a5ac7dc"
      unitRef="usd">607889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzYtMy0xLTEtMjM5OTc_d6e6f55c-2a24-4740-95cd-ffcf11400127"
      unitRef="usd">679508000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzctMS0xLTEtMjM5OTc_4d2e1ae0-63bd-4557-a1c4-2e60613d46f9"
      unitRef="usd">1024116000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yMi9mcmFnOmY1MmJlMGY4MTcwYzQwZjg4NDdlYWRiZWEyZjk3MDc5L3RhYmxlOmUxZWIxMmEwOWNlYzQwNGVhNmQ3ODU2NjFjNWIzNDM1L3RhYmxlcmFuZ2U6ZTFlYjEyYTA5Y2VjNDA0ZWE2ZDc4NTY2MWM1YjM0MzVfMzctMy0xLTEtMjM5OTc_710ed402-a50a-4ba3-acdd-c37995d8c1ca"
      unitRef="usd">1117189000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d291e1ee86449d78994eae53c1540db_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMy0xLTEtMS0yMzk5Nw_1444555a-28ae-4ac4-9b99-00325ae9b8f1"
      unitRef="usd">5688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0493e53874bc4daeb52c5b06f4b53a6f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMy0zLTEtMS0yMzk5Nw_47a0bd62-1027-42f0-9ee9-91b2b5449b93"
      unitRef="usd">4795000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5631866fb8ab42c39ed3826b2e8b778f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfNS0xLTEtMS0yMzk5Nw_b360a600-c338-42fb-a9e9-fcc43b0d01cf"
      unitRef="usd">17561000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5f35b8ae306472eb8a7b3141def628a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfNS0zLTEtMS0yMzk5Nw_ab7da408-d321-41bf-9793-0babaa4ad10a"
      unitRef="usd">18798000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i549689688dfc4b71bf8359d07ae4b440_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfNi0xLTEtMS0yMzk5Nw_cd6e60e4-f0fa-44d5-acbf-502bd7d035e4"
      unitRef="usd">1573000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcecb9b74c07454d95c3030eacfc1003_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfNi0zLTEtMS0yMzk5Nw_11669f51-6d96-413c-a12c-58510c48748a"
      unitRef="usd">54000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfNy0xLTEtMS0yMzk5Nw_1808df48-fda5-4a38-a41c-8a565fd2fe78"
      unitRef="usd">24822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfNy0zLTEtMS0yMzk5Nw_03392947-d7b2-43ed-bc9f-4b71d64b6e55"
      unitRef="usd">23647000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfOS0xLTEtMS0yMzk5Nw_d73027dd-19b2-4492-b3b2-82ca5e4df68f"
      unitRef="usd">5315000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfOS0zLTEtMS0yMzk5Nw_22a54358-80f4-48a6-91c4-3aae96e501e0"
      unitRef="usd">5756000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTAtMS0xLTEtMjM5OTc_5d4a04a2-432c-42b5-b3ae-96ba88627add"
      unitRef="usd">107253000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTAtMy0xLTEtMjM5OTc_2383c39a-4702-45fc-92ba-d5540c766381"
      unitRef="usd">95604000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTEtMS0xLTEtMjM5OTc_2c1574d5-c352-47a5-8e10-21000523f7ea"
      unitRef="usd">27339000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTEtMy0xLTEtMjM5OTc_869e618b-d88c-4273-b872-ef18ed48222a"
      unitRef="usd">31679000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTItMS0xLTEtMjY5MTg_e62c000d-cc53-4f87-bed4-ec723d361295"
      unitRef="usd">1475000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTItMy0xLTEtMjY5MTg_418fd160-e41b-4e42-80d4-5b886e8f51a1"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:CostsAndExpenses
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTMtMS0xLTEtMjM5OTc_fdca7504-eaac-4ca4-9f70-f12670b7aa07"
      unitRef="usd">141382000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTMtMy0xLTEtMjM5OTc_1f780cbe-e11e-47d2-8108-54a241898e1a"
      unitRef="usd">133039000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTQtMS0xLTEtMjM5OTc_1e551cf1-5d91-40da-b44d-82acef675143"
      unitRef="usd">-116560000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTQtMy0xLTEtMjM5OTc_f67a1bcc-d7c2-4e95-90a0-ca9d45f651a1"
      unitRef="usd">-109392000</us-gaap:OperatingIncomeLoss>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTUtMS0xLTEtMjQyNTg_5a5a2d73-f3fe-4252-b2f6-c76ac4ba37fc"
      unitRef="usd">33427000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTUtMy0xLTEtMjQyNTA_926f896a-c8d0-4fc9-9569-1a6e727e22e8"
      unitRef="usd">-1599000</us-gaap:LiabilitiesFairValueAdjustment>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTYtMS0xLTEtMjM5OTc_a5693c8c-a195-4a58-8388-95ff477b41e7"
      unitRef="usd">7529000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTYtMy0xLTEtMjM5OTc_048a3f3f-0431-47e2-81de-94a31752daad"
      unitRef="usd">13296000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTgtMS0xLTEtMjM5OTc_4f1b5b22-ce34-404c-a69c-bbf246a813cd"
      unitRef="usd">395000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMTgtMy0xLTEtMjM5OTc_cfe061e3-8bdb-401c-8982-315b9e6ae0a7"
      unitRef="usd">1412000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjAtMS0xLTEtMjM5OTc_b4126af7-82e9-4686-8ed8-41813e9e8b2e"
      unitRef="usd">26293000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjAtMy0xLTEtMjM5OTc_9d674631-36a7-418b-b151-e6ab35a6a763"
      unitRef="usd">-13483000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjEtMS0xLTEtMjM5OTc_7cd93a7a-a0e0-4b9e-b16d-fe7fb64ae1f7"
      unitRef="usd">-90267000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjEtMy0xLTEtMjM5OTc_f842139b-6067-44e2-9ab0-bb2c49d6f287"
      unitRef="usd">-122875000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjItMS0xLTEtMjM5OTc_c281a75a-3371-475b-bc6e-0c1cb3b28a03"
      unitRef="usd">126000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjItMy0xLTEtMjM5OTc_fdb67c3c-0185-4e09-bfec-def698603a8d"
      unitRef="usd">92000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjMtMS0xLTEtMjM5OTc_9b1108d5-5cef-4ef0-9abc-cce090e17976"
      unitRef="usd">-90393000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjMtMy0xLTEtMjM5OTc_7e146ee8-6821-4c53-855b-653be1b88fb5"
      unitRef="usd">-122967000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjUtMS0xLTEtMjM5OTc_0be6c400-df00-49b5-b234-f53e41a2fcae"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjUtMS0xLTEtMjM5OTc_6b8efe01-560b-4310-941e-0cd9adf8aa90"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjUtMy0xLTEtMjM5OTc_01d3d469-4241-4430-abbe-179948ca56df"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjUtMy0xLTEtMjM5OTc_20e7f839-1f4c-468c-9b46-28a52018c260"
      unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjYtMS0xLTEtMjM5OTc_091c5824-ed3e-4fcb-8733-ffe95b2cc812"
      unitRef="shares">185848000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjYtMS0xLTEtMjM5OTc_50ebd230-b3f5-4419-bb1c-cb587bd4cf29"
      unitRef="shares">185848000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjYtMy0xLTEtMjM5OTc_4d5c0bbc-688f-4101-ad66-bee3c7a6c33d"
      unitRef="shares">181370000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yNS9mcmFnOjBiNjM0OGI2ZDFjZjRmZjBhOTJhMmZiODlhY2Q3MWJhL3RhYmxlOmIzNGZhNWI2NWM0NTRmNDBhNzRiYjA2Y2RiZDBhMjMxL3RhYmxlcmFuZ2U6YjM0ZmE1YjY1YzQ1NGY0MGE3NGJiMDZjZGJkMGEyMzFfMjYtMy0xLTEtMjM5OTc_894cfe89-5d75-49d5-8df7-7bd15fc228a1"
      unitRef="shares">181370000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfMi0xLTEtMS0yMzk5Nw_25031e7b-f287-45a7-b8e2-1cc5d5925373"
      unitRef="usd">-90393000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfMi0zLTEtMS0yMzk5Nw_59ab58a3-adf4-47bb-bbea-8cc0d7d3ef60"
      unitRef="usd">-122967000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNC0xLTEtMS0yMzk5Nw_24b5f934-823e-4259-a5e2-04ac131ea2b7"
      unitRef="usd">-2091000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNC0zLTEtMS0yMzk5Nw_c48fcb54-dc53-4df8-86ac-836d083a2394"
      unitRef="usd">-766000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNS0xLTEtMS0yMzk5Nw_eba72aad-6832-43c4-94db-02419d82984f"
      unitRef="usd">-284000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNS0zLTEtMS0yMzk5Nw_6667a155-f9d7-4107-b767-092bdd75c23c"
      unitRef="usd">-60000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNi0xLTEtMS0yMzk5Nw_319d61cf-5cc0-40a9-b379-c38baf495a27"
      unitRef="usd">-2375000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNi0zLTEtMS0yMzk5Nw_11b7c7ca-0cbe-4e23-a540-5d0ee7dfdb01"
      unitRef="usd">-826000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNy0xLTEtMS0yMzk5Nw_a35f32e4-d3ef-4ef8-bbd8-42cd2b8742ba"
      unitRef="usd">-92768000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8yOC9mcmFnOjJmMDQ1ODNjNmNlZDRhNmVhNjVkZTNhMjI2NjI3NjU2L3RhYmxlOmFjYzJmNTVjY2MzNjQwNGViMzRmYjM0ZDA0ZjkxNzc1L3RhYmxlcmFuZ2U6YWNjMmY1NWNjYzM2NDA0ZWIzNGZiMzRkMDRmOTE3NzVfNy0zLTEtMS0yMzk5Nw_f1284c1a-dfd3-4cf6-a5e0-3e544395cea1"
      unitRef="usd">-123793000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i47e463c44a0047f5afbcfc85015e338b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfOS0xLTEtMS0yMzk5Nw_2bffb798-2e29-4439-a829-7bc696992ba3"
      unitRef="shares">180091000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i47e463c44a0047f5afbcfc85015e338b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfOS0zLTEtMS0yMzk5Nw_3c2cfa08-6cf8-4010-9928-491b327bb4f1"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i48ddc45b0f0c4083b93472ac00c57ec5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfOS01LTEtMS0yMzk5Nw_7abc9f8f-9187-47e5-8f3d-dfaf1ab2a82a"
      unitRef="usd">3388730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia03ac38b30664485a603bb967899051f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfOS03LTEtMS0yMzk5Nw_2fde482d-a2d1-4757-af55-8daa2e9010e0"
      unitRef="usd">-2295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie8db36c3bbf94862b20ee7306f48fec8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfOS05LTEtMS0yMzk5Nw_bb1b649e-ed14-4750-95d8-b924594b61e6"
      unitRef="usd">-2309158000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c98e2f4e6a9464da1ee6d7c11f30ef9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfOS0xMS0xLTEtMjM5OTc_69df574c-7b5a-4271-92af-980b92f9270e"
      unitRef="usd">1077295000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i1920e38e3b36491da8e42b40798bf230_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTAtMS0xLTEtMjM5OTc_8ca05cc9-e054-410d-84ee-9f270f9f9558"
      unitRef="shares">2199000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1920e38e3b36491da8e42b40798bf230_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTAtMy0xLTEtMjM5OTc_d69949ca-9882-42af-8fba-5848389ab95d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8b52fa5cc03e457a953ca86da5e2495c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTAtNS0xLTEtMjM5OTc_d4f10197-90d6-4c2e-bd04-94fed8407da2"
      unitRef="usd">17106000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTAtMTEtMS0xLTIzOTk3_a360d45b-2618-4412-bcba-42230d3d7391"
      unitRef="usd">17106000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8b52fa5cc03e457a953ca86da5e2495c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTEtNS0xLTEtMjM5OTc_3e446650-2f62-4fa1-a1a6-293af268b277"
      unitRef="usd">23898000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTEtMTEtMS0xLTIzOTk3_01aa6bcc-1cd4-4ac8-8bf9-5357f28cf92c"
      unitRef="usd">23898000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2de6ed15fee342229522ad57966bdd88_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTItNy0xLTEtMjM5OTc_03650ad4-2dea-4167-aadb-e839c883e658"
      unitRef="usd">-826000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i34c494178abb4445bac7b7c1e7b7011f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTItOS0xLTEtMjM5OTc_8bdfea4a-338d-4d6a-8d05-ef08c52c0065"
      unitRef="usd">-122967000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTItMTEtMS0xLTIzOTk3_4329fad8-2e44-45d3-b107-2569aa7e5245"
      unitRef="usd">-123793000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i2eca34de7440481fa184c63c4e404045_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTMtMS0xLTEtMjM5OTc_5b95c59a-0f16-47c4-a0e2-0c5ab956c621"
      unitRef="shares">182290000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2eca34de7440481fa184c63c4e404045_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTMtMy0xLTEtMjM5OTc_d40b6f11-f759-42f0-8cfc-980a91c5ffff"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15f2e796e9b648b4b037302677e091aa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTMtNS0xLTEtMjM5OTc_2a8eab40-2b48-44be-8a56-c5d7c7e9eb29"
      unitRef="usd">3429734000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i737ff7f610ad425cb44817f0b8750038_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTMtNy0xLTEtMjM5OTc_003f6f2c-8b6c-49f3-a473-aef1e2bdb2bb"
      unitRef="usd">-3121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b3e44be00774da7b32a55b730041c18_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTMtOS0xLTEtMjM5OTc_e3456c6f-97c8-47e4-90b3-a133756db486"
      unitRef="usd">-2432125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a5fea39b5bc466ca1d6c54f925e0d11_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOmY0NzkxMDdlZmJkYjRkMzk5YTg3MzNhOGMxYjZmYzU1L3RhYmxlcmFuZ2U6ZjQ3OTEwN2VmYmRiNGQzOTlhODczM2E4YzFiNmZjNTVfMTMtMTEtMS0xLTIzOTk3_b6544e01-a5f7-4a9a-887c-b25bb61bb952"
      unitRef="usd">994506000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i8e522901bf134d0aa1265a2daa7a8e8e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMS0xLTEtMS0zMDM5MA_3bd1f445-c580-4454-8710-689277bf3af4"
      unitRef="shares">185468000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8e522901bf134d0aa1265a2daa7a8e8e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMS0zLTEtMS0zMDM5MA_9c482362-0196-40cc-9bae-6b12c0b2e3e3"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d218052e54546b08d4740f17cfa7fac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMS01LTEtMS0zMDM5MA_62261542-ddc7-4b0b-807d-803dbac020d2"
      unitRef="usd">3516641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4998b2e879846b19c3d3a8b60109e10_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMS03LTEtMS0zMDM5MA_d3c18d02-c6d7-498c-bc61-1c6b4463b4e0"
      unitRef="usd">-4157000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2355825e97324b7fa8064d255dfefb27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMS05LTEtMS0zMDM5MA_5ebf55cd-087e-4db6-974e-c0a9e5868343"
      unitRef="usd">-2832995000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMS0xMS0xLTEtMzAzOTA_5052e28c-253f-43a1-9ba9-4041fba7ccad"
      unitRef="usd">679508000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i871843ba5eb74770b94f361271dbd894_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMi0xLTEtMS0zMDM5MA_df1339d3-b8cb-4977-b771-a063ced13ac7"
      unitRef="shares">806000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i871843ba5eb74770b94f361271dbd894_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMi0zLTEtMS0zMDM5MA_4a41366a-3b64-4677-adda-30f3e7380e33"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i30daae3c1fab4806bce1a44e0d836de2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMi01LTEtMS0zMDM5MA_187c38a7-ad58-48f7-8033-1757e4469aa3"
      unitRef="usd">188000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMi0xMS0xLTEtMzAzOTA_863e6ccd-333c-43e5-aae5-8ef3d9478b22"
      unitRef="usd">188000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i30daae3c1fab4806bce1a44e0d836de2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMy01LTEtMS0zMDM5MA_567f530e-dbc0-4000-8538-beb550fbb6db"
      unitRef="usd">20961000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfMy0xMS0xLTEtMzAzOTA_e0f92587-24f2-463e-ba53-6ef80a2b2268"
      unitRef="usd">20961000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8248c0ee6bae46cb8d2cae0e9c5f9907_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNC03LTEtMS0zMDM5MA_abc912be-d7fd-4ffb-882d-e9808058f993"
      unitRef="usd">-2375000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie7d3488f0d274f62a82178cb60b7e96b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNC05LTEtMS0zMDM5MA_bf27d47b-b84d-4a0a-81da-c40f95abec48"
      unitRef="usd">-90393000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNC0xMS0xLTEtMzAzOTA_3b8c5429-ef61-4384-bd6a-d68da2cd0488"
      unitRef="usd">-92768000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="idf4a7ec238a2443fb9cd9d9e2db0d68a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNS0xLTEtMS0zMDM5MA_794fd5a7-155c-4717-bac6-6a336d3198c5"
      unitRef="shares">186274000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idf4a7ec238a2443fb9cd9d9e2db0d68a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNS0zLTEtMS0zMDM5MA_eb465d51-127e-4f82-89d4-59c9f910a877"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iada92997824446879653178ad1bdbef4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNS01LTEtMS0zMDM5MA_a1046659-9eb2-4054-9603-051f4acd097b"
      unitRef="usd">3537790000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icfcf6a6304234f45bb0a0682da1f41f5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNS03LTEtMS0zMDM5MA_d18f91c0-6e79-4621-ba6b-cefb905e7729"
      unitRef="usd">-6532000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2791447615864815a607224b5191a937_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNS05LTEtMS0zMDM5MA_a59411dd-4df0-4964-9f4d-49238e53bc3e"
      unitRef="usd">-2923388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zMS9mcmFnOjFhMTQ2MzlkZTBiZDRmYzQ5ZTZmYjc4NWUxZGMwYmFiL3RhYmxlOjExNGE5OTI4MWMwMDQ0MGM5NGQwMmYzODg1ZjM1Njk2L3RhYmxlcmFuZ2U6MTE0YTk5MjgxYzAwNDQwYzk0ZDAyZjM4ODVmMzU2OTZfNS0xMS0xLTEtMzAzOTA_e3c1c076-b1b5-4842-8c5a-f4c94f3aac07"
      unitRef="usd">607889000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMy0xLTEtMS0yMzk5Nw_a56d6eff-b3a1-4c9b-bf23-57e7994195c1"
      unitRef="usd">-90393000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMy0zLTEtMS0yMzk5Nw_0a69b4ce-ee48-416c-9462-2c386e152cfb"
      unitRef="usd">-122967000</us-gaap:ProfitLoss>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNS0xLTEtMS0yMzk5Nw_0b476af9-1d25-4c4e-8de1-3ab0e046a959"
      unitRef="usd">17561000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNS0zLTEtMS0yMzk5Nw_c26e19ed-932a-49e9-b9bb-fd19a96ac0f8"
      unitRef="usd">18798000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNi0xLTEtMS0yMzk5Nw_0274ae8a-5397-4ae8-aea7-1f6209426f8c"
      unitRef="usd">7529000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNi0zLTEtMS0yMzk5Nw_f602c4d4-c5b0-4b95-b193-d91d34d4275d"
      unitRef="usd">13296000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNy0xLTEtMS0yMzk5Nw_5e715232-091d-43df-bfcc-26f3c820b5f8"
      unitRef="usd">33427000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNy0zLTEtMS0yMzk5Nw_2687e98e-60bc-41b1-a2d7-4bfddca5668a"
      unitRef="usd">-1599000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfOC0xLTEtMS0yMzk5Nw_b0efd8d1-d1e4-4761-b825-a4b1c34d0a6f"
      unitRef="usd">4951000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfOC0zLTEtMS0yMzk5Nw_565873cf-b4be-4230-943d-d2a95a9c243c"
      unitRef="usd">2248000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfOS0xLTEtMS0yMzk5Nw_3dc5bb99-2052-4846-a428-c890167b0b47"
      unitRef="usd">20961000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfOS0zLTEtMS0yMzk5Nw_6da5840a-e355-407b-9da9-00bb2a90969d"
      unitRef="usd">23898000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTAtMS0xLTEtMjM5OTc_4592e6fa-a350-4fbb-ba52-45e0470d33eb"
      unitRef="usd">3730000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTAtMy0xLTEtMjM5OTc_2f62323e-4e21-48be-85c7-f0959cccc896"
      unitRef="usd">3543000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTItMS0xLTEtMjM5OTc_a545a658-0eae-463d-8092-9141548ba964"
      unitRef="usd">-1276000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTItMy0xLTEtMjM5OTc_71285fd8-4056-4cb5-bd05-dfd341801bf8"
      unitRef="usd">-2345000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTQtMS0xLTEtMjM5OTc_523e0bc5-8c4b-422b-8b42-79d58825a565"
      unitRef="usd">7728000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTQtMy0xLTEtMjM5OTc_d40721ec-486e-4313-804d-cb9e8ab656b2"
      unitRef="usd">-9733000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTUtMS0xLTEtMjM5OTc_86e276e5-6b6d-4b97-8d05-20ad806e30a6"
      unitRef="usd">-422000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTUtMy0xLTEtMjM5OTc_506cba20-b687-4c16-8d63-11e1e4f34eae"
      unitRef="usd">1516000</us-gaap:IncreaseDecreaseInInventories>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTYtMS0xLTEtMjM5OTc_1d499fc4-25a6-4a4d-8480-575b933caf21"
      unitRef="usd">-1787000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTYtMy0xLTEtMjM5OTc_b0d2b3de-56f0-40ae-aa1f-ed3347be8775"
      unitRef="usd">-1541000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTctMS0xLTEtMjM5OTc_9201db18-d3f3-4249-8994-714b4da6eff8"
      unitRef="usd">-2864000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTctMy0xLTEtMjM5OTc_8fb2875a-9918-43a0-893d-81a34046950a"
      unitRef="usd">-6183000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTgtMS0xLTEtMjM5OTc_8feea3df-4982-4de0-bed0-024e2f569f4a"
      unitRef="usd">2998000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTgtMy0xLTEtMjM5OTc_7340434c-1e95-436a-ac1f-aa94c43e9874"
      unitRef="usd">779000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTktMS0xLTEtMjM5OTc_17a872d5-a0f6-4474-a900-f0ce0b437c36"
      unitRef="usd">6918000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMTktMy0xLTEtMjM5OTc_d9ca3da5-d7c2-414d-9d60-1aa1e082076f"
      unitRef="usd">8981000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjAtMS0xLTEtMjM5OTc_ef693dd8-3891-4620-b217-f633ae89c5e5"
      unitRef="usd">7249000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjAtMy0xLTEtMjM5OTc_f4256b8b-7897-491c-9959-c03bfd0180c9"
      unitRef="usd">-7950000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjItMS0xLTEtMjM5OTc_bd4d4027-0b35-4313-bde8-dec56366e2d7"
      unitRef="usd">-88424000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjItMy0xLTEtMjM5OTc_4002b0a4-9692-4037-bc0d-4c15d2069965"
      unitRef="usd">-77085000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjQtMS0xLTEtMjM5OTc_4cb10717-432f-47a4-9bdc-01e8d70ae32f"
      unitRef="usd">93493000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjQtMy0xLTEtMjM5OTc_8bdd1329-32a2-4496-b1a6-6d8edc68d5a1"
      unitRef="usd">295314000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjUtMS0xLTEtMjM5OTc_e1e42c3a-3f4a-4549-be02-89fdfdde28b3"
      unitRef="usd">227974000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjUtMy0xLTEtMjM5OTc_1be7219d-69b6-429e-8c4d-67e0286d3e1f"
      unitRef="usd">303612000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjYtMS0xLTEtMjM5OTc_704e3ec4-5816-447e-963b-9d4b483c565e"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjYtMy0xLTEtMjM5OTc_0354f32b-e23a-43cb-a1e9-e708b09c04db"
      unitRef="usd">5036000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjctMS0xLTEtMjM5OTc_f955c84f-27d3-4bad-84ca-f2ef477af82e"
      unitRef="usd">4203000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjctMy0xLTEtMjM5OTc_e2d3857c-e63c-4dab-b096-d941d78974e1"
      unitRef="usd">2876000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjgtMS0xLTEtMjM5OTc_de9cb717-2ae1-4a08-bc8f-f6c821446924"
      unitRef="usd">130278000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMjgtMy0xLTEtMjM5OTc_8ec8081b-0862-45e3-9146-d07b80521aab"
      unitRef="usd">10458000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzAtMS0xLTEtMjM5OTc_3e657e5c-61c7-4ae6-a2d5-bf9cf3094fb4"
      unitRef="usd">188000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzAtMy0xLTEtMjM5OTc_8bf4f44f-554d-494b-a485-34c991361cf5"
      unitRef="usd">17106000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzEtMS0xLTEtMjM5OTc_69bf7570-21fc-4be0-ad01-bdcf2255662d"
      unitRef="usd">750000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzEtMy0xLTEtMjM5OTc_a07575c5-4336-407b-958a-a07625a8e7a2"
      unitRef="usd">750000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzMtMS0xLTEtMjM5OTc_92038b35-cd26-4bc7-9b32-a72e4b16b33f"
      unitRef="usd">938000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzMtMy0xLTEtMjM5OTc_dad41a11-1df2-40fd-93e9-7c09727a1c97"
      unitRef="usd">17856000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzQtMS0xLTEtMjM5OTc_3e8c8bac-ccc8-454b-8cb3-80a65ef282b6"
      unitRef="usd">-17000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzQtMy0xLTEtMjM5OTc_edefafa5-4e73-4b1e-bedf-c1beb07f6b1f"
      unitRef="usd">-20000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzUtMS0xLTEtMjM5OTc_72840695-680a-4d9b-ad62-0cfdbbe88111"
      unitRef="usd">42775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzUtMy0xLTEtMjM5OTc_e53b5c6a-7025-452c-8483-2ee85a8bb897"
      unitRef="usd">-48791000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzYtMS0xLTEtMjM5OTc_47162961-f985-42e0-b1db-7178f04ac8d7"
      unitRef="usd">25218000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c98e2f4e6a9464da1ee6d7c11f30ef9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzYtMy0xLTEtMjM5OTc_1774a8bc-bf02-4b98-9809-ee3e08b0c3c5"
      unitRef="usd">198955000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzctMS0xLTEtMjM5OTc_16eafc2a-0647-46ee-b9b6-5ce94998f16d"
      unitRef="usd">67993000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4a5fea39b5bc466ca1d6c54f925e0d11_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfMzctMy0xLTEtMjM5OTc_6207c3c2-420d-4e93-87ec-e0fc52ba7ebf"
      unitRef="usd">150164000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNDAtMS0xLTEtMjM5OTc_d3db97ae-228c-4920-845a-5680939f3477"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8zNC9mcmFnOmIzODAzZDUwZTVkNzQ3MzlhZjRiZDliOTBmNmFiMjA3L3RhYmxlOjQ0ODA4ZjQ2YTJiZjRjYzA5ZjJjZmFmNDc1NTFjNGIzL3RhYmxlcmFuZ2U6NDQ4MDhmNDZhMmJmNGNjMDlmMmNmYWY0NzU1MWM0YjNfNDAtMy0xLTEtMjM5OTc_f019d9a4-b944-4092-9651-a743a865c6e2"
      unitRef="usd">1057000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxMzg_83d95f24-6257-4a05-908e-a8b77d462a8b">Organization and Summary of Significant Accounting Policies&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in oncology and immunology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. As of March&#160;31, 2022, we had approximately $704.4 million in cash and investments in marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring, Impairment and Other Costs of Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans for the Company&#x2019;s future:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On March 14, 2022, BMS  and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 7 for additional information on our BMS Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we made the decision to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 4 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. In addition to announcing the decision to discontinue this Phase 2/3 study, we also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, there are no ongoing clinical development activities of bempegaldesleukin.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 25, 2022, we announced our strategic reorganization and cost restructuring plans (together, the Reorganization and Restructuring Plans), which were reviewed and approved by our Board of Directors on April 14, 2022. On April 26, 2022, our duly authorized officers approved certain strategic, operational and organizational steps to undertake in connection with the Reorganization and Restructuring Plans. Under the Reorganization and Restructuring Plans, we are prioritizing key research and development efforts and continuing to evaluate our early stage drug candidate pipeline. We are also reducing our workforce by approximately 70%. See Note 10 for additional information regarding our reorganization and restructuring plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022, restructuring, impairment and other costs for terminated programs primarily include cancellation fees for certain manufacturing activities for bempegaldesleukin which were scheduled to support our efforts at securing potential FDA approval and commercial launch of bempegaldesleukin in metastatic melanoma in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2021 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 filed with the SEC on March 1, 2022. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of March&#160;31, 2022 and December&#160;31, 2021, our accounts receivable includes $26.9&#160;million and $21.4&#160;million, respectively, for unbilled net expense reimbursements from BMS. The remaining accounts receivable relate primarily to product sales. We generally do not require collateral from our customers. We perform a regular review of our customers&#x2019; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three months ended March&#160;31, 2022 and 2021. We have not recorded a reserve for credit losses at March&#160;31, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic or other factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2020, we have sold our rights to receive sales-based royalties for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,  MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as further described in Note 5. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our non-cash royalty revenue of $17.6&#160;million and $18.8&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, represents revenue for granting licenses which we had satisfied in prior periods. Our partners generally pay royalties  after the end of the calendar quarter in accordance with contractual terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Grants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratable over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <nktr:OrganizationPolicyTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxMzk_be2770b2-23ed-4f81-87a3-9d193e738c23">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments in oncology and immunology.&lt;/span&gt;&lt;/div&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</nktr:OrganizationPolicyTextBlock>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMTA0OQ_0a044bcf-7a3f-4f31-be28-3ec58740d2cd"
      unitRef="usd">704400000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfNDM5ODA0NjU2OTg4Mg_9fe8730e-f7bd-4108-9b13-2a9131baf330">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring, Impairment and Other Costs of Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and April 2022, we announced the unsuccessful results from our clinical trials studying bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under our Strategic Collaboration Agreement with Bristol-Myers Squibb Company (BMS). Based on these results, we decided to discontinue all of our ongoing clinical trials of bempegaldesleukin in combination with checkpoint inhibitors. In April 2022, we also announced new strategic reorganization and cost restructuring plans for the Company&#x2019;s future:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On March 14, 2022, BMS  and we announced that the registrational trial for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the registrational trials in metastatic melanoma and adjuvant melanoma. See Note 7 for additional information on our BMS Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 14, 2022, we announced that each of our registrational trials for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in renal cell carcinoma and in cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided to discontinue these studies and all other ongoing studies for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 14, 2022, we announced that, in consultation with SFJ Pharmaceuticals and based upon a recommendation from an independent Data Monitoring Committee, we made the decision to discontinue our Phase 2/3 study in bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in patients with metastatic or unresectable recurrent squamous cell cancer of the head and neck under our Co-Development Agreement with SFJ Pharmaceuticals. See Note 4 for additional information regarding our Co-Development Agreement with SFJ Pharmaceuticals. In addition to announcing the decision to discontinue this Phase 2/3 study, we also announced on April 14, 2022, the discontinuation of our Phase 1/2 PROPEL study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in locally advanced or metastatic solid tumors, including non-small cell lung cancer. With these announcements on April 14, 2022, there are no ongoing clinical development activities of bempegaldesleukin.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 25, 2022, we announced our strategic reorganization and cost restructuring plans (together, the Reorganization and Restructuring Plans), which were reviewed and approved by our Board of Directors on April 14, 2022. On April 26, 2022, our duly authorized officers approved certain strategic, operational and organizational steps to undertake in connection with the Reorganization and Restructuring Plans. Under the Reorganization and Restructuring Plans, we are prioritizing key research and development efforts and continuing to evaluate our early stage drug candidate pipeline. We are also reducing our workforce by approximately 70%. See Note 10 for additional information regarding our reorganization and restructuring plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022, restructuring, impairment and other costs for terminated programs primarily include cancellation fees for certain manufacturing activities for bempegaldesleukin which were scheduled to support our efforts at securing potential FDA approval and commercial launch of bempegaldesleukin in metastatic melanoma in 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="if2be3ac308a24e8ca217c972b757f923_D20220425-20220425"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfNDM5ODA0NjU3NTA1Mg_f3fbcb68-f46b-4077-80b8-619504be4653"
      unitRef="number">0.70</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxNDA_f42ddf28-7ea1-433d-a78e-bcea5d9fd55a">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized  gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2021 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 filed with the SEC on March 1, 2022. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxNDg_47e333f3-b9e3-4309-b2de-948e2fc78f29">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)  requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxMzQ_8881ddcd-cf7a-4a33-a806-744e838851c0">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. As of March&#160;31, 2022 and December&#160;31, 2021, our accounts receivable includes $26.9&#160;million and $21.4&#160;million, respectively, for unbilled net expense reimbursements from BMS. The remaining accounts receivable relate primarily to product sales. We generally do not require collateral from our customers. We perform a regular review of our customers&#x2019; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable and recorded no bad debt expense for the three months ended March&#160;31, 2022 and 2021. We have not recorded a reserve for credit losses at March&#160;31, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic or other factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2e6976d0fdcb42bba1c4b5e008c93f28_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfNTkxMA_b717ad2a-9995-4ddb-8c0d-dac6778acaf8"
      unitRef="usd">26900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib3e957a413d448a7a3513ceccf209004_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfNzY5NjU4MTQ1MzMzOQ_6ddc4396-da09-4888-9d32-29c0c2ef62e8"
      unitRef="usd">21400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfNjU2Nw_997e91da-f755-4a05-90c6-c562c9bc11f9"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfNjU2Nw_c72df6af-31b1-40ea-9ef3-b16410d1cd02"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxNTA_9461406c-3e40-4960-bff7-15bb40c58170">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxMzc_f8f833f4-9d69-44c3-93ce-90520e28ff0d">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2020, we have sold our rights to receive sales-based royalties for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,  MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as further described in Note 5. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our non-cash royalty revenue of $17.6&#160;million and $18.8&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, represents revenue for granting licenses which we had satisfied in prior periods. Our partners generally pay royalties  after the end of the calendar quarter in accordance with contractual terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Grants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5631866fb8ab42c39ed3826b2e8b778f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMTA5OTUxMTY5NjA3Ng_14471313-4580-49ba-b26a-fba3a2c19739"
      unitRef="usd">17600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5f35b8ae306472eb8a7b3141def628a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMTA5OTUxMTY5NjA2Nw_f3b659ed-77a5-4960-a998-b4b13e6bda4b"
      unitRef="usd">18800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80MC9mcmFnOmZiNTJkZWQxMDlmNzQ2ZGQ4YTJhMTkyMGM3MGViMjQ4L3RleHRyZWdpb246ZmI1MmRlZDEwOWY3NDZkZDhhMmExOTIwYzcwZWIyNDhfMjIxNTE_43d294c1-0782-41e3-a271-2e0d44357370">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratable over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNzMz_df4d6d63-c3da-40da-a1f3-330893d77029">Cash and Investments in Marketable Securities&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of March&#160;31, 2022 and December&#160;31, 2021, all of our long-term investments had maturities between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTM5_77184183-0367-45c7-a343-6cddbeacc01a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTM5_bbd38367-e438-4378-87e6-f0c97cd95e48"&gt;one&lt;/span&gt;&lt;/span&gt; and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022 and 2021, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. At December&#160;31, 2021, our gross unrealized losses totaled $0.7&#160;million, and our gross unrealized gains were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNzM2_d1e727c3-d1d1-42a3-9c10-379445611ac7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfMi0xLTEtMS0yMzk5Nw_6642de90-88da-4d10-982a-8278223890bd"
      unitRef="usd">67993000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfMi0zLTEtMS0yMzk5Nw_c8ea2612-56b2-4248-b7b8-44cb7296401f"
      unitRef="usd">25218000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfMy0xLTEtMS0yMzk5Nw_2bf4f9cd-fbe7-49eb-9a05-ef2c34134ec4"
      unitRef="usd">599032000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfMy0zLTEtMS0yMzk5Nw_a94e14b4-08fe-4e07-92da-22fd5d55cb6d"
      unitRef="usd">708737000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfNC0xLTEtMS0yMzk5Nw_8809bc7f-30ee-465e-880e-cbc7ffd3db69"
      unitRef="usd">37363000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfNC0zLTEtMS0yMzk5Nw_0f843dc4-8c61-4b0e-b4d7-48ec83582c52"
      unitRef="usd">64828000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfNS0xLTEtMS0yMzk5Nw_3da52dab-e6aa-48a3-b4bf-75531b78d1e4"
      unitRef="usd">704388000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjdkYmIzMDZiMmM2ZDRmOTlhODRhNzdhYWNjNWI5MjkyL3RhYmxlcmFuZ2U6N2RiYjMwNmIyYzZkNGY5OWE4NGE3N2FhY2M1YjkyOTJfNS0zLTEtMS0yMzk5Nw_1892c7c2-b927-4a8c-b3a1-3c6b70c27f1c"
      unitRef="usd">798783000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:DebtInvestmentMaximumMaturityPeriod
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfMzk5_e0e6780e-3e40-4a40-962e-c76df55897d8">P2Y</nktr:DebtInvestmentMaximumMaturityPeriod>
    <nktr:DebtInvestmentMaturityTerm
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNDU0_be9fa91f-fbc0-4f22-bb58-4e9d943c5028">P1Y</nktr:DebtInvestmentMaturityTerm>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="id45946e930114e44bce50be83bd56339_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTQ2_17188d71-65ce-4c1b-b39d-0012c454d07e">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="id1d12f77ed264cd9a637f0e3cf2ae918_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNTQ2_41e8d7bf-68fe-4b3c-8a70-636524cb4fcc">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNzMy_e0479555-109f-4b37-9594-3a8469c9f585">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i685b6f64ad5c4faa9de52180509da5da_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMi0yLTEtMS0yMzk5Nw_04338fe4-2fd7-4dbf-a25d-86dceb89a607"
      unitRef="usd">196643000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i685b6f64ad5c4faa9de52180509da5da_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMi00LTEtMS0yMzk5Nw_01e3aa59-bba1-4718-919d-9d8f5597ad1b"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i685b6f64ad5c4faa9de52180509da5da_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMi02LTEtMS0yMzk5Nw_34873d48-5fc0-45a9-9a7d-79ea9a8edcbc"
      unitRef="usd">1270000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i685b6f64ad5c4faa9de52180509da5da_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMi04LTEtMS0yMzk5Nw_279834de-e75f-418f-b96e-51317cde1b21"
      unitRef="usd">195377000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e22be348e714ef8918b6c87eae1bdcb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMi0xMC0xLTEtMjM5OTc_431c670d-6892-4fd1-9c1b-ae4e0321263f"
      unitRef="usd">278121000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icd4b2f49b55b430ebc75e5792a0b2792_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMy0yLTEtMS0yMzk5Nw_05fc1c81-debc-45ae-b2cf-eda9991ed924"
      unitRef="usd">439280000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icd4b2f49b55b430ebc75e5792a0b2792_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMy00LTEtMS0yMzk5Nw_b6fd8d13-ed1b-4b9f-9df5-a69cd002ffc6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icd4b2f49b55b430ebc75e5792a0b2792_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMy02LTEtMS0yMzk5Nw_c19b9150-e835-401f-bd5e-781e48e1d183"
      unitRef="usd">1479000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd4b2f49b55b430ebc75e5792a0b2792_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMy04LTEtMS0yMzk5Nw_38ba693e-e0d4-4a98-bf41-b2a76018bd63"
      unitRef="usd">437801000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iafca660c02b34e799b6bda3ecba63141_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfMy0xMC0xLTEtMjM5OTc_7277c2cc-6037-4e33-9c56-d92734d02a83"
      unitRef="usd">478629000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i33a6252cab2b4155abda79adc4038b32_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNC0yLTEtMS0yMzk5Nw_7c4288f2-5af0-4795-aad7-152734a122ea"
      unitRef="usd">4880000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i33a6252cab2b4155abda79adc4038b32_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNC00LTEtMS0yMzk5Nw_70080397-1121-46c8-b412-a334b6657412"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i33a6252cab2b4155abda79adc4038b32_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNC02LTEtMS0yMzk5Nw_3382b0cd-bd0c-4219-87db-2aa082d5a8a4"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33a6252cab2b4155abda79adc4038b32_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNC04LTEtMS0yMzk5Nw_b52fadc2-80d8-4ef1-9d4a-11867b24c0a4"
      unitRef="usd">4871000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01be499d3940498b883cfe405f68c613_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNC0xMC0xLTEtMjM5OTc_29c5502f-3597-40c5-a825-09a72193cb09"
      unitRef="usd">5875000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0d7497814c41422f9a5b7ea68e05c094_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNS0yLTEtMS0yMzk5Nw_6f4c01d2-f5bd-406a-acfb-788183151382"
      unitRef="usd">640803000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0d7497814c41422f9a5b7ea68e05c094_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNS00LTEtMS0yMzk5Nw_a9d0d4cc-8b93-4d44-9567-42ba28d4bdb2"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0d7497814c41422f9a5b7ea68e05c094_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNS02LTEtMS0yMzk5Nw_4778f179-4835-4445-8de6-f0a93a1587fb"
      unitRef="usd">2758000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0d7497814c41422f9a5b7ea68e05c094_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNS04LTEtMS0yMzk5Nw_57a8dd93-9e8c-4f41-bc97-4460f1be759c"
      unitRef="usd">638049000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f6f4d1cbe6a4471822b84152102c34f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNS0xMC0xLTEtMjM5OTc_30c7fb55-4458-48ce-9d1a-1e7baa1832c9"
      unitRef="usd">762625000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i98b42c2b599741359d987d496e64c309_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNi04LTEtMS0yMzk5Nw_5bfab534-241d-47ff-9ee4-84d1baf43060"
      unitRef="usd">43523000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i85b44d16760d4680ac9a0259407bc098_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNi0xMC0xLTEtMjM5OTc_1e8e5cac-ae34-4eb9-a080-acbc7fac923d"
      unitRef="usd">23968000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i875ef83363e04d6a85c3349eaf3dd3ab_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNy04LTEtMS0yMzk5Nw_2851a1e8-2ada-4e5d-86b4-e4b4e3c98fea"
      unitRef="usd">10894000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if4c024b46d2c49a3b471bb84a8b0399d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfNy0xMC0xLTEtMjM5OTc_ff904ff2-f262-45f1-ad73-bff6db5cd896"
      unitRef="usd">10940000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfOC04LTEtMS0yMzk5Nw_606c631e-2c8e-4020-b622-f7599938c6c5"
      unitRef="usd">11922000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfOC0xMC0xLTEtMjM5OTc_e2092286-99a1-49f1-adb2-76bb8d5ccb80"
      unitRef="usd">1250000</us-gaap:Cash>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfOS04LTEtMS0yMzk5Nw_0fee9c00-801c-49d0-a6b7-887b06934307"
      unitRef="usd">704388000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RhYmxlOjRkNGYxYWRhMzAyOTQxN2ZhNGE0MzA0MzY4ZjRmZDU5L3RhYmxlcmFuZ2U6NGQ0ZjFhZGEzMDI5NDE3ZmE0YTQzMDQzNjhmNGZkNTlfOS0xMC0xLTEtMjM5OTc_bcf00ad5-872a-4a19-b6ed-acaa5ebddcd5"
      unitRef="usd">798783000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80My9mcmFnOmUxZWU5ZTM5NDk5MTQ3YTZiNWExODhiOWYyNmZlMjU4L3RleHRyZWdpb246ZTFlZTllMzk0OTkxNDdhNmI1YTE4OGI5ZjI2ZmUyNThfNzY5NjU4MTM5NTcxMg_941f4181-f0b0-4cbb-8e3b-f9b4cf1e7f33"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RleHRyZWdpb246MWI0ZTVhNTdhZjk3NDA5N2JjMzZmZjBlZWU3NWVhN2VfMTA4OA_d1d853c7-1b26-4cc8-9f4c-e1db3c424042">Inventory&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RleHRyZWdpb246MWI0ZTVhNTdhZjk3NDA5N2JjMzZmZjBlZWU3NWVhN2VfMTA5MA_0a4e02c0-895f-4989-8763-e95fc77b6fa4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfMS0xLTEtMS0yMzk5Nw_39d05993-156a-4c7e-abfa-a8e00dd479a1"
      unitRef="usd">2084000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfMS0zLTEtMS0yMzk5Nw_25b07162-45f3-4ae5-93a9-fa094339bf71"
      unitRef="usd">3166000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfMi0xLTEtMS0yMzk5Nw_be232371-daf4-4008-be38-2db2254cd1ad"
      unitRef="usd">9420000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfMi0zLTEtMS0yMzk5Nw_b4b66833-d162-4e20-8acb-25f3bc9b9b58"
      unitRef="usd">9342000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfMy0xLTEtMS0yMzk5Nw_01c8a07c-80d0-4afb-a078-08ad3d423aec"
      unitRef="usd">3875000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfMy0zLTEtMS0yMzk5Nw_966ee4f3-c9ed-41ae-a1eb-e6aa3db73628"
      unitRef="usd">3293000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfNC0xLTEtMS0yMzk5Nw_3974ef9e-44c9-46e1-8fc1-7c3bbb3423ef"
      unitRef="usd">15379000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0360dfe057384ef3ba43ab8dd1071974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RhYmxlOmVkY2Q5ODJhMDU3YjRiNjk4ZjI2OTg1ZmJjY2JlZGRlL3RhYmxlcmFuZ2U6ZWRjZDk4MmEwNTdiNGI2OThmMjY5ODVmYmNjYmVkZGVfNC0zLTEtMS0yMzk5Nw_e7ddac04-ee89-493d-9377-978f556d3df6"
      unitRef="usd">15801000</us-gaap:InventoryNet>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80Ni9mcmFnOjFiNGU1YTU3YWY5NzQwOTdiYzM2ZmYwZWVlNzVlYTdlL3RleHRyZWdpb246MWI0ZTVhNTdhZjk3NDA5N2JjMzZmZjBlZWU3NWVhN2VfMTA5MQ_7c78c783-f1c0-41b5-87b4-d1abe7440237">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</us-gaap:InventoryPolicyTextBlock>
    <nktr:DevelopmentDerivativeLiabilityTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RleHRyZWdpb246YTg2Y2I2OWY1MWY3NDQwMTkwOTJhMDI1YmFjMWVkZDlfNjI5Mg_8887ea83-105f-4739-ad6e-a41d9257ca40">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 12, 2021, we entered into a Co-Development Agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ would pay up to $150.0&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ has primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we are the sponsor of the SCCHN Clinical Trial. The SFJ Agreement provided for us to pay up to $637.5&#160;million in Success Payments in the event of FDA approval of bempegaldesleukin for the metastatic melanoma, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 1, on March 14, 2022, we announced that the metastatic melanoma trial did not meet its primary endpoints and that we and BMS decided to discontinue the registrational trials in metastatic melanoma trial and adjuvant melanoma. On April 14, 2022, BMS and we announced that, due to the negative results of our trials for bempegaldesleukin in each of renal cell carcinoma and cisplatin-ineligible, locally advanced or metastatic urothelial cancer, BMS and we decided to end the development for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and that these studies and all other ongoing studies in the bempegaldesleukin program will be discontinued. On April 14, 2022, due to these results, SFJ and we agreed to discontinue the SCCHN Clinical Trial. Accordingly, SFJ will not be entitled to any Success Payments, and SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. SFJ has no right to seek reimbursement from us for any costs incurred for the SCCHN Clinical Trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We presented the SFJ Agreement as a Development derivative liability in our Condensed Consolidated Balance Sheets, which we remeasured to fair value at each reporting date. As SFJ conducted the SCCHN Clinical Trial, we recorded non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remitted funding to us to support our internal costs of conducting the trial, we also recorded a corresponding increase to the development derivative liability. We presented the gain (loss) from the remeasurement as change in fair value of development derivative liability in our Condensed Consolidated Statements of Operations. As of March 31, 2022, due to the negative results of the metastatic melanoma trial and initial discussions with SFJ, we concluded that it was remote that SFJ and we would continue the SCCHN Clinical Trial. Accordingly, the fair value of the development derivative liability was reduced to $0 as of March 31, 2022, and we recognized a corresponding gain in the Change in fair value of development derivative liability.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the development derivative liability for the three months ended March&#160;31, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</nktr:DevelopmentDerivativeLiabilityTextBlock>
    <nktr:CollaborativeArrangementCommittedFunding
      contextRef="i276bda16441d48ad80af19d97efc426a_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RleHRyZWdpb246YTg2Y2I2OWY1MWY3NDQwMTkwOTJhMDI1YmFjMWVkZDlfMzAy_7b702c40-cd8a-41dc-9eda-2315b412cd6f"
      unitRef="usd">150000000</nktr:CollaborativeArrangementCommittedFunding>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsAmount
      contextRef="i276bda16441d48ad80af19d97efc426a_D20210212-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RleHRyZWdpb246YTg2Y2I2OWY1MWY3NDQwMTkwOTJhMDI1YmFjMWVkZDlfMjc0ODc3OTA4NzAxMQ_f3237377-4fe5-4046-9b32-7cacb2fcb8cb"
      unitRef="usd">637500000</nktr:CollaborativeArrangementSuccessBasedPaymentsAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RleHRyZWdpb246YTg2Y2I2OWY1MWY3NDQwMTkwOTJhMDI1YmFjMWVkZDlfNDM5ODA0NjUzNzA4NQ_6123fb88-bf42-4bc3-a070-a5f911089fe4"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RleHRyZWdpb246YTg2Y2I2OWY1MWY3NDQwMTkwOTJhMDI1YmFjMWVkZDlfNjI5NQ_5eaadccd-3d6b-4730-b903-e8e317ddd283">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the development derivative liability for the three months ended March&#160;31, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i67220c05393f459bb392d5a646a36d88_I20210212"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMS00LTEtMS0yNzI5Mw_279b59d5-9796-404d-b464-1975e8c21a2a"
      unitRef="usd">27726000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib32a3a93199343bfb4bfa43354beb247_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMS00LTEtMS0yNzI5Mw_fc848e29-0b34-4bcc-9121-f3ff2f4ce957"
      unitRef="usd">27726000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="icebb6494d94b4db1a4f1c110b85abaf9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMS0yLTEtMS0yMzk5Nw_22a11e0b-3c6b-4571-8fde-7a1c426cb9d0"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense
      contextRef="ie96ec436f9fc449ebdff998acc527edf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMi00LTEtMS0yNzI5Mw_8e9abc3e-0bee-4f3c-a2ab-9d0e574e8cf0"
      unitRef="usd">4951000</nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense>
    <nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense
      contextRef="i72d23832d5824e05a9160a3dc1fdbe35_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMi0yLTEtMS0yMzk5Nw_714863e7-db9b-4e77-a9c2-73c6dcf686c8"
      unitRef="usd">2248000</nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="ie96ec436f9fc449ebdff998acc527edf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMy00LTEtMS0yNzI5Mw_e3d12ee4-9405-4578-8c42-2ddb7164e640"
      unitRef="usd">750000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i72d23832d5824e05a9160a3dc1fdbe35_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfMy0yLTEtMS0yMzk5Nw_8d689ed2-e158-4f92-ad58-c98f3d0455cb"
      unitRef="usd">750000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="ie96ec436f9fc449ebdff998acc527edf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfNC00LTEtMS0yNzI5Mw_a81cafec-9d00-48d7-9ed5-f96c41bb3cf9"
      unitRef="usd">33427000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i72d23832d5824e05a9160a3dc1fdbe35_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfNC0yLTEtMS0yMzk5Nw_d017dfae-2520-42e0-a4bf-454a0a1e4bdd"
      unitRef="usd">-1599000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i81672743daf84e089f134278b21e4900_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfNS00LTEtMS0yNzI5Nw_eb9b4200-10e2-42d1-a52c-676f7bdc30aa"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i232e4fff92244a1286cab431418b53bb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF80OS9mcmFnOmE4NmNiNjlmNTFmNzQ0MDE5MDkyYTAyNWJhYzFlZGQ5L3RhYmxlOjE3NWRiNGQ0M2VjYzRhMDliMTE1OGI2NjRhZmYzZWZhL3RhYmxlcmFuZ2U6MTc1ZGI0ZDQzZWNjNGEwOWIxMTU4YjY2NGFmZjNlZmFfNS0yLTEtMS0yMzk5Nw_2790f71d-abfd-4e8e-b24f-acca29676e2a"
      unitRef="usd">4597000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RleHRyZWdpb246YjAyMTAxZjA3ZTIyNDc4YmJjZmMxODRlYTUwYjVkOWRfNzM2OA_8da597ce-d58d-419f-9da2-23bfb841ddbb">Liabilities Related to Sales of Future Royalties&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Drug&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Manufacturer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty under Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date Sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; and ADYNOVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (brand name for ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; in Europe)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare Royalty Management, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (naloxegol tablets) and  MOVENTIG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (brand name for MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; in Europe)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca AB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare Royalty Management, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare Royalty Management, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (certolizumab pegol)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;UCB Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RPI Finance Trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 24, 2012&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (Continuous Erythropoietin Receptor Activator)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;F. Hoffmann-La Roche Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RPI Finance Trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 24, 2012&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to our ongoing manufacturing obligations in both arrangements, we account for the proceeds as debt (Royalty Obligations) and therefore continue to recognize these non-cash royalties as revenue. As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense over the lives of the respective Royalty Obligations. The following table shows the activity within the liability account of each arrangement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period from inception to March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty monetization proceeds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(289,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to RPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of liability related to the sale of future royalties (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1) Loss recognized from Settlement Agreement to resolve UCB&#x2019;s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We periodically assess the estimated royalty payments to RPI and HCR from our licensees and to the extent the amount or timing of such payments is materially different from our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the applicable Royalty Obligation. As of March 31, 2022, our imputed interest rates for the arrangements with RPI and HCR were 16% and 15%, respectively.&lt;/span&gt;&lt;/div&gt;</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock>
    <nktr:ScheduleOfPurchaseAndSaleAgreementTableTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RleHRyZWdpb246YjAyMTAxZjA3ZTIyNDc4YmJjZmMxODRlYTUwYjVkOWRfNDM5ODA0NjUzODc0MA_6e3b49a3-4592-4a69-be9b-fd8122d6d74f">&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Drug&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Manufacturer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty under Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date Sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; and ADYNOVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (brand name for ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; in Europe)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare Royalty Management, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (naloxegol tablets) and  MOVENTIG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (brand name for MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; in Europe)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca AB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare Royalty Management, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare Royalty Management, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (certolizumab pegol)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;UCB Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RPI Finance Trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 24, 2012&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; (Continuous Erythropoietin Receptor Activator)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;F. Hoffmann-La Roche Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RPI Finance Trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 24, 2012&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nktr:ScheduleOfPurchaseAndSaleAgreementTableTextBlock>
    <nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RleHRyZWdpb246YjAyMTAxZjA3ZTIyNDc4YmJjZmMxODRlYTUwYjVkOWRfNDM5ODA0NjUzODc0MQ_27ca0e71-6194-4c57-a6ec-0ab755954e28">The following table shows the activity within the liability account of each arrangement (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period from inception to March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty monetization proceeds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(289,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to RPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of liability related to the sale of future royalties (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1) Loss recognized from Settlement Agreement to resolve UCB&#x2019;s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i3c501231db134e1eb8a1723fe66a287d_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfMy0xLTEtMS0yNzkyMA_6da50e73-78b0-4c77-8ded-fd064534e793"
      unitRef="usd">124000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i880e4bb37a104926b7f1b627aba88cce_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfMy0zLTEtMS0yNzkyMA_a70711f4-aa65-43fa-b1fe-bdca737d88ae"
      unitRef="usd">150000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfMy01LTEtMS0yNzkyMA_d9c27806-e93e-4da9-b5e0-aa8d98f9bc41"
      unitRef="usd">274000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i3c501231db134e1eb8a1723fe66a287d_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNC0xLTEtMS0yNzkyMA_ee41dda5-e1f1-4dcb-8a2c-4e4804351915"
      unitRef="usd">-289655000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i880e4bb37a104926b7f1b627aba88cce_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNC0zLTEtMS0yNzkyMA_3c319012-a1c2-41a5-8d24-631826a8993a"
      unitRef="usd">-61357000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNC01LTEtMS0yNzkyMA_f5ae4f4d-080a-4a0f-851f-005b0f9a4c03"
      unitRef="usd">-351012000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i3c501231db134e1eb8a1723fe66a287d_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNS0xLTEtMS0yNzkyMA_dc85896a-34ed-4925-9d4d-027c62ca73c4"
      unitRef="usd">226506000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i880e4bb37a104926b7f1b627aba88cce_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNS0zLTEtMS0yNzkyMA_5ffe3043-725e-4cf6-9124-381decd91ed2"
      unitRef="usd">25296000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNS01LTEtMS0yNzkyMA_66956afa-6023-4344-af5a-75e524e02a68"
      unitRef="usd">251802000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i3c501231db134e1eb8a1723fe66a287d_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNi0xLTEtMS0yNzkyMA_714f68ce-a671-41df-a093-8cc000588ab2"
      unitRef="usd">10000000</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i880e4bb37a104926b7f1b627aba88cce_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNi0zLTEtMS0yNzkyMA_4ca88fb6-366d-4767-b233-abb88b13928c"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNi01LTEtMS0yNzkyMA_b2501cee-7c55-480a-8297-3d4a197b50eb"
      unitRef="usd">10000000</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i3c501231db134e1eb8a1723fe66a287d_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNy0xLTEtMS0yNzkyMA_a41edcf0-a246-446d-b796-1a3519e14ee0"
      unitRef="usd">23522000</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i880e4bb37a104926b7f1b627aba88cce_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNy0zLTEtMS0yNzkyMA_605490a7-791f-439d-89c2-5ef51be0f27d"
      unitRef="usd">0</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfNy01LTEtMS0yNzkyMA_d4db6b35-c166-4403-b0e3-a7a787fd288c"
      unitRef="usd">23522000</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ia68e0b50ca474c9fb590f027a73cf228_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfOC0xLTEtMS0yNzkyMA_f1ba7628-4900-48d6-a6d9-de93b5d0cef3"
      unitRef="usd">74373000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i3ce5f5ad632f42c5ac8d5b2eab7fde07_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfOC0zLTEtMS0yNzkyMA_e8684691-7d3e-43f0-afc2-b523389e1080"
      unitRef="usd">113939000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfOC01LTEtMS0yNzkyMA_79c0b30f-c4d8-4cea-b188-461ac215bbf6"
      unitRef="usd">188312000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="ia68e0b50ca474c9fb590f027a73cf228_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfOS0xLTEtMS0yNzkyMA_075b01c0-2ec5-4449-9d38-d7ba5c5d94e7"
      unitRef="usd">0</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="i3ce5f5ad632f42c5ac8d5b2eab7fde07_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfOS0zLTEtMS0yNzkyMA_c66cb91e-c178-409b-ae4c-8125a7a4a4c4"
      unitRef="usd">2708000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfOS01LTEtMS0yNzkyMA_6988c603-23ae-4555-84b5-d67a1435a0aa"
      unitRef="usd">2708000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ia68e0b50ca474c9fb590f027a73cf228_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfMTAtMS0xLTEtMjc5MjA_f94fca89-2d6a-426b-9ad0-ab89d06b6a58"
      unitRef="usd">74373000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i3ce5f5ad632f42c5ac8d5b2eab7fde07_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfMTAtMy0xLTEtMjc5MjA_8a42967b-c0e8-4b88-9913-570d176284ed"
      unitRef="usd">111231000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i50cc006393ad4e1888a5e96af4811b81_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RhYmxlOmNhYzE4N2RhZTRjNDQ2ZDU4NjM0Njc0Y2E3ZjFkMWQxL3RhYmxlcmFuZ2U6Y2FjMTg3ZGFlNGM0NDZkNTg2MzQ2NzRjYTdmMWQxZDFfMTAtNS0xLTEtMjc5MjA_00fbd360-6223-450c-90db-97abec28255a"
      unitRef="usd">185604000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:RoyaltiesLiabilityMeasurementInput
      contextRef="ia68e0b50ca474c9fb590f027a73cf228_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RleHRyZWdpb246YjAyMTAxZjA3ZTIyNDc4YmJjZmMxODRlYTUwYjVkOWRfNDM5ODA0NjUzODM1Mg_fd7fb352-d261-4ca2-823d-b68c9724caa5"
      unitRef="number">0.16</nktr:RoyaltiesLiabilityMeasurementInput>
    <nktr:RoyaltiesLiabilityMeasurementInput
      contextRef="i3ce5f5ad632f42c5ac8d5b2eab7fde07_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81Mi9mcmFnOmIwMjEwMWYwN2UyMjQ3OGJiY2ZjMTg0ZWE1MGI1ZDlkL3RleHRyZWdpb246YjAyMTAxZjA3ZTIyNDc4YmJjZmMxODRlYTUwYjVkOWRfNDM5ODA0NjUzODM1Nw_e9f84075-31e6-4278-a674-3c283084a79b"
      unitRef="number">0.15</nktr:RoyaltiesLiabilityMeasurementInput>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81NS9mcmFnOmQ0NGVjY2JjM2RjODQzZDU4ZGU3MzlhNjczMWNhZDk1L3RleHRyZWdpb246ZDQ0ZWNjYmMzZGM4NDNkNThkZTczOWE2NzMxY2FkOTVfNjQ4MA_d7a23f9f-0cf0-4f99-ac56-860271ce3a5a">Commitments and Contingencies&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv-06607, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made, between January 2017 and June 2018, about the clinical trials of bempegaldesleukin. The Mulquin complaint was amended in May 2019. The defendants moved to dismiss and the court granted the motion without prejudice in July 2020. The Mulquin plaintiffs again amended their complaint and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice. The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit was completed in September 2021. Oral argument occurred on December 10, 2021, and the matter remains pending with the court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A second putative securities class action was filed against the Company and certain of our executives in the U.S. District Court for the Northern District of California in August 2019 (Case No. 4-19-cv-05173, which we refer to as the Damiba action).  The Damiba plaintiffs challenged public statements Nektar made, between February 2019 and May 2019, about its bempegaldesleukin clinical trials and collaboration with Bristol-Myers Squibb. After the Damiba plaintiffs filed an amended complaint and the defendants moved to dismiss, the court dismissed the action without prejudice in January 2021. The Damiba plaintiffs subsequently voluntarily dismissed the action, with prejudice, in March 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the two securities actions (the Mulquin action and the Damiba action), three additional sets of derivative actions have been filed against certain of the Company&#x2019;s current and former officers and directors, purportedly on the Company&#x2019;s behalf. These derivative actions are based on the allegations in the securities actions and on the premise that the Company&#x2019;s officers and directors breached their fiduciary duties by exposing the Company to one or both of the securities actions. The first derivative action was filed in the U.S. District Court for the District of Delaware in February 2019 (Case No. 1:19-cv-00322-MN-JLH). After amending their complaint several times, the plaintiffs in that action voluntarily dismissed their claims without prejudice in April 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A second set of derivative actions was filed in February 2020 in the U.S. District Court for the Northern District of California (Case No. 4:20-cv-01088-JSW). The derivative actions in California were consolidated and the Company moved to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;dismiss on the basis that the plaintiffs had neither made a demand on the Company&#x2019;s board of directors nor shown that a demand would be futile. On September 1, 2021, the court dismissed the action with prejudice.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A third derivative complaint was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF). The parties agreed to stay further proceedings in this action until thirty days after the U.S. Court of Appeals for the Ninth Circuit&#x2019;s final resolution of the appeal in the Mulquin action.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the nature and status of these securities class action lawsuits and derivative complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at either March&#160;31, 2022 or December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnifications in Connection with Commercial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.&lt;/span&gt;&lt;/div&gt;To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i860898a72fc245f2b9c0e62294906402_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81NS9mcmFnOmQ0NGVjY2JjM2RjODQzZDU4ZGU3MzlhNjczMWNhZDk1L3RleHRyZWdpb246ZDQ0ZWNjYmMzZGM4NDNkNThkZTczOWE2NzMxY2FkOTVfMTA5OTUxMTY0MTM2Ng_3788077c-fba6-4808-b563-9053577a62d8"
      unitRef="action">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i7bf89d8a3c5743f8a48bec4907711413_D20190201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81NS9mcmFnOmQ0NGVjY2JjM2RjODQzZDU4ZGU3MzlhNjczMWNhZDk1L3RleHRyZWdpb246ZDQ0ZWNjYmMzZGM4NDNkNThkZTczOWE2NzMxY2FkOTVfMTA5OTUxMTY0MTQzMw_07339662-192b-4e6f-9334-7988b0489ba1"
      unitRef="action">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i0ab30e6ae04746708e8844aad00bca73_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81NS9mcmFnOmQ0NGVjY2JjM2RjODQzZDU4ZGU3MzlhNjczMWNhZDk1L3RleHRyZWdpb246ZDQ0ZWNjYmMzZGM4NDNkNThkZTczOWE2NzMxY2FkOTVfMTA5OTUxMTY0MzMzMQ_08901008-9bda-4cc2-8ae7-3a5887090d0b"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="if5c65e86d0ca4792813758a0541762ed_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF81NS9mcmFnOmQ0NGVjY2JjM2RjODQzZDU4ZGU3MzlhNjczMWNhZDk1L3RleHRyZWdpb246ZDQ0ZWNjYmMzZGM4NDNkNThkZTczOWE2NzMxY2FkOTVfMTA5OTUxMTY0MzMzMQ_d92b9140-34c8-4aa9-8a6a-6e342cd38001"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfMTIwODk_0294c0a1-48b0-4ef9-98db-6f43b11ed6a3">License and Collaboration Agreements&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our collaboration agreements in the three months ended March&#160;31, 2022, other than as described below for our Strategic Collaboration Agreement with BMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bristol-Myers Squibb Company (BMS)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;: Bempegaldesleukin, also referred to as NKTR-214 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS have jointly developed bempegaldesleukin in combination with BMS&#x2019;s Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#x2019;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing and commercialization of bempegaldesleukin, 35% of the costs to BMS and 65% to Nektar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million. In 2020, we received non-refundable milestone payments of $50.0&#160;million in aggregate for the first patient, first visit in the registrational trials in muscle-invasive bladder cancer and adjuvant melanoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 1, on March 14, 2022, we announced our registrational trial in metastatic melanoma did not meet its primary endpoints and that BMS and we decided to discontinue the trials in metastatic melanoma and adjuvant melanoma. On April 14, 2022, we announced that our registrational trials in each of renal cell carcinoma and cisplatin-ineligible, locally advanced or metastatic urothelial cancer did not meet their respective primary endpoints. Due to these results, BMS and we decided that these studies and all other ongoing studies in the program will be discontinued. The decision to terminate the program does not affect the cost-sharing provisions under the BMS Collaboration Agreement. However, without further development of bempegaldesleukin, we will no longer be eligible for the development, regulatory and sales milestones under the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#x2019; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#x2019; expenses as research and development expense. During the three months ended March&#160;31, 2022 and March&#160;31, 2021, we recorded $24.9&#160;million and $26.7&#160;million, respectively, as reductions of research and development expense for BMS&#x2019; share of our expenses, net of our share of BMS&#x2019; expenses. As of March&#160;31, 2022, we have recorded an unbilled receivable of $26.9&#160;million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eli Lilly and Company (Lilly&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;): NKTR-358 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) to co-develop NKTR-358, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $150.0&#160;million and are eligible for up to $250.0&#160;million in additional development and regulatory milestones. We are currently in Phase 1B and Phase 2 development, where we share costs with 75% of the costs borne by Lilly and 25% of the costs borne by us. Lilly is responsible for the costs of Phase 3 development, but we retain the option to contribute up to 25% of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the costs of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Phase 3 development on an indication-by-indication basis in order for us to achieve maximum royalty level under the Lilly Agreement, and further&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if approved, we will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales.  Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lilly Agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The Lilly Agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we are entitled to significant development milestones under this arrangement, through March&#160;31, 2022, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEGylation materials for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 5, we have sold our rights to receive royalties from these other collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we have a collaboration agreement for a product under development, under which we are entitled to up to a total of $40.0&#160;million of regulatory milestones, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential product under this collaboration agreement, we cannot estimate the probability or timing of achieving these milestones, and, therefore, have excluded all development milestones from the transaction price for this agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="i06904e4d49ac4e03999c919c6e4361cc_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODUzMg_07709dcf-6c86-4fbf-a954-0c8634ad5e08"
      unitRef="number">0.675</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="ic736db4d693a4b8595ef22ef35f99636_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODUzOQ_c4f01e67-55f1-4307-ba99-cca80187e2a5"
      unitRef="number">0.325</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="i16f1e513809d4671b267573756667622_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODU0Ng_8be3f89f-b5e6-44a0-b4d9-7fc4cc39ef94"
      unitRef="number">0.35</nktr:PercentageOfSharingInProductionCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="i037d8ae4d167406ebb243ed52a646788_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODU1MQ_46334716-7653-4868-b2da-234cac6b2331"
      unitRef="number">0.65</nktr:PercentageOfSharingInProductionCosts>
    <nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
      contextRef="i5a262bb734414dd4857c079289efd56c_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODU1Ng_b3919eae-4a96-4f06-bb4d-30f8c070fa64"
      unitRef="usd">1000000000</nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements>
    <us-gaap:SharesIssued
      contextRef="ic31ce00edf3c4891b98bdd4f17ff4e56_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODU3MA_a3aba0a5-7bb1-4d72-a670-f0622124e2a9"
      unitRef="shares">8284600</us-gaap:SharesIssued>
    <nktr:SaleOfStockConsiderationReceived
      contextRef="i6264ab40d7dc48aa86cf10e2b939d8ae_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODU4MQ_1e24a11e-36bc-4d34-b7c0-42441af8b711"
      unitRef="usd">850000000</nktr:SaleOfStockConsiderationReceived>
    <nktr:PotentialDevelopmentMilestones
      contextRef="i78c51641e8cc496894dae390b3acb852_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODU5Nw_ee4a3272-5aba-42e7-ae61-776881b6b793"
      unitRef="usd">50000000</nktr:PotentialDevelopmentMilestones>
    <nktr:ReimbursementOfExpenses
      contextRef="i93c0c909992548e0982362d608cdb5c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNDM5ODA0NjUzODY1Ng_d2a7bb9b-2dd1-42c3-bf35-0e6e1f399fa5"
      unitRef="usd">24900000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i48032d659bf148a09d2a83b4693bb85b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNzY5NjU4MTQzMDU1NA_ebc2ea25-f4ad-4ce6-8cc1-f225d0d1d8fe"
      unitRef="usd">26700000</nktr:ReimbursementOfExpenses>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2e6976d0fdcb42bba1c4b5e008c93f28_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNzY5NjU4MTQzMDc2NA_b717ad2a-9995-4ddb-8c0d-dac6778acaf8"
      unitRef="usd">26900000</us-gaap:AccountsReceivableNetCurrent>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i1a2cc7ccba3642dfb8f9446b1b854843_D20170901-20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNzgyMQ_661200ee-8185-428c-9cfb-87d9da9052b1"
      unitRef="usd">150000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="i887bd71a1b294a4fb94e4d8c2a792b9d_I20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfNzg2OQ_c4d8aa84-2a47-404c-aad4-deab4c3eed1f"
      unitRef="usd">250000000</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="i38fc13ebd3cd490ca1a6005558c5ad94_D20170823-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfODE2Mw_e898f286-9fa7-4970-ae8c-0bcef8feb82d"
      unitRef="number">0.75</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="i31ef1bddb0d74c048cd77ffc33b52ad9_D20170823-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfODIwMA_691ec4ce-bec9-4fb9-a74d-7727838d2112"
      unitRef="number">0.25</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="ifefea51825e94f008a861cb1ddc9bfe5_D20170823-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfODM1Ng_c23061bb-ebf6-4087-b20d-9555ef8a28cd"
      unitRef="number">0.25</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
      contextRef="i3a089f68509044168386924efba61d4e_D20170823-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfODc2OQ_d5dd9277-6731-4735-8aa4-7171636b1fce"
      unitRef="number">0.50</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
      contextRef="i3a089f68509044168386924efba61d4e_D20170823-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfOTAwNA_aea55946-f0d2-4016-b49a-a9a94b307963"
      unitRef="number">0.75</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur>
    <nktr:PotentialDevelopmentMilestones
      contextRef="ib19687a8076a473ba979d1fd42e0df4c_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82MS9mcmFnOjMyMWYxZTVmMDFmNzRhYTQ4ZmY5MWQ3ZTE1ZDlhNGRkL3RleHRyZWdpb246MzIxZjFlNWYwMWY3NGFhNDhmZjkxZDdlMTVkOWE0ZGRfMTE2MTU_22db0fb6-8a1c-45b2-a43f-2ed263638d97"
      unitRef="usd">40000000</nktr:PotentialDevelopmentMilestones>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RleHRyZWdpb246ZmQ2ZTNmNjhjN2M4NDQ5YWJjMGZlMjk2MDg0NjA1NTZfNjM5_224ce699-3ea3-432e-aff4-e259cba3d9e1">Stock-Based Compensation&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issued stock-based awards of our common stock as follows (shares in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RleHRyZWdpb246ZmQ2ZTNmNjhjN2M4NDQ5YWJjMGZlMjk2MDg0NjA1NTZfNjM1_68f75c17-9ba4-4985-aca0-8ffad33dc925">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e034360701446c8a364586fa2b0d27b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfMi0xLTEtMS0yMzk5Nw_8e8e95a7-9b72-4494-b30a-cd24b6ba6d16"
      unitRef="usd">669000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i10110540b97b4a4ab4a50614d0cff3c9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfMi0zLTEtMS0yMzk5Nw_c3d20a19-c775-45de-91c0-069d08c0089c"
      unitRef="usd">727000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifd9f8f2918f94fd6923a1d4a51027353_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfMy0xLTEtMS0yMzk5Nw_af4a3049-a309-40f5-b8f7-8e0d562ef5f1"
      unitRef="usd">12041000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i728e5d8a85be40679bfe48b2fbce4909_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfMy0zLTEtMS0yMzk5Nw_f1a4e945-c12b-4aae-ac46-1959daf4597a"
      unitRef="usd">14162000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if6179ae9a7f44883ab15f4ae9457eb07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfNC0xLTEtMS0yMzk5Nw_a0a23892-be8d-43fb-a68a-7eb3df09d220"
      unitRef="usd">8251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieb2c55128bc8497c8854c8a78a73cd58_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfNC0zLTEtMS0yMzk5Nw_a2d5750d-66b3-4422-9ab4-023ba0aa8ce8"
      unitRef="usd">9009000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfNi0xLTEtMS0yMzk5Nw_ec7e53c0-ce2f-48dc-8167-f2e3dd1dec0e"
      unitRef="usd">20961000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjg0NWFjZjQ2YWZlYjQ1NjM5MGNlOTMzMDRkMGVlMDE0L3RhYmxlcmFuZ2U6ODQ1YWNmNDZhZmViNDU2MzkwY2U5MzMwNGQwZWUwMTRfNi0zLTEtMS0yMzk5Nw_53a969d9-f428-447d-972d-3fea8ef07bc0"
      unitRef="usd">23898000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RleHRyZWdpb246ZmQ2ZTNmNjhjN2M4NDQ5YWJjMGZlMjk2MDg0NjA1NTZfNjM3_50d91bdf-52c3-4c68-8dec-ebf89da91326">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issued stock-based awards of our common stock as follows (shares in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average grant-date fair value of RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfMi0xLTEtMS0yMzk5Nw_e03e28ff-bcec-41fb-8193-ee908dee8aa2"
      unitRef="shares">22000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfMi0zLTEtMS0yMzk5Nw_82e73f87-26ce-46c5-a8c5-1a665747f676"
      unitRef="shares">121000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfMy0xLTEtMS0yMzk5Nw_50f65467-0594-4b0d-bef1-b01e770ae6b6"
      unitRef="usdPerShare">6.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfMy0zLTEtMS0yMzk5Nw_1d446080-e01f-4302-a830-039e551d0fc6"
      unitRef="usdPerShare">10.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic59b05e471ec4124afe9fde97642790e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfNC0xLTEtMS0yMzk5Nw_53b02a59-7f19-4c5b-bf5e-cd4fd6a5c444"
      unitRef="shares">405000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if023fd27426a491e84900754f5b3156f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfNC0zLTEtMS0yMzk5Nw_c5a3255e-13cb-40ee-94f2-a8d6e6ef40be"
      unitRef="shares">367000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic59b05e471ec4124afe9fde97642790e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfNS0xLTEtMS0yMzk5Nw_33560991-7a4b-4db9-8c77-906281203c7d"
      unitRef="usdPerShare">9.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if023fd27426a491e84900754f5b3156f_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82NC9mcmFnOmZkNmUzZjY4YzdjODQ0OWFiYzBmZTI5NjA4NDYwNTU2L3RhYmxlOjEzZjRlODNhZDIzNjRhZWI5MWM5N2QxYjdkODY0NDNjL3RhYmxlcmFuZ2U6MTNmNGU4M2FkMjM2NGFlYjkxYzk3ZDFiN2Q4NjQ0M2NfNS0zLTEtMS0yMzk5Nw_68ba050c-1f88-49dd-974e-08e6902fd54f"
      unitRef="usdPerShare">20.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82Ny9mcmFnOjNmODc1ZGE2YTdlNjQxODI5NWMwOGE1Y2Q3YjNiMmVlL3RleHRyZWdpb246M2Y4NzVkYTZhN2U2NDE4Mjk1YzA4YTVjZDdiM2IyZWVfOTM5_c421b984-9a54-470f-a05e-26c3f61ef007">Net Loss Per Share&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022 and 2021, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the three months ended March&#160;31, 2022 and 2021, potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82Ny9mcmFnOjNmODc1ZGE2YTdlNjQxODI5NWMwOGE1Y2Q3YjNiMmVlL3RleHRyZWdpb246M2Y4NzVkYTZhN2U2NDE4Mjk1YzA4YTVjZDdiM2IyZWVfOTQy_42d9099f-e1a2-464b-a05c-251db88d0214">During the three months ended March&#160;31, 2022 and 2021, potentially dilutive securities consisted of weighted-average common shares underlying outstanding stock options and RSUs as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82Ny9mcmFnOjNmODc1ZGE2YTdlNjQxODI5NWMwOGE1Y2Q3YjNiMmVlL3RhYmxlOjY5NDhhMWY3ODA4YzQyNGNiNGFjNzhlMDRhZDNlZGRkL3RhYmxlcmFuZ2U6Njk0OGExZjc4MDhjNDI0Y2I0YWM3OGUwNGFkM2VkZGRfMi0xLTEtMS0yMzk5Nw_4619b6c2-75f4-4464-bc20-c1468e98a42b"
      unitRef="shares">22338000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2c6b0470e88b43f587484c709acc8c5a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF82Ny9mcmFnOjNmODc1ZGE2YTdlNjQxODI5NWMwOGE1Y2Q3YjNiMmVlL3RhYmxlOjY5NDhhMWY3ODA4YzQyNGNiNGFjNzhlMDRhZDNlZGRkL3RhYmxlcmFuZ2U6Njk0OGExZjc4MDhjNDI0Y2I0YWM3OGUwNGFkM2VkZGRfMi0zLTEtMS0yMzk5Nw_909c0535-90f0-4eaa-be9d-06fef9d28eb4"
      unitRef="shares">19393000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xMDE4L2ZyYWc6YmYyMGZiYzE4N2RhNDcxYmE0NGU4OGMzZGY2OGI1NmMvdGV4dHJlZ2lvbjpiZjIwZmJjMTg3ZGE0NzFiYTQ0ZTg4YzNkZjY4YjU2Y180OTQ3ODAyMzI3MTU2_85349b16-df5b-4006-915c-f3a80da1b784">Subsequent EventAs discussed in Note 1, on April 25, 2022, we announced our Reorganization and Restructuring Plans, pursuant to which we are prioritizing key research and development efforts and reducing our workforce by approximately 70% from approximately 735 to approximately 225 employees. We will recognize all costs of the Reorganization and Restructuring Plans, including severance and benefits for employees laid off and employee compensation and third-party costs for the wind down of the bempegaldesleukin program, net of BMS&#x2019; reimbursement of our costs, in the restructuring, impairment and other costs of terminated program line in our Condensed Consolidated Statement of Operations. We expect to recognize approximately $30.0 to $35.0&#160;million for severance and related benefits for employees laid off under the Reorganization and Restructuring Plans, primarily in the three months ending June 30, 2022</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="if2be3ac308a24e8ca217c972b757f923_D20220425-20220425"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xMDE4L2ZyYWc6YmYyMGZiYzE4N2RhNDcxYmE0NGU4OGMzZGY2OGI1NmMvdGV4dHJlZ2lvbjpiZjIwZmJjMTg3ZGE0NzFiYTQ0ZTg4YzNkZjY4YjU2Y18xMjA5NDYyNzkxMDAwNQ_f3fbcb68-f46b-4077-80b8-619504be4653"
      unitRef="number">0.70</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <dei:EntityNumberOfEmployees
      contextRef="i111ab39f489a4f079ea9e751923f01c7_I20220424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xMDE4L2ZyYWc6YmYyMGZiYzE4N2RhNDcxYmE0NGU4OGMzZGY2OGI1NmMvdGV4dHJlZ2lvbjpiZjIwZmJjMTg3ZGE0NzFiYTQ0ZTg4YzNkZjY4YjU2Y18xNDI5MzY1MTE2NDQzMA_004c2a59-ac4a-4465-bd0e-a085019f164f"
      unitRef="segment">735</dei:EntityNumberOfEmployees>
    <dei:EntityNumberOfEmployees
      contextRef="ie8720ccc92154ed5bcfc18a705606b0d_I20220425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xMDE4L2ZyYWc6YmYyMGZiYzE4N2RhNDcxYmE0NGU4OGMzZGY2OGI1NmMvdGV4dHJlZ2lvbjpiZjIwZmJjMTg3ZGE0NzFiYTQ0ZTg4YzNkZjY4YjU2Y18xNDI5MzY1MTE2NDQ1MQ_1c8d0a17-2245-4d25-8fbf-95fea013dbb7"
      unitRef="segment">225</dei:EntityNumberOfEmployees>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i3db39c27bf794516854c382d356e95bb_I20220425"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xMDE4L2ZyYWc6YmYyMGZiYzE4N2RhNDcxYmE0NGU4OGMzZGY2OGI1NmMvdGV4dHJlZ2lvbjpiZjIwZmJjMTg3ZGE0NzFiYTQ0ZTg4YzNkZjY4YjU2Y180OTQ3ODAyMzI3MTcz_3ff0710b-fdc9-4780-9c4f-30d62266d76b"
      unitRef="usd">30000000.0</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="idec2e4f024964e8eb19d315571eb57d8_I20220425"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwZGQ0NDVlMzk1NjQ1N2Y5MDhiY2Y5YjVlMTI4ODVkL3NlYzpmMGRkNDQ1ZTM5NTY0NTdmOTA4YmNmOWI1ZTEyODg1ZF8xMDE4L2ZyYWc6YmYyMGZiYzE4N2RhNDcxYmE0NGU4OGMzZGY2OGI1NmMvdGV4dHJlZ2lvbjpiZjIwZmJjMTg3ZGE0NzFiYTQ0ZTg4YzNkZjY4YjU2Y180OTQ3ODAyMzI3MTgw_676592ff-21ea-4bbb-8037-9477d721a89d"
      unitRef="usd">35000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>50
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M+7QK\K"Q=SA18I/OC2V%4B+.#P/.?"[U W!_)80ZG>@?*+97!_\!4$L#!!0
M   (  6CI53^*WGBDP8  *T:   8    >&PO=V]R:W-H965T<R]S:&5E=#(N
M>&ULM5EM;]LV$/XKA%<,&^#$(JG7-@G0)MA6H,6"IMT^,S(="Y5$CZ2<9K]^
M1\F1;/&E&;#E@Z.7X_&Y(^^>.^KB4<BO:LNY1M^:NE67BZW6N]>KE2JWO&'J
M7.QX"V\V0C9,PZU\6*F=Y&S=#VKJ%8FB=-6PJEU<7?3/;N75A>AT7;7\5B+5
M-0V33^]X+1XO%WCQ_.!3];#5YL'JZF+''O@=UU]VMQ+N5J.6==7P5E6B19)O
M+A=O\>MKFI@!O<0?%7]41]?(F'(OQ%=S\WY]N8@,(E[S4AL5#/[M^36O:Z,)
M</QU4+H8YS0#CZ^?M?_2&P_&W#/%KT7]9[76V\M%OD!KOF%=K3^)Q]_XP: >
M8"EJU?^BQX-LM$!EI[1H#H,!05.UPW_V[>"(HP$X]@P@AP'DI0/H80#M#1V0
M]6;=,,VN+J1X1-)(@S9ST?NF'PW65*U9QCLMX6T%X_35M6C7L"A\C>!*B;I:
M,PTW[UC-VI*C.Z-8H3/TY>X&_?3J9_0*52WZO!6=8NU:7:PT8#":5N5AOG?#
M?,0SWT<FSQ'%2T0B0AS#K\/#;W@Y#L>GPU=@^6@^&<TGO3[J,[^3DK<:,:7
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M_17"*+ -4$<BJ1L+QT"="[9 %QO$;?=AL0^,1,=")=$5Z3C]^QW*BFQ)E"]
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M7BLM\QH,#/*TV+[SE[H1>P!,!P"D!I NP!L T!I .P"*!P!>#?"Z@'  X-<
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MP>&@, 'P_4)*_;HP3Q^:!V#3_P%02P,$%     @ !:.E5(<D.<@J!P  RAP
M !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6RE6=]SH[86_E<TGCYT9]9K
M)($%.TEF$J>=VX=M,TW;^ZQ@V>8N(%<2R6;_^AX) C82).E]B;%SCO2=G]\1
MNGB2ZJL^"&'0MZJL]>7B8,SQ\VJE\X.HN/XDCZ*&_^RDJKB!KVJ_TD<E^-8I
M5>6*1-%Z5?&B7EQ=N-_NU-6%;$Q9U.).(=U4%5?/-Z*43Y<+O'CYX?=B?S#V
MA]75Q9'OQ;TP?Q[O%'Q;]:MLBTK4NI U4F)WN;C&GV\ILPI.XJ]"/.F39V1-
M>9#RJ_WRR_9R$5E$HA2YL4MP^'@4&U&6=B7 \7>WZ*+?TRJ>/K^L_K,S'HQY
MX%IL9/G?8FL.EXMT@;9BQYO2_"Z?_B,Z@Q*[7BY+[?ZBITXV6J"\T496G3(@
MJ(JZ_>3?.D><*, Z8072*9"Q0CRA0#L%.E9@$PIQIQ [S[2F.#_<<L.O+I1\
M0LI*PVKVP3G3:8/Y16WC?F\4_+< /7.UD?46HBBV")ZT+(LM-_#EWL 'A-=H
M)'=HP_4!_0PIHM$2_7E_BW[\X0/Z 14U^N,@&\WKK;Y8&4!CUUSEW<XW[<YD
M8F>*OLC:'#3Z"1!L _JW\_J8S*VP C_TSB OSK@ALTM^X>H3HO@C(A$A 42;
MMZOCD$'_>O<S:V@?6NK6HU.AM5';N:CME*P0] K%35'OVV(K3"'TYYE]XGZ?
MV.T33^SS*W2G4NI@"K2::Z=I6]#CU3*+:$8O5H^G?@V(84*R->OESI E/;)D
MU@/7V_]!!;5I;"2TJ5S6>5$*5'>0[:_V.;>N:FP50$Z_UT_K'LUZWD^R7KJ-
ME'SFI7D&/(^B;@1\EJ[H (PY"*1Y*5S9[1K3*-&) XB0@]LMDS//L62-1PX.
MB:4L2\_%;M=>'&B"(TS"86"]X>QMAA>U$4IH@\2WHVTZ"!I_6?"'HG1._K\<
MP3P+64*RD1M\(4PAS49>\*5(@M-HP@MI[X5TU@N; Z_WPB;8CA<*/?(20@_&
M;2$+2GFT60K/JGCDE@E[OSR'C$W]<%(:$S8RUQ?#29:%S<AZ,[(W9K'0@JO\
M@*#]GQG1!3>$._, Q5DRSE5?B) X#:/&T<!ST2SN>R/SKTL[(FQ1+BL+D=O)
M(TA<D0\ARKRB"HG1-)N">D+)>!;JK8 1+B]X.QB!=WDEE2F^3^/%'A#*:#2&
M&Y!*8CJ!E@QHR2S:ZQ-P-I\!>U4TE48_;@N=RP::[X>/KLM:4R04MD+U2Q(9
MQ2$.;@0,CQ#$3V'"UF/+?"E"XV3"LH$_\2L$ZBI6CSA!:P%T8FTY:5US_( '
M(L7S3'J=M_ZR3"6@$3R4P2KJ5CDK?\9(.O:*+Y8Q.A7O@5-Q,@OREQI8RT@5
M;$R=[EF%$S(&Y@LM<8+7$\@&?L7S!/M;'Z120)UKEW5!E#X=8I:.NV=(*HGQ
M!,J!#/$\&_[F*J!-HR"X /VDZW@,SI=:XW0JN -'X7F2ZC/PR)\GT\^G%9*-
M1XE-0(JQ">[! _G@>?8!?*IY2P?W262=80^C+P7M>R+"9* :,D\U780[J!T=
M!F--? 9A)!Y/+0&I)<N2: +GP#-DGF=^?<OD&X3M,\DR36,R3M*0'&-1.M&9
MR< YA+SK:%- 3]+O&-G)P &$SOKHKH$1QS832VWM-NX\$70+]<W-:.R==D)R
M)$LHCB?\,A (F2>0+QP&Y7:6?@-<GQ\(81GSHNC+T8BNITX%9& 2,L\D]R_S
M_6M ?;X8SS8!D00P3B <&(7,,\I9](_*UH=Y_HB.):_;<4;\W11NZ@WB#IRZ
M8A)YZ1 0(RF; C\0#7GEV/52W@#\L=A"B3\\!RLEB#UT5(H(&[?0D%P4)Q,S
M,!F(B*3OJO!=47,XN[^]P@=*(?.4<J=D+L2VVT<?N+(CG]:V=S<UG,A<D.&X
M?LHY+@7"CO,Y!:>>UP)"#$<3(:<#\]!YYMFT!S,8'H^F,^C?'"]I@):2<<F]
M(G1NP<!)](V<=)JTH> '<?M\D]&Q[P-",/PE4[X?.(G.GX-^VNU$;MSK"JE$
ML:^!^?/VS ^D:EM(W5IF^X9[L'GU"#UPHNU1_U2SQ.,A-21$IJ)P\N9PGO5L
M%(HZ5W:,AG.<:)\^V!GA?2;X3!<3QI*Q$0%"C%.634QB=.!#.L^'FRFPB!OT
M(/9%7=NLLLT=2D.&WD+?T !-)L2;)0-B.$NS9&+6H0-+TGF6G+5!V"/U+'J?
M&-<L\T:2@!A.(CP^=MQV<NO)Y<Z-'(B6KF?;_7US/);NPH&7R+XW**5N5,N[
M^0L50/JU%UW0@.=Z/QTHDKYR%CL_,2)E;XF6<K>$B;@]HKF7QONZ^-Y.R'U)
M Y!.Y^0M0#  S/.8UTE]$1PEXW??JY-+GDJHO;LLT\B=U]HKCO[7_D+NVEU#
MC7Z_P9\W[;7:L$Q[R_>%*R@)#8;M8,GH$X-HJ_;BK/UBY-%=)3U(8V3E'@^"
M ZU8 ?C_3DKS\L5NT%]?7OT#4$L#!!0    (  6CI50Q$@8\AQT  .!>   8
M    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULW5SKD]M&<O]74#KG2JKB/B5+
M/K^J5BO)I_@D[6GM<UU2^3 $AN1X 0P\ RQ%__7IUSP @JM=YY(/J<K%6A*8
MZ>EW_[J'WVZMN_$;K?OB4U.W_KM'F[[OOCXY\>5&-\H?VTZW\,W*ND;U\*=;
MG_C.:5712TU]<GYZ^ORD4:9]]/VW]-F5^_Y;._2U:?65*_S0-,KM7NK:;K][
M=/8H?/#1K#<]?G#R_;>=6NMKW?_<73GXZR2N4IE&M][8MG!Z]=VCB[.O7S[#
MY^F!?QB]]=F_"SS)TMH;_.-M]=VC4R1(U[KL<04%_[G5E[JN<2$@XS=9\U'<
M$E_,_QU6?T-GA[,LE=>7MO[%5/WFNT=?/2HJO5)#W7^TV[]J.<^7N%YI:T__
MO]C*LZ>/BG+PO6WD9:"@,2W_5WT2/MSGA7-YX9SHYHV(RE>J5]]_Z^RV</@T
MK(;_H*/2VT"<:5$HU[V#;PV\UW__P:U5:WY7S**V*JY9.H5=%==FW9J5*57;
M%Q=E:8>V-^VZN+*U*8WVWY[T0  N<U+*9B]YL_,#FSTMWMFVW_CB=5OI:OS^
M"1 >J3\/U+\\OW/!=\H=%T_/%L7YZ?GY'>L]C=QX2NL]O0<W%L6E;3V<M4K,
MN7+:Z[;G#X!#;TRKVM*HNKB&#S4H:^^+_[Q8^MZ!NOW7'10]BQ0](XJ>_=_(
MYW]MLV+T[B^Z4 [^5R"_E"LW1V@Y5;$TMMLH,*92#SVL51>E;3K5[HH-.)3?
M!N5Z[> YTQ;7JBW>..2N+RW(0M4&7%!K%!%FVM*ZSCI@.CW]2M=J"UL>AZTK
M?0L.IT,25=&93N-9\1R5&]8%G*)"N0+=_4;U!1!3F]_A^\$5JKJ%76'9SM:[
M1CL@L?UU6,/#1:_+36MKN]X57:UZ=(E^46PWIMS(IAZX!*_VMM"M6M;PRB;2
M@MJ!%+3@JAH+;FFHE8/G>M.;0$BOW!H\\4UKMVW1P'; 4]]X?$V1&SLN/@"-
M@:W$BWSY_*2XCVEOM>_-FL0"[,;3>^1>/0"Q>U_WX-=[UF)@J@4FTV&)XTTS
M\-D_0P+Y63[21MUJ>/"WP:!0?:9!MEU;E T30.\!SU BM!XR4W_JP',S,T$$
MH&V#QG_+>J/ETC+'Q85GO0.W#+()ZTQ7 18,&)O 5&$!M.#:>@\TX_:M1HX
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MHU^<O3A^/NZ,GGUU_%7\Y.%=MFDS-=:O/D]Q4DX:\;Z(9N+M6@]B]"&5HFL
M:0 6SQ3M,+EL-+O$?6Y1$G[05C'< H<@MW-Q"(A'($$\E,OQ!4^)M&A*F$K
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M*Q,MP@4WI5"FU6C@]_G"6$TE\\<S-M+>1NIMI/]7C'\@//32_*YT<RMM>NF
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MS-@AU%@$9A#TVN-[U)J)R(V_#IS)8)*!I^LC^X>HG;1LA<?W5C\I&:IULDQ
M8BE:'1YM]PL>]%PP7V&UCT_H^K-YED#1^F#K Y@\J)7IW^+Y$(<3P'+V T!V
M &31[]Y0]/)>!+%9.=N!X]/$QHLH-:+).67X4CX'1W\5X<+FH]FC"=:]K-)
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M:L7,E!&1YZ)G/\HU(%H(^O:;X<GX.SJH9#ES5JL_ZU+,#@EL3G/E?#CBS%(
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MV9)IBY/)]O%ACG9D_V+#-;L]_TU2G!!,D D>CZD1VL6C$:!X& 'T9@1 #KD
MIA;#H6$6F3(/:U4(EGHA- .3;GD*1K12 UYQF$HI> B+H9T+Y0C\A40A%+%8
MG.1&RQAB29&IV#PDM*CSC<$[.T,4STF5S$#F*!>>Y7D9&8T3MET'Z&5L>(*Z
M@ *74AA;/B*)_NLW]5^\$(Z$!Y%LA8]/!HC48MHQ@B.G>%2*K!!S!Y)H?(PG
MEC)Q2^)?[>V#:_^KK3L L,!5D0XP'?O#!*V$Z"95+2KRI3 +R9G?RAOL?DGA
M"UBY!:G)U%4A[%,E$]/[F'NLI(;4WAM>I.7GNU/JI&B2L5/%#LBZ-L-GC#<2
MD>NZ:/N=0J."^P@$=\FXM,4[::+\3PF'MSV.XM>DKK$#*$GU\VK >=D1H\8V
MQLS"J#]WH":FO*'GZ7^9V#18S:W6=A51&V?0!EJ)%A-F-HW@10=;Y@I+T!&5
MZ0(J^0+ZA8_11;YWO(,1S^R]8H]^C1Z]5X 6UM?T@<U(8EA$VM3P4(SGI<PQ
MG:.A->J&4=V3.P\=H/AD%>?>;FP!,G[20.L>T2O*3KHGV6L\?/O-FVR8?8<Q
MZVM9:=Q]>SRDK)N-W] TG<BEJA#56)^,OY/C0?SWD+VGH'HQW@>C47><G1QB
M^#M^^_91($(<'_CV@8.VB!ZUCKR"@<=O3VC7_;F_]>FCE&X1/_" /3!;A?05
M9+.Z^88T29].'K:G#U!((Z[QGK2<X^B@=W+<26VQ_1%L%3^D8$P.MHR/?+.1
MCC?@_=RB9)L?K&#S9>W\WU!+ P04    "  %HZ543J#^2 $'   F$0  &0
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M*8H+FTNK?%IGEH=5S(^H)?0GK^K1.TO(1(Q]2'S;-(("^GED1\%ZZ/+* B=
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M+J3 C,T'\'VFM6M>6$#[U\C%GU!+ P04    "  %HZ54P9\KCCL+  !F'0
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RM66USTSH6_BN:[LP.S*1I
MDA8H;.E,&BX7& H=NG?YL+,?%%M.=+$E(\E)\^_W.4>RXZ1IN>SRI4ULZ;P_
MYRT7:^N^^:520=Q5I?&OCY8AU*].3GRV5)7T0ULK@S>%=94,^.H6)[YV2N9\
MJ2I/)J/1\Y-*:G-T><'/;MSEA6U"J8VZ<<(W527=YDJ5=OWZ:'S4/OBB%\M
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M/7<XKO:%88*["8CBZLO->Q;LW>S+CMH#(#%5!IZ#R-8]CZ]3AH466_P2K7T
M43<5N_9^O!X0^#@FF!_8D+;)M:36AL<U1ACM4],N.E>$#%2=/+90:[4=&?9F
MJ!\P8I\D^T=S1VRV6U0.HFU0T?%$'P.(H]RU'\![FVLT%< XU=K!%A2\(^>I
M-LB(I'TJ_3R7JW8%DP (+^';(#4BL71NH=C)'7O]X:%?8DYZOWVA."WX%S[/
M:^T0?P;KGG8_(D[C;V?;X_$72-3)!:V)2E7@ZFCXXMF1</%7O?@EV)I_2<-(
M%FS%'Y<*EG9T .\+BWR2OA"#[J?5R_\"4$L#!!0    (  6CI51=*K.4; P
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MU)8;'<EO"P?5")50Z >I8?EOS8;,4R"[2E_HJ7J%$F\CAHDHZ?,3()5"+X"
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MM=$P-2W \Z6')](%,>B^2'GY7U!+ P04    "  %HZ54YV0<S!T#   *!P
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M0F45Z#R3TAP6UD'W_,U_ 5!+ P04    "  %HZ54M(XA*5T#  !5"   &0
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M'(,HW'0.J,?6)DHSYY)2,NU-1^H8#4RRMQ4(,ZM0:;UGLH#P=557TDS!@57
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M57!J;XZ5@MX)>I&:\!Y B.2DA??#9&&SAQZH;H$#F/,A3(S#VRZ!,#F9F<(
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M4JK;\28)1()X&;T)R40,,T"=(EZ@C6H')JW=/9H-\CU1UQNUH\.A/P("8)"
M1S/5HG.>#B?)(9PT[RM?&WTX_Z9"4IVU!#1] GGM.4E.8DZ1-W8 ?'7Q=/X-
MDJ@,T=E7X%R?A%]F204*(ZDE52B$_ B*Q<C$\X5H'L_VXLUM\*C8O\6IJ_V]
M.%U2@C!*)3!IP$**9'K5+2RY4S'P3,$6GR55]B#OG)/0#NT E8I6U'3!&>,
M[N/;(9K)(52'P-\9_Y%((AS-UE@]Q]1)FK4/[.8RDEJVT2TC=IEG?^%!5!&8
M187 $R#M8#9*H,N2$@[$@TS12V)U"&^1!P 7%,K*HN?%\JZIS 2O_R/95YR<
M^W?<AJ<<;A$T9S09O#(!TV(_3JC%2=D7<Y&E(9,D.67L8THRG?B()6%C4,O5
M-CH4<;;4RX(.N?<9B.I*! Y,I.!K)8"W7%I- OVX+K^/T@',B@D;T;CK.B:!
M<N4E5^0P+VTQZJQ7&*O!H7*.TNEH5$&R-:61*HMRBI$<6MEXBCF!1UB)O.HL
M6%1TX6*;A$@AWU&J'1>3"(:ZK@D($;T8 'N/"MM+)I@=)9XYH(NK=[]=OSPY
M_P:D%KA14;D"Q4RHA 4WMCHL]Z2%G-H?]4WMC9-#D\-P2$3A#VYOHO%EELGO
MR13$G"@;0,!%*:U) 5@ ,DXB7\31E'O71:@'\6LDR2H2&NMP($T:<][H\T4"
M%QVP#L#%+(%9F/PS::%@/_UZS/5_$UW_-T?=]=7 ZE\F'G'*]7_I7*A[&B6%
M,TOYH,DB=</LL.\ !M()T >"20;R<2XU%!THB;IRB$1 RQB!QFS,U 3X=-DY
M<J.I]/4E!VK-XZ:V25'4A@:K4O1MJDS+WGMJ_6CU073!V!8LF_LG2/?;>=:*
MA#J$/_?=MS1R8#_?:-]D&Y%85 D+3BK,,4O]_VQ< :J+H"1),:BO_(]8G8"'
M*TGC\I.0!<?0-IA"3WN*.6)XJ0%WU..:V1"8#.UF@K4^@XVF@0/@#;M3)1UG
M$1K1$&<0$(C&'O$9F9?9N#C%[\5MQ 4!-L5J(=K:J3,'5V,EZ@E^-. #$@*P
M\M0P@&1FMZ-;3"W<O/II)]F_:.!G>]VFPZIE]#X'<1]Z7Y-'WGH.II.-@Q"M
M ;5NCVEZ9'\:46W75'7G9$YJ"Y98%D"5">G>'&$]4/[R]BI[?O9\EAVQ. _E
MI4<]]PXN9.J-+6&"#]3MUQ<%$HFF8$+&+RS:*-!!?, 67AJC\#<(_D-B;+Q2
M1/(@<M9+)33-GP+,\R+(6^6*6'!*YJ D]43D,%@'*>>/DVZ:_A%"AG)$UY?O
M)FW682:QQB69$7"N2-@.>Z.OEU+)"55'U6MD&N-,K4A&#_,'7.>)]:"TZ2IJ
MBJ3R 8"( >62]@#I'8YU(O^97GP6T4;,(,0M'R+UT[.GLY ?Y*U=144G9W 5
MX^&'\OXC .IV"T-@[V:"3(=983R!YO[P@\K]2)B!^38WW P036&@53IN.B[\
MK%-(+.&(C(%OM%BDH$!$C+4D0W>X!40,-OI&CL6D_;,"8,>MEAL=WIH-])\*
M%W$'W"1=8*Z:LDX\XABL.C_K;YN<?:;-FYG^'D(8T/!#M?_[ST+](;I,*](H
MB@.#%DJEA>:>#YVDW46*!:^S-8^BFEH%JC+T0B/9\D,6G?,Y#!TH7Y)B9@XA
M#FPAN))R)YP.>XZE3*[S8UR>ZPF3&"!W3"70<SI&N.E MLW91<#X5).B]$IX
M@YNLIV%#WXTRL#7<JK-/^(!8*-74E ?)TNL;03R^(1+,E'5A&/7,W<-6T="!
M)X+_L&OSK=:DH;%O( _]IV+B2DZJ1:B%R^QC&!$;Q1D3U#;?PIL,>[TN2\F$
MPWDK<"XANQO+X%O=X^MQSCMD4SYTQ2KDRH<R<7 ME*:0E9T@>)(U#<XYT)6R
M0T!U;#U+=Y0"T)#1QGHK!-]H+R=;&5M347]9\#+T)K5\HO-P,>'<RZ-T/<;9
M1E!6;G',\0H(Y:)N"5K>I)FI43IU4%X\C-A[[25GM)^P8G1#JB2=-"&C?7C2
M5!_P=YHC29H%7O87%'K .P"Y@/@9 -\;[NZ+&]TG$N&(,SD28G0\R!X'&P,?
M@$[+]T40V4QLEI =/31S@#%J'P<_0@XSG(+]T^04SM6))8*H 6DQ@G5DH@SU
M( :\?Y#(X.J3,A3Z_*7Y1'U]J >DM""YF*3H%A^HA&1CUPZG4IR\B\WIG[*'
M-S?7C]*&!NG9V-@PGV,/](<>9D31J0)_3!O2@9BIA&-RBX+JR_H](&-CW6_?
MYB!3GGOH_=HT3(X C!*$X 9B!)KX^"PKU$X (^4E&Z*Q[)O. -K6!IG!;7MI
MV*024LZW%C!T)L7#!'/2O;#0J.MQ4]^1XTJE:C*!BBFP85<$\*_VAW+"/6$Y
M&<]):(X-8.$F<![$J2!;!P<,+, (*P)(PFJ>"+"R%H(';TLPO&]M?4(]>AS/
M[J(=^RG0<M:GQ@XG9@:>C5@O-RECF-Q3A-R9/A8U]'Y.$C*81RRQ#B8B"N1L
M=V#Q0#(ZZ:*1GO-D4[-CN1P4EW;7<+H[> &F:X.ICD@//ED2Y:.X#B)]3IP,
MX_V^#(5D[OT)V'C,R_=@DR@R>3Q0EM6:2I4;'>JB1K*5H;C2Y['/*(]]UE.9
MUJ7&8IZ&TCZ8FS_ '^+RU?6;_[Z^##<$9MF;Z_=7K]ZG/[S[[?+M+]<_][]<
MOOSG6_CQEU?A)VKF?O7B^NT_W\:??)(X U-J%NQCJ4GZ:P9*_R;A"M%0<K\M
MR)+Q O1T0?UX6'AMN2#+1H<*SY$>K&G[OJ+7R+'*L+$;1@TB)6C$>A&BK"Y:
MGKZ,B^GX1* "F['L6!]247CUJ_-G\Z?#LMCY\_GS^,O]2RSC2EJ,I'T*<7I,
M&C./,:^Z5N"(@(T^0"EJW^_[0?%,40][DXUJUU.?ZU.4R:B+Z&Z!0H#M7.R)
MX8Y 8 ]A.;Z8*9X650FA!"SX-][B;"QC$<&'@\F+V4]X.)]]>R_!5)**Q>#A
M3O9K-FA73?,L831/"'(+  2(#28])C]B6\UD1#7LNAIEB!++#AO84M@U3"*,
MM":N;H:H!Y_QY7'L!:KUTB0;#.-C4AND2$I/L8,0!YJ6];_/8 ?+&98=:QTS
M2SPF*(?32U X17<91SG@478W202%4*8(""3N-RAQ9"$($<@T^OM55X<;BV1L
M!)=R-WK?;SQ]R6-D&*9M_EWA$&9ZL-M3L<  F703,B-[#'\3([2;0)9OL\OV
MLR,Y;R*XN._(":TL@)E12:>2A=N84NCS\[NI2+'O4,=O%. >-A"BA))GPB\1
MY+V ?[:?P%4C?(4U-56F74<-UM5MYZF_1N2J" DR#KQ*S9 3I;;L4@+%IB)$
M(+=(OZF#,< &;$^_!6'O!,@RY2&TBPUGJH_OY+[@TI0![%N7XM<D]HM77T+W
M';7_C,H,/+V 0E$F:BM@K2PUW8I>4M:18E+C\J[",#KG@E(?7V\EAR_,[=N:
MIAC#HHN$$/?'>)G?-JL5HQJJ(O?5@<(>G97(L4_N87;"4.GT+NF'!=V>Z1L5
M>M=:4Z*T[_!6;;X^Z1H>$<[6-\1'.>+; KV?3$2M]XF'S;:D/:7GC?/@1^EQ
MA*@CNRG:CN5W?5"=0D@:N@VP'?"HQTY3&TEV#.\1<,, Q9;#9-JT!+Q/<U?I
M1=W;4%MB?QRZ" <6W![[V,B(Q.JP2Y]V-1214^(FPU+\BK6)S"&5QU)V5K;0
M98*:8D\Z4GK);;P<?U%N4TY&#5A]_T^2K-L()" O%$QT_.[ L5QT\N6C\\]]
M<F2:\*\XXSV9F/[7IAPR.^451[E2!>/.945X!A-+A7S(($8"BIN<!'RDWKXO
MT_&,(9=JNQ:]2B3]+.E=X>\+B% AY>G".HT?]&?=)<L:8N9Q897Z>_IB_+A$
MG996VK5Q1:PD<D[U<,'\]9$% P1U](F)Z=7#G4]2 ?[>#G\I90M1!'8;$)+#
M&QN#2GBHJ/6;W9$QEU+*/2@6DL:<BQ[*1'+H6<+*,3WXVS%O;J,:NT+B;C^Y
M;=O;M7&%Z4"7Q*#"1-YP.&TT3M*0*3X_7GSN53<D=QP*-48QKM/%7FM<"!"3
M9M+<)O=]AJ A):>0GN_R#42)DXE]+Q%%26);O!X7;9(48:U75B#+C.\I2&NH
M> NJZ"=]:NCZI:W+8 \'6M/8H\AW0L5TPX."OI]S,RPAI$EX+[UYZ)L1K. -
M^2 *?--CX&2"%I%WX6)*^-B1KAV(37@Q?N1"ZI)-J>,M@%#D'/2$)50>=7R.
MDW5)%36&08!%7(M(@E%';'/'G'.,_L>?)4I,X&A)%IPCZ\5/9?$2@TJ"S#Y(
M;?42=TB8J)^H5_? O+2C3ZZTC8I2Z07W45>1'"->!1ALJ;4M;+;?6,AC3AX/
M_7M#B6%B:P+Q@FY)NWQ\@ZV#PB^9['J'VR\7WDN6"OBLCCGA(6J>KI4C@I#,
ME=1]!FAC)&61%KPUW6]-?%>\7<#H8:%+E/\0P<.AN;C&IEX2_M3A*7<*DDL]
MK:DD=\R"-!"V^UBIH7':;Y8=]<W\/S12 9U,9B(F(Q<*)>YEVWC%*4M%G[2(
M9F1(=_#P7"A\O7=;MX]=8E_$9% ?LU52,0_>4J:62V&^P\^/&.H6QB^#&K[1
M3QG6^,TQI+CLBHH5>/=MT:^@V7,#F 8QY<]P*@+.).X:TRY43EGL**%K1)Q[
MH>N&%]IW1I=%?UMF?^LVUI)$U@8F2!**-,LL1-O#S8E6SB2W+_,* I/EQU]\
MQ&M6N'B\IA0[GP9D3FA[B"@#2S( *"&;'"F-&3V>0?-9MI).W&)E<X$YI;1.
M]T6;ZHDQM:_/),)3A1HTVL<R*X%57I\[X8;:('YVU5^/2OL0TQT1YJ_0!_]Q
M0&7%,Z6WX0:2$1U M%"4+ALDX*Y"DU6:/$X[.?=63MW&4*?'^;F)W%/L!SUB
M(J@A=;97LF1KR/:>/PHUG#9&K*3)PVOMLAQW_G.,B\^BK.W=*J0)^7"L,P<9
MCS*+P70K'XA1^\<FQN:J,2WW84]N?S_RYEXH_$+" J-[WCQ>IJ4=XQAI_;E+
M"#.LA =I%QL>*K>\![DH(91)=Q1](IUH$9H:$@UAP2.]25/-?5I=C"SBC:1=
M\,!GB)),Y2 QWT7E$0KT^3R,DK?X0KBHJAA8X$5^:G<(F\499/3P<R#(SYBC
M$FP2;367*ED&DP]\?#XB\_OK]3903'B)P\)W:C?8[<6']W+[)5CB <J.MH^\
M6,BBD205.OP1*NS [\F;FBP=?)VSQ9N@E#:\PXG:_G[GW6YVGE_TN9^+HXF:
MZQJY8-UN,LES?"Q0"+^IQ=F"FO/14CL"D7,!37*A L, 5$R2+AHV"Z64K3,M
M)G[QYH%>ZNC)]2=R,?WLA.[V)^KM\3I>84M:+LBS._N![ZEW'NP-<3>H9S]_
MTEMQ-)^8:KQ/[13!D8[$@L0N]!)-,^LT^5IYI=V*OLGNN4F /UP>?\W"=]\O
M^6OG_>O\T?@WRJWP\FFIES#T;/[LZP=<]P]_M+:A;Y\O;-O:BOZ)R2WM\ 5X
MCM\,"G_@ O%K^#_^'U!+ P04    "  %HZ54%DJX< 0$  "E"0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q.2YX;6RU5FUSFS@0_BL[W,U-,T,""#"0LSWC
M..G+3'K-U$WOP\U]D&%M:P+(E83=]-??"ASB7!(W^= /!FG9EV=W'WDUW$IU
MHU>(!KY79:U'SLJ8]:GGZ7R%%=<G<HTU?5E(57%#6[7T]%HA+UJCJO28[P^\
MBHO:&0];V94:#V5C2E'CE0+=5!57MV=8RNW("9P[P6>Q7!DK\,;#-5_B#,WU
M^DK1SNN]%*+"6@M9@\+%R)D$IV>QU6\5O@K<ZKTUV$SF4M[8S8=BY/@6$):8
M&^N!TVN#4RQ+ZXA@?-OY=/J0UG!_?>?];9L[Y3+G&J>R_%L49C5R4@<*7/"F
M-)_E]CWN\FD!YK+4[1.V.UW?@;S11E8[8T)0B;I[\^^[.KS$@.T,6(N["]2B
M/.>&CX=*;D%9;?)F%VVJK36!$[5MRLPH^BK(SHRG7*^ UP5\J#>H#97;:! U
M?.3J!@V?EP@SS!LEC$ -;[Y8B3X:>H9B6P]>OHMSUL5AS\0)X:.LS4K#15U@
M\=#>(\P]<'8'_(P==$@ 3R ,7& ^8P?\A7TAPM9?^(R_MUPH^,K+!N%<Z+R4
MNE&4\3^3N3:*N//O@1A1'R-J8T3/Q)C1D2H:*JE<P*L*[Y)67C:%J)>=X<6W
M1FQX:8V>ZL5!&/:<G^HUSW'DT$'6J#;HW!-!/,13W>/1>WA$CR>WAGB/QP6N
M$+B&A2SIR!-IR(M9R4:3=WUT"A?:"#I.6,!>S;FQF>>KOJ5PCCE6<U1WDN"^
M9/\/";_#('&S+*0%BUT6I#!;266.#:KJ04)QEKE^R"#Q4S<)$[B4]?*Q5IBX
MX2"$0>2F+(4OTO"RB_G2^A".Q(_<,$WM*J-8:0@'"!3W!(I?3* K2I!*+.2K
MV?048P[&?9HQGQH%ZWT0KRM1QR!\S(\]5KP7J"PK;N$2-UC^G"*3B@")'\2M
MJ=0&WBFI-5S7-*[*5OJ.QI1^++ZD/2'9B[RWG$I%:1)AH9:&M&R&<TE8@5%W
M@VS@#B++O(A^;P*7)?Y1*X_=,$DL(Y/4#2Q]>S^YK"I4N2!:K?F:\#.(PLQE
MJ0]__):R@/UI'45)=D3RQ$W] ")R,F 9?)J78LGM0-.VY-<GLQ-8R@VJVI8;
M:([6N:TN>733?7_6EYLF <3TC&&RX:*T+3FFP7ZLZ1P]Z!H=J,BGP'U>S$WB
MU.8U"%/7CS++ZP$C2+']8\?;79-AT=C"$-[0C5D(+'2S00I3I*XL1,YM_0AV
M@6NIA2&4 47)(OO*(K^C\5_>!(+ S:C!5,W8_Z4'T-L;G=2397M!T-2AIC;=
M%.VE_1UDTHW>>_7N D/D7%IVE;@@4_\DH3.ENDM!MS%RW0[BN30TUMOEBNY1
MJ*P"?5](XM=N8P/T-[/Q?U!+ P04    "  %HZ54;W,F>6P"   <!0  &0
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M?*'Q 71>:.UVAD\P/(C+OU!+ P04    "  %HZ54" M5-S #  #H!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R-55UOVC 4_2M7V32U$FN(@=(R
M0 *ZJIO6J6J[[6':@TENB#7'SFP'VG^_:P=2*K5L#Q!_W(]SSK6OQQMM?ML"
MT<%#*96=1(5SU2B.;5I@R>V)KE#13JY-R1U-S2JVE4&>!:=2QJS;/8U++E0T
M'8>U&S,=Z]I)H?#&@*W+DIO'.4J]F41)M%NX%:O"^85X.J[X"N_0?:MN#,WB
M-DHF2E16: 4&\TDT2T;SOK</!M\%;NS>&#R3I=:__>13-HFZ'A!*3)V/P.FS
MQ@5*Z0,1C#_;F%&;TCONCW?1+P-WXK+D%A=:_A"9*R;16009YKR6[E9OKG#+
M9^#CI5K:\ ^;K6TW@K2V3I=;9T)0"M5\^<-6A_]Q8%L'%G WB0+*"^[X=&ST
M!HRWIFA^$*@&;P(GE"_*G3.T*\C/31?Z_06NJ385*>U@MC*(8;01KH"[R\]P
M4W!BGV+M1,JE!:XRV'>Y0"/6W&L+7P1?"BG<(QS=\Z5$>SR.'8'TJ>)T"VC>
M &*O .K!M5:NL/!199@]]X^)7,N0[1C.V<& U]R<0"_I .LR=B!>KU6L%^+U
M7HFWQ_>3LL[47H5&EBO,5D*M8.:/FG "+5P(FTIM:X/P<[8D<SJ&OPZ@Z+<H
M^@%%_Q44=W0[LUHBZ/RE"OC4W,$E%P:^<UGC2X4XF,%W@Y&MJ/"3B*Z[1;/&
M:'I?(.1:TE7V/)TO,H1=+X&CS;3@:D7)A0K3;.^@9$\P97M0J*T$0U?0P8.R
M*3WZT@,5+BW:R@6!:9",X/Z0[1-EN!)H_/HC?/$PFC ^1&.T#D;<-A*F6"[1
M[-(E(=TE+DU-K0H2MET]$BK%RO>3XP[U)%MAZ"KR$7KP%MBP,V2G-'CWYHPE
M[ -\U>I]RFWA33% ]&'W1<$':J\6H=\Y'R3 .JQ_!HO&(T51D:JYT66XB,-!
M-_P60>*=POD3%>+Q3[V/>KU.GPV/(>D,SL^?">&\ECY(18XZ"XQV1-X2P,'Y
M$%XZN?%>]RG1K$*/M9#J6KFF$;6K;1N?-=WKR;QY ZB,=($L2,S)M7LR'$1@
MFK[:3)RN0B];:D>=,0P+>HK0> /:S[5VNXE/T#YNT[]02P,$%     @ !:.E
M5 @WI,:R!0  -PT  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULG5=M
M;^(X$/XK(^YT BE;\E)>^BH!;;?H:(LHNZ?=TWTPR4"B)G;.=DK97W]C)P2Z
MU[*K_0+.9#SS>%Z><<[70CZI&%'#2Y9R==&(M<Y/VVT5QI@Q=21RY/1F*63&
M-#W*55OE$EED-V5IVW?=;CMC"6]<GEO95%Z>BT*G"<>I!%5D&9.;(:9B?='P
M&EO!+%G%V@C:E^<Y6^$CZD_Y5-)3N[82)1ERE0@.$I<7C8%W.NP8?:OP.<&U
MVEN#.<E"B"?S,(XN&JX!A"F&VEA@]/>,(TQ38XA@_%O9;-0NS<;]]=;ZC3T[
MG67!%(Y$^E<2Z?BBT6] A$M6I'HFUK=8G<<"#$6J["^L2]TN*8>%TB*K-A."
M+.'E/WNIXK"WH>^^L\&O-O@6=^G(HKQBFEV>2[$&:;3)FEG8H]K=!"[A)BF/
M6M+;A/;IRTG"%DF:Z 05S#!E&B/0 AY92@*QA)M"%Q)A)C8LM4K-.5O0N]9Y
M6Y-[8Z0=5JZ&I2O_'5<!W FN8P77/,+H]?XVP:ZQ^UOL0_^@P3LFCR#P'/!=
MWS]@+ZAC$5A[P3OV'G2,$O8C<I6H,!7*1.#OP4)I247TSP%/Q[6G8^OI^!U/
MC]1;49&BB?"TD&%,=06,1S;N,%A)1"I\_5:,#QL><PJ&YUM;%!77@36"$JE-
MZFPZAIN$,QXBS"75%C1)U++*Y*T\<L8X-6,$BPW<(N4\#EF=_PW<V;<&FP.3
MR0B:5'^VP9XQW3AP.YJU'.I5E>]DHI @36\H@T%BB/0"9%U0!56#M%II$E*W
MEX$@&,62HEW(A*^ ;2.BJ#UT#"%*380#><RH,T,L=!*R%'(F-4>I@*F*99)O
MYBB&>BH_E.(R0@?";D6EHN\>4GQ]U%.XDL7*A*A"3NY&HN :I0&VJ1 <<DPM
MC/!HTC6X^G+_\'DPOX8_?O-ZQV=6NQ2.MZ+F0AHI9QD"T?/_]U"$K@M)!-Z"
M.7O"B,'T=<!&(LL9WU#-9XGI_)_(^!4E,%O0.;RN4P;HCGS>S\=_UK X2\4+
MKHC+M.$*K<H2([UKTOOX'OSO[>RA'YC6^XH<0P:#X:_!G%T/Q_=?[K?6[\6S
MH!\9)>H)QCP\<EZ+!NU'B_H[X<=?<SX:WWT=#^J3F_H5:?*MR-@"<A.J%GP:
M#:OTO-&H-[B0!0U-\(^=LG[OQK/1]6QG<D3<FO!"%,2O<J-C"IQ(D$1$ZR'F
MVM2'*51&JQ;<',&M6"ZIR_B'"3D41$@PT='/N#[ ?YV:_SH_QW\/RYIO-_7\
MF9?SQ[R<"FV8B4KU^T'T%C<>=CJ/39VEQ 6&4FQI@HK%6ME>M]<#@\(0#$7-
MR-(:&@M#T\F&KY&%,3!)M5NF')I6FP)/Y:):IS!%F8@(EE)D5,,F]N;Z0=Q'
M\XJV;@?6CVGH1_1#@=(4F6T59H)3OK\QZRZ7(D2,%/P.'B7.=5VSZKC5RN^5
MLGO!/X1,Q14?;XC0GI$7"$V_?^)T.YT6-+N>$W1ZM @ZGD.86[M=B2$WI"+!
ME]Q2M^]WG8[;!;_C^"?FSW/Z+IV2;4KVKJ90T[- 6E2]?=_SSW:"B5!T[S#W
MO6>6%N59*.B[3,C=)<6D2+%RBB[+\MB-E:;7 C]P.A3HK9/J<7_ OV%-O6G.
MVO#.:$Y&IGH6++4M0F$,>@%X7N"<!"?@]?M.0%F=H%*GQ/<L$U+;&43\Q14K
M;Z*A4%KMCNX[/;??JO]_!9X#E'I*:P6',NUYCA]X9M7O.%WWV,;#!I<FL%AQ
M"\J6*-V[=5K6TZZR[*2F>P--:N(E"[5WIH JD<8]%;[-I)G9.3,-2@!HY-HI
M;<'2Y8&V.3;7IFX+4J"#/X1:6%H,; MX1V]127OO,INA7-DK.[DV_5?>:VMI
M_54P*"_#._7RDX(:;I5P!2DN::M[U"."D.4UO7S0(K=7XX70=-&VRYB^;% :
M!7J_%,0_U8-Q4'\K7?X'4$L#!!0    (  6CI5209RQD30,  ,8'   9
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;)U52V_;.!#^*P,AAP9PK)>?@6W
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MJ5%[;0/,P%8):FT#'PC"EJHQ3.;F\AKN2XT(55L+Z&H!B,FL[*ATGYCL&.M
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MV@G0_58I^[IQ!KJG>_$#4$L#!!0    (  6CI51!+5\UHP(  ,(%   9
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M90>6O &6PI56KK9PJ0HL_LZ/B=C +GEFMTSV EXQ<PSI^ B249+LP4L'M6G
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M4-7E6W6,7+C[:R(-WH:NF>/_"I0MP.\S*<VZ8Z_$Y@\X^ M02P,$%     @
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M&FPGW&>!'1\HNP'79U*:S< :\#WD\"=02P,$%     @ !:.E5)&<J??1!
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M>\&<KX70AX4U4'ZFC/\!4$L#!!0    (  6CI514;8SB*@8  .\B   9
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;,U:6V_;-A3^*X2Q82FPVA))WPHG
M0"Y-&Z!IC63='H8]T!)M$Y%$E:2<!-B/'RDIHES+E'(9X#S$DLSO\)#GG.\C
M*<_NN;B3:TH5>(BC1![WUDJE'P8#&:QI3&2?IS31WRRYB(G2MV(UD*F@),Q!
M<32 GC<:Q(0EO9-9_FPN3F8\4Q%+Z%P F<4Q$8]G-.+WQSV_]_3@AJW6RCP8
MG,Q2LJ*W5'U/YT+?#2HK(8MI(AE/@*#+X]ZI_^$*3PT@;_$GH_>R=@W,4!:<
MWYF;J_"XYQF/:$0#94P0_;&AYS2*C"7MQX_2:*_JTP#KUT_6+_/!Z\$LB*3G
M//J+A6I]W)OT0$B7)(O4#;__3,L!#8V]@$<R_P_NR[9>#P295#PNP=J#F"7%
M)WDH)Z(&\/$> "P!L"L E0#T,V"X!X!+ .[:P[ $#+L"1B5@U!4P+@'CKH!)
M"9AT!4Q+0)Y?@R)^>? OB"(G,\'O@3"MM35SD6=0CM8Q9XE)]ELE]+=,X]3)
M%Q;HS*6 )"'0"1.1!1<D3\/3E:!4I[62X#TX#4-FGI((7"5%B9DV1Q=4$1;)
M=[K)]]L+</3+N]E :;>,\4%0NG!6N #WN'!)%WW@H]\!]/Q) _S<#3_-5GT
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M1*R($EG32Q-6I.&G=:E3:>Q\L$L%7[M6_S#L[7ET&-.AG>,.=2NAW4:ACZ"
MR2@A>"+@ ;O&FV-I*M50@UY%W?NT/OG>[H3U/MBIDK!N@T^]UOX'=2RLY8?T
MN%]^[4KP&P5_ PX2)1O#6(R73JJT9.:Z;:H'W='3S^O:[J#V@X]V+3@XX+JT
M?6#:853/\WI[GKFU&ST'N;"-CD()*ZZ+RZ]:K9JI&]M"[*V/3)-E.X4=3=&A
MX=6V2+DB&<R1TKOJX'LDBZ:GF&BQM'W#3&CL0NPPP481I G YW,A]'9B-JA:
MS^$_4$L#!!0    (  6CI534J*E?_ (  *X(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;,U638_:,!#]*U;4 RLM)"1\K@ )V%9=J:LB*-U#U8-)
M!F)M$J>V@>7?=^R$-"4![:&'<B"V,_/FO?'8D]&1BU<9 BCR%D>)'%NA4NF#
M;4L_A)C*%D\AP3=;+F*J<"IVMDP%T, XQ9'M.D[/CBE+K,G(K"W$9,3W*F()
M+ 21^SBFXC2#B!_'5MLZ+RS9+E1ZP9Z,4KJ#%:AUNA XLPN4@,602,83(F [
MMJ;MA_E0VQN#[PR.LC0F6LF&\U<]>0K&EJ,)002^T@@4'P>80Q1I(*3Q*\>T
MBI#:L3P^HW\RVE'+ADJ8\^B%!2H<6P.+!+"E^T@M^?$SY'JZ&L_GD33_Y)C;
M.A;Q]U+Q.'=&!C%+LB=]R_-0<D"<>@<W=W O'3I7'+S<P3-",V9&UB-5=#(2
M_$B$MD8T/3"Y,=ZHAB5Z%U=*X%N&?FJR4MQ_;<XP$0&9\QB+0U*3WR:9Z@PS
M=2*-1U"417>X]H'81(94@#P_6$*^A7PO:1+(D:V0D@:V_3S\+ OO7@GOD6>>
MJ%"2CTD P=_^-DHI]+AG/3/W)N S%2WBM>^)Z[AN#9_Y^]W;-^AX17H]@^==
M2Z].4G-33>]4")KL ,^#(IL3*=LMZ,DL3X]4!.3'%X0D3PIB^?,&H4Y!J&,(
M=:X0^IKJ\)+L,+S"8 W<OVPG[^IV+P/K&C!](1PF.JN'<D*K)FV=ND,-R6Y!
MLGN3Y(LY?,B.'D#@79*Q;094 =E2)LB!1GL@?$MXC9R 1Q$5DJ0@,FFURC(&
M@Q+M7JO7OM!6-6H[K8%;KZY7J.O=5+<$J03S-5US^L@Z84J2QG*UOKNQP_T"
MOO]_E-R@(#2XK7>U?G>]#2K%U'&Z%YM2M?%Z_?HM&184A_^@X.YUQ574O*_<
MAI5*&K:\H5/Z7=9>U<-U6CWO0JA=NOIC$#O3$27Q^3Y1V:U9K!9-=VIZS<7Z
M#)MQUCO_P&2='._$'<,S%L$6(9U6'U,OLNZ8311/38/9<(7MR@Q#_*  H0WP
M_99S=9[H ,4GRN0W4$L#!!0    (  6CI503^_P60 (  ",%   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;(U46V^;,!3^*Q9/K;2%!)+U(H*4I)TV
M:9VB9I>':0\.G(!58S/;A/;?[]@FC'5)M!?L<SC?=^Y.6JF>= E@R'/%A9X'
MI3'U;1CJK(2*ZI&L0>"?G505-2BJ(M2U IH[4,7#:#Q^%U:4B2!-G&ZMTD0V
MAC,!:T5T4U54O2R!RW8>3(*#XI$5I;&*,$UJ6L &S-=ZK5 *>Y:<52 TDX(H
MV,V#Q>1V-;7VSN ;@U8/[L1FLI7RR0H?\WDPM@$!A\Q8!HK''E; N27",'YU
MG$'OT@*']P/[>Y<[YK*E&E:2?V>Y*>?!=4!RV-&&FT?9?H NGYGERR37[DM:
M;SN["DC6:".K#HP15$SXDSYW=1@ D.<X(.H T6O ] 0@[@"Q2]1'YM*ZHX:F
MB9(M4=8:V>S%U<:A,1LF;!<W1N%?ACB3?L9!^22U)FM09%-2!>3B#@QE_)*\
M)=HJ].%@@GPI9:.IR'42&O1N.<*L\[3TGJ(3GF+R((4I-;D7.>1_XT.,N@\]
M.H2^C,X2/E U(O'D#8G&470DGM7_PR=GPHG[2L:.+S[!=T^58*(85O+'8JN-
MPDG]>89_VO-/'?_T!/]:&A"&4<Y?2,YX8\>?:,@:Q0S#[EQ@>WRC+H\UQY//
M'+E=[7T:17%\G83[8<G^M9K<Q#=Q;^4C#P?S5H$JW!IJDLE&&-^_7MMO^L(-
M^"O]$E\ O[!_:/SS@=TIF-"$PPXIQZ,KC$GYE?2"D;6;ZJTTN"/N6N(K!LH:
MX/^=Q'IU@G70OXOI;U!+ P04    "  %HZ54[*W]WYP"  "6!P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S.2YX;6RU5=M.VT 0_961U4H@0>PXY )*(D&@
M*E*I$!'EH>K#QIDD*_9B=M=)J/KQG;6-"9"X/)07>R]SCL^<6<_V5]K<VP6B
M@[44R@Z"A7/I21C:9(&2V89.4='.3!O)'$W-/+2I03;-05*$<11U0LFX"H;]
M?.W:#/LZ<X(KO#9@,RF9>3Q#H5>#H!D\+=SP^<+YA7#83]D<Q^ANTVM#L[!B
MF7*)RG*MP.!L$)PV3T;-R /RB!\<5W9C##Z5B=;W?G(Y'0215X0"$^<I&+V6
M.$(A/!/I>"A)@^J;'K@Y?F+_DB=/R4R8Q9$6=WSJ%H.@%\ 49RP3[D:OOF*9
M4-OS)5K8_ FK,C8*(,FLT[($DP+)5?%FZ]*(#4#<VP&(2T#\&M#< 6B5@%:>
M:*$L3^N<.3;L&[T"XZ.)S0]R;W(T9<.5+^/8&=KEA'/#<3:Q^)"A<G"Q],^]
M<W2,"[L/A_!F\Q N9"KT(R*,<8F&J03A$W %5UP(*HOMAXY4>>XP*16<%0KB
M'0I.4]. N'T <13'M^-SV/NT;W%.1\5M(1N]A^RH(-O*$I)!E4MQY5*<T[;>
MZ]+/;Q0!EPZE_57#WZKX6SG_T0[^.SKJ]$N2F0X-59GY(WX *=*2<O0[;;.U
MGK(;-:+H<XVVHTK;42W1]TQ.T("> 9:UM_ '=E?HK*!KYW2^BRR'<=SNA\O-
M*KZ-Z;:>8U[H;%<ZV[4ZK[CB,I,U&7<JILZ'5+M;\7=KE5ZL4VIB.(5$6P=.
MPP2I(R9ZKOAOG&ZSM.#K;-C5BK:[U:LT].K=8NM_N'5<,1U_B%O-Z+E%1?_9
MKY+PA6&OCU>XT33]C77%S)PK"P)G!(H:73INIK@$BHG3:=Y')]I15\Z'"[HX
MT?@ VI]I[9XFOC575_'P+U!+ P04    "  %HZ54N!(#"!L#   P$@  #0
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M;V]K+GAM;,6976_:,!1 _XJ5I^V!A23 VJI4:LL^*K$6-5-?)Y/<@(5C,]O
MVE\_.RF:L[97>_'R1&(;<W)Q[O%-S@]2;992;LBOF@L]C=;&;,_B6!=KJ*G^
M(+<@;$\E54V-/56K6&\5T%*O 4S-XW0XG,0U92*Z.#_.M5"Q?R(-%(9)81M=
MPP.#@_[3[T[)GFFV9)R9QVG4''.(2,T$J]D3E--H&!&]EH>O4K$G*0SE>:$D
MY],H:3L>0!E6O&C.'>1WNM1-BZ'+>VI!IM%D:">LF-*F&=',3RWC'NS@]FQG
MY&?&#:@9-?!%R=V6B96;QEY%[%U&$X?C9QO$,_4O8915Q0J8R6)7@S!M'!5P
M!RCTFFUU1 2M81I=RSTHLJ K<!=E?^6F;"_06#(O7.J,V0YU4S:,(7E$"4)#
M2>R1EIR5EJ,D5Y1340#Q(%,$,NT1\D?J068(9-8+9.YP[%<]R!$".>H1LA/)
M,0(Y[A,R\R G".2D3\B1!_D1@?P8%O).K:A@3TT'H<+B[>J:JD<B*Y*SE0=Y
M@D">!(XDU>L&[D;L01LW6A,FR#>J-F"H!WF*0)Z&A71LPDCUZ*?M(9:WAZ'7
MWV &>^!RZP:2RY4":(X.S*Q)[F.B>@GLESFCS5: @2;W;H"]1XPD.>6V058^
M)B:8)+AAZIH]+SVW%.T];>P6 41AP7U(3#!)8,/,[3";<9X!.:=+J=I;N_GW
M?4Q,,4E@Q^1&%IO!%6US8VUGTLT@GP^S2Q)8+[=VWKG4FBSL3BQ?4]6)'*:4
M)+!3\MU2P\^=NXL_N73C<V$62?K42&?7D& >2?H421<3,TGROU1"WMD"Q>;!
M]_XN&W-*VJ=3.@%,,:>D?3JEBXD6+8&=\E8>?/[;?4S,*FE@J[Q,AZ^N2\PH
M:6"CX/G'+PA23"QIZ+H%S3\=3,PR:>C*!<7T*Y<4DTX:6#HXYMC'Q*23!I:.
ME\UGMEIAO'O;8*)) XL&3^?^>LPPZV2]6L=?CQEFG:Q7ZW2BB5DG"VP='+,3
M3?1A6?"G94C!108^)F:>++!YT)*K^^01,T\6V#QO;C4&Q'7YF)AYLM#US=N8
MEX5A/B9FGBRP>5[;$;6YW4_M&6:=++!U_JX47Y5/ALDG:^03']]XE% Q >6M
MG5W;]H+R8J&(^VB?S8S&KF:J=IQ?V[8[,9>T/+Y .;[\N?@-4$L#!!0    (
M  6CI51 N\,MAP$  +P7   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'/-V,MNPC 0A>%707D G)GA6@&K;MA6O$ $YB)R4^RJ\/:-8 $'==$-\EE%
MMI7)O_H4>?'ERR*>FCH<3VT87*JR#LOL&&/[X5S8'GU5A&'3^KH_V3==5<1^
MV1U<6VS/Q<$[S?.)ZYYG9*O%\\S!YMKZ_TQL]OO3UG\VV^_*U_&/P>ZGZ<[A
MZ'W,!INB._BXS-RE?&P'=WO(L)^<#=:[9=:M=Y*YU$$*09H^R"#(T@>-(&B4
M/F@,0>/T01,(FJ0/FD+0-'W0#()FZ8/F$#1/'R0YRI@3)+U@3:"U(-="X+4@
MV$(@MB#90F"V(-I"H+8@VT+@MB#<0B"W(-U"8+<@WD*@MZ+>2J"WHMY*H+>^
M_&P3Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+H;:BW$>AM
MJ+<1Z&VHMQ'H;2^7)01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;>_4
M.\1KZ<.CY[[&V\AW4AW[=_WC\[?E?1-Q'MUP=G!9O_H%4$L#!!0    (  6C
MI53_>6J2GP$  !T8   3    6T-O;G1E;G1?5'EP97-=+GAM;,V9S6Z#,!"$
M7P5QC8)CNTU_E.32]MKFT!=P80DH@"W;29.WKR$_4JL4)4JES@4+O#LS>*7O
M )/WK2$7;>JJ<=.X\-X\,N;2@FKE$FVH"3NYMK7RX=8NF%'I4BV(B=%HS%+=
M>&K\T+<:\6SR3+E:53YZV83'KM3--+94N3AZVA6V7M-8&5.5J?)AGZV;[(?+
M<.^0A,ZNQA6E<8-0$+.3#NW.[P;[OK<U65MF%,V5]:^J#E5L4S'GMQ6YI%_B
M1$:=YV5*F4Y7=6A)G+&D,E<0^;I*=J*#?F<?3IAV5WZU?R?39Q@JYU8;%R9F
MZ7*[PTC:[J$)0F1]V?^*1\<@??7[43OMC+(SO</Q?FJ[[.;A6+=<?\;?9WS4
MOS"' ,DA07+<@.2X!<DQ!LEQ!Y+C'B3' T@./D()@D)4CH)4CL)4C@)5CD)5
MCH)5CL)5C@)6CD)6@4)6@4)6@4)6@4)6@4)6@4)6@4)6@4)6@4)6@4)6B4)6
MB4)6B4)6B4)6B4)6B4)6B4)6B4)6B4)6^9]D_=!Z^=<?K-LUJ579'/Q9]U=@
M]@502P$"% ,4    "  %HZ54!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  6CI53XE $P[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   (  6CI5297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ !:.E5#1RLF9 !0  :A4  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   (  6CI53^*WGBDP8  *T:   8              " @8,-  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  %HZ54#7M2'M$"   <"0
M&               @(%,%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ !:.E5/.-3)B[!0  CQ8  !@              ("!4Q<  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (  6CI51M:*,T^P(
M &0(   8              " @40=  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    "  %HZ546WZ-.*T$   ,$P  &               @(%U
M(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ !:.E5(<D
M.<@J!P  RAP  !@              ("!6"4  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    (  6CI50Q$@8\AQT  .!>   8
M  " @;@L  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  %
MHZ54C4CK&=\$  !<"P  &               @(%U2@  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ !:.E5 '[S6&; P  !@@  !D
M         ("!BD\  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    "  %HZ543.F5:EX'  !E$P  &0              @(%<4P  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (  6CI51.H/Y( 0<  "81
M   9              " @?%:  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ !:.E5,&?*XX["P  9AT  !D              ("!*6(
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  %HZ5472JS
ME&P,  "=(@  &0              @(&;;0  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    (  6CI53G9!S,'0,   H'   9
M  " @3YZ  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M!:.E5+2.(2E= P  50@  !D              ("!DGT  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    "  %HZ54? *)F(,#  #:!P  &0
M            @($F@0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    (  6CI52&BAA?"!T  !E?   9              " @>"$  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ !:.E5!9*N' $!
MI0D  !D              ("!'Z(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    "  %HZ54;W,F>6P"   <!0  &0              @(%:
MI@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (  6CI50(
M"U4W, ,  .@&   9              " @?VH  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ !:.E5 @WI,:R!0  -PT  !D
M     ("!9*P  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  6CI53?;('X% ,  $\*   9              "
M@9"_  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ !:.E
M5)&<J??1!   $18  !D              ("!V\(  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    "  %HZ54W<'>P&,"   J!@  &0
M        @('CQP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   (  6CI52K__I+B@(  *P&   9              " @7W*  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ !:.E5%$=%>B6 P  <PH
M !D              ("!/LT  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    "  %HZ54O@7AACD"  #D!0  &0              @($+T0
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (  6CI50Q0T5A
M_ 0  !L8   9              " @7O3  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ !:.E5,X.+JCD @  L@@  !D
M ("!KM@  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  %
MHZ545&V,XBH&  #O(@  &0              @(')VP  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (  6CI50<C<)G!P,  (8*   9
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M;',O+G)E;'-02P$"% ,4    "  %HZ54KXYP@G0#  " &@  #P
M    @ $4\@  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ !:.E5$"[PRV'
M 0  O!<  !H              ( !M?4  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ !:.E5/]Y:I*? 0  '1@  !,
M ( !=/<  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "\ +P# #   1/D
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>102</ContextCount>
  <ElementCount>198</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>42</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Cash and Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</Role>
      <ShortName>Cash and Investments in Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Liabilities Related to Sales of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties</Role>
      <ShortName>Liabilities Related to Sales of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131110 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables</Role>
      <ShortName>Cash and Investments in Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/Inventory</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Liabilities Related to Sales of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables</Role>
      <ShortName>Liabilities Related to Sales of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/NetLossPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/InventoryTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Liabilities Related to Sales of Future Royalties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails</Role>
      <ShortName>Liabilities Related to Sales of Future Royalties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Liabilities Related to Sales of Future Royalties - Activity Within the Liability Account (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails</Role>
      <ShortName>Liabilities Related to Sales of Future Royalties - Activity Within the Liability Account (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Stock-Based Compensation - Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/NetLossPerShareTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nktr-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/SubsequentEvent</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nktr-20220331.htm">nktr-20220331.htm</File>
    <File>nktr-20220331.xsd</File>
    <File>nktr-20220331_cal.xml</File>
    <File>nktr-20220331_def.xml</File>
    <File>nktr-20220331_lab.xml</File>
    <File>nktr-20220331_pre.xml</File>
    <File>nktr2022-03x31xexx311.htm</File>
    <File>nktr2022-03x31xexx312.htm</File>
    <File>nktr2022-03x31xexx321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="322">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nktr-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 18,
   "contextCount": 102,
   "dts": {
    "calculationLink": {
     "local": [
      "nktr-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nktr-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nktr-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktr-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktr-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nktr-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 333,
   "entityCount": 1,
   "hidden": {
    "http://www.nektar.com/20220331": 2,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 7
   },
   "keyCustom": 36,
   "keyStandard": 162,
   "memberCustom": 18,
   "memberStandard": 23,
   "nsprefix": "nktr",
   "nsuri": "http://www.nektar.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.nektar.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Inventory",
     "role": "http://www.nektar.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DevelopmentDerivativeLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DevelopmentDerivativeLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Liabilities Related to Sales of Future Royalties",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties",
     "shortName": "Liabilities Related to Sales of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.nektar.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - License and Collaboration Agreements",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124108 - Disclosure - Stock-Based Compensation",
     "role": "http://www.nektar.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Net Loss Per Share",
     "role": "http://www.nektar.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131110 - Disclosure - Subsequent Event",
     "role": "http://www.nektar.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables",
     "shortName": "Cash and Investments in Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Inventory (Tables)",
     "role": "http://www.nektar.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ScheduleOfPurchaseAndSaleAgreementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Liabilities Related to Sales of Future Royalties (Tables)",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables",
     "shortName": "Liabilities Related to Sales of Future Royalties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ScheduleOfPurchaseAndSaleAgreementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.nektar.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.nektar.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
     "shortName": "Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DebtInvestmentMaximumMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DebtInvestmentMaximumMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i0360dfe057384ef3ba43ab8dd1071974_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
     "shortName": "Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Inventory (Details)",
     "role": "http://www.nektar.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ib32a3a93199343bfb4bfa43354beb247_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Fair Value of Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ib32a3a93199343bfb4bfa43354beb247_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ia68e0b50ca474c9fb590f027a73cf228_I20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "nktr:RoyaltiesLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Liabilities Related to Sales of Future Royalties - Additional Information (Details)",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails",
     "shortName": "Liabilities Related to Sales of Future Royalties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ia68e0b50ca474c9fb590f027a73cf228_I20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "nktr:RoyaltiesLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:RoyaltyMonetizationProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Liabilities Related to Sales of Future Royalties - Activity Within the Liability Account (Details)",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
     "shortName": "Liabilities Related to Sales of Future Royalties - Activity Within the Liability Account (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ibe35cc2297684d9ba873339293f3ce35_D20120101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:RoyaltyMonetizationProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i0ab30e6ae04746708e8844aad00bca73_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i0ab30e6ae04746708e8844aad00bca73_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i50cc006393ad4e1888a5e96af4811b81_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - License and Collaboration Agreements - Additional Information (Details)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "License and Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic31ce00edf3c4891b98bdd4f17ff4e56_I20180430",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i1e034360701446c8a364586fa2b0d27b_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Stock-Based Compensation - Activity (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationActivityDetail",
     "shortName": "Stock-Based Compensation - Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Net Loss Per Share (Detail)",
     "role": "http://www.nektar.com/role/NetLossPerShareDetail",
     "shortName": "Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "if2be3ac308a24e8ca217c972b757f923_D20220425-20220425",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Subsequent Event (Details)",
     "role": "http://www.nektar.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ie8720ccc92154ed5bcfc18a705606b0d_I20220425",
      "decimals": "INF",
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i47e463c44a0047f5afbcfc85015e338b_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "i47e463c44a0047f5afbcfc85015e338b_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Cash and Investments in Marketable Securities",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities",
     "shortName": "Cash and Investments in Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20220331.htm",
      "contextRef": "ic9128d92b5314c7b854bc1c4f488f26d_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 42,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nktr_AccruedClinicalTrialExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expenses current.",
        "label": "Accrued Clinical Trial Expenses Current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_BristolMyersSquibbCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb collaboration agreement.",
        "label": "Bristol Myers Squibb Collaboration Agreement [Member]",
        "terseLabel": "Bristol Myers Squibb Collaboration Agreement"
       }
      }
     },
     "localname": "BristolMyersSquibbCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb Company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol Myers Squibb Company"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Line Items]",
        "label": "Cash And Investments In Marketable Securities [Line Items]",
        "terseLabel": "Cash and Investments in Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesLineItems",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Table]",
        "label": "Cash And Investments In Marketable Securities [Table]",
        "terseLabel": "Cash And Investments In Marketable Securities [Table]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesTable",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, restricted cash, cash equivalents, and available for sale investments.",
        "label": "Cash Restricted Cash Cash Equivalents And Available For Sale Investments",
        "terseLabel": "Cash and investments in marketable securities",
        "totalLabel": "Total cash and investments in marketable securities"
       }
      }
     },
     "localname": "CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementCommittedFunding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Committed Funding",
        "label": "Collaborative Arrangement, Committed Funding",
        "terseLabel": "Committed funding (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementCommittedFunding",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-Based Payments, Amount",
        "label": "Collaborative Arrangement, Success-Based Payments, Amount",
        "terseLabel": "Success payments (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsAmount",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DebtInvestmentMaturityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt investment maturity date description.",
        "label": "Debt Investment Maturity Term",
        "terseLabel": "Weighted average maturity term for debt securities investment (or less)"
       }
      }
     },
     "localname": "DebtInvestmentMaturityTerm",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_DebtInvestmentMaximumMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt investment maximum maturity period.",
        "label": "Debt Investment Maximum Maturity Period",
        "terseLabel": "Maximum maturity term for debt securities investment"
       }
      }
     },
     "localname": "DebtInvestmentMaximumMaturityPeriod",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_DerivativeActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Action",
        "label": "Derivative Action [Member]",
        "terseLabel": "Derivative Action"
       }
      }
     },
     "localname": "DerivativeActionMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_DevelopmentDerivativeLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Derivative Liability",
        "label": "Development Derivative Liability [Text Block]",
        "terseLabel": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability"
       }
      }
     },
     "localname": "DevelopmentDerivativeLiabilityTextBlock",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly and Company.",
        "label": "Eli Lilly And Company [Member]",
        "terseLabel": "Eli Lilly And Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly.",
        "label": "Eli Lilly [Member]",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross",
        "label": "Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross",
        "terseLabel": "Loss on revaluation of liability related to the sale of future royalties"
       }
      }
     },
     "localname": "GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "negatedLabel": "Operating leases, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LegalMattersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Matters",
        "label": "Legal Matters [Member]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails": {
       "order": 2.0,
       "parentTag": "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities On Sale Of Future Royalties Unamortized Transaction Costs",
        "label": "Liabilities On Sale Of Future Royalties Unamortized Transaction Costs",
        "negatedTerseLabel": "Less: unamortized transaction costs"
       }
      }
     },
     "localname": "LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Line Items]",
        "terseLabel": "Liability Related to Sale of Future Royalties [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesLineItems",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Table]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Table]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTable",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails": {
       "order": 1.0,
       "parentTag": "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To Sale Of Potential Future Royalties Non Current",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current",
        "terseLabel": "Liabilities related to the sales of future royalties \u2013 ending balance"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties non current net of issuance costs.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs",
        "terseLabel": "Liabilities related to the sales of future royalties, net",
        "totalLabel": "Liabilities related to the sales of future royalties, net"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties.",
        "label": "Liability Related To Sale Of Potential Future Royalties [Text Block]",
        "terseLabel": "Liabilities Related to Sales of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Abstract]",
        "terseLabel": "License And Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsAbstract",
     "nsuri": "http://www.nektar.com/20220331",
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseCollaborationAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License collaboration and other revenue.",
        "label": "License Collaboration And Other Revenue [Member]",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LongTermInvestmentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term investment maturity period.",
        "label": "Long Term Investment Maturity Period",
        "terseLabel": "Long term investment maturity period"
       }
      }
     },
     "localname": "LongTermInvestmentMaturityPeriod",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One [Member]",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MulquinActionAndDamibaActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mulquin Action And Damiba Action",
        "label": "Mulquin Action And Damiba Action [Member]",
        "terseLabel": "Mulquin Action And Damiba Action"
       }
      }
     },
     "localname": "MulquinActionAndDamibaActionMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar214Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar 214.",
        "label": "Nektar 214 [Member]",
        "terseLabel": "Nektar 214"
       }
      }
     },
     "localname": "Nektar214Member",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar358Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar-358",
        "label": "Nektar-358 [Member]",
        "terseLabel": "Nektar-358"
       }
      }
     },
     "localname": "Nektar358Member",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense related to sale of royalties.",
        "label": "Non Cash Interest Expense Related To Sale Of Royalties",
        "negatedLabel": "Non-cash interest expense on liabilities related to the sales of future royalties",
        "terseLabel": "Non-cash interest expense on liabilities related to the sales of future royalties",
        "verboseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToSaleOfRoyalties",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash royalty revenue related to sale future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "negatedLabel": "Non-cash royalty revenue related to the sales of future royalties",
        "terseLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash royalty revenue related to sale of future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]",
        "terseLabel": "Non-cash royalty revenue related to the sales of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OpdivoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opdivo.",
        "label": "Opdivo [Member]",
        "terseLabel": "Opdivo"
       }
      }
     },
     "localname": "OpdivoMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization.",
        "label": "Organization Policy [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_OtherPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other.",
        "label": "Other Partner [Member]",
        "terseLabel": "Other Partner"
       }
      }
     },
     "localname": "OtherPartnerMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PartialRepaymentOfRoyaltySaleProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partial Repayment Of Royalty Sale Proceeds",
        "label": "Partial Repayment Of Royalty Sale Proceeds",
        "negatedTerseLabel": "Payments to RPI"
       }
      }
     },
     "localname": "PartialRepaymentOfRoyaltySaleProceeds",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received, if conditions occur.",
        "label": "Percentage Of Development Milestones Payments To Be Received If Conditions Occur",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced if conditions occur"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received under certain conditions.",
        "label": "Percentage Of Development Milestones Payments To Be Received Under Certain Conditions",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced under certain conditions"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of funding Phase three development costs on an indication by indication basis borne.",
        "label": "Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne",
        "terseLabel": "Percentage of funding phase 3 development costs on an indication by indication basis borne"
       }
      }
     },
     "localname": "PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in development costs.",
        "label": "Percentage Of Sharing In Development Costs",
        "terseLabel": "Percentage of sharing development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in Phase 2 development costs.",
        "label": "Percentage Of Sharing In Phase Two Development Costs",
        "terseLabel": "Percentage of sharing in Phase 2 development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInPhaseTwoDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInProductionCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in production costs.",
        "label": "Percentage Of Sharing In Production Costs",
        "terseLabel": "Percentage of sharing production costs"
       }
      }
     },
     "localname": "PercentageOfSharingInProductionCosts",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PotentialDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development and regulatory milestones.",
        "label": "Potential Development And Regulatory Milestones",
        "terseLabel": "Potential future additional development and regulatory milestones (up to)"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development milestones.",
        "label": "Potential Development Milestones",
        "terseLabel": "Potential future additional payments for development milestones (up to)"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestones",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PreferredStockShareDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock, shares designated.",
        "label": "Preferred Stock Share Designated",
        "terseLabel": "Preferred stock, shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareDesignated",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_PurchaseAndSaleAgreement2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2012",
        "label": "Purchase and Sale Agreement 2012 [Member]",
        "terseLabel": "2012 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2012Member",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PurchaseAndSaleAgreement2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2020",
        "label": "Purchase and Sale Agreement 2020 [Member]",
        "terseLabel": "2020 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2020Member",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ReimbursementOfExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of expenses.",
        "label": "Reimbursement Of Expenses",
        "terseLabel": "Reimbursement of expenses"
       }
      }
     },
     "localname": "ReimbursementOfExpenses",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RoyaltiesLiabilityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Liability, Measurement Input",
        "label": "Royalties Liability, Measurement Input",
        "terseLabel": "Royalties liability discount rate"
       }
      }
     },
     "localname": "RoyaltiesLiabilityMeasurementInput",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nktr_RoyaltyMonetizationProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Monetization Proceeds",
        "label": "Royalty Monetization Proceeds",
        "terseLabel": "Royalty monetization proceeds"
       }
      }
     },
     "localname": "RoyaltyMonetizationProceeds",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SFJPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SFJ Pharmaceuticals",
        "label": "SFJ Pharmaceuticals [Member]",
        "terseLabel": "SFJ"
       }
      }
     },
     "localname": "SFJPharmaceuticalsMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SaleOfStockConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock consideration received.",
        "label": "Sale Of Stock Consideration Received",
        "terseLabel": "Sale of stock consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceived",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Liability Related To Sale Of Potential Future Royalties",
        "label": "Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]",
        "terseLabel": "Schedule Of Liability Related To Sale Of Potential Future Royalties"
       }
      }
     },
     "localname": "ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_ScheduleOfPurchaseAndSaleAgreementTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Purchase and Sale Agreement [Table Text Block]",
        "label": "Schedule of Purchase and Sale Agreement [Table Text Block]",
        "terseLabel": "Schedule of Purchase and Sale Agreement"
       }
      }
     },
     "localname": "ScheduleOfPurchaseAndSaleAgreementTableTextBlock",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received from license agreements.",
        "label": "Upfront And Milestone Payments Received From License Agreements",
        "verboseLabel": "Upfront and milestone payments received from license agreements"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received under license agreement.",
        "label": "Upfront And Milestone Payments Received Under License Agreement",
        "terseLabel": "Received upfront and milestone payment"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement",
     "nsuri": "http://www.nektar.com/20220331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r98",
      "r207",
      "r211",
      "r216",
      "r289",
      "r290",
      "r295",
      "r296",
      "r326",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r98",
      "r207",
      "r211",
      "r216",
      "r289",
      "r290",
      "r295",
      "r296",
      "r326",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r44",
      "r46",
      "r96",
      "r97",
      "r219",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r218",
      "r224",
      "r249",
      "r250",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r375",
      "r377",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r218",
      "r224",
      "r249",
      "r250",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r375",
      "r377",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Nektar's"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r151",
      "r237",
      "r238",
      "r345",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r151",
      "r237",
      "r238",
      "r345",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r218",
      "r224",
      "r240",
      "r249",
      "r250",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r375",
      "r377",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r218",
      "r224",
      "r240",
      "r249",
      "r250",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r375",
      "r377",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r45",
      "r46",
      "r96",
      "r97",
      "r219",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r329"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r16",
      "r154",
      "r155"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r51",
      "r52",
      "r53",
      "r363",
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r50",
      "r53",
      "r60",
      "r61",
      "r62",
      "r100",
      "r101",
      "r102",
      "r294",
      "r378",
      "r379",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r267",
      "r268",
      "r269",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r251",
      "r253",
      "r272",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r253",
      "r264",
      "r271"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r156",
      "r168",
      "r169",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r93",
      "r140",
      "r143",
      "r149",
      "r166",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r289",
      "r295",
      "r312",
      "r327",
      "r329",
      "r348",
      "r362"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r41",
      "r93",
      "r166",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r289",
      "r295",
      "r312",
      "r327",
      "r329"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "verboseLabel": "Debt securities, available-for-sale, accumulated gross unrealized gain, before tax"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses",
        "terseLabel": "Debt securities, available-for-sale accumulated gross unrealized loss, before tax"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r161",
      "r171"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r158",
      "r162",
      "r171",
      "r350"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r160",
      "r171"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r160",
      "r171"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r255",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r29",
      "r329",
      "r385",
      "r386"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r29",
      "r88"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r83",
      "r88",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r83",
      "r313"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r283",
      "r284",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Corporate commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r195",
      "r351",
      "r367"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r203",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r329"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000 shares authorized; 186,274 shares and 185,468 shares outstanding at March 31, 2022 or December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59",
      "r67",
      "r355",
      "r370"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive income (loss)",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r130",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Significant Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r241",
      "r248",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r71",
      "r345"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "auth_ref": [
      "r186",
      "r187",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.",
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "terseLabel": "Restructuring, Impairment and Other Costs of Terminated Program"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r86",
      "r178"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Development Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r42",
      "r43",
      "r46",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Development derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r68",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r113",
      "r115",
      "r117",
      "r118",
      "r119",
      "r123",
      "r124",
      "r301",
      "r302",
      "r356",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r68",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r115",
      "r117",
      "r118",
      "r119",
      "r123",
      "r124",
      "r301",
      "r302",
      "r356",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r60",
      "r61",
      "r62",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r127",
      "r167",
      "r226",
      "r227",
      "r267",
      "r268",
      "r269",
      "r279",
      "r280",
      "r300",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r378",
      "r379",
      "r380",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Portfolio of Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r304",
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r220",
      "r241",
      "r242",
      "r247",
      "r248",
      "r304",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r241",
      "r242",
      "r247",
      "r248",
      "r304",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r304",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r306",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "negatedTerseLabel": "Change in the fair value of development derivative liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Cash receipts from SFJ"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value at end of period",
        "periodStartLabel": "Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively",
        "terseLabel": "Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r176",
      "r177",
      "r329",
      "r347"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r64",
      "r140",
      "r142",
      "r145",
      "r148",
      "r150",
      "r346",
      "r352",
      "r357",
      "r372"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r180",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r111",
      "r112",
      "r139",
      "r278",
      "r281",
      "r282",
      "r373"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r23",
      "r174"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r38",
      "r329"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r39",
      "r91",
      "r126",
      "r172",
      "r173",
      "r175",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r25",
      "r174"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r24",
      "r174"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments, fair value disclosure"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r93",
      "r144",
      "r166",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r290",
      "r295",
      "r296",
      "r312",
      "r327",
      "r328"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r93",
      "r166",
      "r312",
      "r329",
      "r349",
      "r365"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r93",
      "r166",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r290",
      "r295",
      "r296",
      "r312",
      "r327",
      "r328",
      "r329"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "negatedTerseLabel": "Change in fair value of development derivative liability",
        "terseLabel": "Change in fair value of development derivative liability"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Litigation matters, liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "New claims"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Previous claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r83",
      "r84",
      "r87"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r54",
      "r57",
      "r62",
      "r65",
      "r87",
      "r93",
      "r103",
      "r105",
      "r106",
      "r107",
      "r108",
      "r111",
      "r112",
      "r116",
      "r140",
      "r142",
      "r145",
      "r148",
      "r150",
      "r166",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r302",
      "r312",
      "r353",
      "r368"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r140",
      "r142",
      "r145",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r2",
      "r99",
      "r136",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r33"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r40",
      "r329"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r48",
      "r49",
      "r51"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Net foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r55",
      "r58",
      "r60",
      "r61",
      "r63",
      "r66",
      "r226",
      "r314",
      "r319",
      "r320",
      "r354",
      "r369"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Amortization of premiums (discounts), net and other non-cash transactions"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest income and other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r75",
      "r77",
      "r159"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r329"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2022 or December 31, 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r80",
      "r82"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Proceeds from Derivative Instrument, Financing Activities",
        "terseLabel": "Cash receipts from development derivative liability"
       }
      }
     },
     "localname": "ProceedsFromDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r79",
      "r266"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from shares issued under equity compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r75",
      "r76",
      "r159"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r75",
      "r76",
      "r159"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r54",
      "r57",
      "r62",
      "r81",
      "r93",
      "r103",
      "r111",
      "r112",
      "r140",
      "r142",
      "r145",
      "r148",
      "r150",
      "r166",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r288",
      "r292",
      "r293",
      "r297",
      "r298",
      "r302",
      "r312",
      "r357"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r179",
      "r329",
      "r359",
      "r366"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r275",
      "r344",
      "r406"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSU)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r182",
      "r185",
      "r188",
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected cost to be recognized"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Workforce termination, percentage"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r86",
      "r181",
      "r187",
      "r188"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring, impairment and other costs of terminated program"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r227",
      "r270",
      "r329",
      "r364",
      "r381",
      "r383"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r167",
      "r267",
      "r268",
      "r269",
      "r279",
      "r280",
      "r300",
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r137",
      "r138",
      "r141",
      "r146",
      "r147",
      "r151",
      "r152",
      "r153",
      "r236",
      "r237",
      "r345"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue, excluding assessed tax",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use asset recognized in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r253",
      "r263",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r253",
      "r263",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r26",
      "r27",
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r258",
      "r260",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r255",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, of RSUs granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r252",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r37",
      "r60",
      "r61",
      "r62",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r127",
      "r167",
      "r226",
      "r227",
      "r267",
      "r268",
      "r269",
      "r279",
      "r280",
      "r300",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r378",
      "r379",
      "r380",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r127",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r227",
      "r254",
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r20",
      "r21",
      "r93",
      "r157",
      "r166",
      "r312",
      "r329"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r321",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r321",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r321",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r321",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r330",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesActivityWithintheLiabilityAccountDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtoSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r182",
      "r183",
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r95",
      "r241",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Obligations of U.S. government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r128",
      "r129",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r114",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding used in computing diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r113",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding used in computing basic net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3,4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r407": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r408": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r409": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r411": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r412": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3505-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0000906709-22-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000906709-22-000010-xbrl.zip
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MKGZJ9U626+=7M'/K:]X%\0*;=%7.X*,J0\=>K$SA),..8RJ0M(#[L"9)RE-
M%4F2 *0@M4PMI$S5%J%"6C0%O].%O1$,)4YKPJBSG/@<Q[0Z,K#FWH7CWEKO
MYER1A&B=4L8PLY8)GAKD/3KI,LN3L8_ 0LS$?Z"HYMR:<V]Q+GM8I*BZE:)9
MH'"*C4/(V8P:)B364FA@X RG6<8<3T)8=R$9=KH>:VYS50Y]:'TG"Q7#IS<'
M' $-)P'X%V6RI\+)-SCB$?&.A"1,:89L:H$CE!*)R3!R1$OJP\)N"719S1H+
MH%E283A.&';"&"83(9E5CDJDJ3+@[I/%31'_'4UAM1B6MQV\K7MM@6S\VT[W
M1Y6F%]_>SB6+75*#C$122L*9<$@*0A-B$R2,U=PLTX$ZU:$ DUKU'PI3<=F-
M&O5W17ZV+DZAM9FPR%/(WL(IZ>?)@F<"46!5+G6&P=@C:8D25+-$4@U*6B]1
M%GS-N\_'N\^218\5,28U1BN:,&(S+3+)_)&>P+A,L"I1 9BL JKP87&!ZO<0
M0,4VE(NEM[[7,&D:(_E 3!ING0DF%2+5-L4*:R*98IF6?F57&*)2"0Y.6'$'
M3@$#OFB<<K_,;[7S#WF[/025]C#*+1Y7/E75Z2E_&7A*Q&02^WM,YJ+(#*9.
M6VHLD\@HK!*$..?@_RA;G7Y:\52\J,SUI 3_,2?/7_-,D_X'FF?ZUL><P(!=
MAK7UA_2ES" &OD&:9IFA5',";%)SR8(;JZ=GF<QE3G$<3KYF&4)"B00;C:TU
M -<=7P*6J:U6S?B_H"N5WQ*;" Z<R!A.!!6)),QE6B78,E<S?JV7GY$]-9:)
M2)5 ::)82K62J;0XLXPX9#-F%C>Y^GZN#(E90+E^]X>5VQ\7=IU=]C1VB#*:
MH!1A\/J-\%$ +I),$>U/O%ZFXZT?%+KR9T+N9'XAZT6>:PUTPH@SI&6JP357
M\(>C!#.+3)91<_/$JYJ<BQV<RZS,1$8D]D&YS(+]I@IL-^!91%+*Z4N3SL<$
MEI=27E,B'+?@DW#M&,RY=TF8T"33QM<P>7'R^IP$?AX)3G JE9,JS1@3@BJ-
M><;@!\93I]&+6]9\[P#[J#;0=\-V\F[>ZY=AE^ +EF&GB>$<$Z&-8#(U0G &
M0"H5?EN\Y>*ER?#SDOA9I-APJ1%W+,7.,$R8RIS,K)-IPD@JD5LB*=XX5Z6]
M79HY')R>&_!%0WK7YV[>[^WN?7Z)\IHA0C/P;7S59B:Q$[Y86,I9QC7%/,F6
M2%X7BIC/LWR-L=)49DQ(Q3*42J>D2SD&I)PA;,85+QAABTI#GU[I_C/P,.C,
MW54U_<8-LPIT!289F/Z@S+N'WH\"A>[A67EVX_U;G=-V,71N#P!;J;IF#AK^
M>FB#Q83]6FAC4M%A]/*[2SJ,+H[;>'!-!R=2@HPQDF#.G.7:9 :#E4<\08E&
M=L)KO.:U)>(U/HOE:PM*R)!49RD@>YQX"$@%L90G3G*M%Y<U?OE$^)KIGIOI
MK#.^=B4B3";,":>QM(!@.*!4S5,K%I?I7BQK_)*XS3]1YU>9[E5^\;ITO6)0
M&M>KOAXY94-_;'ZV_A?\&8-J:QGCCDJ>,)YF$H$[G$G-'3C&@MMO'D-?/=/K
M#]O ;> ^QD<N/SSJOZ;):?_->6[[1Z\Q0O]G)=RW_E?O5'7'=YNB792O_^99
M,<O>9-#).%.=O#U\_7];,,.]J.G.H]VBH[K_=[6GNKT8")J/;NSEEPX:AG>$
MK^?52QE";]IYUXT[@0GZ/V_\T&.0K='F , #,&!_%_1)+4Q?HJ/297]?^=N/
M9SY=66\IW791D46^G "P3.^O5PK(X2=W3)5;M FO5NW\L/O:.']F# R_']H9
MW:"+$CH3&[^3XK3G7H\_O+%Y[[2MAL!E83SAH3<=51X"M771[Q>=UQP&?^9/
M S*J/7I)>%]U^8H/UE#%"WW@N+X=OWET>2U<>M6WMZ])L2;1_9?1&IY<>Q7:
M+L<WC-GQU(-'> Y&Y:?I[RMTY<; 1T.!.R-;#/S$!'8 ,IXJ:T&QO$81#LU<
MO>=5F(R[)*&:GGYQ^IK!W-PU^?>( KSO5]B/W&"_] [V6UG_W-QN;6U&>ZV-
MUM;>=8;Y :L\1V_WMMY^WMUN;6_M11O-S6CK?]_^<Z/Y?BMZN]-H;._M;>\T
MGW$(-^7][B%\W=C[YW;S?6NGN1IMKKU=BPCB3#Y?M\6#>OUM-O_=.\PIZ4B>
M1#K8@X;];F>W$?T%1K%;=)N##C1BHI'MW/7*.3<2=+"51'.*F4E]2KTVV+",
M"9&1Q-X5-XRZR@,QGV6P69A!9X2+5D:8CWX9ZLWB[ /9/=NGC8$]WCH[>"^/
M=SK[YP?O/Z'FYI=VX_($-X\_X2;9YXW-HWP?_MT_AM];VVQG\\O)!]IL[U^>
M=AKO=T^:FY_P0:O!FZU]U&S9SDYK@^UWFIV=K]OP^]9P9_,0'[P3%Q_(P7#_
MJTF:7WV[V\/&^WVZ?[E[W-QL'QU\W;K<^;I_T22?+W;>OSMIOF]<[FSNG]GW
M7YC]Y[_:!Z1]IH\+?+#YF>X?;Y\?'-MCN ?M?'W7WH=W'QQO47@7V__Z">U?
M-EBS+8:-X\_TFQ3<2&MY; @2,=-"QR++7)Q2E%J9@M--S,HZ1O&G $VNJ+ >
M_682LS2&F:XE##_(+O^4N6=KF,N?,??WV?:QZ2:G%]YX3ZN:MLMNSTUQ^G#^
MV2ASU8X^=W-36!<U]NY3/OA'R+":^OGKG4\#58*$M(>[[K0H^RN1+T"E^O""
MB_[K++]P-@8W:CE5T[M<O_^<-#L')XUC>(8T6*-E+N&=;/_X!!UT_G74?+]/
M=J!?C>/#R^;EX>B9+_ NWCUH%>2@\PG4U/;E_N7A1?.R >,[RG=:NYW]SA8Z
M.(;Q'1]"'QMTYYTX_]#:Z#?VT,6'UO;E3NN$?L.8(\,MC4DJ$U!M-(N%2E7L
M>(I4@H7!"5U9_Y^_R90E;VYJMXER&S'[$_/Q VWH33:^I0@#&W_ZO+';VMK]
ML!_M;GW<V6U%'S_O[GW>:+:BUDX$@*X%J"W"--K9C3#_P_X9[;R+6O_<BJ:P
MW@3G;;QM^<M84G9MBAX,O9\&7#P,";XKRJA_Y*+_C(4PJKSTR($/:)\"=GP,
M[]NJ%F>N"[_/6HT[\,XC_UALU3 >.E7&KKN4RN#7<4KS>/^;-B;)D" Q33&-
M&<$R%I(*8(O,)-PZ#@1866_XO)?_^1M.T!N*5R,_\??*];.SZ ]E-[!H4=;X
MH\8?<_1[2NA?[@-?]P.03+5[2XU WG]F@!XNFL?M3O/R$VV^AWZT3BY]6_N=
MAO^70QOD#@2"#EJ'M'&Y1:!]VMPT:/_XD.^T&J# ON2@H.#?-BBN_;L1B*]'
MI+$Q,;%>:UGI8HEX%G,KC4]$Q,JA$0)A+QJ!M'8WFGO; 6=4$&2OQB W,$A_
M(HAC$)*51:<R9M__&_6+A]Q6_5T<^_>PZ7E;=#IYSR_L1.]RL'\@'=J5K^>)
MS:H])_YMU<N64O,])BRTC[XIJ@W7%&!G2GG,&. M93B+C5\+%>!8:9:NK*.8
M@.%*?O?(T/=DB3Z%+!'ZH&'/769VW6%(5>WVFW#EMY.;S^P;%I)I3%RL+ >+
M+W$:@Y7BL>,PC0ISJK1:66]N_;NUL>OMV^[&QZW/K>VW>PLD0P_4S']L72C3
M#SS@ESW+">TCU8MZI\[XQ 4;Y=TH[_<B<Q1<[#]_,]6P-$X;2]=PRF?NM9$U
MD(&9MPJ=193-V1>LN/ I,/0/Y6W>SF"EO?W.A/)TE 81-BB\+0;=?CE\"[[L
M-;\0AF!\\G'?G9;%F6]G28-2(__P^.#DX!@T^3%H\J\'1\W-@^/]8^C7U\_D
MX'CCLO'U\WES<_M\OV5N1:B;G=U.<W,W;UQ"/SI;J-EIYCOO_W5TT#KH-#8;
M%P>M#=0X_L=1$]_A'U*3(LNEB"FU-F:*BUAH;F.>R!11HC.CR,KZIFNK<U6Z
M1SB(U[(D:DGXD22TU,7V*/6NVIVSQ([ 4[/X]G46EUHCIX6(39JPF"4<Q]J*
M+$;".FM291/M5M8EBRFF3#+T72:?M3*OC.>3 XW Q'\$#1N!]U_XD@;1\:#,
M>S8/)_T!GOI+EZ_6\VF-'&XM#U4WOPS?_WQF^7_6R=O>W8M&B:-EF*KK\AHU
MB[4_ES\V-'=%MV%MZ7J]T3\?H -X*97<HZ(=^%OF2(J18K%+TB1FC)A8.N%B
M1TQ*,ZF4S?C*.N,\:HQB4?]0P^@?Q:#MSE1IH[UBT#]:/@_NJ=CK+7S<*5O%
M^7*"Q$<Q%_FF*$Z-I6F<F93'C#@:"T!WL2\ZK[$FF6)R97T/R/_.I[_G/5/<
M9*75^8<[1Z0*1FFG_ BP'HS/"T7]CXKQ\&_.<69D8N.$*@R0!KE8BD0#B <Z
M.*F,L8#:WX* P^1U<W5;,3P1,3\60*WV07Y:.7"_&:7VS[_I)%-:*Q<3GCD/
M/DTL'.4Q5UAG*O'[694'GYB+!=+>#PM4_3$BLH^]G98@K/FI:D?NPIF!KQ0
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MXD81D?$8LM#C,Q\!]?&5GH\2 4CI5^![%#:.IB+&U\+$4Z'EZ-ZHM ]%C%\
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MBQ56-DX2+$66I"FR@"\P7Z6I7""'J(YV+"B^J 5W3H)[$T]@GG%&J8V=X3Z
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M8+7%DDD5VX2 )DL4B27Q7RDH*4*<D-KOTD%\E2S-@3_U&5]+"&=JP9^SX-^
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M>![ZMH\:QQL7.ZV#H\;EP7&C+2YV-KX)[#0X7"+&CMJ8<9G$("<Z-HG6">5
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M&@7H>>FP#EQQG(CRR:ID_6T K.%H*T,WLH!NDE))!*<H!*\0=]@AC56 ?UB
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MHC(T6G'MM.*2(TY+%J7W 3'&/.(L"@1,1R =$PN&*^TH73>U^!2J$)KAO<W
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M"=^,!O#-U98]M<*=M:B)W\_;L=?O^9(;ER=Y-A;5RI%M9XFJ6,&%E4(C'"W
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M#>J912QQB[C@!KF(*=(FA11"I-HQ0#*JVD;=NMBK"3BNK_"OGK TPK]VPK]
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M=V!S0)#C?CHHN_4F[](._*$'4AW!^B]__MV"LGPQMV?9-]#,&KN1+CQ?;LO
MHA0J"H\D\0I8<I3(YJY1+AF?&#8\N<R2==,DZ@<6[SL-.]Y.O!L>O$+97\KV
M3H#@/"$A>$#<<(<LUP(Q[HTA#! AY<$=JDUP$X]\.$$NO+>,6C\=U;0FQ$^Q
MVR\><?AYT/EDLRRUNG6/D^^;B?IX@Q?KPF2VIENQTQN.!N.\/R\G5LJ\==\
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MPLO7.XS^./J/IW"-S!F/.ZXSZ@^&&RT0E44!Z0[[<U*2;8CA=!$&L;_HRO$
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M4GMQ JJRBGA7)FE)3 OQ-)9=:6W9D6WM]GN9R6?) IY]TAF-8BRW<F+#)/8
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MF+&U:(J1_1AKIM*+?@9KUU^+C5:9]GN#3U1[-RC61S_'RL[S2Q_CV=71]9A
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M]"]&+:_%QY]%,]YOQCKO-#CF?9$A^OA6=%E@?L'N"NV=+XG37@(N>;DAOMY
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M/-C9?-"QHPG0>OE%EQQ7.=-=$LG 5MV8RD3NA<J=C5U>*A2^G&30R!2O+@K
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MUO+,^UX=.:[;\]6+A5"5*!\,G!2>3\..NU;F?IO=,T41GINXNA:+)I2RNM!
MRR3_,(>B@TAQG,T951J]YR]5UK]HR/>BHGPH^5['O]6Q?H6*Z$R\1A6Z1L'3
MYF.-D)>%:,%YQ?'%#M3A$,Z;>NZ^4+9HEL&6DRY,PEUPEY-U(Q1/5Q'(NZ-@
M$-87VX4Y6&F:(>TZ,$Y5G>(FGKOIZOMJ#:Y00 ?NL5!KR9];N?AIT1:FU",7
M'!N5YN9U\/+JW5,2"+/BE[(8 YSWVJ:_@3I"9^"9:RKL8PUNL*)9W2KXRB;!
M2P7:UVIY7I!=*V(9??;XW']9L0@@*]+Q\HO\V7GHTO-R>N+^>P6D^<7%O\^F
MVR/3DY//UOM!WE>U]#>FF-]%>:/WX>O1QP^Q?V;G<]P[>$</#X[R_L=77_?@
M77L?#R_ZPZ-![_3#ZHW>P>O!T<' S2_:._C\M;]C3OK#77QX\(KMO=F-CTYW
MR='PPT7_P+5?['W[9#)F$I-0I*F1B$7PC\09191&7%"3IA$1R]=Y(LF(M)C#
M,4>,,RMYK+6R21R36*=DY3K/'8-GD]VJ/X3GCOHP.O5IK-H\2^T*5K6[:^=S
MZPNXAR7-]_K$FOG [F7KB?3]">AB!Z!)-?;+Z\V_,*623P;;E*2:(H,-1HQ(
MBH3&$:(I:/!Q@K'4Z<I%\J-4!RC)/5\D]V%-[LU&'K6[VZ<VVIH4NE[7\-[?
M@7?&_>9%RG@.LS/3WY^7K%&,6=KSKE 6\M=P9U/[O/SA3Y-/SP;RXGD^\E/V
M#_U9,$/A!%B3/>O9(WQ<V\1;4;"+9Q/XSY1O+C[>\A_],3.KGR5B"X[JTH^C
M+7SI9U<-B^D62=([#7OU9S'F#S+9]/*/F\/^X?<W[#$<HSOL_^\9?58[-HPC
MF^=1!WO0*L>KOBI6ODK.OKHO_[GBP5E)FO8G?M\,Q*_3$SQ9O:H\ZJ]E/NG\
M*P=SIQA7@N ^MJ;^:L$O3AQ$#OU=*:'<=-PJ_WQ2V^:S$SME8N+";MU]Y;_2
M!M;EI8H>H;>A."7UY^.):WZ"BNGJ+(LR?=46#&RV6JW@03;@>LD5+4BN94FT
M3$W7+?JF-!%UGL*V_.\'6WYSV;YRV4:M^\';:2.ZSFH##7A9)YZ]E).)RPCT
MPN!F2?'T:2K))X?#KX.]4_/Y<+C[K;=SE/>&/7*TLP_O&9SL[>R?]+^9D\./
M_=/^Q]VX=_KYHGP&WC4_(A^2/MG/#T][YZ!,7QQ^._K<?W,8[WU\Q?IO7M$^
M>7UR2'KX$)[;._@[Z^71UW\.7LUZ[Z,+V(.X?_XI21@Q5D2(<V<0&M"P!2<2
M<9)R0B@7D3+/7B1I5PAZ22K]0[$+X$3GEFQSE=RZ#K&795\+>BWHW4.O^1;T
M'A_TOBV!GN96D@03%">*($881RI5W'6V4"D1"8MP]NP%B;L$7U8_9-- [X86
MTE. (N\/0SY-I.%2N=3"(6L7N19UGS3\W)?.M5W>';T>3UQQ_=H7NV/5K/[M
M92@FWP+1O0'1Q8KV153&,J$-RI1-$1-6(2&C&-F,:,HP95:S9R]B(;H1);=#
MHH?3I*YU%OPJ''E?"D'+D8_'D<NJ@12 K4PQ%/',(F:C% D"EA$AF8E-'&N5
M@#V41KR;TO3'<^2OX);Z9SPZOHOXO]'B?SX4^M%Z07\\TBT0W2\0]5^NJ :<
M1T+I-$,TL@!$26P1_,DB[?Z8&6I4(IZ]H&F7)O?EF-D@YTO+WH^E9+3L_2#L
MO:QG1!EGU&B&N$XP8@HX6S$#-@"WFM.8$QV39R\2UN7DOEP0/][-$)B1;KB^
M<> 3!?5MPC@NV_K@Y"G"*V#='3.>NR>]FZ?A L(_K;OX/G;@I\'N[U7-1I]G
M$^\NW@>*G.1Z9LWZ$+)E<&]$DK4H?F\H_GY%2:-&QF =*F03*0&[)745J#.4
MQC'%*N4&6^:L1=:E_+8P?@^<]&/\/BWXM>#W (IK"WX;!G[+*BSF@NA4$Z0$
M <55<HT4E1A1G:@TTB3-L ;P$[R;\MN:J(\(?E[%_<-K?&LR<J^NBK<Y]9T^
M5C6$0(<=Y, PIMLY@2^XI@"^B[D!LZ^ATH:*DTO*[])WE@L0^))&-M3!L#Z3
M>JMS,.X,\U$^+,M?VJ]GX^F\KL;C:BL85S+8]V[-_/P6QEDH@.1R]^K7^_(D
MP,[E[RZ!^F%B]SWX.,.X!I.>_)H/Y\->>/W%6Y_GLP P<%;ZN9E/SH$^IW;T
M-%'ESE'[#A4^V<@FJ7-34<LBP 3X1R3$(ITF)HMC+E+#G[V8G8\[%U9.5K(_
M7)Z6KQ(0RE4 7?@4TDX@=9=.Z;HS']N2""Y^- F$M[IDC?;DZWR-G0_1)V5%
M)@7.4*8TG'Q&0"ZHF"-FA1&,ZC@B</(N>=6=_&4'OU7T?KVL]TH9M+OP$?SK
MF@T4I5@&ZZX/?+N5!G(H.SMW^;L+V.Q.$>5?T4EN ,"?_SKG!^-_2E/,&>84
M@=X&TCS6*9*4491H8Y258,ABN23+?NG]4LI0[K;*,@I43E..>&H3E$5:I-J(
MV+) [Y6*X__'4_%5B&58+%AB!8TP9I8!7-DX4I939>*$4K'4ABKHSPW$<K=G
MB\EDK<2Z]!S?D4\8Z)Z;%*,DUA8QC15HL<*@*,)$L]AUIK57IPBZ!#62I:DU
M)&%P\C*A:199JEV:HL#\.AG3GMCM3HQA"P>F,I3X*WI%->(RC5!"DY@PK5BF
M]14ZQO+O-RVB\!BIHRXCRH>#NAYQLVG/2J=*F[W1OE.*7:FKOURANE\X4?0"
M5$Z6BCB.$8Y$YL@A10(@%%')62*TR&(>;T2BJ*_H/Y[,,K!7Q[XZR6VN',IJ
M:T\_+90F6R1.'B!_DZ;LWO,WDRT>D2<R5[$%6/)$\F(?:JY/:5^?TEP?B@9N
MA@/WE_][AZ\^B6S61N[T?W([<>;S1><?5Z?F!JG!UT?AX*>Y*[=.DOY9R>.[
MDIT?EKWN]ZL_37KZ=E&ASW1>CJ>S-K__UAOX9C*>3CL?1A/KZ\R9SAN9CRZ/
M(VXW\L8;^<_8%?MM=_([A/3]BJ*??8-^A:R'E^/)V=C?HX[&91%"-08+_R9\
M=N?PZN_;Q!])0#?<QAM5PFE+ ;2E +XKMBGAL4JRA$D3:Y9)*8R-">91' DC
M8R/OFG.S&(I?J8!. _2.WE\AGFG?Q2%]/?RX?]+[MGVQ=_#N:Y\<G?3?O(K@
M=_COD!V=[@^/=C[$*_%,L*:CT]<G1V]>?>OM[,([7]&CX:OH\. =_/[N6__T
M9-A_<_2Y?S!P50$NED/R&:4\LPR1S 7B&Y4A26*#N"LYKKB0290^>X%%TDU8
M6PNE!< 6 !\< '71#MH:;X34-HBSY?[R;9@/Y-<6^&X'?-$R\&%+I8P%4DIB
MQ%+,D<#"(&%X%L<BE0:K9R]8"WDMY/ULD/?;$\(\YW9I8%ZK"=X;()+EM![&
M4VH81W'F8AEC*9"0J4&IL%)(;HU6&C3!+DFC%5#\O<7#%@^?+!YN !Q>EIC>
M(MX](AY;+D25"DZ9L<BF<888YAE2(K$HQA2GVEBL7%\%+.(N36]9]J8%OA;X
M?BK@8Y8094%'L"EF-N,"<Y5HGEH); *JP7U7Y&B![QZ![VNO++5SVHOW#O0G
M1K%.TLB@A N"6&:PZS.BD+3,1I1@DE!7"S3E7>RB)IX$\MWZOBSS_^^)WI?I
M\7!H)[YU\ID\LY,[W0 M[<"=+LRNW\6?YL+LIMMU5?FF-=OU\Y5OTH8IDC&A
MXE@Q&EFET]C&J2 R4J!TD?:F:..%QL7J35&<::PYAOU4VOD'+%)$9\@:*83
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M?'%+\!=$_M+(7<2$\PVW?B=C$.$G<C(<N/#WA?7YT'-_KUO=&#I%UGU^L1
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MIO_&6^X\"VUQ4^=9'Q9UIIBXC+@\BA2/!WT0'O(D)5*IIUS5-YF)*I60"WJ
MO&:%3@D/P&:J$X&L#FE)7(ZZ41G%FIAAC65:D<,N SQW4M8/$R/A)]@M\1&+
M^8>#R^.#OT-P;7NCH.\FG=@'W\GKN^-@%+KA*!P%XVYG,.IWU]SF0.*(F< (
M.'>@W#W<R(=E^\ZF1$.WF/B?/V-P-TBRB&%@94IU.-9B0<T+LM B++)4DT1*
ME-$JSE.5'K$+YA%YAM^1%*S-H4HKI+%+L;E5,U</!I93,8TDTR%^GF@[ZE^J
MJRW)CX0-"R9(LAB)TB:PU>0P3,^W>WM^D"'NZO1L%:-4F9XR%>"T6F?YE6.(
MO2$,9 JWMZ"G7IDO%5\E6P)!:ZRG4HZ,88*:810U/0A"K(%RM>$A ) VK&+,
MF^RVSORHJB^G-0>)O7$%&(VYPKDMOPTIOA$R6 ARA!#S8WI5AZ5YK>K;S3RO
M);\=J7M8?"1S$)I!6Y)NH"BV*8UW8CO[.Y,54WQQBO%L#7L3I:%D.A]AF(RL
MM7UMXX^4FIZI]KC2XHJV"=W,6R0I[\(I$8*Z$2D:7]64YUX:ET9[_>L(X32/
MF^$Y0=0#HQ\UR:Z>4H@4T3 J^-\F0))0$,N(XYXYTDA<QD@S7/ER]3#4\2ZO
MVXP=5*<ZA8"@%;4JX;H9\MU.N[>L36L!/?Y5C4?:WF.^L(:RINV&^<^Q-^H/
M!^&P,^B'X-F/P]%@%'M)'/BB$R=!=&W_DGVUT:U)1U_Y1Q_^_-OWXW$G&??A
M3N5%;M ;^VX8=!/7%[$/MZON,!X-?OHMN#Y[18"H%2FJUE7'F2,:,O*C$N@R
M2B%Y#.&8"8GNOTZ-K%&1')B9+BRL]ZEN@Z0:DLXHHM) ^DJ7T) 3UX\).1UK
MSI7-2ERC(H9'C%6K 0RHZWLDKX*AA*PM(=(BHJ(2(,O@/-:=%PS-K/&.KO!C
M.)R?EA;+_[Y":[U>]3OK*[1N0 <=_+0OZWH@95U;R><]_%%\WH:W^R1!%)8
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M#1J3#MH.APZG@U-]ME-KA[:JMD:WG^\C6S;O)J*U#(2)(B'@LG'%K#.1+',
MJSE?=9^Z4W/V8JD+0^/J45=2:R>^J2ATG)LNS0]>%9*'GYMGZ+M-WYXV18RW
M:MXW*241G6[0[7<&'2\(^M$0*TIZPWX2^N-.[ _&U]4B=Y>*]M@_%O%J]UG6
MI>H :G<WO>2S3Y.OV<D7\'X_OO[R^<L?_J>/G[-/.#:XL1V].<Y./AS]<_3R
MW?G1&QC?RU<=]1UXU_RS_V<?GN]]^@B>]<O/9Y\G?Z7'+__T87Z7G_P_>_#-
MR^,W?UQ^_OCGY=&'=\E1VOGZ^X=7U='[S@(^@Q1/0S$4HUZ(?O; =X-@%+CC
M;B=TH]@/QOUQV(^]_D^_]?OKBOKNZF" 1G!N>$"N,DS7Z>>F<=NKM[UZJZNW
MCN=U>D%G/!J,@Q"I#L->I^\%<2=*DFXTNJ[&?J_>?HAZ^Z>AWJ)N['=";^1&
M@T'/#7JQ<$=>U'$[_5'<&4:=SG 4_?3;P%]7B[]MZNW&?J@$9.^<'_IN#;G!
M:F]4+X5_LZ58J9YW6D\E\2@9)O[(PTK>).Z/_&[HQ:"LO(X_Z/:Z=^:&;9+D
MWBNQ#9388LE'"Y,@[':"D0O_';E!)^FYXV$R<(>B$_?ZODAZ"58 ^ZU.X'VK
M'ENM+^[4%6N\<FV<X=&?[8$_%+UX& Y[8Q%T^@,L.@N&8S\91R(8=>[.!]F?
M[>]VMIL.2N*%@1@%/3?R_+$;A*%PPRCHN]ZH-XKAX/=&@Q#.=M#R^OX6G>U'
M$P][PXU4)2'G))U*6LT+\0V>R(K%>'C:*NE[@U$H1N$@"8+AL!N.O1X8,A3V
M@1AWKB6GVVNK>]96QR^6/9%.Z'>'(]\=BV'L!MUD[(;]8>C"AG;C!(GG_ YU
M,.A]LR.R6F'<9TQH?[35T19C/^KU/'\XCH;!:! -A[T@&H8#^/_=*.X-]X[(
M]A_MIB,2^G%OT.O$;K\_[KI!X/ON*!P';L?O8M.2<!B)X4^_C5J=SO<*!6]1
M/(1/:'?+P[0?K@27W-0-E*$J"?6 N3MQ/D?@" 6KK$"6]WC"V]]S:1Z,MK\5
M-&ZO[;=(VR^G_40T$+UNU'$CX2=N,(PC=^CU!V[BBVX<>[#*'22I[;1&_>\5
M4OH>A^J>0U%[E;I7J=]%I?I1?]P)!ATQ'([A%M4;#H(AJ-;.*(PBI*[;.]#;
MKU*;#G0/N^F,XI&;!/X0'.A![(X&?NQV$Q$.1=(9C".X&_O=UG T?  JE3SO
M7P@U_-LRN/\V)=$_"IV_!H[/;3 65'[SB*'WW;_A$CCRQG'B]K"%01#UA^X0
M= 22J@V1<=;K^OUM@=ZGU(&T=B<*+\,B7MTDT\;/RZ8M5$R^1]#O$?1[!/T>
M0;]'T.\1]-_>>V#&Q5JG18@D_M^>)OPFK.D.79-6=RS_WL&G-=Z?H6YZOE@J
M&SY ET+NZQO<UO)PRH6:#^32] H^_RX[>7E\]OGEX3_'7]Z=??YXV#OZ"._U
M__CZZ4M\?O(2WO_R^$OSTG2$GN6;/X,C__7YT9<C__C-:[ATG7_]],]Y]_/+
MURE\/X"Y=N OJ^#GHM,5_C!)W'$$'F;@85\#<&A<(48=<#K%, R1/?J;H0^[
MA3[?:X<-M<-WCZ/LM<-]:H=F2&7HBT$W&0Y<OQ\)-^A'/3>$;76]L-_O#8)!
MTA_T$?CXO< &>_3V=[N9XP\B=D,86G@JV!ERJ<M1$J:%@Z2#W(MN$V_IFV&?
MNQ\_?R!Q<-"+I#^_KY?GWZT:5])\P,),?WP)HOP:)/DO%.2]=K]>NR_#VGN=
MI-\+^@.WTQL%;C#NQ.Y8))X[[GAB,.B$HC_&TL/V=\M [E F<:_1MFENM]!H
MW^B9[C7:+FBTIK_JQ4'0[PP[KNAXB1MT.S[XJ]V.V^F.1*_GQ9TD0G^UTQ[N
ML?SW45/X_L_O&)9[\)?KJ#<:=WHB&&"#+\\/PD2,DEB,!OW 'XPZXL>%WE[]
M;YY6B\-I615SXL4B_NT/9^%T?^W^5C6V N7?ZXX[?M@;N8/$&[E!U!N[XZ0G
MW"C&BM*P%P5!@)R\R[T@]AC_AZ0 DH[?36)_$/C],!AY8AB,.IU!+TAZXZ[7
MZR<_+KJV5P!WJ@"66!-Z8=?OP8GWNM'8#;#Y\"A(T)F)^Z(ODJ S%C_]UNU_
M+]:$?6SM3F)KU_L[^VOH [^&?J,/]_VNH3?4X/L+ZG=0[.^7/+MNM]?OC$:>
M.P@#4.SQ>.0.H\' '77Z_A#42S<:Q#_]-FIWO[G&:Q]RV^NZ'ZSKOM%=W>NZ
MW=9U32>V/QR'G5XG<KUD.'2#48QX_$"XG:'HCSI^$H-D($ZMW>]ND;+; %:_
MNB_*AOT_!KK_QU:VCQC]J/81K\)B"GM5*EVR-8C_A>K#!'][&7F?W[SR/WV(
M,WC/UY.7<,@^'EV>O'GE??+_Z'[Z<IP>3?[*EOHP^9^"XW_^.O_TX?/9L?^G
M?_SR57#TY=S[] ^\\\-?7SZ_C-,C_Q ^_U=R F/Z.PI\;SP:!NXH[ 5N,.@D
M+AP=@;"+;M+W1 )ZM-D8(H[[H1_U!V'?ZP5>U VC,.Z$@]YP, S\86_0K! X
M%I7S>UZ6#JRX0TM^BY80U[YT5_KPP?&/L%>5H'[D$?61RG!U9K Z%(PQ/::P
M?=)E\]+'G755URFL<.!ZAGQ>86M%:LT9SPO9SDDV;83'PV<0*\S]&\THXA2;
M(,7?,@XU@*1><V$-R&X;JGM:90M^.3;(*T4$0\8.6VWGM>SYO3QRV;D;>Z-.
M8/<6^+@;=E)H46V(GFQX$:89E7Q0CW S^K,\BT51.N)_<^Q B*_E1IC64K6=
MG>O1]SKG5O;5FKJ >KM2$A7TF%I26(F2<;W X/]1=U)0N*I;J;W<HM1=K M8
MV+3@SFOP*=E1[#KA4,T J3VU:O(.3E.J/RN21$25:M!6'U_[KDV+J30[L,;T
M7@__E>R;]KK()^A9SBO9!69ODY1-^F/Q=^#'([BJ)J[P0M\-^G!?!9L4N7[/
MB\?#80SR&#1MDI<(/^C%PR#VQH'?ZXX3X25Q(F*O"^9!B*9->FD4Y(V/PG4R
M"B,KTQ*/"&B>);595]K<*8P4F:V_I0*5"#E\-47TZEU@ZN5KJRWJ2EMZ[6+M
MR^#V97#[,KA]&=R^#&Z'R^#NP[U\>[5I7"M&^VJ7'UP+]XW^Z<$$=JC:$5*1
MV_FP,HCYJ7?\\NP,>UJ?O(3G__/'XOC-<7K\YO67XW_.LJ.7[\X^OSS./G-/
M[%H0\_C+>0>>^_7SERB N7PY?GG8^>3#_WT\ZIZ\^?,2GG%^Y/]U3CVQE^OC
M@KXW&O<CWQWTDL -P UVQY'?<2,OZ _%:!@&_ACKXUK=[C>3BNQKY!ZDUOC^
M7$-[K;%E6J.9^H"+<]3I=7ONJ)-TW$"$H3L6H]CM]!.1C&*XW8V#GW[S1JWN
MZ)MS'S^R=,[.B]0S(-^>&0'Y'VYW;L3K_*CDR/OYN!3_FX,3]^IBB[IF?SUZ
M^2KXW?^\^/0QZG^:?%H<O?F<?OKG57#LOSL[?AE]_31YU<&,X<F;HW\^O_GD
MG[PY](XG1Q?QF[^"^-__R3[[V<7XRRS]_.7P\O/D/U^./IQVX4AWCO]YG7[Z
M\$?G\X=3.*;'YY3A_/*G_\D;=DX^_(''%X[68??HPY_^W\->-QB-O;X;)ST$
MQW7Z[LCK16[2#8>=./3&@^%28&H0)J'PQ_U!Y'G!:!2%@RCVQ;CGC?Q@W W"
MI2[:>@,<VH&K4R4;ICSZ]Q9O7AV NG91?CLHX?Y01O.RY+ _'X,6QG4/9D6:
M.7Z/XW(MYQ*#P%-03!%&W.:%\T[DQ6DX3?_A-U+T3&!&/JHXZO<V"S$1,)L7
MY3SD^+.,*W,(&UZ0HVG[!S]\+A9.L:8E$4:;\Z+B"%TAXGG$@;S"N<R+<_A3
M))SQP@EGLR+_"N:M$G O6FO#.:'2A#;X8]$-HVYG&/J!&$:A[PVBT< ?#U"5
M^:JK3^#W7/6/*Z$-M94XF,;O!&:!J.WX,;W_)'F;ERD%'E]EZ22=XI\9K@#_
MQ7NVMM&N__BTPM>C+P=@W#\MCO\YA_<?7![_\7?23<;1N#]TDZ"/>F$P<(>=
M\= %#[[7"<8BZ/>Z/_TVZ"P9W'\Y"?A,F\I'*4XGM/SU]G2>%XZ[(]#QHS!(
M.H.1"$=B@$>IFW2\:/#WH92+P):+P^/72C)BD?[Z"DYHM5 "H)K8EWJG.X]P
MH\'SZAW]\\D[^O#*AW'^<W3P=Z<31%0>$49!B'>RGCN..\(-.\->QQLE7A^!
M)8/N<GD$ZIAOVF8Q'/B=*(I&OM<+1-P#%R;RAN&@T^MWP,N/]3;W]MO\+=OL
M'?WQMQ<-XT[H#5S?#WIN$(-N'2;CQ!WU$A%VO&X\'@_PZKUBFX5:T[;S43B7
M:9:!78CR4[!&@I+:$2A:2DECZFE32V62YZ7 -!*8.OKP6$Q%DE:8%2K,JYTL
M3#'WE-!GU*]KC/$R#9L6L3L+BVHAAY7([/!EBG8NOYRJ@8[A*>(TS&)19F)^
M#@891/FT""<M2K/"IYX?O2<7=? ,)IQ.QF!;.;FKV1CA!2V5P2_L6<)O)[,P
M+>CC.+ <07/62HE"FB'U5@<=#7P6/ODZ $ ]_T_[(K[.,$D,9]+:G-KI_/D&
ME+X@#]U1Y _&R6 4]+P^ML3H#OVXV^N+46\\7GTTW=X-3/,K&C#_V]/'M?_X
MCFO#*8_^^;N;@-'S.F,WB:.1&PR&'7<$5QZWVXG[OM_OQX/^^*??NIWVLOE%
M ;C)1L/F^0)LK!^,^N"+B;$WBKM>KS?PP'<=Q,/OO]&;1$KV4G!Z^7=_T.^-
M_"1Q?4^ 91Z/Q^""=0?N*!@,XH'OA<-1#%+06R$%'/6 NT^&VX\JL*YD"]Z=
M:Y4MI?)OI-;AG@&W-KAT*;78A"+@9_\S!U77[?!M9SG.T5Y[(93WL  S\#/I
MTO]*DTDOA$F\_ZN.G)-I^X[Y2C@&I3JOUG]E*0UW3W=-*]_&,2'KOYM'@P8=
M'0LZ*TS>]U2XXT*$YVZ8P Q_#;/+<%'^]$O]"@[W;WO5FPNV=EF2Y,Z6A0,!
MH#-R-H"_,N($/@5C"K=F+ Y(/JC8_V>#_?GI-R+J1K/^ K7SM"K_SR_A;ZOV
M?GUX1 8F7<R@_CKP[RV\=P@^"BL@O\W_N_S?HW :<MF!]+!*YR7'1I1V.9B&
MV:),R5MZ#:[2-$K#C!RCU-9 \ZR)AMRQ:-('T)$,@"*0JUD$5(EA.B7=C'48
M;I;GYPRDTC#0ZBRL0-%>Y-D%.*!I><YA&XP;%?AE!I^>@$<)AF$>HN/.*Q81
MVC!.DP3T._J'!2>XZ>Y>G>6EL&)5X+F*MO,:'I$7\IW\_2B<PP?S@L9:I&/0
MJ.A_E//H3#Y;P$A*Z>N+E@.?H&C4-*\<#,2@#8(O-%](I@.VOA3LOX2E<RG@
MHH%8,3D*\-HC>"-_^"WX^\[A8<LQHN<=4'C9[SQ[!\NB!M^FWWG/EF5D0T7:
MW=J@^@G8]XM47&XH_G<W2GKBKVD%UC/:8-SOL0&I.$TC4 "%W&\\SR"SS^<E
M?+S<M1-]+,ZKL'#@8!?A3,RK-((3  =3AUPEM?\XS6=G(3C#$7THS!P) ><C
MAL<AOT"\MA6AQ;,TS2_(WX%KZJ4S$7$:X2KA.8"C%9(V/(/A@!:8P#V6/@#/
MG@H1LRI8&_F=I3-!MU!X CX;% NX>.DIZ55X1%S,3_5A+@UF%/T\F"KB1-&/
MS*>XTJ<+>GXZF<RG]"/=4C,A(:-XRX7+*;B+ A:+/PL_7PA0?&=B@GUI%\X,
M'#N\+J".4,LA1UV":T:#Q$&!(@*S@'=DT':P[JA,ZK]V8(4SO!+C>\/X(J3(
M^BS/%A.ZED^_S$^Q<J 2T1D/5[\<G%J.I*/BXA>SUA)3!MF?B=HJRL6;Y)G
M<@3PJS%"A8M#VPJS/85M.9]B*&("KP.GNIS0KK'S3NND$B[XGDEX+AQ\;9K
M3DXKN2]L 5)K%=02+61_7YRE"M[;>]M<&U*O<!?(4IB&'"6JW[24@9*R<DH^
MI@L<T'B>@O+/<O U,(YA%Q=PN?YZ!_ZJ&H+[.[&'4RVTE'M)<C!$F)>1^XJ+
M6#MH+-6NEO0GA^[)4R4G=-8K<_HY#!/"7TSQ"0D!/A:4 #R!3N@LK,[0 ^<=
M@(,WX6H6W,QR7J(]Y_W(XX7VFF@D%'R:@>_# :2"+FVYD^ 4<:/!&V@[A_QM
M&"GI"9JH^ HR2O4SSAB&"!8=%H<&4],+,D*%IY!_O2)X]F16B(LTGY<9YI;
M]!=\2D"XCO_[X1U<8H.G.#K0<6.,?*&>OTRK,_#<0#YR)3'?=?O[F+N_WH5?
MODFB?+K=]@J@-VXAWS3 SQ@$S^YDW!N*+2]GEH5C>?G@!7T.CF"59^[1 HW'
M^__-T_'8>2%-RY/G1^^?RGL]Z@5C?E_4GG1P"M=VW'U21V%68BG1-)Y'7+,4
MBYF@8UL3%,P0.@)50,C"O20EJP1 AD;/1'0^RU/2;V?I."4WCQ39*6DZ^JRQ
M.6@K,QHAFH]5BK068Z[@?V'EKQS<TLC^*Q95,8_#O7#>0CB?S,0$E I8W?DD
M'#\E!23SW";''6.0W?F"VYXMK)RW-$)"ND14)D57CK%0023\ZVF6CU$6KM):
MZ))L)HA[373KS>8BNE*[+9@6 O\@M\^>S&VLTEA'[XV:P5APS+:C^43U)#CB
MF^WH_@#??D];]K4;-\Y:?;3HCM_WE<MS"1\9"]QLJ6#Y7KZT'TN[=LMRTWMU
M%9>4F%):Z(B7VIX6RQ%S3/_5\X1XRYB6SI,J!W\0S&#K!L'VI^RGLD=Y<WP/
MJ5C*YHXQ/@\CPY1E5"7SC&,R0CD-VME,YO!^8=M5E MV[WH]>A/]T.T-E?IE
M$\[9!S3:A3 C4Q_9.2'0,R977[GP]OV.;TZ'O[M>3_GU-=<</90+NG N.?33
MJ7+ZPSB<T46?G/RT@BOT 7]/!DF6WR&F9R&%W*AD>5Y<P*<S>E@",JJ^!V^8
MXW:<P^[#>)X<__>I$\%)Y\U*T<V#1^BOH[H%)TW6(>=\!7_Q<OC_@=LUR<'[
M^L#?;H.4RB,/<G8&9G\JAP?KA &"&&Q\E,'F@\S*2"//GIXX@3L.RF(83\"<
MEW"UI(\Q<C"3X80IQS;B' NO*82(8H@I++KA5PM5HUWE7^&^AFOVX:S(Y_ =
M+#V=P'3$]%3&GNMK6(A(S"J*9J)K^;7EV/M<O_G3*NLUA8<>_Y?6 !S4&=[:
M=(TK9SOENILKLPZ+D-O"RZB4Z03V$18IYE JW?LDPT$,NX8A!ZP.=ZLY?*EY
M_VL[;V$:RAU*4G*5<"M/3_$6KR=T%K*(6#$<>-EB*N"XE621<*MH+P6K;GPG
M;I5K7'^<,$4XHD65J_56@0\55V#[82W:BX-W[@<3,B+#3V7O,&@8"=]&W\(
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M/[\$+4\..9.BZ:%CD)8NB/9E+]1>'M_]5SU>39^V9#F^87T5%@O_YR2J<CF
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MGE/9( MU"5HCV$\$CU$^5)]6"IV?AA(YCR4-C@1BE!&F%U$F.0(O2^/A2>2
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MOVV/KQ"^MR^$WX*Q/)A"^!OB\=_9I3M66VM5B;>](/Q!VQ]T;@7"'[9[W3M
M7WMM[VYP[=W-VI\^W,%VV@/O3IKKWM%@?7\/PM^#\/<@_#T(?S=6=0_"WX/P
MMQF$?Q]1^G?K:MH%.\9W!]Y]F'#0AP)>]CJ#EM^[92N3AP)?W@OSPQ#F4:_5
M[]RRZ<M#D>5'(*X[))&>U^H'#ZC#S<,$ZW@W;<WQ4  [NPBUN,Z395JCLBHM
MXD'D0X8GX2; <.?Q@A*898O24T4852O2F_#7."TPC40_,75-A81)FB"JY2 %
M5I&&&5%)SV89,7%+@B/FV"$.:XN)>R:*$DF_,OG8)YR5Q;>680;#Q2=(6(5D
M]2ZK/#IWF><2^73@X13O?]IVKET,RHKJQ*]B#,M!),]$&"M&+F*3ENNF.#8E
M)H7F$$9I1J@%5Z4O:?!MYZ,"B4@*KTVXR"1#5>A\R5/*I:WADS7LW,N4091
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M<;M \UX(Y\\7SR6M7HFPVRP3TU.AN7]F8:4949C"D5>5 +!U\&RX0.8B'8#
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M^LH[^RN:/?(I?H>TL@Z6OJ^+R:NOLL#\!?K69<FQ?PK'@)R#8TR;RK4(\+J
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M7]GN?F1/;Z:G9VQ=+!!%PS=_<-'Q._2WE"X\JO1  NK8;LO'&[-@)2!U\O&
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M",L:L4>TA!1]0X_$78,D,3/N&0X86?FI/UWS];JQ\HZA8"3.;/6D8.(X:;V
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MHJ'6W%S\(955E.WO%OZ\6)4HOK/P.J*0:(K01$A5D@EAW/Q0+8DRILJAV:2
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M#3C^-=L'<VL_= 3B/JR.8IPJ&U]ADTR;<@X%%<TD3(ONBN(S'H6R]DD(?A,
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MFQKPG,X[J%+6(@5+"R8: YOB,:M@'</AG^UBI\P_ Y=;$U+!+T=28\^+),Q
M_=YA"F'JH?&+.7)M2IIMVZY>XZ1=45\"O=AH$#(HMGIIW46:9@9A3 ^.L/-P
M2DX0-Q'X0XCVE2BQ]#O)&L7(1<VQ1;D2Y0[? 910#4:=245'1#3:=W'V?1K3
M+9[1O6J090?%"$M/B7( ]5N3>"E>9)LJI O4/+@AE?)&S<K+$%2%J#87E(RN
MRI[@BQ.A#4]\04V%8[2*2IQIEB?Z@"U"9QYH>M5Y\$+X%Q9K9Y8'"V-<SR1
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M5ZSE:%^5DN38& ^'=5^4*"L:K+AN7!E_4+!VB(_$$HW$7E+9"QUGTM3@#-S
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M6M N!KZKCM]$> +0S*BI)T;B[CSULV0UT-?>G;CK5'7E0PEC^Y '=#5T]VJ
MF','B"89XRZ8!+^R #%?@ZJ^:63"(=L=V%-U;_7?U,;<%F#9LW"LA0"(&3A>
MHB9,/!W_*!49(@ZS+;,GS +V"<#/$@9<*X7((I&JV-C^.@0^JUW"<)JW);/3
M<)(9_RP7!L"WX]*NS CVE$74P[?KAIO\M)^!@.Y%O[[Z3J4-XR<94%H<<MUO
MYW'Y>CB9&O=>,YOO-9/[I_$>1VW69$E]\ UW^Z!SLD5([/L'[JMK].[3'\S\
M&&D/)>3@\U[45#NM&^*<"U'P6M UR^V:".Z*UG)?><75#[3Y"S&<$K<@6\."
MOL@RD/7+9SO/N8+/?]V&TW>%+I'@/X3WV--+P<<Z#H"$7C22$R1 >LFXB B#
ME) Y7^=43J39GJ^MC\0.RL^GYZ>\!0X^EDARN_Q]B/M#U,Z]%G)L;9;"'9)
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MA=(GH#(<G$P5\_V7RIEB:@3',7__,;]KC%:J?CD2,VD!:P]P(4^%".Q/Y G
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M3,U'N9!Z& -1G,5(T\V"(\Q)CA1^Y$..='  Z$R+-&U45&C;(-=&C4>X+W3
M.;& OHJ9%0'$T3"%"G?3;XZ+Z ,MH@0#YQ>2GW*&^)7K*7'*<SK-+2BCHDGI
M4,4%4^1:L%GUS$I?![JSTJ>0YJKC OC@5J27 NC1P)CMSXPAE+T)LB0 HC'1
M$34#H.1% &W.[V.!F"=KI(*<DQ3&)HMXI!*Z9JHC:0_3Q2/X1F(Y%+2[SX+N
M7R-_/D34XR,BZA8\R\?6.CD:OW<T?J4OTF^D2$_U%>V0BG9'.>&W;3\SP@8N
M1*W4U1$C,0*(4@--Q:>DG&J41E'."50PFXA12=SMXXGWP5P>R[D2TS TSI!V
M-7\X=TR_&N&8BJ;/W52%2K>& W06U3PO"O):-DM2_)B%.4<>*>^8U2,O*5 +
M\7"POIE^3#"9C!E$( C'(!PPQ$R#/0&87TO;YEPM6"W\&_KHN%H^F(E ?H/,
M0L_G'3<>U.A62N>B=5Z[K C<+&W6QC1B2=PY'88#"2J??;I)LHIY&,*ZAV00
M-P/XK]XK3B].L]A0+E14;5M031KD.)0E:>]KRBE-3C3%AJ*<JG-YI2OTEW);
M*&W&<&5YIGX^R\VZ9T98D$JNR:@XY3W6JE:-6N\WFT)T*A>8D)E'EO)^(Z)
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M/A_2,P'@7XRD&/G"3#PC';PX@MKR,8T(L^^I\:&U?F_(1G!_KP(K/$BU4*F
M%[NSB5D$F51K,.A+=_:1I\PL@JA@+7P!MV?F,VY0XO5E!6GF0H!TT9:->/J;
MOA(@B 02#C<&S(=!N&1,2KC6EOFV,UOHL<%JCSF6 \O4TW+@$D\G3T9QV2G%
MI!,Q NS -E1??#L2(D8%BDT.0;TF:FM*L3E%=]P.(>-;E+QY7_=-]T>NC.Y.
MPGC4H-*.J"8O9ET-@J('#[_B.WDSRAM7FD,O-9%?Y5%39=LQ!ZI  #&IJYR
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M$%T8>N(GC,R0=N$GU-W#?BVO2!9.K*)V(KKU.(&7.("GDY=FU\-9MZV025\
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M)C9SX^"R?)'[5-06-?:QYVC?:RBX&BI(.N+2!2(HGVGF-)%+0O\V]_&[?:=
MIFP$]Y6<SS3:>/VFF#=H2G]=2/6'XVRWS&-%4U>[AE:)LB__N <&)'"5>PV
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M=&6^?-1O)J=/Y##_ZW].F[_\]8B6,;3,PR-:YA8\R\=6'+WYAOG8S<14)>9
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M(J8%[Y@_G!1;K$!L4>#/ ?A-!?[#!+\IP.]AWR_1D)IFBU#DE3QL6R4<D%)
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M\_#<(_ %5UOV=#=C?H:<W8')S<T6NOQFB^'W@]_L3R=Y[)[]#U!+ P04
M"  %HZ544J*SLNP-  #QD   $0   &YK='(M,C R,C S,S$N>'-D[1U;;^*X
M^GU^A0\O9XZT% +I5=-9T<YTQ5$[H%[.[MO*) :L)C9C.[WLKS^V<R&0Q"1
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MY\/(QRWU6-%I-]M6L[- R14)6)K,82M\V !0"(9'@4!7E/G?T!@&G@0)R,\
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MS;AVR<EN39)V"FD7Z2^7N#J3CLLBC%7(7"F):7"9'!\=F2\>T%D=2^SC6U^
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M(G#GN3'*=4H"WV]Q]0&J=.ZD^1NVD]UGQ'NOI)ZSFV09E0D"F<"Z!2:4Q(*
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MS-/IWKO7Y=T>#+C\DT9[H,>F[ML[Q%J14=_^%4;5[=?4PJC[V@=E.2DNJ&
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M=;KFA'_R?OT188D__^W_ 5!+ P04    "  %HZ54<SIB%X$W   _60( %0
M &YK='(M,C R,C S,S%?9&5F+GAM;.U]69-;-[+F^_T5&M_7@85]Z6CW#5FV
M>C0A2XJ2??N^,; D)(Y9I,Q%4O6OGP3)VLABU2$)D+4HW%VJ]>!#YG> 3""7
MO__7M]/!LR\PGO1'PY]^8#_2'Y[!,(Y2?_CQIQ_^^/T5L3_\US_^XS_^_K\(
M^9^?3]X\^V449Z<PG#Y[.08_A?3L:W_ZZ=F_$DS^?);'H]-G_QJ-_^Q_\83\
M8_Y'+T>?S\;]CY^FSSCE?/6GX[]19U2D4A*A?"12*48"XXPDG3*/T1FGT__^
M^+= LS=26,*I3$1F7WY-<&)E-N \MXGR^4,'_>&??RL?@I_ ,YS<<#+_\J<?
M/DVGG__V_/G7KU]__!;&@Q]'XX_/.:7B^?EO_[#\]6]KO_]5S'^;.>>>SW]Z
M\:N3_DV_B(]ES__GMS<?XB<X]:0_G$S],%X.@,.GZ<4?7D6CGB]^B+\ZZ?]M
M,O_[-Z/HIW/UW#F%9QM_HWQ%SG^-E&\1QHE@/WZ;I!_^\1_/GBTDY\=Q/!K
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M V&<-RI6?2.<(Y3.J*.NVTFP@ZQ;7X^6J[+YQ=D$QE\6K#=2<2H!65^"KJ0
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M[)(?(*(A-:V?@E-CV/V+']>>^TJB#8L0,U6Q],J4EAO/DS3<).J9HY:'7@T
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MTA(!;XDT:#!8YRU1/DI(QG"CVF0WU9S%?L%@&T8J1]']Z112.3E"Y[!G2W)
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M ,U#,F ;&=<.S/7C^?WT5?,P<XT[&3<$@L49,E D^ 0$+4.C.$TRL7K-16X
M<-B SEIZ&=43:H-[^0^S,.FGOA^?7:E1->>S%#;KE RAE#'TYZP@/BI#O*:4
MQBQTEKE-&M(F2$_<7JBKL@:%@J[ >>M/\=,K\SZWJSL@;'HM?S?&X]S$5U+J
M*E7::*3!!7P'I#X&G:T6Q%$$*:4+Q.:,;S PH8&!E[Y17N21.'/'-?O1*+.-
M(FH?$\V+:E[T0%^]RK7*62@E\D1I?!X<FF !33"N!.51\216&;*ICN4MHQS^
M+K6V2D8MY%G[2/<B$7S.Z!P#5=)8W" U+1T6.'$E]85Y*KTI1;]5MQRA:X]]
MX@;%GG*N72'N LF2TUVPW&PKW*7[8VST^PK[1IWM(:GJ/0I7,%%$%$0.1-#2
M95L(7)NBHD0%*PPUS +M%M=T$*UMV&I;*FT; 353UKLAG ?@&*D,S9E$%TOM
M(:.)+]FFV;@2(&Z4LG8[?5T\^W [YOZ"OE%CNTFI@;?^&G>$4_@P]=/Y-O!F
MM"@A-2>FH )R"HEX9A*17@)NUA&(23EI !-5:N.OWP+JB6^PM=56L5CF'="6
MKTX7<$W=]5OA'<=3KZ;,;B390Q,-W/3;05+IHD@\HQ>B9>G'@_Z"]A;=4/R^
M$=1XS1\+3>YPSH_#DFT4<+ $U&4=\_,=5-F@%,6%4[$2OJ C<3Y)(K*P+BOO
M96S3Y[8#N,.[]A75V2DC='==5+1F%K<KL^$4QI_]>'I6#C46&;"<>NMS27*D
MB =$N0O1G*3H),A27%#6NV"Z"<$3MU>J**9B1>:"YP0^KYY.K4(\?ULZ@*P>
MG- 9WC%B%?;5Y.A0:JA\>=T=K,TA>D4U8>BVEZ0T2ZP"A_Z<C=IY;02#Q\*5
M6X,:CD*5;:1_Y#2]E(,13C'"HC6X509&G"A%(3D/C <AF.W6(NN^INDUU-P>
MR7G;B+VRA7)2]M:%O6ZDB)(ZHIUR1 KO20BXE2I@TD;%E?2=3-9NB\3YL-]M
MD1U54+.8_P6*RPCY.W'4MS$N 1S>BMA1!ZM:W$-^M8V#*W!*]+Q.0$F()2>=
M&5J212T"TQ %,*]IY3?["&GY];6XC=@J:^\W_ZU_.CL]SX6(*@MI(O$Q 9$J
M,?PL!V+1-E%,^ZA$/8?QVM 'WIAW%?ZHAN0V;JQ_?[XR^S?XY?P'\^^7V9U
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M=] '7H6,*A<F.>$]:&ET 5I)RMZMQWW_=SLOU"" J\VWL\;AIPNP@6(;C&S
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MG3!("44P0'$H6911)IR*BG3T-37#N9(-1#V3TAW THZ8/2$T,+&V$\35@EZ
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MC[2%Z%0>2>MV^N237"[N3&:GJTW%KM^H,>97+TV%6$XHYBQ)H,!<FF3D"N(
MA]!<"#$62)00JRA/J]ZF9@(;><%>13/PT(@,'KOKM?8 NYO"O$,X,%]5Z!E9
MP598L);V5+7;'NBY)&3TB.)8.1<MOD5?/DZV\'2G33S5R(B9$2WUV4U^:/M2
M[PO[0INWFMWK_UXM+CDWT;5E'=MO%H!91$.$8LIA1C4%HT 02%@FH>2"*RPD
M3DAJYY7LTJW5US^J)_):QB8GAA'2^<[\--K6E]]^$!SM%KL2$_RX%O@G4Z=@
M@^C7TXCVN9JVALCW'?/ICL>^++:&XL"MK_V[/;/TY7?WJVOUK92792E7UZS.
M W:U^/"=WYO*>=H&;2Z9%W>?C!";:C@SP7$08XH@PDFF#<*40JI8 %4LL H"
MR7#JY"IYABQ3,QPW8H)Y-?<*HQI<*OBD_T*-=H;)EG>+:J>FIZ-L5*Q<@^IW
MYMMS$,=<@6>,J1T%CC12 S/CU_6@:#U I0A8:V*&Y$-[2+8#6JFSK4CF,4'A
M^:#ZS6)XACSCICH\'[A7^1 ]--F/D'67U^I#N<JU:2_+693$5 8!AAFC)LD2
M(I &*($*(Z+T;CQFS*G*^&[S4Z--,Q&7"FSD<^.]/>CLJ*P_( .STSX6%Z#)
MY3QH3N?#<'CEE;TN1J6*P^KMS_XC3_6;T(="[HT_^+]+<;<3=-\[5ON,'B;T
MO1_,1U$'1S2*M#)2#!W@[0%2KW/F''E&G6 >@-N?C3Z:['$R_FXYUS\OBZKG
M5AGQ.JIC)<7'IX70_<^80 CQ*((2FVQE&$401WI7)'% ];]1F3E$(=OV.K65
M>R,?4+6 X,>G1[!:_N1PP&N-N,4Q^1 X#DR .R+O%J[?HMN(/02J#L?G0Z [
MTC&Z%Y3=3M-=T>H\5;=N;+S3=5?]=D[9G5_N9X7=\'LIGDQT\8>'Q_GR1<H;
M63SG7)K2H?)7O8$3NL='N2BK[^]R7HVI_LFX.*X/:NIS_ZJPQC90-4MB&8I8
MP@"Q!**0"TA0FD$:*4QEE$C$I<L.;3!)I[9DK!4UNYR;E1805LJ!MG;@PW?S
ML^-A_W"#;6>03V((!UZM*E4@JT:L24R]RZ;-R(DZO)D^YBLZ-WI5+BI/^NG?
M;RO/P4&VL8./@%?K?CAI1[7]!P=]?V<P?(=GNK W_HMF0ICZ2Z_<%LM=O\5=
M)\?-B>)?:;XPH7]7"SY_$N84LDJ?950KY+W6KMH:F<"_F4@98FF40$F9@@B1
M&%(:8ZA8@**4A1*EV*' ZYLKU.,F>HSZL._JBX%\4:6_4L9[^MG LU_<X?Q<
MIF_W*=DM==/^,L;WGF_!4!?K>^TE7^ZYR5^\=JW?X'$!#"+K$/0U*N;#6U=G
M; $#=@+6!W"X?ZLQ'L8K?W1MWL9U_ZT&[:A__YL)U*<X07%'M950FP\+<?/T
M\$"+EVMUDVOC0>6<+E:-2X86L+J7R:66<1U<%%*<D3 34)',A)V% E)!]$]1
MQ@55*B7*_FCP/%FFMOMK:P.T.J#1Q^30:VD$MBJ!M4X]0LA\#*;%J>-X0S3P
MDO:/-SHN51Y&&Z6Q*D*T1\MLM\MFM+0Y6K9&BVY'Z[%1RUL="2^8=M><.*^+
M$>M3>,%BMY:%GR8'S*"XN;,. KT:1P+!$#.]TJ6)@D12#M.0<Q8EDH>95<!(
MK]ZGMLK9I_GKF?#=;6SL]G2#(3[X!9H_L(?)J#BHCX";!-/+IWC*#Z!?(VZ4
M)V0^:T+M7L*(W>:KN9PE&4YX(E.(&480\8!!PE4(*4V2D$<13PFR8;1#C4^-
ML"JAC-T01C^RG];1II:'5@?1Z^:<<S$9F%)<X;"FC2Z]#[!"*?G/=\OG7_1K
M%2'\'9D?8?UCQ0('&QQEDG>ILI[#G<^\>9Z8ZB)J%C,>HPQ1&*N80D1-K%6H
M39A(Q'&<2<[U?OV-<L3<NL84_2/GAZF4?;O4,+<.H6!O.<0C'FJ/.+IOF0WF
M=K"P-.]"_J-F@;GM"G<;K)\^WI^TO-=6YC;VM[Q:_$:+/^3*M+S-QK ]@$)9
MDF4!3J'@4NGE0S*(PRR#1(1"1E$H];_;NX&Z=C^UQ:$JEV(V82T5S+755HE6
M)I.^1X;N@V1QACLH]$/O@ WJEWNH7[TYZBZ>I4.B/Y:+J?]OW]'AM"^(W9ZG
MSJV.Z(+:5^-=7]3>K?3,+V9B"\M9'%$D6:8@H:$RB744Q!P+B*(D%8P&(<7"
M*6M8U:S3BC!"+K!;TT<=^^P8U]? 9&>2NRL_,"=?=FOLGHAK1T&_Z;7JIL=-
MFK6CSJM46+O_VL.0^[7(R]5R_MN+-GIN_OZ4,];R.%\N+N\*6;DBK(O%,QQG
M:9+!4(88HB#65ER:(HA(2 (A:"I$:&W%N?4]-1.ND1Y4XH-:?K"C -AHX& ^
M. Z(A<4V',P#4X,+PJ<3XY__[=N;:<-!/I*-=A!ZO@,]72OAZXZ\'VB=-IEC
MD^,99/UTW;'&>C;1_XY[N:C"4"KG\?+R:76_+(R#^"P6::BD*4O  @F12&*(
MA8QAK&1,DD1R2IUOM(_T-;4UH!85E$;6"U!6T@*Z$1?\J+<U]6\M SUM\+8S
M]#RA./2.O ;PI@:P%A1L)?5[_WP"#N^WS<?Z&_UN^83BAVZ23[W2P]1<NZ1>
M?_XJ33A $VK2.LW<%#J]O9<':YW^M=#OSTR5T8BF!,9$I!"%C$(B> Q)S%DD
M*$4HM<^YZDNJJ5%355E/3ZUBJY6YJ-W$61PJ4GYFC7)O VQAU+[%L W,A>U0
MANO/H*67<2MM7S*UZFIKY8[6UKX E8IO,8(.MO);C.1(5O3H(^IF</M&OM,4
M]];9>$:Z;WQVS'?OC?=8D9MJX^M2ATU(\EZY\4UW,X52'K, 04*5R7".%&2(
M*YA%VLQ/TH21,+;+MMNC=ZOI/6K272T_Y.8N(V\T +)6P2R[K>R4AU;:\LRE
MUG'D@D D(<^PMI-2#A$1 E(5Z9&C,<<!4REFW-IB&F#<1K2+_H%&C69"AH@$
M$'$3K<Q%;*IR93#C62KB-(D9([-G6;#E&X];6X8W&+GA1L#"$!T.U8'-32TX
MJ*YBUZ*O4U*TC9&U(?)U^*_=P60<#O.1#,/C)-1BG?6.;,,TO@Y:^\'7:=TY
M-CF>#==/UQU+K6<3_0Y:_63J^+3U+5&8)4H2F,H$010*#!G%&$94DH"D:80Y
M<SF<]2S?U*R#=MJ>G41+K=P]@+V @^E]_J2%N-A]S6A[1DE'WU^#W='Q&X[Q
MP&N>AZQ,-F/I?#H]$.)>3[1]RSCJ*?A  .^?G _538^]_9?E2G_1.9V_WR;<
M^2W7>YC5<F'V%CPAL0@%Q,:S"E$104R3%,8I%IE4D?XG^]0+W7U-C>,WTJZW
M<E2(W R'_LUC30IE5=2@G:KH8:-.C\RM)\;"8I?A#^&!&78+;DM2L!75'VH.
M^P5_Z(VT/]BB>/@;]+43L .FT_(_T<1XEKZ=+CN6O>4K/=CWMZ?YWY_RA4F^
M764D>$\?<D;KOS;N1"A0F0P0@YR9,SEJ3E-))$R>5)5E<8159!\0<;J_J;%P
M(S&H9:R\\FNAF]\X$(4%V!84ZQ?"@6GV%'I]W.$L8'3@7+]PCL2[O3]*-]JU
MQZ:3>BV:&8]^[77:H6"'UWH>J-!BD2_N2FU?K\WQG,^R1(4)S2A,3*8"E% .
MF4H83)%(PB@1"$NGVFP'>YD:Y59"@85<@;EQ#GF41>V<5KFI">,\6+1^Z^BQ
M=AAGRP.'<]$;F&W7\IFBO/71ST45TLL]G@!T0>!W'W^PIW%WXUW*OMI3=S[<
MLZRC-)52N"E7N[C3K-,<YIK=MSD!XLW/X2P+*<E2H??%B%"(,IE!:E*=*"I8
MF.)8!)E;#4?+CJ=&'6OA #<'FJLE8+)5H=&Q_J(M^';D,02D _/)CLC54>/Z
MRLU(6I]"\O5?/590=$3*;[E$V\['K8WH",FK0HBN[_?C*^,HM,WH]/)%5C4_
MWLUI_E!^?JI-<TXE4V%F[!ALRBQIBR;# 0P54SPA-$L5<6&JTUU.C:.^%/(Y
M7SZ5@%="NI&2!<)V=.07MX&)J'(2;DE[ 1IY02WP!:A%]L=!]O!X91^+;D?E
M'7L8]AG'X<U^7/.E6'(I1?E1"WU5ED]4*W2MZD" ;PO=SI7^Q:(J1[00AV\X
MONB/K)R)F$0!CB,842HA2KEF))%AR##*HCB+1!1:Y87S+=CT>*O6"YC/9!U$
ME&L%M0'P9/0"4F^15R_:]FK=+#\:5=PXSMO(VC'A6XS7T+<;C4H78*U059VI
M4NGBL%/ [NVR2<9NZ/7ZL1K$#]]EP?/29Z"3;]2]TK WX48E:]^0[E.Z]_;=
MDWJ^;\Y7;_6K,XP5PS*.(8TCKDU)Q2&)]?8WD@@3E-$D$JF=W^E^TRY3>1RG
MTK5TP(AGG\9S!Z]N.CP'@X'IS$YYIZ2=AS3MG;!SI['1DG4>4J&=J//@O[M-
MN;)8S;[H>5S5<7RDBY?U_4HL)$XPAE0D(40J#2%.L8 B"&,2R$3OZ*R*)1YI
M?VJ6SV?YQXH6_]72C#D&6O?T\P#%T$9%)1UHQ#M]<V<]'T^HWK6RZU=;J[K^
MV_Z*?JSM46;I"<76D_748[W/CJ5^R63":KD--(Z#,X4YHBKE,%"!@(A%*:29
M#* B1*1*X! CIW*GG;U-;3ZOA:V.-%N>*\[GPQT 6Q\*^X%M^)/@+6)MCZE3
MA5W['/Z>1L3WB6]'CV,?\YY6_L#9KL5+/1;^8BF>>)6EO_$3+=\O'VB^F!$D
M)%=*P$PAD]\NUKM)E!"HXE $,4UDF%J=F'3V,C72: 2M9D CJ8,]<!1+"ZO
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M-?E& A@R1A CB:2QDQ'6T=?4*+>2#80]<\X>P-+. O.$T,",VLX+6PMZ 1K
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M<JT J#0 O]]6^ ]2.Z<OBL.D4+(5XFTR(CE"=#3!D6L[PSA\;O)!H"Q@7*(
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M"&O%RB(KF7#R"%XB-+8-JKF*;9B]J2,^#*1@P[#O/?89?%UOL*]';9B[ZQZ
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M*3@KRI1 6MCF]<H>NPJ60&H^EDE1Y*GTLEVB<#DV);81LJIKV8BYZ:E8ERZ
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M?_F6#@#"5G Y16C8(BX=HA[5<>EZMG\:H+ 'F-,E,C=N:9[D"::VG9U$MNB
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M@A.S/!-$RA3F968K^2,!:8X(3&E28J13BI%7N:=N<F-;S#M/P*RZCVY=[-\
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MCVSY4O6AWTD$=B*!C4R>#IRAORF.+J$1SW]L)U-+])O]:[KF&J]UKV>^#EL
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MA12GD#">PUQDN< \TZQPKQO7FXVQZ2S;%JI25\M:%+"L93'_UL%>ZP58_U#
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M->1<I!!)QG"2T51G7H66.VB-3<&<6# 5M]>IFS:X_=1,3\B&5R\5HQ&"[1T
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M][41?6L_ S6VN+O**?I;/+&WX1N\;@SV]<RK.RWUKT)PV81,/(F@DB_15Q+
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M.IGDHUXJZW83-RE82^KB^H@:-!^54QEL$B4Y2X3RHF4@)$FUUXZ&W?$9#_0
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MRH**.4CKN&2JSF/-CQ#_VP<:1\;_]I'3V/Y0CU"4XR(PKSVB0CH03DHPF@K
M36JB17)"F'_)^-]><MXS_K</T]O%T%4H*C@3L[847$ZJM.,SX)()H AWG D1
M#.L7K?G1XG\5,'00TQNX#H>=I1"M0P8JB*49@4A!@R^L$)Q2QDQV3N0J=^7_
M/XRJDLDW&CS&5J^;Z,C%;]T\K:;_7(O_W:(+*<7EA"3+C2,*-"O#NF4P8*22
M>,ZM3K&," _][N9'%OF11D[M(_:[,<SC93 VEMZ4FJOEY^UVWJ>O:7Z>'H\
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M +0! N-9L,SJ/%$/0OX/UR?KD-MN/$!\WZ?@1O*4]]Q:IPK'T0#&HR_!.L^
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MYW?K](JVQ103,M26!Z!L08B*/FG%(Z+.=2I*JTSK?K)Z-K&]H^9Y:K8C$0X
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M0Z8T(Z 6:'@P6;J#KAH<CH ^3<,9(ML6^@GKU[/8_S6>C#\L/CSZY2GEXK&
MB2CJ#<_:J:R>X$?OL]6VV'C07G&0X#][=<^B/T5P]UVL8M_B#W\^(5P+%PCC
M# CCM5I-4%B6-$(2T1AI8D)UT.'08>)_^NI^(I7.Q'_R*@[ ;]S:^G[8%'!S
M[;3E'D1PM5-F[?9BB0]1-'.*7*,8+I*?_>&HB\?M2N(;)VA/6_@! .@S9WH9
MF7UJ)O3CHFK$;?GI?K::/OGZ;OQA/*F_7A7@K\=9CI@M2O!"4$!E:T)(@:_M
M^H6NJ<I4@DUMJF4Z('Y0:;L34?12IN4"(NT1Q1G'H]>3^7C^\,C98S W&TD=
MLT;F08K:$Y,[ ]$9 \8D"A5YDMF]U,-YANGO[^\__H->L03D[ZI^A-7')0I?
M>/F@<G?GH:JK)1ZVK:L-(M/Z,Q]9(7D,F@%+DL*(2+M#5+F ML9E^D#[0IL4
MWJ$4#BK>;FZU3A=.^RJ<]2_JE]IV[Y]_^Q]02P,$%     @ !:.E5+1SS>@%
M"   JB0  !D   !N:W1R,C R,BTP,W@S,7AE>'@S,3$N:'1M[5IM;]LX$OY^
MOX+KX+H)X/>7Q''2 &V210-LFV[.A^ ^'2AI9!&A12U)V?'^^GM(RHX3)XW;
MN]VFP16H(XDSY'#FX3-#2L<_G5V>CO_U^9QE=BK9YW^^__7BE-4:K=9U[[35
M.AN?L0_CC[^R?K/=86/-<R.L4#F7K=;YIQJK9=86HU9K/I\WY[VFTI/6^*KE
MNNJWI%*&FHE-:B?'[@E^B2<G?SO^J=%@9RHNIY1;%FOBEA)6&I%/V'5"YH8U
M&I74J2H66DPRR[KM;I==*WTC9CRT6V$EG2S[.6Z%^^.6'^0X4LGBY#@1,R:2
MMS71VQ_VTH,>1?O#PW[<[T2#'@UYW!ZVVU%[/^K^NP,C6Q /.L8N)+VM347>
MR,B-/^IWFP>#PA[-16*S4:?=_GO-BYX<IRJW&$]#/UR&;C8ZLW1K&UR*23[R
M4ZH%U65SK*32HYVV_W?D6AHIGPJY&/T\%E,R[!/-V96:\OSGND$8&H:T2(.@
M$7\0;()Y_G8>3#Y /U+DM)Q"I^N,/K_-1"0LZW6:G?L6KT^<ZPGF;E4!+72[
M9GL,9Y/^3L:?GE^-+WZY.'TWOKC\](]MS?_3C>T_:NQ%G7U0<ZX3=MU$?Y'(
MZRPF;46Z8#;C]LW.8'BTS1SV,5S!DP0+I"$IQ7B#94Q$GB >HX9[\IVFV6DN
MY_#7CW[?+;V#IG?#!<OXC)BFF: YJ,5FPK#?2JX!7+E@5U0H;9G*V2]*3UFG
MW?B-I4I#C%@!*U3""&Y-V$>NX^S-3F>_?=3KU ,%J126WUBNV3@CS0LJK8@-
M0GGX"D+9?7&A?,\- H%031?L)E=S2<F$ZB&B.L0Q43 A5\@D&(&+G/%\P<K<
MZI(P ^06GV80-\ZFN-."2Y;R&(\T4U,PH55!;D,@IYB,X7KA1*;\ACQ$5GT:
M/$M@#(:4/D=A#"<0"XV<!+$<ZK D(<WFF8@S9DKW<Z<_)TU5)VX"4V$DDI?+
M@W-A,TS0%!1[ ]>P&:L9U!(6+=;=\$H0V/MQ$$@L%3EB[."R%E.>0QJM>JU9
MY. 78 N%$ZYC63IV 6S6XE<'Y(1CIP)1=X!U0);R#I$5&,R#D0'ZQ%=D=2=1
M2@@ A@I8\<,%>V)N,I9*-3=+C&J:"&-1SEG&W<.ZEX.5]36HF:4Q&]:^$K3U
M7QS:QO=B\V9GV.T<')D*4%7QX/A!I:G [:[9\X&[8%R3APA"+B))/J$18!E)
M83*GX<2FH$='D>X^$2:6RI30<\2IE0Q8*;2**<%CPW8!C82 M1#_\]LXX_F$
MV#MPTE4I(='I\49GL$O!BLX@"7?A5KA",0\8=?TS1UQKT U0<K8\.U!(PM5H
MZ;W1TKV]^BI]K\,:(JX,^/8J:]AY"-7>_G>#ZB[?>RE8[?:;AQWGB#,RV!$@
M9CZO/0^HNDNY,2_-]BHN]T4$<%0CA6RJ2HT.0%(S83SU08IRWX\KK.](<YUX
M-4GNT5:ETSNLU"M2=HT"! I;C)(B\?M24T9&)()KX28@0M+WF2!W/97&)6*_
M/HW/VIXHL?&%0=B1>J4"E:>(2\D=OV-:WHB[A Z-4!ZL5S6XBL@)@H*A3\FW
M4^[+PG'TDG#<ZV_B>&O:VH#S]H2W-:JQ$F8B<6#E1N7<,3LW +JK+1V"L;M<
MH@GX%CP24MB%R_*/#>O6E@>>QU18%O=$U^H8GT!NJPD5I2Z :>.KDCA6.O$&
M^"IU0CF*#0EHHX4*MV:<""KP %^L+5%X#G\= (Y?$H #$9_/N"P]6[GH4IJB
M4!0SQ,4\4O"MBHHMV#?</EX#>KQ"$<QI0J49J=(^;<$V^8&OI,F5T>GS^QX6
M+>MSOP0I> +V>+B%N@&CO +<)2\)=Q5QAI!N0L-MP:L:SK<\BK^OH$N7U%4<
ME]H!8"V#/M+K5!F+Y^Z8$GV9&!W]'HY^V.X3*BF0#")[(%T9CKT3^=,#=["0
MERN[]H)5&3>K<L-1H$<^)3XW>']4O+U@4MR0K(X2'LC7_VL7-7_\S=C@]6S&
M_/%CLEP<]3N.<I2Y#M [NG(0^XK*8Z.&75G'4<=:I<TJV?L'Z'(Z%=82?2$A
M1,H=5J,]$;#/=[(+&(-_C>-W_'75]'+MT>^E@/E^G95Y[$\;]OZ_V_K3DOP[
MB?H,]:( V-P&UVV88T& 1I6H5[N>.?$;EWE#O>9SKZ\T_8GG\F3HJP!7;5#"
M(<,CC,83*!I:$=J3X*SJ4Z@ 82@CZR']&^1^4TZ!#WC)3Z9*)(^>H?G4SEY'
M5G^!VZ%W2-ZI!FW4$7;R9 ?@^ /J"F'UD/M$/E-R1BX!YGQ2G;/KBA]I6DBU
M(+3.,Q48D=_#+_#V/ZD.5FG#^NU1Y<$(X"+=@",E+PR-EA='H.5"\L5(Y-X=
M7NFHPDNDK%73D<N*,T?O* >JMYX>+Z&Y>@4\'#0/]_ON+;#5^)\L!ZY>$#?]
M"^*633;;^L-F;WCX9'.[V?G&MOW!TX-^2?,98P?[VQG4\HX(SH"[3<'SM[5>
M;:E0@6W4+6[9:@D&[SK\/?1X</9?ORS]F_TS -VG,O:1+]@@O/M;L4WEB"_,
ML<T\96\C^B.XX\U.'TO2_[(/E]?OKL[\*^W+]Q>?[CEE2P1\A7>V$*U6NG_9
M7\ U[N2.+7WR,KV\\7&#]_*#CP7<)R6GF:"4G=]27+KM-+L,E6:=?<9V6;CL
MY9/E656O;0:CY?EM+4,^^;W*6O9\\,E+H<(W/Z-P@CJCC8]@[D+A^;-]I\(C
MQ*.TFRK/?#=3_8:O>/SW1"?_ 5!+ P04    "  %HZ54\%W"[Q@(  "X)
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M FRA1L+W1%:.70";M?@U 3GAV*E$U!U@'9"E7"&R!H-Y,#) SWSQU702E80
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M,S,Q7V-A;"YX;6Q02P$"% ,4    "  %HZ54<SIB%X$W   _60( %0
M        @ %4% ( ;FMT<BTR,#(R,#,S,5]D968N>&UL4$L! A0#%     @
M!:.E5.*$N**IFP  IG8& !4              ( !"$P" &YK='(M,C R,C S
M,S%?;&%B+GAM;%!+ 0(4 Q0    (  6CI52;_2U*@%L   D1!  5
M      "  >3G @!N:W1R+3(P,C(P,S,Q7W!R92YX;6Q02P$"% ,4    "  %
MHZ54M'/-Z 4(  "J)   &0              @ &70P, ;FMT<C(P,C(M,#-X
M,S%X97AX,S$Q+FAT;5!+ 0(4 Q0    (  6CI53P7<+O& @  +@D   9
M          "  =-+ P!N:W1R,C R,BTP,W@S,7AE>'@S,3(N:'1M4$L! A0#
M%     @ !:.E5($,)\_\!0  #Q<  !D              ( !(E0# &YK='(R
J,#(R+3 S>#,Q>&5X>#,R,2YH=&U02P4&      D "0!? @  55H#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
